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Abstract
Microglia, the resident macrophages of the brain, were originally assumed to be passive 
cells, however increasing evidence suggests that microglia play an active role during 
development and in neurological disorders. Activated microglia release a variety of 
toxic inflammatory mediators including reactive nitrogen species, cytokines, glutamate 
and oxygen free radicals, all of which exert a detrimental effect on neuronal survival if 
secretion is sustained. Microglial responses depend on the signals received from the 
surrounding microenvironment. Therefore, in this thesis the effects of albumin, 
chromogranin A (CgA), p-amyloid (Ap), ischaemia and combined insults (ischaemia 
plus albumin or ischaemia plus Ap) on microglial signalling have been investigated 
because these activators are associated with the pathology of stroke and/or Alzheimer’s 
disease.
Briefly, albumin was found to induce iNOS expression, to cause the release of 
glutamate and to elicit a calcium-dependent proliferative response in microglia; events 
that were mediated by a possible interaction with myosin IX. Interestingly, peritoneal 
macrophages were unresponsive to the same concentrations of albumin. CgA and Ap 
triggered microglial signalling via scavenger receptor-dependent mechanisms. Both 
activators caused microglia to undergo mitochondrial depolarisation, which 
precipitated apoptosis. CgA, but not Ap, also induced iNOS expression and glutamate 
release. CgA-induced iNOS expression was mediated by the Src kinase-dependent 
phosphorylation of ERK. Ischaemia per se did not elicit any discemable effects on 
microglial signalling. However, microglia subjected to ischaemia followed by albumin 
treatment endured mitochondrial depolarisation, which led to apoptosis. Similarly, 
ischaemia followed by Ap treatment potentiated the levels of microglial apoptosis and 
mitochondrial depolarisation induced by Ap alone. A common characteristic displayed 
by microglia subjected to albumin, CgA, Ap, or ischaemia was the ability to induce 
neuronal death. Thus, manipulation of microglial signalling pathways to reduce 
reactivity and neurotoxicity may provide novel therapeutic strategies for the 
amelioration of neurodegeneration in disorders such as stroke and Alzheimer’s disease.
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1.0 Introduction
1.1 General introduction
1.1.1 The central nervous system and glia
The CNS consists of a network of approximately 10 12 neurones, which facilitate the 
transmission of action potentials enabling organisms to communicate with their 
environment (Alberts et al., 2002). Despite the essential function of neurones, about 
90% of the cells in the CNS are glia (Sherwood 1993). Glia were originally believed 
to be passive cells that only acted physically to support neurones, hence the name glia 
meaning 'glue' (Coyle and Schwarcz 2000). However, glia are now known to play an 
active role in many central homeostatic processes. Four main types of glia exist, 
namely oligodendrocytes, astrocytes, ependymal cells and macrophages of the brain 
(Sherwood 1993), which are commonly termed microglia irrespective of their 
cerebral location (see below).
Oligodendrocytes comprise several short processes, which wrap themselves around 
neurones. Oligodendrocytes are responsible for the myelination of neurones in the 
CNS (Alberts et al., 2002). Oligodendrocytes also regulate extracellular potassium 
ion concentration (Ransom and Sontheimer 1992) and secrete a number of nerve 
growth factors including nerve growth factor (NGF), brain derived neurotrophic 
factor (BDNF) and neurotrophin-3 (Dai et al., 2000). Peripheral axons are myelinated 
by Schwann cells and these cells in contrast to oligodendrocytes faciliate neuronal 
regeneration following injury (Torigoe et al., 1996).
Astrocytes are classified into protoplasmic and fibrous astrocytes. Protoplasmic 
astrocytes display short processes and are associated with grey matter, whereas 
fibrous astrocytes exhibit long processes and are associated with white matter 
(Kimelberg and Norenberg 1989). During development astrocytes act as a scaffold
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facilitating neuronal migration and synaptogenesis (Ransom and Sontheimer 1992). 
In the adult astrocytes are involved in the maintenance and permeability of the blood 
brain barrier (BBB), accordingly astrocytic processes or ‘end feet’ surround every 
capillary in the brain (Kimelberg and Norenberg 1989). Astrocytes also support the 
metabolic requirements of neurones (Magistretti et al., 1999) and play a role in the 
degradation of a number of neurotransmitters including serotonin, glutamate and 
gamma-aminobutyric acid (GABA) (Kimelberg and Katz 1985; Kimelberg and 
Norenberg 1989). Additionally, astrocytes regulate extracellular potassium ion 
concentration, which is crucial for the propagation of action potentials in neurones 
(Ransom and Sontheimer 1992). Furthermore, astrocytes play a role in immune 
functions (Fontana et al., 1984) and are involved in the formation of neural scars 
(gliosis) following brain injury (Kimelberg and Norenberg 1989).
Ependymal cells line the ventricles and the central canal of the spinal cord (Del Bigio 
1995). The functions of ependymal cells remain largely speculative; however these 
cells possess micro-villi, which beat in a co-ordinated manner. Therefore ependymal 
cells may be involved in the directional movement of cerebral spinal fluid (CSF). 
This action is postulated to facilitate the transport of nutrients into the brain and the 
removal of toxic metabolites. Ependymal cells have also been suggested to serve as 
an axonal guidance system during early development.
The fourth type of glial cell is the brain macrophage. Several distinct populations of 
specialised brain macrophage exist (Jordon and Thomas 1988). These cells are 
located in the ventricular margins, the choroid plexus, the meninges in a perivascular 
location and in the parenchyma, where they are known as supraependymal cells, 
epiplexus cells, subarachnoid/ leptomeningeal macrophages, perivascular
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macrophages or microglia respectively. Together these unique macrophages guard 
every surface and area of access to the brain. The ventricular surface is protected by 
the ventricular macrophages and the macrophages associated with the choroid plexus. 
Meningeal macrophages guard the pial surface, perivascular macrophages provide 
protection from blood borne pathogens, whilst microglia protect the internal region of 
the brain (Jordon and Thomas 1988; Perry 2001). Microglia are the focus of this 
study and are discussed in detail in section 1.2. In brief, microglia were originally 
identified as a distinct cell form by Rio Hortega in the 1960’s (see review by Jordon 
and Thomas 1988). Subsequent studies have revealed that microglia are involved in 
immune surveillance and transform into active phagocytic macrophages in response 
to neuronal injury or pathogen invasion. In the reactive state microglia release a 
number of inflammatory mediators, which in excess may contribute to degenerative 
processes in neurological disorders.
1.1.2 The immune system
The immune system is divided into two functional divisions, the innate and the 
adaptive immune system (Roit et al., 1987). The innate immune system provides the 
first line of defence against infectious agents. The innate immune system is made up 
of the skin, macrophages, neurophils, natural killer cells and soluble factors such as 
activated complement proteins and lysozyme. Macrophages can be further classified 
into Kupffer macrophages of the liver, alveolar macrophages of the lung, microglia of 
the brain and monocytes in the blood (Roit et al., 1987). The adaptive immune system 
provides a second line of defence and is associated with the production of antibodies. 
Antibodies facilitate phagocytosis and the activation of complement proteins. 
Furthermore, antibodies provide an immunological memory; therefore re-infection 
with the same agent does not culminate in disease (Roit et al., 1987). Macrophages
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provide a vital link between the innate and the adaptive immunity, since activated 
macrophages express major histocompatibility class II antigen (MHC II), thereby 
facilitating antigen presentation to T cells, a process that is required for the 
production of antibodies by B cells. Dentritic cells also perform the function of 
antigen presentation, however in these cells this activity is constitutive and not 
inducible (Holgate and Church 1995).
1.1.3 The brain, an immunologically privileged site
The brain was originally regarded as an immunologically privileged site due to the 
inaccessibility of the organ to circulating immune cells and soluble inflammatory 
mediators. This notion arose from the observation that tissue grafts survived for long 
periods of time when transplanted to the brain without any evidence of an immune 
response (Head and Griffin 1985). More recently, the immune privilege has been 
demonstrated by injecting mycobaterium into the brain parenchyma (Matyszak and 
Perry 1998). In peripheral organs mycobacterium induces an aggressive immune 
reaction, whereas in the brain this pathogen fails to initiate such a response. The main 
factors believed to contribute to die unique immune status of the brain are the 
presence of the BBB, the lack of a conventional lymphatic drainage system and the 
expression of low levels of MHC antigens. The latter is in part attributed to the 
absence of a cerebral dendritic cell population and the quiescent state of the resident 
microglia (Perry and Gordon 1988; Perry et al., 1997; Perry 1998).
The brain however is not in complete isolation from the peripheral immune system, 
since circulating blood monocytes (Lawson et al., 1992) and activated T cells 
(Wekerle et al., 1986) cross the BBB in health and at an accelerated rate in disease. 
Thus, the BBB is not an impenetrable barrier to the peripheral immune system.
Furthermore, under a variety of pathological conditions microglia upregulate the 
expression of MHC class II antigens, thereby facilitating antigen presentation to 
immuno-surveying T cells (Streit et al., 1989; Benveniste et al., 2001). Reactive 
microglia also secrete a plethora of inflammatory mediators, which serve to 
coordinate the inflammatory response (Colton and Gilbert 1987; Banati et al., 1993a; 
Forloni et al., 1997; Bhat et al., 1998; Casal et al., 2002). Therefore, the brain is able 
to sustain a low-grade inflammatory reaction in which microglia play a key role. 
However, cerebral immune activity is normally suppressed, this probably serves as a 
protective mechanism since neurones are post-mitotic and if lost or damaged cannot 
be replaced.
1.2 Microglia
1.2.1 The origins of microglia
The origins of microglia is an issue that has been highly debated. Proposals suggest 
that microglia either originate from the mesoderm like peripheral monocytes or from 
neuroectoderm along with neurones and other glia (Kitamura et al., 1984) (Fig. 1.1). 
However, the most recent and convincing studies support a monocytic origin. Ling 
and co-workers demonstrated the hematogenous origin o f microglia by injecting 
carbon labelled monocytes into the peripheral blood stream of postnatal rats before 
the complete development of the BBB (Ling et al., 1980). Using this approach, 
labelled microglia were detected in the brains of the recipient rats implying that 
microglia derive from circulating blood monocytes.
Experiments using rat bone marrow chimeras have also shown that microglia are 
bone marrow derived as are meningeal and perivascular macrophages (Hickey and
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Kimura 1988). In these studies, the haematopoietic progenitor cells of a recipient 
animal are destroyed and are replaced with cells from a donor animal. The 
experiment is based on differences in MHC antigen expression, thus bone marrow 
derived cells can be traced in the chimeric animal (Hickey and Kimura 1988; Perry 
2001).
Developmental studies provide additional evidence that microglia exhibit a 
hematogenous origin. In the developing brain macrophages are initially observed in 
the choroid plexus (Sturrock 1978) and in the meninges (Boya et al., 1979). These 
macrophages subsequently migrate along the ventricular surface entering the brain 
parenchyma where they ultimately transform into ramified microglia with the 
amoeboid cell form acting as a morphological transitional state. Initial migration 
events precede the development of the vasculature; however studies undertaken 
following vessel formation also demonstrate that brain macrophages are derived from 
blood monocytes with perivascular cells acting as a possible intermediate (Baron and 
Gallego 1972).
Collectively these findings provide evidence that microglia are of monocytic lineage, 
but there is still some uncertainty as to whether microglia are a specialised branch of 
this lineage (Periy 2001). There are two possible scenarios, in one microglia are 
derived from monocytes and there is no selection bias as to which monocytes enter 
the CNS. Monocytes having entered the CNS, come under the influence of the 
specialised micro-environment, which induces microglial morphology and 
phenotype. The other possibility is that there is a subset of monocytes that are 
destined for the CNS (Perry 2001).
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Figure 1.1 Origins of microglia
Proposals suggest that microglia either originate from the neuroectoderm (A) or from the 
mesoderm like circulating blood monocytes (B).
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1.2.2 Microglia] phenotypes
In recent years advances in technology have lead to the characterisation of three 
distinct forms of microglia termed amoeboid, ramified and reactive microglia, all of 
which serve different functional roles.
1.2.2.1 Amoeboid microglia
Amoeboid microglia are associated with the developing CNS. In rats, amoeboid 
microglia arise in the last week of gestation and disappear in the second post-natal 
week (Ling et al., 1980). These cells exhibit a rounded morphology possessing 
pseudopodia and thin filopodia-like processes and contain numerous lysosomes and 
phagosomes. During the post-natal period amoeboid microglia are believed to play a 
role in gliogenesis (Guilian 1987) and tissue histogenesis through the elimination of 
inappropriate axons (Innocenti et al., 1983).
Through the use of carbon labelled monocytes it has been demonstrated that 
amoeboid microglia ultimately grow long crenulated processes and transform into 
ramified microglia (Ling 1979). In support of this, the application of retinoic acid or 
dimethyl sulphoxide (agents known to accelerate cellular differentiation) to amoeboid 
microglia in vitro stimulates the growth of thin processes several hundred microns in 
length (Giulian and Baker 1986). These process bearing microglia subsequently lose 
macrophage associated properties including nonspecific esterase activity, the ability 
to proliferate, to perform phagocytosis and to bind acetylated low-density lipoprotein, 
functions which are down-regulated in ramified microglia (Giulian and Baker 1986).
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1.2.2.2 Ramified microglia
Ramified microglia are found in abundance in the brain parenchyma and constitute 
approximately 10-20% of the total population of glial cells in the adult CNS 
(Vaughan and Peters 1974; Banati 2003). These small oval cells comprise a variable 
number of branching processes and possess scant cytoplasm. In the adult, the resident 
population of ramified microglia is maintained through local cell division and the 
recruitment of circulating blood monocytes (Lawson et al., 1992). These processes 
contribute almost equally to steady state turnover.
Until recently, ramified microglia were considered to be inactive under physiological 
conditions. However, it has been demonstrated that microglia exhibit pinocytotic 
activity and motility within a circumscribed local area (Booth and Thomas 1991). 
These findings in conjunction with the observations that ramified microglia are 
evenly distributed throughout the brain parenchyma and express degradative 
enzymes, led to the hypothesis that these cells function as a CSF cleansing system 
(Booth and Thomas 1991; Thomas 1992). In this respect, it has been suggested that 
ramified microglia contribute to the removal of cellular metabolites and the disposal 
of toxic factors released from damaged neurones. In addition, it has been proposed 
that ramified microglia limit the spread of diffusible neurotransmitters thereby 
contributing to the transmission of nerve impulses. Accordingly, microglia express 
receptors (Zhang et al., 1998; Biber et al., 1999; Taylor et al., 2002, 2003) and re­
uptake transporters (Nakajima et al., 2000) for a number of known neurotransmitters.
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1.2.23 Conversion of ramified microglia into the reactive phenotype
In response to neuronal injury, ramified microglia transform into active macrophages 
otherwise known as reactive microglia. This phenomenon has been investigated using 
the axotomized rat facial nucleus model (Kreutzberg 1996). The facial nerve is 
employed in this paradigm because these cells possess centrally located cell bodies 
but project axons into the peripheral nervous system. Therefore, microglial activation 
can be studied in die absence of infiltrating haematogenous cells, since nerve 
transection leaves the BBB intact.
Using the facial nucleus model it has been shown that in response to neuronal damage 
ramified microglia proliferate and up-regulate the expression of CR3 complement 
receptors, major histocompatibilty complex (MHC) class I and II antigens and the 
intermediate protein vimentin (Graeber et al., 1988a, b, c). Whilst microglia are 
activated by neuronal damage and regeneration they do not become phagocytic. 
However, neuronal death induced by injecting ricin into die facial nerve (causing 
death by retrograde transport) evokes a rapid increase in the expression of MHC class 
I and II antigens, which is accompanied by the conversion of microglia into 
phagocytic macrophages (Streit and Graeber 1993). This suggests that factors 
released from dying neurones are required to induce phagocytic activity. Thus, 
microglia transform into active macrophages with at least one intermediate form. This 
form, possessing partial macrophage properties, has been termed the active microglia. 
In contrast to ramified microglia, activated microglia exhibit stouter processes and 
thereby resemble the reactive form (phagocytic microglia).
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1.2.2.4 Reactive microglia
Reactive microglia are rod-like in appearance, devoid of branching processes and 
contain an abundance of lysosomes and phagosomes. The reactive cell form 
represents a transient population of macrophages that are associated with brain injury 
and neuroinflammation. Following a damaging event, reactive microglia rapidly 
accumulate at the site of injury (Murabe et al., 1981a). In acute lesions the peak of 
microglial activation occurs 2-3 days post insult, but if the pathological stimulus 
persists microglial activations continues (Banati 2003).
Like macrophages, reactive microglia produce a number of inflammatory mediators 
including super oxide anions, nitric oxide, interleukin 1, interleukin 6, tumour 
necrosis factor and interferon-y (Colton and Gilbert 1987; Banati et al., 1993a; 
Forloni et al., 1997; Bhat et al., 1998; Casal et al., 2002). Interestingly, interleukin 1 
induces astrocyte proliferation (Giulian and Baker 1986) and it has been postulated 
that reactive astrocytes secrete microglial mitogens (Frei et al., 1986). Thus, a 
complex interplay between microglia and astrocytes is likely to be involved in CNS 
repair. Reactive microglia also express MHC class II antigens and other surface 
molecules necessary for antigen presentation including CD40, B7 and ICAM-1 (Streit 
et al., 1989; Benveniste et al., 2001). Consequently, microglia are considered to be 
the most potent endogenous antigen presenting cells in the CNS.
1.2.3 Inflammatory mediators secreted by reactive microglia
Reactive microglia secrete a plethora of inflammatory mediators, which are involved 
in the host’s immune response to injury or invading micro-organisms. However, the 
following discussion is limited to the description of nitric oxide, prostaglandins, 
superoxide, transforming growth factor (3 (TGFp) and the archetypal pro-
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inflammatory cytokines tumour necrosis factor (TNFa) and interleukin 1 (IL1). Other 
inflammatory agents secreted by activated microglia include proteases, interferons 
(IFN) and colony stimulating factors (CSF) to name but a few (Banati et al., 1993a; 
Calvo et al., 1996; Yan et al., 1997; Kingham and Pocock 2001).
1.2.3.1 Nitric oxide
Nitric oxide (NO) is an important free radical, which is involved in many 
physiological processes including microglial and macrophage cytotoxicity, 
neurotransmission and the regulation of blood pressure (Moncada and Higgs 1993). 
Synthesis of NO is mediated by the enzyme nitric oxide synthase (NOS), which 
converts L-arginine into L-citrulline and NO. Three isoforms of NOS have been 
described, two which possess constitutive calcium dependent activity (cNOS) and 
one inducible form whose activity is calcium independent (iNOS or type II). 
However, it should be noted that calcium has been implicated in the signalling 
pathways leading to iNOS expression (Raddassi et al., 1994; Hoffmann et al., 2003), 
although activity itself is calcium independent. Constitutive forms of NOS are found 
in the endothelium (eNOS or type HI) (Sessa et al., 1992) and in neurones (nNOS or 
type I) (Bredt and Snyder 1990; Schmidt et al., 1991), whereas iNOS is expressed in 
many cell types including microglia, macrophages, and vascular smooth muscle cells 
(Xie et al., 1992; Koide et al., 1993; Bhat et al., 1998). Unlike cNOSs, which are 
constitutively expressed and produce small amounts of NO intermittently, iNOS is 
typically synthesised following exposure to inflammatory stimuli. Many agents 
induce iNOS expression including LPS (Bhat et al., 1998) and cytokines (Koide et 
al., 1993). Expression of the iNOS gene is regulated intracellularly by the 
transcription factors NFkJ3, STAT-1 (Murphy 2000) and AP-1 (Kristof et al., 2001).
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1.2.3.2 Superoxlde
Like all phagocytes, activated microglia possess the ability to synthesise superoxide 
(Colton and Gilbert 1987; Si et al., 1997; Spranger et al., 1998). This process 
involves the reduction of molecular oxygen by NADPH oxidase to form superoxide 
anions (O2 ). NADPH oxidase is composed of a number of subunits some of which 
are cytoplasmic, whilst others are membrane bound (Lavigne et al., 2001). Following 
stimulation, the cytoplasmic components p47phox, p67phox, p40phox (where phox stands 
for phagocyte oxidase) and the small GTPase p21Racl translocate to the plasma 
membrane where they form a complex with flavocytochrome bssg, a membrane 
tethered heterodimer composed of gp91phox and p22phox (Abo et al., 1992; Wallach 
and Segal 1996; Leuson et al., 1996).
Superoxide provides the starting material for a vast assortment of reactive oxidant 
species, which are all effective bactericidal agents (Holgate and Church 1995; Guyton 
and Hall 1996). Superoxide dismutase converts superoxide to hydrogen peroxide, 
which subsequently reacts with newly formed superoxide to form hydroxyl radicals 
(Holgate and Church 1995). Hydrogen peroxide also reacts with myeloperoxidase in 
the presence of halides to produce oxidants such as hypochlorite (Holgate and Church 
1995; Guyton and Hall 1996). Furthermore, superoxide readily reacts with NO 
resulting in the production of peroxynitrite (ONOO') (Ischiropoulos et al., 1992). 
Peroxynitrite is a potent antimicrobial agent, which renders lipid, thiol, amine or 
phenol containing bacterial bio-molecules inactive. Thus, superoxide derivatives in 
combination with reactive nitrogen species provide a powerful line of defence against 
foreign bodies.
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1.2.33 Prostaglandins
Prostaglandins are another inflammatory mediator secreted by activated microglia 
(Minghetti and Levi 1995; Pyo et al., 1999; Pinteaux et al., 2002). Prostaglandins 
mediate a wide variety of physiological responses including platelet aggregation, 
kidney function, vasodilation and gastric cytoprotection (Rang et al., 1999; Dubois et 
al., 1998; Vane et al., 1998; Hinz and Brune 2001). Furthermore, prostaglandin 
synthesis is upregulated during inflammation, where they mediate vasodilation and 
potentiate the effects of painful stimuli by sensitising C fibres. Prostaglandins are also 
implicated in the production of fever; accordingly high concentrations of 
prostaglandins are found in the CSF during infection (Rang et al., 1999).
Prostaglandins are derivatives of arachidonic acid, a fatty acid that is liberated from 
the plasma membrane by the action of phospholipases. Arachidonic acid is 
subsequently metabolised by cyclooxygenase (COX) to form prostaglandin Ffe from 
which the other prostaglandins (PGI2, PGE2 , PGD2, PGF2CX, thromboxane) are 
produced by the actions of specific prostaglandin synthases (Dubois et al., 1998; 
Rang et al., 1999; Hinz and Brune 2001). COX exists in two isoforms COX-1 and 
COX-2 (Vane et al., 1998; Rang et al., 1999). COX-1 is found in most cells as a 
constitutive enzyme, which synthesises prostaglandins involved in normal 
homeostatic processes. In contrast, the synthesis o f COX-2 is induced in 
inflammatory cells by specific inflammatory stimuli; therefore prostaglandins 
generated by this enzyme are associated with pathology. However, it should be noted 
that COX-2 is constitutively expressed in some neurones, where it may be involved in 
nerve transmission. Furthermore, prostaglandins generated by a constitutively active 
form of COX-2 are involved in ovulation and in the birth process (Dubois et al., 
1998; Vane etal., 1998).
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For many years non-steroidal anti-inflammatoiy drugs (NSAIDs) have been 
prescribed for the treatment of arthritis and other chronic inflammatory disorders. 
These drugs work by selectively inhibiting the activity of COX enzymes. More 
recently, epidemiological studies have demonstrated that NSAIDs reduce the risk of 
developing AD (McGeer et al., 1996; Stewart et al., 1997), which suggests that COX- 
2 is upregulated in this neurological disorder.
1.2.3.4 Tumour necrosis factor
Tumour necrosis factor a  (TNFa) is representative of a large family of cytokines 
including TNFp (lymphotoxin), FasL and CD40L. These cytokines exert effects on 
the inflammatory response, cell death and proliferation (Vilcek and Lee 1991). 
Furthermore, the over production of TNF family members is associated with septic 
shock and autoimmune disorders.
TNFa and TNFp share approximately 30 % sequence homology (Pennica et al., 
1984) and bind to the same cell surface receptors (Aggarwal et al., 1986). Two 
distinct TNF receptors exist; TNFR1 and TNFR2, which possess molecular masses of 
55 and 75 kDa respectively. TNFR1 is associated with apoptotic cell death. This 
receptor contains an 80 amino acid sequence designated the ‘death domain’, which is 
required for the induction o f apoptosis. In contrast, TNFR2 has been demonstrated to 
play a role in the proliferation of T cells. TNFR2 bears no sequence homology to 
TNFR1, which implies that the receptors couple to different second messenger 
pathways (Tewari and Dixit 1996). Interestingly, TNFa is primarily produced by 
macrophages and microglia, whereas TNFp is predominantly secreted by activated 
lymphocytes (Aggarwal et al., 1986). Microglia also express both TNFR1 and
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TNFR2 suggesting that secreted TNFa may exert autocrine effects on these cells 
(Dopp et al., 1997). TNFa is cleaved from a transmembranous precursor by TNFa 
converting enzyme (TACE) (Black et al., 1997). Following cleavage TNFa 
assembles into homotrimeric complexes (Smith and Baglioni 1987). Interestingly, 
recent evidence suggests that the membrane anchored form of TNFa is the most 
efficacious species of this cytokine (Grell et al., 1995).
1 .2.3.5 Interleukin 1
Interleukin 1 (IL1) is the general name for two distinct proteins, IL la  and ILlp. 
These cytokines are synthesised as 31 -33 kDa pro-cytokines that share approximately 
26 % amino acid identity (March et al., 1995). Cleavage of IL la  is mediated by 
calpain, a calcium dependent cysteine protease (Carruth et al., 1991). In contrast, 
ILlp is cleaved by ELIp converting enzyme (ICE), which was the first identified 
member of the caspase family of cysteine proteases. IL la  and ILlp are believed to 
exert identical actions. Signalling is mediated by an 80 kDa cell surface receptor 
(IL1R1), which requires association with an accessory protein (AcP) for activity 
(Rothwell and Luheshi 2000). A second 68 kDa receptor (IL1R11) also binds IL la  
and ILlp, but does not mediate signal transduction. The third member of the IL1 
family is a naturally occurring receptor antagonist (ILIRa), which binds IL1R1 but 
fails to trigger association with AcP (Rothwell and Luheshi 2000).
In the periphery, IL1 plays a pivotal role in inflammatory processes. IL1 promotes the 
responses of B and T cells to antigen, it increases the synthesis of leucocyte 
adherence factors on endothelium and induces the secretion of other cytokines (Rang 
et al., 1999; Goldsby et al., 2001). In the CNS, IL1 is involved in neuro-inflammation
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(Rothwell and Luheshi 2000) and the induction of fever (Guyton and Hall 1996). 
Cells known to secrete ELI include macrophages, microglia, fibroblasts, astrocytes 
and oligodendrocytes. Interestingly, cells of monocytic lineage such as microglia, 
predominantly secrete the ILlp isoform (Thombeny et al., 1992). Microglia also 
express IL1R1 and IL1R11, therefore secreted IL1 may exert feedback effects on 
these cells (Pinteaux et al., 2002).
1.2.3.6 Transforming growth factor
There are three isoforms o f transforming growth factor-beta, TGF-p 1, 2 and 3, which 
play similar biological roles. TGFp is involved in angiogenesis, in the regulation of 
growth and development and in inflammation and repair (Clark and Coker 1998; Ling 
and Robinson 2002). Following injury, TGFp attracts and activates macrophages and 
then promotes macrophages to apoptose after tissue debris and invading 
microorganisms have been engulfed. TGFp subsequently promotes angiogenesis and 
the deposition of extracellular matrix, which closes the wound (Ling and Robinson 
2002). The vital anti-inflammatory properties of TGFp are illustrated by the fact that 
less than 50 % of TGFp 1 knock out mice die in utero and the remainder succumb to 
uncontrolled inflammation 1-2 weeks after birth (Kulkami et al., 1993). Similarly, 
TGFp2 (Sanford et al., 1997) and TGFp3 (Proetzel et al., 1995) knockout mice die 
rapidly in the postnatal period.
TGFp isoforms are generally secreted as latent precursors, requiring activation before 
they can exert biological activity (Clark and Coker 1998). Recently, thrombospondin 
p (Crawford et al., 1998) and plasmin (Lyons et al., 1990) have been implicated in the 
processing of latent TGFp. Signalling is mediated by two membrane receptors (type I
and type II) that possess serine/threonine kinase activity (Eickelberg 2001). In the 
presence of TGFp, type I and II TGFp receptors form a heterotetrameric complex and 
the type II receptor transphosphoiylates and activates the type I receptor (Eickelberg
2001). Type I receptors subsequently initiate the phosphorylation of downstream 
targets, which include the Smad family of transcription factors (Moustakas et al., 
2000) and MAPK (Eickelberg 2001). Microglia express type I and type II TGF p 
receptors (Jones et al., 1998), which suggest that microglia are responsive to this 
cytokine.
1.2.4 Receptors expressed by microglia
Microglia express a number of cell surface receptors including complement receptors 
(Ford et al., 1995), Fc receptors (Vedeler et al., 1994), mannose receptors (Marzolo et 
al., 1999), thrombin receptors (Moller et al., 2000), scavenger receptors (SR) (Paresce 
et al., 1996) and receptors for advanced glycation end products (RAGE) (Yan et al.,
1996). However, the following discussion is limited to the description of scavenger 
receptors and RAGE since these receptors pertain to this study.
1.2.4.1 Scavenger receptors
SR are a family of macrophage cell surface glycoproteins that exhibit broad ligand 
specificity; hence they have been likened to ‘molecular flypaper’ (Kriger 1992). SR 
ligands include modified lipoproteins such as oxidised and acetylated LDL, 
polyinosinic acid, fucoidan, and LPS (Goldstein et al., 1979; Krieger 1992). Almost 
all SR ligands are polyanionic molecules, although not all negatively charged 
molecules bind to SR (Krieger 1992). Cloning studies have recently revealed the 
existence of a broad family of SR that have been classified into six sub-groups (A-F)
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based on their putative tertiary structure (Peiser and Gordon 2001). The SR-A 
subgroup comprises SRA-1, SRA-2, SRA-3 and macrophage receptor containing a 
collegenous domain (MARCO). CD36 and SR-B1 constitute the SR-B sub-group, 
whilst dSR-Cl, CD68, lectin like oxidised low density lipoprotein receptor-1 (LOX- 
1) and endothelial cell scavenger receptor (SREC) are the sole members of SR-C, SR- 
D, SR-E and SR-F respectively (Peiser and Gordon 2001).
Cellular functions of scavenger receptors include the phagocytosis of invading micro­
organisms (Suzuki et al., 1997) and apoptotic cells (Platt et al., 1999). SR have also 
been implicated in cell adhesion (Post et al., 2002), Alzheimer’s disease (AD) 
(Paresce et al., 1996; Honda et al., 1998), stroke (Honda et al., 1998) and in the 
formation of lipid engorged foam cells in atherosclerosis (Goldstein et al., 1979; 
Krieger 1992). Furthermore, SR have been found to initiate intracellular signalling 
cascades (Pollaud-Cherion et al., 1998; Whitman et al., 2000), which implies that 
these receptors may possess the ability to induce gene transcription and thereby 
modulate cellular function.
1.2.4.2 RAGE
RAGE is a member of the immunoglobulins superfamily of cell surface molecules 
that includes neural cell adhesion molecule (NCAM), vascular cell adhesion molecule 
(VCAM) and intracellular adhesion molecule (ICAM) (Neeper et al., 1992; Schmidt 
et al., 1992). Several other advanced glycation end product (AGE) receptors have 
been identified including lactoferrin (Schmidt et al., 1992; Li et al., 1995), 
oligosccharyl transferase complex protein 48 (OST-48; AGE-R1) (Ming et al., 1996), 
80KH protein (AGE-R2) (Ming et al., 1996), galectin-3 (AGE-R3) (Zhu et al., 2001) 
and lysozyme (Li et al., 1995).
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Advanced glycation end products result from the non-enzymatic reaction of glucose 
or other reducing sugars with amino groups of proteins and lipids (glycation) 
(Brownlee 1995). AGE accumulate with age and at an accelerated rate in diabetes 
(Brownlee 1995). The accumulation o f AGE has also been implicated in the 
pathogenesis of AD, since RAGE binds p-amyloid (A(3) and RAGE is over expressed 
in AD (Yan et al., 1996, 1997). The interaction between AGE and their receptors 
elicit a variety of biological responses including microglial chemotaxis (Yan et al.,
1997), cytokine secretion (Dukic-Stefanovic et al., 2003) and free radical production 
(Brownlee 1995; Dukic-Stefanovic et al., 2003). The signalling cascades coupled to 
RAGE remain largely uncharacterised, although it has been shown that ligation of 
RAGE causes ERK and NFk(3 activation in microglia (Dukic-Stefanovic et al., 2003) 
and THP-1 monocytes (Yeh et al., 2001).
1.2.5 The fate of reactive microglia
Two opposing hypothesis describe the ultimate fate o f reactive microglia following a 
damaging event. The first theory supposes that reactive microglia proliferate, perform 
their immunological function then revert back to a quiescent ramified phenotype 
(Jordon and Thomas 1988). The second hypothesis predicts that reactive microglia 
degenerate (Jones et al., 1997). Cell death can be divided into two forms known as 
apoptosis or necrosis. It is not known which form of cell death reactive microglia 
undergo in vivo, although microglia have been shown to endure a non-classic form of 
apoptosis following facial nerve axotomy (Jones et al., 1997). Apoptotic microglia 
are also found around senile plaques in AD (Lassmann et al., 1995; Yang et al.,
1998). Nevertheless, microglia may succumb to different types of cell death after 
specific pathological insults.
38
1 .2.5.1 Apoptosis
Apoptosis or ‘programmed cell death’ is responsible for the ordered removal of aged 
or damaged cells without the initiation of an inflammatory reaction (Kroemer et al.,
1998). Consequently, apoptosis occurs under physiological and pathophysiological 
conditions. Apoptosis is characterised by distinct biochemical changes, including 
DNA fragmentation and chromatin condensation caused by the activation of 
endonucleases (Kroemer et al., 1998). Apoptotic cells also undergo membrane 
blebbing and phosphatidylserine residues are flipped from the inner to the outer 
leaflet of the plasma membrane, both of these processes facilitate cellular engulfment 
by macrophages (Kroemer et al., 1998). Other features of apoptosis include cellular 
shrinkage, caspase activation and mitochondrial dysfunction (Kroemer et al., 1998).
1.2.5.2 Caspases
To date 13 mammalian caspases have been identified, which have distinct roles in 
apoptosis (caspase 2, 3, 6, 7, 8, 9, 10) and inflammation (caspase 1, 4, 5, 11, 12, 13) 
(Thombeny and Lazebnik 1998). Caspases are cysteine proteases that are expressed 
as pro-enzymes containing three domains, including an NH2 terminal, a large subunit 
(20 kDa) and a small subunit (10 kDa) (Thombeny and Lazebnik 1998; Hengartner 
2000). Caspase activation involves the proteolytic processing between domains and 
the association of the large and the small subunit. A large body of evidence supports a 
cascade model for caspase activation. Initiator caspases such as caspase 8 and 9 are 
believed to instigate the cascade, leading to the activation of effector caspases, which 
include caspase 3, 6 and 7 (Thombeny and Lazebnik 1998). Caspases cause cell 
death by cleaving proteins necessary for cell survival including DNA repair enzymes 
and cytoskeletal proteins such as gelsolin and fodrin (Schulz et al., 1999; Hengartner 
2000). Caspases also cleave nuclear lamins, which causes nuclear shrinkage
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(Hengartner 2000). Furthermore, caspases cleave negative regulators of apoptosis 
including BcI-2, which is an inhibitor of the large mitochondrial conductance channel 
associated with apoptosis known as the mitochondrial permeability transition pore 
(PT) (Thombeny and Lazebnik 1998).
1.2.53 The role of the mitochondrion in apoptosis
Apoptosis is often preceded by a reduction in mitochondrial membrane potential (A'F; 
mitochondrial depolarisation), which is caused by the opening of the PT (Zamzami et 
al., 1996; Green and Reed 1998). The structure of the PT remain only partially 
defined, however it is known to comprise the inner mitochondrial membrane protein 
adenine nucleotide translocator (ANT) and the outer membrane protein porin 
(otherwise known as voltage dependent anion channel; VDAC) (Green and Read
1998) (Fig. 1.2). The opening of the PT triggers die dissipation of the proton gradient 
created by the electron transport chain. This subsequently causes the uncoupling of 
oxidative phosphorylation and the shutdown of mitochondrial biogenesis (Zamzami 
et al., 1996; Kroemer et al., 1998; Green and Reed 1998). The opening of PT also 
causes the release of cytochrome c (Yang and Cortopassi 1998; Eamshaw 1999; Zhu 
Y et al., 2002) and apoptosis inducing factor (AIF) (Eamshaw 1999; Susin et al.,
1999). Cytochrome c plays a dual role in cellular homeostasis, since it is an integral 
part of the respiratory chain, whilst at the same time it is a potent inducer of 
apoptosis. Cytochrome c in conjunction with apoptosis proteases activating factor 
(APAF-1) and pro-caspase 9 form an ‘apoptosome’ (Saleh et al., 1999; Yuchen et al.,
1999). This complex promotes the activation of caspase 9, which in turn activates 
other caspases that collectively orchestrate the execution of apoptosis. AIF causes 
DNA fragmentation and chromatin condensation. Furthermore, AIF potentiates 
cytochrome c and caspase 9 release from the mitochondria (Susin et al., 1999).
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Figure 1.2 Proposed structure of the mitochondrial PT pore
Apoptosis is often preceded by a reduction in mitochondrial membrane potential, which is 
caused by the opening of a large conductance channel known as the PT pore. The PT pore 
is postulated to comprise of the inner mitochondrial membrane protein adenine nucleotide 
translocator (ANT) and the outer membrane protein porin. The opening of the PT pore 
triggers the dissipation of the proton gradient created by the electron transport chain. This 
causes the uncoupling of oxidative phosphorylation and the shutdown of mitochondrial 
biogenesis. The opening of PT also causes the release of cytochrome c (Cyt c) and 
apoptosis inducing factor (AIF), which together orchestrate apoptosis.
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1.2.5.4 Necrosis
Necrosis is induced by biochemical or physical damaging events such as abrupt 
anoxia or heat (Kroemer et al., 1998). Necrosis is characterised by cytoplasmic and 
mitochondrial swelling and ultimately cellular lysis, which results in the leakage of 
cellular contents. This in turn creates a toxic environment for neighbouring cells and 
exacerbates tissue damage either directly or via the recruitment of inflammatory cells 
(Kroemer et al., 1998) (table 1.1).
Apoptosis Necrosis
Physiological or pathological Always pathological
Processes tightly regulated Processes poorly regulated
Plasma membrane remains intact until late Plasma membrane becomes disrupted early
No leakage of cell content Leakage of cell content
Little or no inflammation Inflammation
DNA fragmentation Cytoplasmic swelling
Chromatin condensation Mitochondrial swelling
Mitochondrial dysfunction Cell lysis
Caspase activation and protein degradation
Membrane blebbing
Cellular shrinkage
Table 1.1 Comparison of the features of apoptosis versus necrosis 
Apoptosis occurs under physiological and pathological conditions, whereas necrosis is 
associated with pathological situations. Apoptosis involves a tightly regulated series of 
events, which lead to cell death, whereas necrosis is poorly regulated ( Kroemer et al., 1998).
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1.3 Intracellular signalling pathways
A number of ubiquitous second messengers mediate a plethora of cellular responses 
in a wide variety of cells. In this project the signalling molecules that were studied 
with respect to microglial signalling include guanine nucleotide binding proteins (G 
proteins), calcium, members of the Src family of protein kinases, and ERK a member 
of the MAPK family.
1.3.1 G proteins
In the resting state (receptor unoccupied) G proteins exist as a hetero a , p, y trimer, 
with GDP bound to the a  subunit (Rang et al., 1999). When a G protein coupled 
receptor is occupied by an agonist a conformational change occurs causing the 
receptor to acquire high affinity for the a , p, y trimer (Fig. 1.3). Association of the 
a , p, y trimer with the receptor causes the bound GDP to dissociate and be replaced 
with GTP. This in turn causes the dissociation of the a-G TP subunit from the p, y 
dimer. The a-GTP entity is die active form of a G protein. There are four main types 
of G protein, Gs, G„ Gqand G12, which are classified according to the properties of the 
a  subunit (Simon et al., 1991). Gs proteins stimulate the activity of adenylate cyclase 
and therefore promote die production of cAMP, whereas G, proteins inhibit adenylate 
cyclase and thereby prevent cAMP production (Rang et al., 1999). Gq proteins 
activate phospholipase C p (see section 1.3.2.1 for a detailed description), whilst the 
precise intracellular cascades through which G12 proteins signal are unknown (Fields 
and Casey 1997). G protein activity is terminated by the intrinsic GTPase activity of 
the a-subunit, which catalyses the hydrolyses of GTP to GDP.
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Figure 1.3 Mechanism of G protein signalling
In the resting state (receptor unoccupied) G proteins exist as a hetero a, p, y trimer, with GDP 
bound to the a  subunit. When a G protein coupled receptor is occupied by an agonist a 
conformational change occurs causing the receptor to acquire high affinity for the a, p, y 
trimer. Association of the a, p, y trimer with the receptor causes the bound GDP to dissociate 
and be replaced with GTP. This in turn causes the dissociation of the a-G TP subunit from the 
p, y dimer. The a-G TP  entity is the active form of a G protein, which subsequently activates 
downstream effector systems. G protein activity is terminated by the intrinsic GTPase activity 
of the a-subunit, which catalyses the hydrolysis of GTP to GDP resulting in the reformation of 
the a, p, y trimer.
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The differences in G protein structure can be exploited using bacterial toxins and 
therefore these toxins provide ideal experimental tools (Alberts et al., 2002). Cholera 
toxin catalyses the transfer o f ADP ribose to Gsa, which results in the persistent 
activation of Gsa. Conversely, pertussis toxin catalyses ADP ribosylation of G,a, 
which prevents Gt proteins from interacting with receptors, therefore G proteins 
remain in the inactive GDP form unable to initiate down stream signalling (Alberts et 
al., 2002).
13.2 Calcium
Calcium is a crucial intracellular signalling molecule that mediates many aspects of 
cellular function including proliferation, muscle contraction and secretory processes 
(Henzi and MacDermott 1992; Alberts et al., 2002). The endoplasmic reticulum (ER) 
is the main source of intracellular calcium and release can either be induced by 
inositol trisphosphate (IP3) or through calcium-dependent calcium release, which 
involves ryanodine receptors (Imagawa et al., 1987; Henzi and MacDermott 1992; 
Benidge 1993; Alberts et al., 2002). The depletion of calcium stores may also induce 
an influx of calcium across the plasma membrane, a phenomenon known as store 
operated calcium entry (also known as capacitative calcium entry) (Berridge 1993; 
Duta 2000). The purpose of this is believed to be the replenishment of store calcium.
13.2.1 IP3 calcium release pathway
IP3 signalling involves the breakdown of phosphatidylinositol bisphosphate (PIP2), 
which is a phospholipid that is located in the inner half of the plasma membrane lipid 
bilayer (Alberts et al., 2002). Breakdown of PIP2 is mediated by the membrane bound 
enzymes phospholipase C (3 (PLCP) or phospholipase C y (PLCy). PLCP is activated
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by Gq, whereas PLCy comprises Src homology 2 (SH2) domains and is activated by 
receptor tyrosine kinases or non receptor tyrosine kinases which include members of 
the Src family (Berridge 1993; Carpenter and Ji 1999; Kim et al., 2000; Berg et al., 
2002). In addition to activating PLCy, tyrosine kinases often initiate the activation of 
rat sarcoma viral oncogene homologue (RAS) and the subsequent activation of ERK, 
which alters cellular activity through the transcription of specific genes (Berridge 
1993). A third member of the PLC family PLC8 has also been reported, allhough the 
mode of action of this enzyme is currently unknown (Berridge 1993).
PLCp or PLCy cleave PIP2 to generate diacylglycerol (DAG) and IP3, two signalling 
molecules that elicit divergent intracellular signalling cascades (Alberts et al., 2002) 
(Fig. 1.4). DAG induces the phosphorylation of protein kinase C (PKC), which is a 
calcium-dependent enzyme that modulates the expression of various genes. In 
contrast, IP3 is a small water soluble molecule that leaves the plasma membrane and 
diffuses through the cytoplasm, where it releases calcium from the ER by binding to 
IP3 gated calcium release channels. Signalling is terminated by the action of 
phosphatases, which rapidly dephosphorylate IP3 . In addition, calcium is pumped 
back into the ER by sarcoplasmic-endoplasmic reticulum Ca2 ATPases (SERCAs) 
(Alberts et al., 2002; Berg et al., 2002). Calcium signalling is also terminated by the 
action of the high capacity Na+/Ca+ exchanger located in the plasma membrane (Berg 
et al., 2002). IP3 signalling can be studied in vitro using inhibitors of phospholipase C 
such as U73122 (Heemskerk et al., 1997; Pollaud-Cherion et al., 1998; Tokmakov et 
al., 2002).
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Figure 1.4 Mechanism of PLC signalling
PLCp or PLCy cleave PIP2 to generate DAG and IP3. DAG induces the phosphorylation of
PKC, which modulates the expression of various genes. In contrast, IP3 triggers the release
of calcium from the ER by binding to IP3 gated calcium release channels.
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13.3 Extracellular signal regulated kinase
Extracellular signal regulated kinase (ERK) is a member of the mitogen activated 
protein kinase (MAPK) family. ERK mediates a multitude of cellular functions and is 
activated by G protein coupled receptors, receptor tyrosine kinases (Alberts et al.,
2002) and ionotrophic receptors (Perkinton et al., 1999; 2002). An unusual feature of 
ERK is that it requires the phosphorylation of a tyrosine and a threonine residue for 
full activity (Alberts et al., 2002; Daum et al., 1994; Seger and Krebs 1995). ERK 
activation is mediated by a muti-step chain of events. Firstly, the small adaptor 
molecule Grb2 binds to an activated receptor via its SH2 domain (Fig. 1.5). The 
guanine nucleotide exchange factor son of sevenless (SOS) then binds to Grt>2 
forming a complex which leads to the activation of RAS. RAS subsequently activates 
RAS activated kinase (RAF), which in turn activates MEK 1 and 2 (MAPK kinase), 
the kinase responsible for the phosphorylation and activation of ERK (Alberts et al., 
2002; Daum et al., 1994; Seger and Krebs 1995). In mammals two isoforms of ERK 
have been identified, which are known as ERK 1 (p44) and ERK 2 (p42). These 
isoforms share approximately 90 % homology and induce similar cellular functions 
(Seger and Krebs 1995).
Following activation ERK migrates from the cytoplasm to the nucleus where it relays 
downstream signals through the activation of various transcription factors including 
c-Myc, c-Fos, c-Jun. Elk-1 and ATF-2 (Shaywitz and Greenberg 1999; Adams and 
Sweatt 2002). In the nucleus, c-Fos can combine with c-Jun to form the gene 
regulatory protein AP-1 (Alberts et al., 2002). AP-1 in turn induces the transcription 
of a number of other genes whose products mediate cellular responses. Another 
substrate of ERK is ribosomal protein SG kinase of 90 kDa (RSK) (Shaywitz and 
Greenberg 1999; Adams and Sweatt 2002). Upon activation, RSKs, of which there
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are three iso forms (RSK1-3), translocate to the nucleus where they phosphorylate and 
activate the cAMP response element binding protein (CREB), a transcription factor 
that was traditionally associated with cAMP and protein kinase A (PKA) activity. 
ERK also possesses the ability to modulate phospholipase A2 activity and to regulate 
the activity of the potassium ion channel Kv4.2 (Adams and Sweatt 2002).
Figure 1.5 Signalling cascade leading to the activation of ERK
Grb2 binds to an activated receptor via its SH2 domain. SOS then binds to Grb2 forming a 
complex which leads to the activation of RAS. RAS subsequently activates RAF, which in 
turn activates MEK 1/2, the kinase responsible for the activation of ERK 1/2. Following 
activation ERK translocates to the nucleus where it induces the transcription of specific 
genes through the activation of various transcription factors including c-Myc, c-Fos, c-Jun. 
Elk-1 and ATF-2. c-Fos and c-Jun often combine to form the AP-1 complex, which in turn 
mediates the transcription of a subset of genes. RSKs are another substrate of ERK. Upon 
activation RSKs translocate to the nucleus where they mediate the activation of the 
transcription factor CREB.
RAF
1
MEK 1/2
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ERK signalling can be studied in vitro using inhibitors such as U0126 (Favata et al., 
1998) or PD98059 (Alessi et al., 1995). These agents inhibit MEK 1 and 2 thereby 
preventing the downstream activation of ERK. U0126 inhibits the active and inactive 
form of MEK 1 and 2 (Favata et al., 1998), whereas PD98059 only inhibits the 
inactive forms of the kinase (Alessi et al., 1995).
Other members of the MAPK family include p38 and stress activated protein kinases, 
which are also known as Jun N-terminal kinases (JNKs) (Tibbies and Woodett 1999; 
Hagemann and Blank 2001). These kinases modulate gene expression following 
exposure to toxins, physical stress or cytokines (Tibbies and Woodett 1999).
13A  Src kinases
Src kinases belong to the non-receptor tyrosine kinase family of proteins (Alberts et 
al., 2002). These tyrosine kinases function in a similar way to receptor tyrosine 
kinases such as the epidermal growth factor (EGF) receptor except that their kinase 
domain is non-covalently associated with the receptor and is encoded by a separate 
gene. As expected, inactive Src kinases are closely associated with the inner leaflet of 
the plasma membrane and are held in place by protein-protein interactions and by 
covalently attached lipid groups. This sub-cellular location therefore enables Src 
kinases to mediate membrane proximal phosphorylation events (Alberts et al., 2002).
Members of the Src kinase family possess a kinase domain, a SH2 and a SH3 
domain. In the inactive state Src activity is suppressed by C-terminal Src kinase 
(CSK) an intracellular kinase that phosphoiylates a specific tyrosine residue (Tyr 
527) (Pawson 1995). Phosphorylation creates a binding site for the SH2 domain, 
which prevents association with phosphorylated tyrosine residues on activated
50
receptors. Furthermore, the SH3 domain folds in such a way that protein-protein 
interactions are precluded, whilst the kinase domain is locked in an inactive 
conformation (Pawson 1995). Two mechanisms have been proposed for Src 
activation; either dephosphorylation of Tyr 527 destabilises the inactive Src complex 
releasing the SH2 and SH3 domains and activating the kinase domain, alternatively 
high affinity ligands compete for the auto-inhibitory interactions (Pawson 1995).
At present nine members of the Src kinase family have been identified, which include 
Src, Lyn, Yes, Fgr, Fyn, Lck, Hck and Blk (Alberts et al., 2002; Kefalas et al., 1995; 
Superti-Furga 1995). Src, Fyn, Yes, and Yrk are expressed in a broad range of cell 
types, whereas expression of Blk, Fgr, Hck, Lck and Lyn is restricted to specific 
haematopoietic cell lineages (table 1.2). Src kinase family members play a role in 
bone maintenance, learning and memory and in the regulation o f cytoskeletal 
structures involved in exocytosis and phagocytosis (Kefalas et al., 1995; Superti- 
Furga 1995). Signalling via the Src family of kinases can be studied in vitro using the 
inhibitor PP2 (Hanke et al., 1996; Salazar et al., 1999).
Kinase Platelet Monocyte Granulocyte Macrophage T-cell B-cell
Blk + + + +
Fgr + + +
Hck + + +
Lck + +
Lyn + + + +
Table 12  Expression pattern of Src kinases in cells of haematopoietic lineage
Src, Fyn, Yes, and Yrk are widely expressed, whereas expression of Blk, Fgr, Hck, Lck and
Lyn is restricted to cells of haematopoietic lineage.
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1.4 Neurones
As mentioned previously, neurones constitute a vital component of the CNS. The 
CNS comprises hundreds of thousands of neuronal pathways that link together to 
form a complex network and it is inevitably neuronal damage induced by reactive 
microglia or other means, which precipitates the clinical symptoms of stroke, AD and 
other neurological disorders.
1.4.1 In vitro neuronal models
To dissect cellular and molecular neuronal interactions it has been necessary to 
develop models that provide a simplified replica of the in vivo situation. Such models 
include brain slices and cultures of cells isolated from specific regions of the brain. In 
this thesis cerebellar granule neurones were used as a neuronal model. Cerebellar 
granule neurones are a popular preparation for studying neuronal signalling because 
these cells can be easily isolated from the cerebellum. Moreover, cerebellar granule 
neurones constitute the majority of cells in the cerebellum (Anderson et al., 1992; 
Korbo et al., 1993) and develop post-natally (Jacobson 1991). This means that 
preparations can be made from neonatal animals and cultures are granule cell rich. 
Granule neurones are also predominantly glutamatergic (Pearce et al., 1987; Aronica 
et al., 1993; Archibald et al., 1998; Pocock and Nicholls 1998) and glutamate is 
intimately involved in neurodegenerative processes. Thus, cerebellar granule 
neurones provide a robust model for studying the neurotoxic properties of microglial 
conditioned medium on glutamatergic neurones.
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1.4.2 The structure and circuitry of the cerebellum
The cerebellum from the Latin meaning ‘little brain’ is involved in the control of 
balance, eye movements and muscle tone. Furthermore, the cerebellum plays a role in 
the planning and coordination of skilled voluntary movements (Sherwood 1993). The 
cerebellar cortex comprises three distinct layers, the molecular cell layer, the Purkinje 
cell layer and die granule cell layer (Fig. 1.6) (Kieman 1998). The molecular cell 
layer contains basket cell intemeurones, but is largely a synaptic zone containing 
branching Purkinje cell dendrites and axons of the granule cells. The Purkinje cell 
layer consists of a single row of cell bodies, while die granule cell layer consists of 
closely packed granule and Golgi cell intemeurones. The mossy fibers are the main 
operational input into the cerebellum, carrying afferent information from the 
periphery and other brain centres (Kieman 1998).
Mossy fibers form excitatory glutamatergic synapses with granule cells in the granule 
layer. Climbing fibers provide another afferent input into the cerebellum; these fibers 
originate exclusively from the brain stem. Climbing fibers form excitatory 
glutamatergic synapses with up to ten Purkinje cells. Purkinje cells process the 
excitatory inputs received from the climbing fibers and granule cells and the 
inhibitory inputs received from the basket cells. Subsequently, Purkinje cells relay 
these neuronal signals to die deep cerebellar nuclei. Since Purkinje cells are 
GAB Aergic, basket cell input effectively excites die deep nuclei through disinhibition 
(Bastain et al., 1999).
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Figure 1.6 Layers of the cerebellar cortex
The cerebellar cortex comprises three distinct layers, namely the molecular cell layer, the 
Purkinje cell layer and the granule cell layer. The molecular cell layer contains basket cell 
intemeurones, but is largely a synaptic zone containing Purkinje cell dendrites and axons of 
the granule cells. The Purkinje cell layer consists of a single row of cell bodies, while the 
granule cell layer consists of closely packed granule and Golgi cell interneurones. The mossy 
fibers are the main operational input into the cerebellum. Climbing fibers form another 
excitatory glutamatergic input. Excitatory glutamatergic synaptic connections and inhibitory 
GABAergic connections are depicted by (+) and (-) respectively (adapted from Kieman 1998).
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1.5 Ischaemia
Ischaemia describes the reduced supply of oxygen (hypoxia) and glucose 
(hypoglycaemia) for ATP synthesis and the diminished removal of lactic acid. The 
main cause of cerebral ischaemia is stroke, which results in irreversible brain injury 
(an infarction). Stroke is the third most common cause of death in 1he developed 
world after cancer and heart attack, with an incidence of 1 in 40 and a mortality rate 
of approximately 30 % (Marsden and Fowler 1998). The consequences of a stroke 
depend on which part of the brain is damaged and the extent of the damage, although 
stroke patients often present with weakness or paralysis down one side of the body, 
speech impediments or disturbed vision.
1.5.1 Stroke
There are two main types of stroke termed intracerebral haemorrhagic stroke and 
ischaemic stroke, the latter is subdivided into focal and global ischaemia (Sharp et al.,
1998). Intracerebral haemorrhagic stroke occurs when a cerebral blood vessel bursts. 
Focal ischaemia results when an artery that supplies blood to the brain becomes 
blocked. Focal ischaemia is characterised by an irreversibly damaged core surrounded 
by an area known as the penumbra exhibiting constricted blood flow and partially 
preserved energy metabolism. Over time and in die absence of treatment the 
penumbra becomes irreversibly damaged due to ongoing cytotoxic processes (Sharp 
et al., 1998). Transient ischaemic attacks (TIA) or ‘mini strokes’ are another form of 
focal ischaemia (Marsden and Fowler 1998). TIAs are caused by a brief interruption 
of the brain’s blood supply. The symptoms o f a TLA last under 24 hours and patients 
generally make a full recovery, however TIAs often precede a full blown stroke, 
therefore patients require urgent medical attention. Global ischaemia describes
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complete ischaemia to the entire brain, which can be caused by cardiac arrest or 
severe hypotension (Sharp et al., 1998).
1.5.2 Risk factors for stroke
Hypertension is the principal risk factor for stroke and intracerebral haemorrhage. 
Other risk factors include cigarette smoking, obesity, atrial fibrillation and 
atherosclerosis (Marsden and Fowler 1998; Wolf and D’agostino 1998). Atrial 
fibrillation is a disorder in which die atria do not contract efficiently; therefore there 
is an increased tendency for blood to pool and clot in the heart (Guyton and Hall 
1996). Atherosclerosis is a progressive arterial disease that can lead to occlusion of 
affected vessels (Sherwood 1993). Atherosclerosis develops from atheromas, which 
are benign tumours of smooth muscle cells located in blood vessel walls. These cells 
migrate from the muscular layer to a position just beneath die endothelial lining, 
where they continue to divide and enlarge. Cholesterol and other lipids accumulate in 
the abnormal smooth muscle cells to produce a plaque that protrudes into the blood 
vessel lumen (Sherwood 1993). Blood bome macrophages subsequently infiltrate 
atherosclerotic lesions where they accumulate massive amounts of lipid and thereby 
contribute to plaque volume (Krieger 1992). Thus, hypercholesterolemia also 
increases the risk of stroke, furthermore diabetics are known to have an increased 
susceptibility to atherosclerosis and therefore stroke (Wolf and D’Agostino 1998). As 
atherosclerotic plaques enlarge, they often break through the weakened endothelial 
barrier, thereby exposing blood to the underlying collagen (Sherwood 1993). This 
process triggers platelets to initiate the clotting cascade, which subsequently leads to 
the production of a thrombus. The thrombus may enlarge until it completely blocks 
the blood vessel (Sherwood 1993). Alternatively, the thrombus may break away from 
its site of attachment to form a free floating clot known as an embolus. Emboli travel
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through the circulation until they lodge in small blood vessels resulting in an 
ischaemic episode (Sherwood 1993).
1.5.3 Brain metabolism and the primary effects of ischaemia
The brain comprises 2 % of total body mass and yet accounts for 15 % of total body 
metabolism (Guyton and Hall 1996), therefore the brain exhibits a high requirement 
for metabolic substrates. Glucose is the energy substrate of preference for most 
organs including the brain, however if necessary fructose, galactose, fatty acids or 
amino acids can be oxidised to produced ATP (Sherwood 1993; Guyton and Hall 
1996). The energy produced from cerebral respiration is consumed to maintain 
neuronal and glial integrity. This includes the preservation of ionic gradients, axonal 
transport and biosynthesis, whilst the remaining energy is used for electrochemical 
activity (Guyton and Hall 1996).
Most tissues of the body can go without oxygen for several minutes, during which 
cells obtain energy from the anaerobic metabolism of glucose and glycogen (Guyton 
and Hall 1996). However, the brain is not capable of sustaining anaerobic metabolism 
since neurones exhibit a high metabolic rate; in addition glycogen and fat stores in the 
brain are slight. Thus, a cessation in cerebral blood flow causes unconsciousness 
within 5-10 seconds and ischaemic injury (Guyton and Hall 1996). Ischaemic injury 
is a consequence of disrupted of ionic gradients, the accumulation of glutamate in the 
extracellular space, excitotoxicity and acidosis (Fig. 1.7).
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Figure 1.7 Overview of signalling pathways triggered by ischaemia
Ischaemia triggers energy depletion and the disruption of ionic gradients, which results in cell 
membrane depolarisation. Depolarisation subsequently triggers cell swelling and lysis, 
glutamate release and a rise in intracellular calcium. Signalling downstream of calcium 
includes the activation of proteases, endonucleases, lipases and phospholipases. Other 
pathogenic cascades triggered by excess calcium include the generation of free radicals and 
mitochondrial dysfunction. The accumulation of lactic acid, a by-product of anaerobic 
metabolism, also contributes to intracellular calcium overload in ischaemia.
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1.5.4 Ionic gradients and ischaemia
Ionic gradients across cell membranes are required for the conduction of action 
potentials, the regulation of cell volume and the transport of nutrients and metabolites 
(Sherwood 1993). Ionic gradients are maintained by the sodium-potassium ATPase. 
The ATPase operates as an anti-porter, actively pumping sodium (Na4) out of the cell 
against a steep electrochemical gradient, whilst potassium (K ) is pumped in (Alberts 
2002). For every molecule of ATP hydrolysed, three Na+ are pumped out and two K+ 
are pumped in. Consequently, the concentration of K+ is typically 10-20 times higher 
inside the cell than ouside (internal [K+] -1 6 0  mM, external [K+] -  8 mM), whereas 
the converse is true for Na+ (internal [Na+] -1 8  mM, external [K+] -1 3 5  mM).
Approximately 30 % of a cell’s energy requirement is used to fuel the Na+-K+ 
ATPase (Alberts et al., 2002). Thus, in ischaemia the lack of ATP prevents the Na+- 
K+ ATPase from operating and Na+ / K+ balance is disrupted across cell membranes. 
Consequently, neurones and glia depolarise, creating a large osmotic gradient and 
water enters the cell (the influx of Na+ and Cl' is much greater than the efflux of K+) 
(Dimagl et al., 1999). The ensuing oedema inhibits perfusion of the surrounding 
tissue thereby contributing to neuronal injury {Dimagl et al., 1999). Furthermore, 
depolarisation triggers voltage dependent calcium channels (VDCC) to open, which 
in turn evokes the release o f glutamate and other neurotransmitters into the 
extracellular space (Dimagl et al., 1999). Depolarisation also induces the reversed 
operation of neuronal and glial glutamate uptake carriers, which augments the 
accumulation of extracellular glutamate (Szatkowski and Atwell 1994; Takahashi et 
al, 1997; Katsumori et al., 1999; Rossi et al., 2000). In addition, spreading depression 
exacerbates glutamate release (Willis and Grossman 1981; Sharp et al., 1998). 
Spreading depression is a slow moving wave of glial and neuronal depolarisation,
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which is associated with a massive efflux of potassium and glutamate into the 
extracellular space. Waves of spreading depression pass through the ischaemic 
penumbra travelling at a rate of 2-5 mm/min (Willis and Grossman 1981).
1.5.5 Excitotoxicity and ischaemia
Excitatory neurotransmission is a normal physiological process mediated by the 
neurotransmitter glutamate (Choi 1988, 1992; Rang et al., 1999). However, in excess 
glutamate is destructive and literally ‘excites’ neurones to death by a process known 
as excitotoxicity (Choi 1988,1992; Rang et al., 1999). Glutamate mediates its actions 
through three types of receptor designated N-methy-D-aspartate (NMDA), 2-amino- 
3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and metabotropic glutamate 
receptors (mGluRs) (Rang et al., 1999). AMPA receptors are often subdivided into 
two pharmacological subtypes termed AMPA and kainate receptors (KA). The 
functions of AMPA and kainate receptors appear to be similar but their distribution in 
the brain is different (Rang et al., 1999).
The excitotoxic actions of glutamate are predominantly mediated by NMDA 
receptors (Choi 1988, 1992; Feldman et al., 1997; Rang et al., 1999). Under 
physiological conditions NMDA receptors are involved in long-term potentiation 
(LTP) and long-term depression (LTD), phenomena that are mediated by calcium 
influx (Rang et al., 1999). In ischaemia the chronic activation of NMDA receptors 
facilitates the entry of neurotoxic levels of calcium into cells, which subsequently 
leads to excitotoxicity (Choi 1988, 1992; Rang et al., 1999; Lynch and Guttmann
2001). Normally, NMDA receptors are blocked by magnesium, however this block is 
voltage dependent and is relieved by membrane depolarisation (Rang et al., 1999), 
which is a characteristic feature of ischaemia (Dimagl et al., 1999). The activation of
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AMPA/KA and mGluRs also contribute to intracellular calcium overload in 
ischaemia. AMPA/KA receptors are normally involved in fast synaptic 
neurotransmission, which is mediated by sodium entiy into post-synaptic neurones 
(Rang et al., 1999). Therefore, during ischaemia the persistent influx of sodium 
through these receptors triggers the sustained opening of VDCC (Sharp et al., 1998). 
Some KA/AMPA receptors also flux calcium (Hoilmann et al., 1991); moreover 
ischaemia can trigger the upregulation of KA/AMPA receptor subunits that 
specifically gate calcium (Pellegrini-Giampietro et al., 1992). AMPA and NMDA 
receptor function is modulated by mGluRs (Rang et al., 1999). Activation of mGluRs 
triggers the release of calcium from intracellular stores via an IP3 dependent 
mechanism (Rang et al., 1999). Thus, mGluRs probably contribute to calcium 
toxicity in ischaemia as well. Other excitatory neurotransmitters such as acetylcholine 
and dopamine induce the influx of calcium into neurones, therefore augmenting 
glutamate-dependent cellular injury during ischaemia (Sharp et al., 1998).
Calcium overload in ischaemia activates lipases, endonucleases, proteases and 
phospholipases, which catalyse the breakdown of lipids, DNA, proteins and 
phospholipids respectively (Feldman et al., 1997; Sharp et al., 1998). A key 
consequence of phospholipase activation is the liberation of arachidonic acid (Sharp 
et al., 1998). Arachidonic acid damages the BBB (Kontos et al., 1980), inhibits 
glutamate uptake by glia (Yu et al., 1987) and provides the starting material for the 
production of prostaglandins and leukotrienes (Rang et al., 1999), factors that are 
involved in inflammatory processes. Other pathogenic cascades triggered by calcium 
overload include the generation o f free radicals and the synthesis of NO (Feldman et 
al., 1997; Sharp et al., 1998). Furthermore, the synthesis of ATP is curtailed as a 
consequence of calcium sequestration by mitochondria (Budd and Nicholls 1996).
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1.5.6 Lactic acidosis and ischaemia
During ischaemia the absence of an adequate energy source leads to the anaerobic 
metabolism of glucose, which results in the accumulation of lactic acid (Berg et al.,
2002). Lactic acid is a strong organic acid and therefore dissociates into lactate and a 
hydrogen ion (H*) at physiological pH. The presence of excess fT  in tissues 
subsequently causes acidosis. Lactic acidosis in ischaemia triggers a rise in 
intracellular Ca2+ by inhibiting efflux by ATP driven transport and passive Na+/Ca2+ 
exchange (Cafe et al., 1993). Therefore, lactic acidosis contributes to intracellular 
calcium overload. Acidosis also augments free radial reactions in ischaemia (Cafe et 
al., 1993). The detrimental role of acidosis in ischaemia is supported by the finding 
that pre-ischaemic hyperglycaemia potentiates post-ischaemic damage, which has 
been attributed to the intensification of lactic acidosis (Schurr 2002). Consequently, 
clinicians monitor and control blood glucose levels in patients undergoing 
cardiopulmonary bypass surgery or neurological procedures (Schurr 2002).
1.5.7 Cell death in ischaemia
Excitotoxicity and ischaemia per se induce plasma membrane failure and cell 
swelling; therefore cells are most likely to undergo necrosis in ischaemia. However, 
studies have identified molecular signatures of apoptosis in the ischaemic brain, 
including the translocation of cytochrome c from the mitochondria to the cytosol 
(Schulz et al., 1999), the activation of caspase 3 (Namura et al., 1998; Ni et al., 1998) 
and DNA fragmentation (Heron et al., 1993; Ni et al., 1998). Moreover, caspase 
inhibitors reduce infarct size following ischaemia (Hara et al., 1997; Endres et al., 
1998). Therefore, it is likely that both necrotic and apoptotic cascades are elicited in 
ischaemia and some cells may even undergo a ‘mixed’ form of death (Barinaga et al.,
1998).
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1.5.8 Role of microglia in ischaemia
Microglia are found in abundance in the ischaemic penumbra (Morioka et al., 1993; 
Rupalla et al., 1998). Reactive microglia are detectable 20 minutes after reperfusion 
whilst the strongest microglial reaction is apparent 4-6 days post insult but can persist 
for up to 4 weeks (Morioka et al., 1991). In vivo studies have shown that ischaemia 
triggers microglia to retract their long processes and upregulate the expression of 
CR3, ED-1 and MHC class I and II antigens (Kato et al., 1995, 1996). It is generally 
believed that microglia exacerbate ischaemic injury through the release of neurotoxic 
inflammatory mediators such as TNFa (Barone et al., 1997; Park et al., 2002), IL 
(Rothwell et al., 1997), NO (Park et al., 2002; Suzuki et al., 2002; Zhu et al., 2002a) 
and superoxide (Spranger et al., 1998). Accordingly, microglial activation precedes 
neuronal death in ischaemic lesions (Lees 1993; Rupalla et al., 1998) and neuronal 
death is reduced by inhibiting microglial activation (Tikka et al., 2001). Furthermore, 
hypothermia, which affords neuroprotection in ischaemia, appears to work by 
inhibiting microglial activation (Kumar and Evans 1997). Collectively, these findings 
suggest that microglia play an intrinsic role in ischaemic damage. However, an 
alternative hypothesis supposes that reactive microglia play a protective role in 
ischaemia through the phagocytosis of neuronal debris (Gehrmann et al., 1995) and 
the secretion of growth factors (Gehrmann et al., 1995; Watanabe et al., 2000).
Waves of spreading depression provide a secondary stimulus for microglial activation 
in the penumbra; inasmuch as potassium triggers microglial proliferation (Schlichter 
et al., 1996) whilst glutamate induces activation (Tikka et al., 2001). Paradoxically, 
activated microglia secrete prodigious quantities of glutamate (Piana and Fontana 
1994; Kingham et al., 1999 Barger and Basile 2001), therefore activated microglia 
may actually augment excitotoxic injury by contributing to the extracellular pool of
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glutamate (Lees 1993). ATP originating from injured cells may also contribute to 
microglial activation in the penumbra (Chow et al., 1997; Hide et al., 2000; Moller et 
al., 2000; Shigemoto-Mogami et al., 2001). Moreover, ATP induces microglial 
chemotaxis, which may underlie the accumulation of microglia in damaged brain 
regions (Honda et al., 2001). Additionally, exposure to blood bome elements such as 
albumin (Si et al., 1997), thrombin (Moller et al., 2000a; Ryu et al., 2000) or 
complement fragments (Nolte et al., 1996; Moller et al., 1997) may initiate microglial 
activation if the BBB is damaged (Kato and Walz 2000) and this is one aspect of 
ischaemia that was explored in this thesis. Studies have shown that the BBB is 
disrupted in approximately 50 % of stroke patients and damage is most pronounced in 
the first two weeks of illness (Homig et al., 1983).
In addition to activating microglia, focal ischaemia triggers circulating blood 
monocytes and neutrophils to enter the brain (Perry et al., 1997). In fact, it has been 
proposed that microglia co-ordinate the recruitment of circulating leucocytes through 
the secretion of cytokines (Kato and Walz 2000). Neutrophils are the first invading 
cells to be recruited to the lesion (Kato and Walz 2000). Monocytes follow suit and 
become the predominant cell type five to seven days after ischaemia (Kato and Walz 
2000). The recruitment of circulating leucocytes is achieved through the expression 
of adhesion molecules on the cerebral endothelium including intercellular adhesion 
molecule 1 (ICAM-1) and P and E selectin (Sharp et al., 1998; Kato and Walz 2000). 
Upon entry into the brain, neutrophils and monocytes are guided towards the infarct 
by chemotactic cytokines, examples of which include interleukin 8 (Mukaida et al.,
1998) and monocyte chemo-attractant protein 1 (MCP-1) (Wang et al., 1995). Thus, it 
is conceivable that inflammatory mediators released from monocytes and neutrophils 
augment the endogenous microglial reaction apparent in ischaemia
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1.6 Alzheimer’s disease
1 .6 .1  Types of dementia
Dementia is a generic term that describes chronic or progressive dysfunction of 
cortical or subcortical structures resulting in complex cognitive decline (Ritchie and 
Lovestone 2002). Dementia can be sub-classified into Alzheimer’s disease (AD), 
frontotemporal dementia (Pick’s disease), dementia with Lewy bodies, vascular 
dementia or dementia secondary to another disease process such as auto-immuno- 
deficiency-syndrome (AIDS) (Ritchie and Lovestone 2002). Moreover, patients often 
present with mixed state dementia, which is caused by a combination of different 
types of dementia.
1 .6 .2  Characteristics of Alzheimer’s disease
AD is a progressive neurodegenerative disorder affecting 5-10 % of the elderly 
population (Ladner and Lee 1998). Alzheimer’s patients suffer memory loss, 
disorientation, confusion, impaired concentration and a decline in cognitive function. 
Postmortem examination of Alzheimer’s brain tissue demonstrates a marked atrophy 
of the cortical gyri, particularly in the frontal and temporal lobes of the cortex. 
Neuronal loss is also apparent in the amygdala, the hippocampus, the locus coeruleus, 
the raphe nucleus and the nucleus basalis of Meynert (Strange 1992). Thus, many 
neurotransmitter systems are involved in neuropathology and thereby the clinical 
presentation of the disease. The defining hallmarks of AD include senile plaques and 
neurofibrillary tangles (NFTs), which were first described by Alois Alzheimer in 
1907 (see review by Selkoe 1994). These histopathological structures are 
concentrated predominantly in the hippocampus and the cortex of afflicted 
individuals (Crowther 1990).
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NFTs comprise paired helical filaments (PHF) of an abnormal form of tau, an axonal 
microtubule associated protein (MAP) (Iqbal et al., 1994). Normally, tau is involved 
in tubulin polymerization and microtubule stabilization and is phosphorylated at two 
to three sites (Goedart 1993). However, in AD tau becomes phosphorylated at six to 
eight sites. Consequently, tau dissociates from microtubules and aggregates into 
PHFs forming NFTs. The reduced binding of phospho-tau to microtubules results in 
the impairment of vital cellular processes such as axonal transport (Brion 1992; Berg 
et al., 2002), which ultimately culminates in the degeneration of affected neurones. 
Thus, masses of NFTs are often observed extraneuronally presumably as a residue of 
dead neurones (Brion 1992).
Senile plaques mainly consist of extracellular deposits of Ap, a peptide produced 
from the proteolytic cleavage of p-amyloid precursor protein (APP). In AD several 
types of senile plaque are apparent including neuritic, diffuse and burned out plaques 
(Delaere et al., 1991; Feldman et al., 1997). Neuritic plaques possess dense 
extracellular deposits of Ap surrounded by dystrophic and degenerating neurites, 
reactive astrocytes and microglia. Diffuse plaques represent the early stages of plaque 
formation and contain Ap but no degenerating neurites. In contrast, burned out 
plaques possess a dense core of Ap but no degenerating neurites and are regarded as 
the final stages of plaque formation. Presumably, after the dystrophic neurites 
degenerate, their remains are phagocytosed by plaque associated microglia (Vehmas 
et al., 2003).
66
1.6.3 APP and its cleavage to yield Ap
APP is derived from a single gene, from which alternative splicing gives rise to a 
family of proteins containing either 695, 751, or 770 amino acids (Schellenberg 
1995). Following RNA splicing, APP is inserted into the cell membrane so that there 
is a single transmembrane domain containing part of the Ap peptide (Kang et al., 
1987). The remainder of the protein is arranged such that there is a short cytoplasmic 
segment and an extensive extracellular region (Kang et al., 1987). The structure of 
APP suggests that this protein may function as a receptor or a growth factor 
(Rossjohn et al., 1999). Mutations in the APP gene are responsible for a very small 
proportion of AD cases, therefore attention has turned to the abnormal processing of 
APP as a contributory factor to the pathogenesis of AD.
APP is subject to proteolytic processing at three sites by the action of a , p and 
y secretase (Checler 1995). Cleavage by a  secretase releases an extracellular region 
of APP (APPsa), which exhibits neurotrophic and neuroprotective properties 
(Coughlan and Breen 2000). APPsa also plays a role in neuronal cell differentiation 
and neurite outgrowth (Coughlan and Breen 2000). In contrast, the joint action of p 
and y secretase releases the harmful Ap peptide (Fig. 1.8) (Checler 1995). Thus, the 
generation of APPsa and Ap are mutually exclusive. Therefore, an increase in Ap 
production parallels a decrease in the production of neuroprotective APPsa, which 
may render cells more susceptible to the actions of neurotoxins and indeed Ap itself 
(Coughlan and Breen 2000). Intense efforts have been directed towards the 
identification of a , p, and y secretase. Consequently, ADAM 10 (Lammich et al.,
1999) and TACE (Bauxbaum et al., 1998b) have been reported to mediate a-cleavage 
of APP. The aspartyl protease BACE has been demonstrated to mediate p cleavage
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(Vasser et al., 2001), whilst a multi-protein complex consisting of presenilin-1 (Wolfe 
et al., 1999), nicastrin (Li et al., 2003), Aph-1 and Pen-2 (Taylor-Kimberly et al.,
2003) is thought to be involved in y cleavage (De Strooper 2003). An intriguing 
property of y secretase is that it performs proteolysis in the middle of a 
transmembrane domain.
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Figure 1.8 Sites of APP processing
APP (depicted by blue bar) is subject to proteolytic processing at three sites by a, p and y 
secretase. Cleavage by a  secretase releases the majority of the extracellular segment of 
APP (APPsa), which is neuroprotective. In contrast, the joint action of p and y secretase 
releases the harmful Ap peptide (depicted by yellow bar). (N, N-terminus; C, C-terminus).
Cleavage by p and y secretase is not highly precise, hence Ap varies between 39-42 
amino acids in length. After cleavage Ap exhibits a random coil conformation, 
however the protein gradually adopts an insoluble p-sheet structure, which is 
deposited in the form of senile plaques (Soto 1999). In vitro studies have
y secretase
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demonstrated that the 42 mer aggregates more readily than the shorter species of Ap 
and is therefore the most pathogenic cleavage product (Suzuki et al., 1994). Another 
fragment frequently used in experimental paradigms is Ap(25-35x which is the 
biologically active fragment of the full length species of Ap. At physiological pH 
Ap(25-35> readily aggregates into a p-sheet conformation and therefore does not 
require ‘aging’ before use (Pike et al., 1993; Terzi et al., 1994a,b). Ap(25-35) was the 
form of Ap used in this study.
1.6.4 Theories of increased Ap production
It is thought that Ap is involved in normal physiological processes because Ap shares 
sequence homology with the tachykinin family of neuropeptides (Yanker et al., 
1990). Furthermore, low concentrations of Ap exert a neurotrophic effect on 
undifferentiated hippocampal neurones (Whitson et al., 1990). Thus, plaque 
formation in AD and subsequent neuropathological events may be related to increases 
in the activities of p and y secretase. Alternatively, the formation of plaques may be 
due to decreased clearance of Ap from the CSF (Feldman et al., 1997).
1.6.5 Genetics of Alzheimer’s disease
AD is a genetically heterogeneous disorder, a conclusion that is not surprising given 
the prevalence of the disorder. Population survey studies have demonstrated that 25 -  
40 % of AD cases have a genetic link and in most circumstances the disease is 
inherited as an autosomal dominant trait (van Broeckhoven 1995).
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1.6.5.1 Early onset Familial Alzheimer’s disease
Early onset forms of Familial Alzheimer’s disease (FAD) typically present before the 
age of 65 and have been linked to mutations in APP, presenilin-1 (PS-1) and 
presenilin-2 (PS-2). All three mutations adversely affect APP processing and result in 
the production of insoluble AP, which is deposited in the form o f senile plaques.
1.6.5.2 APP gene mutations
Early in the search for genes involved in the pathogenesis of AD, researchers 
discovered that patients suffering from Down Syndrome (DS) exhibited senile 
plaques and NFTs (Wisniewski et al., 1985). Moreover, as the life span of DS 
patients has increased due to improvements in treatment and care, many patients now 
develop dementia before the age of forty (Kolata 1985; Hardy and Higgins 1992). 
Aged DS sufferers regress from a person with limited intelligence to a person who is 
disoriented, unable to comprehend or speak, all of which are symptoms associated 
with AD. The cause of DS is non-disjunction of chromosome 21, which results in the 
inheritance of three copies of this chromosome instead of the normal pair (Alberts et 
al., 2002). These findings were the first to suggest that a gene on chromosome 21 
might be responsible for the onset of some cases of AD.
Important progress in the genetics of AD occurred with the cloning and mapping of 
APP to a site on chromosome 21 (Robakis et al., 1987; St George-Hyslop et al., 1987; 
Tanzi et al., 1987). Subsequently, several kindreds have been identified which 
express APP mutations. Families have been identified in which the valine at position 
717 is mutated to isoleucine, phenylalanine or glycine (London mutation) (Goate et 
al., 1991; Hardy and Higgins 1992). This mutation is situated three amino acid 
residues away from amino acid 43 of the Ap peptide. Cells transfected with APP
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containing either isoleucine or phenylalanine at this position, do not secrete abnormal 
quantities of Ap, but secrete an increased ratio o f the highly pathogenic 1-42 species 
(Suzuki et al., 1994). Two Swedish kindreds have also been identified whom exhibit 
a double mutation in the APP gene (Mullan et al., 1992). In this family the lysine at 
position 670 and the adjacent methionine at position 671 are mutated to aspartate and 
leucine respectively. These amino acids are located at the putative a  secretase site, at 
the beginning of the Ap sequence. Cells transfected with an APP gene bearing this 
double mutation secrete significantly more Ap than cells transfected with wild type 
APP, which probably serves to fuel plaque formation (Citron et al., 1992).
1.6.53 Presenilin gene mutations
The second gene identified to contribute to the pathogenesis of AD is located on 
chromosome 14 and is known as presenilin-1 (PS-1; S182) (Sherrington 1995; 
Wisnieski et al., 1995). Already 15 different mutations associated with AD have been 
mapped to this gene. The precise functions of PS-1 remain unknown, however PS-1 
mutations increase the production of the long form of Ap (1-42) (Murayama et al.,
1999). Moreover, PS-1 exhibits proteolytic activity and is thought to be a prime 
component of the y secretase complex (Wolfe et al., 1999; De Strooper 2003). 
Increased levels of PS-1 are detectable in the senile plaques in AD, Hereditary 
Cerebral Haemorrhage with Amyloidosis, Dutch type (HCHWA-D) and DS, which 
suggests that PS-1 plays a common role in these related disorders (Wisniewski et al., 
1995). Initial studies of the PS-1 gene suggested the existence of other genes with 
similar sequences. This led to the identification of a novel gene, which was termed 
presenilin-2 (PS-2; E5-1) (Rogaev et al., 1995). Mutations in the PS-2 gene are 
associated with four early onset FAD cases belonging to an extended pedigree of
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Italian origin and three pedigrees with (Volga) German ancestry. Thus, PS-1 and PS- 
2 may be members of a large family of proteins involved in the pathogenesis of AD.
1 .6.5.4 Late onset Familial Alzheimer’s disease
Late onset FAD typically presents after the age of 65 and is influenced by variation in 
a fourth gene encoding ApoE (Wisniewski 1992). Normally, ApoE is involved in the 
maintenance of lipoprotein structure and the regulation of lipoprotein metabolism 
(Gurr 1993; Guyton and Hall 1996). Most organs produce ApoE, the largest pool of 
ApoE mRNA is found in the liver whilst the second largest amount is associated with 
the brain. In the brain ApoE is mainly secreted by astrocytes (Boyles et al., 1985; 
Pitas et al., 1987).
There are three major alleles of the ApoE gene, designated ApoE4, ApoE3 and 
ApoE2 (Feldman et al., 1997). Expression of ApoE4 enhances the likelihood of 
developing AD (Corder et al., 1993). Research demonstrates that ApoE4 binds Ap 
and promotes its deposition into senile plaques (Wisniewski et al., 1992). Conversely, 
ApoE3 and E2 have been postulated to exert a protective effect against the 
development of AD (Strittmatter et al., 1994). These isoforms possess the ability to 
bind tau and prevent aberrant phosphorylation. Consequently, ApoE2 and E3 impede 
the generation of PHF and the formation of NFTs (Strittmatter et al., 1994). Thus, 
over a lifetime, the expression of the ApoE4 may significantly increase the incidence 
of AD, thereby giving rise to late onset AD in genetically predisposed individuals.
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1.6.6 Theories of Alzheimer’s disease pathogenesis
There is no question that AD pathology is characterised by the presence of senile 
plaques, NFTs and neuronal loss, however the precise sequence of events underlying 
pathogenesis remains unknown. Probably the most influential theory to date has been 
the amyloid cascade hypothesis (Hardy and Allsop 1991; Hardy 1992). According to 
this theory APP synthesis and or processing become abnormal due to a combination 
of genetic and environmental factors, which results in the formation of senile plaques. 
The presence of plaques subsequently exerts a deleterious effect on neuronal survival, 
leading to the development o f PHFs and NFTs. Thus, over time, the gradual 
accumulation of these histopathological features is believed to cause neuronal death 
and neurotransmitter deficits ultimately culminating in dementia.
The amyloid cascade hypothesis still dominates the field of Alzheimer research. 
However, the hypothesis has been criticised on the grounds that diffuse amyloid 
deposits are present in non-demented elderly individuals (Braak and Braak 1991; 
Delaere et al., 1991). In addition, some AD patients exhibit NFTs but no amyloid 
deposits (Braak and Braak 1991). In light of this, the existence of senile plaques 
cannot be considered as an absolute pre-requisite for the formation of NFTs. An 
alternative hypothesis supposes that ihe formation of plaques and tangles is a 
consequence of neurodegeneration. Recent evidence demonstrates that neuronal loss 
in AD is caused by the aberrant re-entry of neurones into the cell cycle (Nagy 2000). 
Since neurones are terminally differentiated, cell cycle re-entiy results in the failure 
of regulatory mechanisms. Thus, some neurones undergo apoptotic cell death, 
whereas in apoptotic incompetent neurones, the active kinases cause Ap formation 
and the aberrant phosphorylation of tau.
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1.6.7 Cell death in Alzheimer’s disease
The exact cause of neuronal death in AD is unknown, but there is mounting evidence 
that suggests apoptosis plays a key role. Cultured neurones treated with Ap exhibit 
morphological and biochemical characteristics of apoptosis, including membrane 
blebbing, compaction of nuclear chromatin and DNA fragmentation (Loo et aly 
1993). Presenilin 1 and 2 mutations promote neuronal apoptosis through the 
disruption of intracellular calcium homeostasis (Bauxbaum et al., 1998a; Tanzi 
1998). Similarly, administration of anti-APP antibody (Rohn et al., 2000) and over 
expression of wild type APP trigger apoptotic neuronal death (Uetsuki et al., 1999).
Many caspases have been implicated in Ap mediated neurodegeneration. Ap has been 
shown to induce an ER specific apoptotic pathway involving caspase 12. Caspase 12 
resides in the ER and is activated by ER stress, including perturbation of calcium 
homeostasis (Nakagawa et al., 2000). Caspase 2 has also been implicated in Ap 
mediated neuronal death. Accordingly, down regulation of caspase 2 with anti-sense 
oligonucleotides prevents Ap mediated cell death and neurones from caspase 2 null 
mice are resistant to Ap (Troy et al., 2000). Other reports have shown that Ap cross 
links Fas, a member of the TNF receptor family, which causes the recruitment of FAS 
associated death domain protein (FADD) and the subsequent activation of caspase 8 
(Irvins et al., 1999). Moreover, a novel cytotoxic APP fragment is generated by the 
action of caspase 8 and the resultant fragment called C31 is a potent inducer of 
apoptosis (Lu et al., 2000). Oxidative stress (Soledad et al., 2000) and excitotoxicity 
(Migual-Hidelgo et al., 2002) are other pathogenic mechanisms that have been 
implicated in Ap mediated neurodegeneration. Both oxidative stress and 
excitotoxicity can initiate apoptosis. Oxidative stress causes mitochondrial damage,
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which leads to apoptosis, whilst excitotoxicity is associated with intracellular calcium 
overload and the subsequent activation of caspases (Honig and Rosenberg 2000). 
Thus, apoptosis may elicit the final steps in neuronal death following oxidative stress 
or excitotoxic insults. This provides a unifying theory that takes into consideration 
the existence of other pathogenic mechanisms evident in AD.
1 .6 .8  The role of microglia in Alzheimer’s disease
Immunoglobulins and T cells are not detectable in AD brain, which indicates that 
humoral or classical cell mediated immunity are not involved in AD pathology 
(Eikelenboom et al., 2002). Furthermore, adhesion molecules are not upregulated on 
the endothelial cells that constitute the BBB implying that peripheral leucocytes are 
not recruited into the CNS as occurs in stroke (Eikelenboom et al., 2002). However, 
the presence of activated microglia in and around senile plaques suggests that some 
form of inflammatory reaction does occur in AD (Itagaki et al., 1989; Haga et al., 
1989; Le et al., 2001; Vehmas et al., 2003). Indeed microglial activation may 
represent a specialised CNS response to injury or foreign bodies, inasmuch as 
microglial activation is a graded response with the extent of activation depending on 
the severity of the insult. Thus, in the CNS the benefits of inflammation appear to be 
carefully balanced with the deleterious effects of such a reaction on neuronal survival. 
The primary role of activated microglia in AD has been the focus of much debate and 
has led to the development of two contrasting hypotheses. The first theory supposes 
that microglia play a beneficial role in AD. Accordingly, activated microglia secrete 
TGFp, a cytokine that exhibits anti-inflammatory and neurotrophic properties (Justica 
et al., 2001). Moreover, microglia have been shown to phagocytose degenerating 
neurites (Vehmas et al., 2003) and amyloid deposits (Shaffer et al., 1995; Paresce et 
al., 1996; Paresce et al., 1997; Kopec and Carroll 1998); processes which may serve
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to slow the progression of AD. Ap has also recently been demonstrated to exhibit 
chemotactic properties (Yan et al., 1996; Nakai et al., 1998; Le et al., 2001; Tiffany et 
al., 2001), which may account for the accumulation of phagocytic microglia in and 
around senile plaques in vivo. Nevertheless, the accumulation of large deposits of 
Ap in AD suggests that microglia are largely unsuccessful in their endeavours to 
remove extracellular Ap. The second theory supposes that microglia contribute to 
amyloidogeneisis and die deposition of senile plaques and thereby play a deleterious 
role in AD (Haga et al., 1989; Frackowiak et al., 1992). Consistent with this, 
activated microglia up regulate APP expression (Banati et al., 1993b) and have been 
reported to release Ap in vitro (Bitting et al., 1996). Moreover, imaging studies show 
that reactive microglia are apparent at an early stage in AD, which extends the 
conception that microglia are merely debris removing phagocytes and supports the 
notion that microglia contribute to pathology (Cagnin et al., 2001; Banati 2003).
Regardless of the primary role of reactive microglia in AD, microglia contribute to 
cerebral inflammation. Studies have demonstrated the presence of a wide variety of 
inflammatory mediators in senile plaques, many of which are produced by reactive 
microglia (table 1.3) (McGeer and McGeer 1997, 1999; Kingham and Pocock 2000). 
In vitro, reactive microglia also secrete a number of other potent neurotoxins 
including glutamate (Piana and Fontana 1994; Kingham et al., 1999; Barger and 
Basile 2001), superoxide (McDonald et al., 1997; Si et al., 1997) and NO (Bhat et al., 
1998; Kingham et al., 1999). Consistent with the latter, nitrated proteins are 
detectable in AD tissue, which is associated with the formation of peroxynitrite from 
superoxide and NO (Smith et al., 1997). Paradoxically, numerous factors associated 
with senile plaques including Ap (Li et al., 1996; McDonald et al., 1997; Combs et
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al., 2001), cytokines (Ding et al., 1997; Hellendall and Ting 1997; Possel et al.,
2000), chromogranin A (Taupenot et al., 1996; Kingham et al., 1999) and thrombin 
(Moller et al., 2000) induce microglial activation. Thus, it is feasible that a self- 
sustaining vicious cycle is instigated, which leads to heightened microglial activation 
accompanied by the production of more microgiiai derived inflammatory factors. 
Since inflammatory mediators cannot distinguish friend from foe, neurones in the 
local vicinity of the plaques may incur ‘bystander’ damage, thereby exacerbating 
neurodegenerative processes. In support of this, reactive microglia trigger neuronal 
death in mixed culture systems in vitro (Kingham et al., 1999; Combs et al., 2001). 
Furthermore, microglial derived IL1 triggers die activation of astrocytes (Giulian and 
Baker 1986), which in turn may impair astrocytic sequestration of glutamate and 
potassium thereby exacerbating neuronal dysfunction in AD.
The presence of inflammation in AD is corroborated by epidemiological studies, 
which have demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs) 
reduce the risk of developing AD (McGeer et al., 1996; Stewart et al., 1997). 
Interestingly, NSAID administration is associated with a 65 % reduction in plaque 
associated activated microglia (Mackenzie and Munoz 1998). NSAIDs work by 
selectively inhibiting the activity of COX enzymes (COX-1 and COX-2). COX-1 is 
constitutively expressed in all cells, whereas COX-2 is expressed during chronic 
inflammatory reactions. Therefore, it seems likely that COX-2 is over expressed in 
AD probably by plaque associated microglia.
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Microglia Astrocytes Neurones
Complement proteins + + +
Complement inhibitors + +
Heat shock protein 72 and 27 +
a l  -antichymotrypsin + !
a  1-antitrypsin +
a2-macro globulin + +
Capthepsins and Cytostatins
Cathepsin B, D, E, H, L and S + +
____________
+
Cytostatins A and C +
Apoliprotein E + + +
LPR + +
Lipoprotein lipase +
Cytokines and growth factors
bFGF + +
TGFpl + +
IL1 + + +
IL6 + + +
MCP-1 + +
Thrombin and plasmin systems
Thrombin + +
Tissue plasminogen activator + + +
Urokinase plasminogen activator + + +
Proteoglycans
Heparin sulphate proteoglycan + + +
Chondroitin sulphate proteoglycan 
Other
+ +
ICAM-1
___ _ __  __
Chromogranin A 1 +
Table 1.3 Factors associated with senile plaques
Astrocytes, microglia and neurones release factors that co-localise with senile plaques. The 
origins of the factors are denoted with a + (McGeer and McGeer 1997, 1999; Kingham and 
Pocock 2000).
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1.7 The interplay between Stroke and Alzheimer’s disease
1.7.1 Stroke as a risk factor for Alzheimer’s disease
Stroke patients have been demonstrated to exhibit an increased susceptibility to AD 
(Tatemichi et al., 1994; Kokmen et al., 1996; Moroney et al., 1996; Desmond et al., 
2000; Madureira et al., 2001). The clinical determinants o f dementia include the 
location and the severity of the stroke and host characteristics including age and level 
of education (Desmond et al., 2000). Moreover, it has been shown that 
amyloidogeneis and tau pathology are induced by hypo-perfusion in ischaemically 
damaged areas of the brain (Gehrmann et al., 1995; Kim et al., 1998; Nihashi et al., 
2001; Kalaria 2002). Indeed, Alois Alzheimer originally described the presence of 
vascular changes in the first recorded case of AD in 1907 (see review by Kalaria 
2002). More recently, a large majority of AD patients examined at autopsy have been 
demonstrated to bear stroke like lesions or infarcts that range from haemorrhage to 
cerebral amyloid angiopathy (CAA) (Kalaria et al., 1996; Desmond et al., 2000). 
CAA describes the deposition of amyloid in the walls of cerebral arteries and 
arterioles, a process that may weaken the vasculature thereby increasing the risk of 
haemorrhage or thrombus occlusion. Stroke may also prime microglia to subsequent 
pathological insults. Therefore, ‘stroke primed’ microglia may exhibit an accentuated 
response to Ap or other factors associated with AD, which in turn may exacerbate 
neuronal injury and promote cognitive decline at an accelerated rate in comparison to 
the ‘normal’ progression of AD (Pocock et al., 2001). This was one of the hypotheses 
investigated in this thesis.
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1.7.2 T h e  re la tio n sh ip  betw een v a sc u la r  d e m e n tia  a n d  A lzh e im er’s d isease
The complex relationship between stroke and AD is emphasised by the fact that the 
second most frequent form of dementia is vascular dementia (VaD). VaD is caused 
by cerebral infarction and is characterised by white matter lesions (Kalaria et al.,
2002). It has been proposed that AD and VaD are a continuum of the same disease, 
with pure AD and VaD representing the two extremes (Kalaria 2002). Consequently, 
patients often present with ‘mixed dementia’, which is characterised by clinical 
features of both AD and VaD. Thus, ‘mixed dementia’ is associated with CAA, 
micro-infarcts and small vessel disease (atherosclerosis) as well as senile plaques and 
tau pathology (Table 1.4).
Description Identifying features
Pure AD Plaque and neurofibrillary pathology
Plaque only AD Lack of neurofibrillary pathology
AD with severe CAA AD with vascular amyloid deposition
CAA with plaques Mild AD with vascular involvement
AD with vascular lesions AD with vascular lesions including micro-infarcts
VaD with AD changes VaD predominates with AD pathology
VaD with small vessel disease 
Pure VaD
VaD with prominent micro-vascular changes
Table 1.4 The continuum of AD and VaD
It has been proposed that AD and VaD are a continuum of the same disease, with pure AD  
and VaD representing the two extremes (Kalaria 2002).
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1.7.3 APP mutants and stroke
Interestingly, APP gene mutations often precipitate in a disorder bearing stroke as the 
main clinical phenotype. In contrast, to APP mutations causing AD, the stroke 
causing mutations are located within the Ap sequence and it has been shown that 
these mutants protect Ap from proteolytic degradation (Tsubuki et al., 2003). The 
first such mutation was described at position 22 of Ap, where a glutamine residue is 
substituted for a glutamic acid residue. This mutation results in hereditary cerebral 
haemorrhage with amyloidosis, Dutch type (HCHWA-D), an autosomal dominant 
disease, clinically defined by recurrent strokes, vascular dementia and fatal cerebral 
bleeding in the fifth and sixth decades of life (Luyendijk et al., 1988; Levy et al., 
1990). Furthermore, two different mutations termed die Artie and the Italian mutation 
have been described at position 22 of the Ap peptide (Ghiso and Frangione 2001). 
The Artie mutation results from the substitution of glutamic acid for glycine and 
causes early onset AD with prominent vascular pathology, whilst the Italian mutation 
triggered by the substitution of glutamic acid for lysine, causes dementia with 
cerebral haemorrhage. Other APP mutants include the Flemish mutation in which an 
alanine to glycine substitution occurs at position 21 of the AP peptide (Hendriks et 
al., 1992). Patients bearing this mutation present with dementia associated with 
cerebral haemorrhage. Together these disorders provide evidence that common 
genetic abnormalities underlie stroke and AD.
1.8 Aims of the study
The aims of this study were to investigate the signalling cascades elicited in cultured 
microglia using in vitro models of stroke and AD. Microglia are die resident 
macrophages of the brain. These cells play a role in immuno-surveillance and protect
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the brain against invading pathogens. However, there is increasing evidence that 
chronic microglial activation contributes to neurodegeneration in diseases such as 
stroke (Lees 1993; Kumar and Evans 1997; Rupalla et al., 1998; Tikka et al., 2001) 
and AD (McGeer et al., 1996; Stewart et al., 1997) and this was the fundamental 
premise for this study.
In this thesis the effects of albumin on microglia were investigated (chapter 4), the 
rationale being that microglia are normally exposed to low levels of albumin. 
However, if  the BBB is compromised as occurs in stroke (Homig et al., 1983) and in 
some cases of AD (Alafuzoff et al., 1983; Skoog et al., 1998) then microglia are 
exposed to large increases in this plasma protein. Next the signalling cascades elicited 
in microglia following treatment with Ap or chromogranin A were investigated since 
both proteins are associated with senile plaques in AD (Feldman et al., 1997; Munoz 
1991; Yasuhara et al., 1994; Rangon et al., 2003) (chapter 5). The microglial 
signalling cascades triggered by ischaemia were also explored (chapter 6). 
Additionally, the effects of ischaemia followed by albumin or Ap treatment were 
studied because it was postulated that stroke may heighten the reactivity of microglia 
to subsequent pathological insults (Pocock et al., 2001). Furthermore, the effects of 
microglial conditioned medium on neurones were investigated in an attempt to model 
the interplay between microglia and neurones in vivo (chapter 4, 5,6).
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2.0 Materials and Methods
2.1 Materials
The following section lists the materials used and the company that supplied them. 
All bench grade chemicals used in this thesis were from Sigma (Dorset, UK).
Material Supplier
Adenosine 5’ phosphatase (ATPase) Sigma (Dorset, UK)
Albumin (#A6272) Sigma (Dorset, UK)
Albumin agarose complex (#A3790) Sigma (Dorset, UK)
Ampicillin, Sigma (Dorset, UK)
Avidin-biotin complex Vector Laboratories (Peterborough, UK)
p-amyloid Bachem (Essex, UK)
BAPTA Sigma (Dorset, UK)
Bradford protein assay reagent kits Perbio Science (Chesire, UK)
Cell titer 96 AQue0us one solution proliferation 
assay
Promega (Southampton, UK)
CgA Scientific Marketing Associates (Hertfordshire,
UK)
CNQX (6-cyano-7-nitroquinoxaline-2,3 -dione) Tocris Cookson (Bristol, UK)
C02 gas BOC gases (Guildford, UK)
5 % C 02 - 95 % N2 gas BOC gases (Guildford, UK)
Cytosine arabinofuranoside Sigma (Dorset, UK)
DNAase Sigma (Dorset, UK)
Donkey anti-goat IgG (HRP) (#2020) Autogen Bioclear (Wiltshire, UK)
DPX mountant VWR International (Leicester, UK)
Dulbeccos modified eagles medium (DMEM) Sigma (Dorset, UK)
Earle’s balanced salts solution (EBSS) Life Technologies (Paisley, UK)
Enhanced chemiluminescence reagent (ECL) Amersham Pharmacia (Buckinghamshire, UK)
FITC-albumin (#A9771) Sigma (Dorset, UK)
FTTC-mouse anti-CD45 Serotec (Oxford, UK)
FITC-mouse anti-ED-1 Serotec (Oxford, UK)
Fluoroscein diacetate, Sigma (Dorset, UK)
Foetal calf serum Life Technologies (Paisley, UK)
Formaldehyde VWR International (Leicester, UK)
Fraction V (#A6414) Sigma (Dorset, UK)
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Material Supplier
Fura-2
Glass coverslips 
Glutamate dehydrogenase 
Goat anti-COX-2 (#1746)
Goat anti-mouse IgG (HRP) (#2005)
Goat anti-rabbit IgG (HRP) (#2004)
Goat anti-TNFa (#1351)
Griess reagent
Hoechst 33342 (2'[epoxyphenyl]-5-[4-methyl- 
1-piperazinyl]-2,5'-bi-l H-benzimidazol)
JC-1 (5,5’6,6’-tetraethylbenzimidazole caibo- 
cyanine iodide )
LPS (lipopolysaccharide)
Methanol
Minimum essential medium (MEM)
MK801 (5-methyl-10,11 -dihydro-5H- 
dinezo[a,d]cyclohepten-5,l -imine hydrogen 
maleate)
Mouse anti-p actin (#A5441)
Mouse anti-CDllb (OX-42)
Mouse anti-ED-1 (MCA341)
Mouse anti-GFAP (#G3893)
Mouse anti-p-ERK (#7383)
MSPG [(±)-a-methyl-4(4- 
sulphonophenyl)glycine]
N9 microglia
NADP+
NADPH
Neutralising anti-RAGE antibody 
Nitrate reductase
Nunc maxi-sorp cell culture plates 
Oxygen trap (ischaemia chamber)
Molecular Probes (Leiden, The Netherlands) 
Scientific Laboratory Supplies (Nottingham, UK)
Sigma (Dorset, UK) 
Autogen Bioclear (Wiltshire, UK) 
Autogen Bioclear (Wiltshire, UK) 
Autogen Bioclear (Wiltshire, UK) 
Autogen Bioclear (Wiltshire, UK) 
Sigma (Dorset, UK) 
Sigma (Dorset, UK)
Molecular Probes (Leiden, The Netherlands)
Sigma (Dorset, UK) 
VWR International (Leicester, UK) 
Life Technologies (Paisley, UK) 
Tocris Cookson (Bristol, UK)
Sigma (Dorset, UK) 
Serotec (Oxford, UK) 
Serotec (Oxford, UK) 
Sigma (Dorset, UK) 
Autogen Bioclear (Wiltshire, UK) 
Tocris Cookson (Bristol, UK)
Dr P R Castagnoli (CNR Cellular and Molecular 
Pharmacology Centre, Milan, Italy)
Sigma (Dorset, UK)
Sigma (Dorset, UK)
Dr L Denner (Texas Biotechnology Corporation,
Texas, USA)
Sigma (Dorset, UK)
Scientific Laboratory Supplies (Nottingham, UK)
Chromatography Research Supplies (Louisville,
UK)
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Material Supplier
PE-mouse anti-CD 1 lb
Penicillin
Percoll (#P1644)
Pertussis toxin
Pluronic acid 
Poly I
PPADS (pyridoxal-phosphate-6-azophenyl-2 
4’-disulphonic acid)
PP2
Propidium iodide
Protein A/Gplus agarose (#2003)
PVDF membrane (Immobilon-P- 
polyvinylidene di-fluoride)
Rabbit anti-iNOS (#610333)
Rabbit anti-TGFp (#7892)
Rabbit anti-total ERK (#9102)
SDS polyacrylamide gels (10 %)
Sheath fluid
Soya bean trypsin inhibitor
TGFpl Emax enzyme linked immunosorbent 
assay (ELISA) kits (#G7591)
Tissue culture plasticware
TNFa Quantikine ELISA kits (#RTA00)
TSA-3 astrocytes
U0126
U73122
Wistar rats (bred and reared in house)
Serotec (Oxford, UK)
Sigma (Dorset, UK)
Sigma (Dorset, UK)
Centre for Applied Microbiology and Research
(Wiltshire, UK)
Sigma (Dorset, UK)
Sigma (Dorset, UK)
Sigma (Dorset, UK)
Calbiochem (Nottingham, UK) 
Sigma (Dorset, UK) 
Autogen Bioclear (Wiltshire, UK) 
Sigma (Dorset, UK)
BD Biosciences Pharmingen (Oxford, UK) 
Autogen Bioclear (Wiltshire, UK) 
New England Biolabs (Herfordshire, UK) 
Bio-Rad (Hertfordshire, UK) 
BD Biosciences (Oxford, UK) 
Sigma (Dorset, UK) 
Promega (Southampton, UK)
Scientific Laboratory Supplies (Nottingham, UK)
R & D systems (Oxford, UK)
Gareth Pryce (Department of Neuroinflammation, 
Institute o f Neurology, University College London,
London, UK)
Promega (Southampton, UK)
Sigma (Dorset, UK)
Charles River UK (Kent, UK)
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2.2 M ethods
2.2 .1  C ell cu ltu re
2.2.1.1 Preparation o f microglia
Primary cultures of microglia were prepared from the brains of 3-6 day old Wistar 
rats (Kingham and Pocock 2000). Animals were killed by cervical dislocation and 
decapitation in accordance with the Scientific Procedures Act, UK, 1986. Brains 
(minus cerebellum) were removed into ice cold phosphate buffered saline (PBS; 140 
mM NaCl, 5mM KC1, 25 mM NaHP04, 11 mM glucose, pH 7.4), mechanically 
dissociated, pelleted by centrifugation (500 x g) then resuspended in 70 % percoll (10 
ml). A gradient was produced by overlaying this cell suspension with 35 % percoll 
(10 ml) followed by PBS (10 ml). The percoll gradient was then centrifuged (1250 x 
g) for 45 minutes and the microglial cells were extracted from the 35 % - 70 % 
percoll interface (Fig. 2.1).
Figure 2.1 Schematic diagram of a percoll gradient
Following centrifugation, red blood cells form a pellet at the bottom of the tube. Microglia 
collect at the 35 %- 70 % percoll interface. Myelin and other cells gather at the 35 % percoll -  
PBS interface.
P B S
M yelin  and  o th er  ce lls
35 %  p ercoll
M icrog lia
70 % p ercoll
R ed b lood  cells
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Cells were washed with PBS, pelleted by centrifugation (500 x g) then resuspended in 
culture medium (Minimum essential medium (MEM) supplemented with 25 mM 
KC1,30 mM glucose, 25 mM NaHCC>3, 1 mM glutamine, 10 % foetal calf serum, 100 
U/ml penicillin, 100 pg/ml streptomycin and 6 fig/ml ampicilin). Cells were plated at 
a density of 6 x 105 cells/well on 35 mm culture dishes or at 6 x 104 cells/well on 13 
mm glass coverslips in 24 well plates. Microglia were maintained at 37 °C in a 
humidified atmosphere of 5 % CO2 in air and were used after 1 day in vitro.
2.2.1.2 Preparation o f peritoneal macrophages
Macrophages were isolated from the peritoneal cavities of neonatal (3-6 day old) or 
adult (> 6 months) Wistar rats (Soares et al., 1998). Animals were killed by carbon 
dioxide induced anoxia followed by decapitation in accordance with the Scientific 
Procedures Act, UK, 1986. Macrophages were harvested from the peritoneal cavity 
using sterile Earle’s balanced salt solution (EBSS; 30 ml). The peritoneal lavage fluid 
was subsequently centrifuged (500 x g) for 5 minutes to pellet the cells. Cells were 
resuspended in culture medium (composition described in section 2.2.1.1) then plated 
at a density of 6 x 105 cells/well on 35mm culture dishes or at 6 x 104 cells/well on 13 
mm glass coverslips in 24 well plates. Peritoneal macrophages were maintained at 37 
°C in a humidified atmosphere of 5 % CO2 in air and were used after 1 day in vitro.
2.2.1.3 Preparation o f cerebellar granule neurones
Cerebellar granule neurones were prepared from 3-6 day old Wistar rats (Kingham et 
al., 1999). Animals were killed by cervical dislocation and decapitation in accordance 
with the Scientific Procedures Act, UK, 1986 and cerebella were removed into chilled 
solution A (100 mM PBS, 0.3 % fatty acid free BSA, 10 mM glucose, 0.38 % 
MgS0 4 .7 H20 ). Cerebella were mechanically dissociated then incubated in trypsin
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(0.25 %) for 20 minutes at 37 °C. Solution B (100 mM PBS, 0.3 % fatty acid free 
BSA, 10 mM glucose, 0.38 % MgS0 4 .7 H2 0 , 16 U/ml DNAase, 0.5 mg/ml soybean 
tiypsin inhibitor; 20 ml) was subsequently added to the cell suspension and the cells 
were pelleted by centrifugation (500 x g) for 5 minutes. The resultant cell pellet was 
re-suspended in solution C (100 mM PBS, 0.3 % fatty acid free BSA, 10 mM 
glucose, 0.38 % MgS0 4 .7 H20 , 100 U/ml DNAase, 0.05 mg/ml soybean trypsin 
inhibitor; 2 ml), then placed on top of an aliquot of EBSS/BSA (Earles’s balanced 
salt solution with 26 mM NaHCCh, 3 mM MgS0 4 .7 H2 0 , 4 % fatty acid free albumin;
5 ml) and centrifuged (500 x g) for 10 minutes. Finally, cells were resuspended in 
culture medium (composition described in section 2.2.1.1), then plated at a density of
6 x 105 cells/well on 13 mm glass coverslips in 24 well plates. Prior to use, coverslips 
were soaked in 100 % ethanol for a minimum of 2 days, baked at 180 °C for 24 hours 
then coated in poly-d-lysine (15 mg/1) for one hour at 37 °C. Cerebellar granule 
neurones were maintained at 37 °C in a humidified atmosphere of 5 % C 02 in air. 
After 1 day in vitro, the culture medium was replaced with fresh medium 
supplemented with cytosine arabinofuranoside (Ara C: 10 pM) to prevent excessive 
astrocyte proliferation. Cerebellar granule neurones were used after 7 days in vitro.
2.2.1.4 Growth and maintenance o f the N9 microglial cell line 
The N9 microglial cell line was originally derived from embryonic day 13 mouse 
microglial cultures (Corradin et al., 1993). Stocks of N9 cells were preserved in 
freezing medium (10 % DMSO, 90 % FCS) and stored at - 80 °C. A working stock of 
N9 cells was maintained in culture medium (DMEM supplemented with 4.4 mM 
NaHCC>3, 50 pM p-mercaptoethanol, 5 % foetal calf serum, 50 U/ml penicillin and 50 
pg/ml streptomycin) at 37 °C in a humidified atmosphere of 5 % carbon dioxide in
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air. N9 cells were passaged weekly (1 in 10) using a sterile cell scraper and plated 
when required at a density of 2.5 x 105 cells/well on 35 mm culture dishes or at 4 x 
104 cells/well on 13 mm glass coverslips in 24 well plates. Plated N9 cells were 
routinely used after 1 day in vitro.
2.2.1.5 Growth and maintenance o f the TSA-3 astrocytic cell line
The TSA-3 astrocytic cell line was originally derived from neonatal day 2 murine 
astrocytic cultures derived from Biozzi ABH mice (Personal communication: Gareth 
Pryce). Stocks of TSA-3 astrocytes were preserved in freezing medium (10 % 
DMSO, 90 % FCS) and stored at - 80 °C. A working stock of TSA-3 astrocytes was 
maintained in culture medium (DMEM supplemented with 4.4 mM NaHC03, 50 pM 
p-mercaptoethanol, 5 % foetal calf serum, 50 U/ml penicillin and 50 pg/ml 
streptomycin) at 37 °C in a humidified atmosphere of 5 % carbon dioxide in air. 
TSA-3 astrocytes were passaged twice a week (1 in 10) using a sterile cell scraper 
and plated when required at a density of 2.5 x 105 cells/well on 35 mm culture dishes 
or at 4 x 104 cells/well on 13 mm glass coverslips in 24 well plates. Plated astrocytes 
were routinely used after 1 day in vitro.
2.2.1.6 Treatment ofprimary, N9 microglia and peritoneal macrophages 
Primary microglia, N9 microglia or peritoneal macrophages were treated with 
albumin or fraction V (at defined concentrations) for 2 hours in serum free medium 
(SFM), after which the SFM was replaced with serum containing medium (SCM) for 
the remainder of the experimental period. In other experiments, primary or N9 
microglia were treated with CgA, AP(25-35>or LPS (at defined concentrations) in SCM 
for the stipulated time periods. In experiments using inhibitors, primary or N9
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microglia were incubated with the agent (at defined concentrations) in SFM or SCM 
before the addition o f the appropriate activator and also during subsequent treatment 
with the activator (table 2.1).
Inhibitor and 
concentration (s) used
Action Time References
Aminoadipate 
(2.5 mM)
Xc' transporter inhibitor 1 hour Piani and Fontana 1994 
Kingham et al., 1999
AMT-HCL 
(0 3  pM)
iNOS inhibitor 1 hour Kingham et al., 1999
BAPTA-AM 
(1-10 mM)
Intracellular calcium chelator 45 mins Nolte et al., 1996 
Hoflmann et al., 2003
Neutralising RAGE antibody 
(200 pg/ml)
RAGE antagonist 1 hour Yeh et al., 2001
Pertussis toxin (Ptx) 
(1-2 pg/ml)
Gi/0 inhibitor 18 hours Post et al., 2002
Poly I
(0.1-0.5 pg/ml)
Scavenger receptor antagonist 45 mins Post et al., 2002 
Whitman et al., 2000 
Husemann et al, 2001
PP2
(50 nM-500nM)
Src kinase inhibitor 1 hour Hankeet al., 1996 
Salazar and Rozengurt 1999
U0126 
(1-20 pM)
ERK inhibitor 30 mins Favataetal., 1998
U73122 
(0.5-2 pM)
Phospholipase C inhibitor 1 hour Heemskeik et al., 1997 
Pollaud-Cherion et al., 1998 
Tokmakov et al., 2002
Table 2.1 Description of inhibitors
Cells were pre-incubated with inhibitors for the defined period of times at concentrations 
stipulated in the text and figure legends (within range stated in table). Inhibitors were also 
incubated with the cells during exposure to the appropriate activator.
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2.2.1.7 Depletion o f  microglial conditioned medium
Microglial conditioned medium was depleted of proteinaceous factors by boiling the 
conditioned medium for 45 minutes. The medium was then applied to neuronal 
cultures (see section 2.2.1.8). TNFa and TGFp were immuno-depleted from 
microglial conditioned medium using goat anti-TNFaor rabbit anti-TGFpl, 2, 3 
antibodies respectively. Aliquots (500 pi) of conditioned medium were incubated 
with antibody (2 pg) for 3 hours at 4 °C with end over end rotation. Protein A/G 
agarose was then incubated with the microglial conditioned medium for 1 hour at 4 
°C with constant rotation (Zhao and Eghbali-Webb 2001). Next, the immune complex 
was removed by centrifugation at 13 000 x g for 2 minutes. The supernatant was 
subsequently collected then added to cerebellar granule neurones, hi other 
experiments, ATP was depleted from microglial conditioned medium using ATPase. 
Aliquots (500 pi) o f microglial conditioned medium were incubated with ATPase 
(0.5 U/ml) for 2 hours at 37 °C. The medium was subsequently added to cerebellar 
granule neurones.
2.2.1.8 Treatment o f cerebellar granule neurones
After 7 days in vitro, half of the culture medium (200 pi) was removed from the 
neuronal cultures and replaced with microglial or macrophage conditioned medium 
(200 pi) or ‘depleted’ conditioned medium (200 pi) for 24 hours. In experiments 
using inhibitors, neurones were pretreated with the broad spectrum purinergic 
receptor antagonist PPADS (100 pM) or the glutamate receptor antagonists CNQX 
(20 pM), MK801 (10 pM) and MSPG (200 pM) for 1 hour before microglial 
conditioned medium was added. The inhibitors were also present during the exposure 
to microglial conditioned medium.
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2.2.1.9 Simulation o f ischaemia in vitro
Ischaemia was modelled by exposing primary microglia or N9 microglial cells to 95 
% N2 in 5 % CO2 in the presence of Dulbeccos modified Eagles medium (DMEM) 
lacking glucose, pyruvate and foetal calf serum (ischaemia medium) (Pringle et al., 
1997; Lyons and Kettenmann 1998; Yenari and Giffard 2001). Microglia bathed in 
ischaemia medium were placed in a humidified glass chamber located within a 37 0 C 
incubator. The chamber was airtight and comprised two modified valves, which 
enabled gas to be let into or out of the chamber. Oxygen was removed from the 
chamber, by flushing with a mixture of 95 % N2, 5 % CO2 for 30 minutes. The gas 
was passed through an oxygen trap (0.25 inches, model 1000) to remove any residual 
oxygen from the delivery pipe before reaching the chamber. Resazurin was used as an 
oxygen indicator, in the absence of oxygen resazurin indicator strips change from 
red/pink to white. Microglia were exposed to ischaemia for 3 hours before 
‘reperfusion’. Reperfusion involved changing the medium from ‘ischaemia medium’ 
to ‘normal’ culture medium containing glucose and semm (see section 2.2.1.1 for the 
composition). Microglia were then maintained at 37 °C in a humidified atmosphere of 
5 % CO2 in air (normoxic) for the stipulated time periods. Additionally, after the 
ischaemic insult some cultures were exposed to Ap (45 pM) in SCM (+ glucose) for 
defined periods of time, whilst others were exposed to fraction V (1 mg/ml) in SFM 
medium (+ glucose) for 2 hours, then SCM (+ glucose) for the remainder of the 
experimental period.
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2.2.2 Immunocytochemistry
To check for purity cultures of microglia or peritoneal macrophages were stained 
with OX-42, an antibody which recognises the CR3 complement receptor 
(CDllb/CD18) (Graeber et al., 1989) and ED-1, an antibody that recognises a 
lysosomal protein (Graeber et al., 1990; Slepko and Levi 1996). High levels of ED-1 
are associated with macrophages and activated microglia, whilst low levels of 
expression are associated with quiescent ramified microglia (Graeber et al., 1990; 
Slepko and Levi 1996). The presence of astrocytes in the microglial preparations was 
also assessed by staining for GFAP, an astrocytic marker (Eliasson et al., 1999). 
Additionally, the presence of contaminating microglia and astrocytes in cerebellar 
granule neurone cultures was assessed by staining with OX-42 and GFAP 
respectively.
Microglia and peritoneal macrophages were cultured for 1 day in vitro then fixed with 
methanol at 4 °C for 5 minutes, whereas cerebellar granule cells were cultured for 7 
days before being fixed. Cells were washed in three changes of PBS then blocked in 
normal horse serum (diluted 1 in 40 in PBS) for 45 minutes at room temperature. 
Samples destined for ED-1 staining were permeabilised by adding triton (0.1 %) to 
the blocking solution. Cells were incubated with the respective primary antibody 
(mouse anti-CDl lb, mouse anti-ED-1, mouse anti-GFAP) diluted in blocking reagent 
(1 in 500) for 18 hours at 4 °C. All incubations were performed in a humidified 
chamber to prevent excessive evaporation. Control cultures were also set up to test 
the specificity of the staining, in which cells were incubated in blocking buffer in the 
absence of primary antibody. Following primary antibody treatment, cells were 
washed in four changes o f PBS, then incubated with an anti-mouse IgG secondary 
antibody conjugated to biotin (1 in 200) for 2 hours at 4 °C. Subsequently, cells were
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washed in three changes of PBS and incubated with a pre-formed avidin-biotin 
horseradish peroxidase (HRP) complex for 1 hour at room temperature. To visualise 
the staining, cells were washed extensively in PBS and incubated with 
diaminobenzidine tetrahydrochloride (DAB) for 5 minutes at room temperature. Cells 
were then bathed in PBS for 5 minutes to allow the staining to develop, after which 
the cells were counterstained with haematoxylin for 1 minute. Cells were 
subsequently washed in water then dehydrated through an ethanol gradient (70-100 
%) before being immersed in xylene for 3 minutes. Finally, cells were mounted onto 
glass slides using distyrene, tricresyl phosphate and xylene mounting medium (DPX). 
Immunoreactive cells were counted on three coverslips per treatment on three 
independent occasions (each coverslip comprised 10 fields of view). Immunoreactive 
cells were expressed as a percentage o f the total number of cells counted as 
demonstrated by haematoxylin staining.
2.2.3 Fluorescent activated cell sorting
2.2.3.1 FACSCaliburflow cytometer
Fluorescent activated cell sorting (FACS) was performed using a Becton and 
Dickinson FACSCalibur flow cytometer (Fig. 2.2). Flow cytometers enable the 
physical and antigenic properties of individual cells to be assessed. Cells are 
channelled through a single beam of light produced by an argon laser. The light is 
subsequently disrupted and detected as forward (FS) or side scattered (SS) light. 
Forward scattered light reflects the size of a cell, whereas side scattered light provides 
an indication of granularity. Cells can also be stained with fluorescent antibodies 
directed against cell surface or intracellular antigens. The fluorochromes absorb light 
from the laser beam then emit light in different regions of the spectrum. The 
cytometer subsequently measures the intensity of fluorescent signal emitted from
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each cell. The main advantage of FACS over immunocytochemistiy is that thousands 
of cells can be analyzed in a relatively short space of time.
The argon-ion laser situated in the cytometer produces light at a wavelength of 488 
nm. The light is directed through a focussing lens onto the cells. The forward 
scattered light is measured by the forward scatter diode. The side scattered light and 
the fluorescent emissions are gathered by the collection lens, which is positioned 
perpendicularly to the light source. The side scattered light and the fluorescent beams 
are subsequently focussed through a series of optical filters then spectrally split by 
specific dichroic mirrors. Green/yellow light characteristic of fluorescein 
isothiocyanate (FITC) staining passes to the FL1 photomultiplier tube. In addition, a 
fraction (10 %) of the FL1 signal provides the side scatter measurement. 
Yellow/Orange light characteristic of phycoerythrin staining (PE) is reflected to the 
FL2 photomultiplier tube. Red light that is associated with peridinin chlorophyll 
protein (PerCP) staining is channelled to the FL3 photomultiplier tube. Finally, the 
optical signals received are converted into electrical data. In this thesis data was 
analysed using CELL QUEST software.
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Figure 2.2 Schematic diagram of the flow cytometer
Light passes through the focussing lens and on to the cells. Scattered and emitted light is 
collected as indicated. Optical outputs are subsequently converted into electrical signals.
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2.2.3.2 FACS analysis
Primary microglia and peritoneal macrophages were analysed for the expression of 
the CR3 complement receptor (CD1 lb/CD18), ED-1 and CD45 using FACS. Primary 
microglia and peritoneal macrophages were cultured for 1 day in vitro following 
isolation. The cells were then harvested by cell scraping, pelleted and fixed with 
formaldehyde (8 %) in phosphate buffered saline. Samples destined for ED-1 staining 
were permeabilised by adding triton (0.1 %) to the fixative. Following fixing, the 
cells were pelleted and resuspended in the appropriate primary antibody conjugate 
(PE-mouse anti-CDllb; 1 in 20, FITC-mouse anti-CD45; 1 in 10, FITC-mouse anti- 
ED-1; neat) and incubated for 1 hour at room temperature. Finally, cells were pelleted 
and resuspended in sheath fluid, then analysed by flow cytometry in accordance with 
the manufacturer’s instructions. Experiments were performed in triplicate, therefore 
the results shown are representative of a single experiment consisting of data 
collected from 4000 cells.
2.2.4 Western blotting
2.2.4.1 Preparation o f cell lysates
Following the appropriate treatment, cells were harvested in lysis buffer (20 mM 
Tris-acetate, 1 mMEDTA, 1 mMEGTA, 10 mM sodium p-glycerophosphate, 1 mM 
sodium orthovanadate, 5 % glycerol, 1 % Triton X-100, 0.27 M sucrose, 1 mM 
benzamidine, 4 pg/ml leupeptin, 0.1 % p-mercaptoethanol, pH 7.4) then incubated on 
ice for 10 minutes. Following the incubation, samples were centrifuged (13500 x g) 
for 5 minutes (Kingham and Pocock 2000) and the resultant supernatants were 
collected. Protein concentrations of supernatants were determined according to the 
method of Bradford (Bradford 1976) using bovine serum albumin as a standard (Fig.
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2.3). In brief, samples (2 pi) were mixed with Bradford reagent (1 ml) and the optical 
density (OD) was read after 20 minutes at 595 nm.
1.0
0.6
0.4
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155 100
(Albumin] (pg/ml)
Figure 2.3 Representative standard curve of protein concentration against OD
Albumin standards (0-15 ng/ml) were incubated with Bradford reagent and the OD was 
measured at 595 nm .
2.2.4.2 SDS polyacrylamide gel electrophoresis
Proteins from cell lysates were resolved by SDS polyacrylamide electrophoresis 
(SDS-PAGE) using a Bio-Rad mini-protean 2 electrophoresis cell (BioRad, UK). 
Prior to electrophoresis, samples were boiled for 5 minutes, mixed with laemelli 
sample buffer (1 % SDS, 10 % glycerol, 2.5 % (3-Mercaptoethanol, 125 mM 
Tris/HCl, 1 % bromophenol blue, pH 6.8; 30 -  40 pg/well) then loaded on to Bio-Rad 
SDS-PAGE Tris-HCl precast gels (10 %). Electrophoresis was performed at 180 volts 
for 1 hour in the presence of running buffer (125 mM Tris, 1M glycine, 0.01 % SDS).
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2.2.4.3 Electrophoretic protein transfer
Gels were equilibrated in transfer buffer (25 mM Tris, 192 mM glycine, 0.01 % SDS, 
20 % methanol) for 10 minutes. Meanwhile, a PVDF (Immobilon-P) membrane was 
activated by immersion in chilled methanol for 1 minute. The gel and the membrane 
were then assembled in the transfer cassette and the proteins were transferred using a 
Bio-Rad mini trans blot electrophoretic transfer cell (BioRad, UK). Transfer was 
performed at 80 volts for 2 hours or at 22 volts for 16 hours.
2.2.4.4 Inununoblotting
Membranes were washed in Tween-20 Tris buffered saline (TTBS; 10 mM Tris-HCl, 
150 mM NaCl, 0.5 % Tween-20, pH 7.4) for 15 minutes. Membranes were then 
incubated with blocking buffer (TTBS, 5 % nonfat dried milk) for 2 hours at room 
temperature to minimise non-specific binding. Membranes were subsequently 
incubated with primary antibody (rabbit anti-iNOS; 1:5000, goat anti-COX-2; 1:750, 
or mouse anti-p-ERK; 1:750) for 2 hours at room temperature. Following the 
incubation with primary antibody, membranes were washed in four changes of TTBS. 
Next membranes were incubated for a further 2 hours at room temperature with the 
corresponding secondary antibody conjugated to HRP (goat anti-rabbit IgG; 1:500, 
donkey anti-goat IgG; 1 in 1000, or goat anti-mouse IgG; 1:1000). Finally, 
membranes were washed in four changes of TTBS and the proteins of interest were 
detected using enhanced chemiluminescence. To ensure equal protein loading 
membranes were reprobed with either mouse anti-P actin (1:1000), or rabbit anti-total 
ERK (1:500). Western blots were performed in triplicate and therefore the blots 
shown are representative of a single experiment. Densitometry was performed using 
Gel Pro software (Version 3.1) in accordance with the manufacturer’s instructions.
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2.2.5 Albumin ‘binding protein9 precipitation
N9 microglia, peritoneal macrophages, TSA-3 astrocytes or cerebellar granule 
neurones were harvested in RIPA lysis buffer (150 mM NaCl, 50 mM Tris, 1 % 
NP40, 0.5 % sodium deoxycholate, 0.1 % SDS, 1 mM benzamidine, 4 pg/ml 
leupeptin, 0.1 % P-mere ap to ethanol, pH 7.4) then incubated on ice for 5 hours. 
Following the incubation, samples were sonicated for 1 minute then centrifuged 
(13500 x g) for 5 minutes and the resultant supernatants were collected. Albumin 
conjugated to agarose beads (12 pi) was incubated with cell lysates (1 mg/ml) for 3 
hours at 4 °C with end over end rotation. The beads were subsequently pelleted by 
centrifugation (13500 x g) then washed in three changes of RIPA buffer. Following 
the last wash the precipitated proteins were resuspended in laemelli sample buffer, 
then boiled for 5 minutes to elute the proteins of interest from the agarose complex. 
Next proteins were resolved using a Bio-Rad SDS-PAGE Tris-HCl precast gel (10 
%). The proteins were then transferred on to a PVDF membrane, which was stained 
with coumassie blue to enable protein visualisation.
2.2.6 Protein sequencing
2.2.6.1 N-terminal protein sequencing
N-terminal sequencing of the putative albumin ‘binding protein’ isolated from N9 
microglia was performed by Dr Fox (Alta Bioscience, Birmingham University, UK). 
The protein of interest immobilized on a PVDF membrane and stained with 
coumassie was subjected to repetitive cycles of Edmun degradation. Edmun 
degradation sequentially removes one amino acid from the N-terminus of a protein 
(Berg et al., 2002). The method employs phenyl isothiocyanate, which reacts with the 
uncharged terminal group of the protein to form a phenylthiocaibamoyl derivative.
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Then under mildly acidic conditions a cyclic phenylthiohydantoin (PTH) derivative 
of the terminal amino acid is liberated. PTH-amino acids are subsequently identified 
using high performance liquid chromatography (HPLC) against a standard mixture of 
PTH-amino acids.
2.2.6.2 M ALDIfingerprinting
Matrix assisted laser desorption and ionization (MALDI) fingerprinting was 
performed by Dr Packman (PNAC facility, Cambridge University, UK). The putative 
albumin ‘binding protein’ isolated from N9 microglia was resolved on a Bio-Rad 
SDS-PAGE Tris-HCl precast gel (10 %) and stained with coumassie. The protein was 
then enzymatically digested with trypsin. Peptides were extracted from the digestion 
buffer and desalted using a Millipore C l8 ZipTip according to the manufacturer’s 
instructions. Subsequently, peptides were identified by tandem mass spectrometry 
using a ThermoFinnigan LCQ classic mass spectrometer with static nanospray 
source. Basically, the peptide fragments were accelerated down a flight tube. The 
mass to charge ratio of an individual peptide is related to the time it takes to reach a 
detector. Therefore, the identity of a protein can be elucidated by comparing the 
trypsin fingerprints with known sequences on a database. Database searching was 
done with Mascot and only statistically significant hits were considered.
2.2,1 Measurement of glutamate
The presence of glutamate in culture medium was assessed by fluorometric 
quantification of NADPH, which is produced through the reaction of glutamate with 
NADP+ in the presence o f glutamate dehydrogenase (Nicholls and Sihra 1986). This 
reaction yields one mol of NADPH for every mol of glutamate; therefore NADPH 
levels are directly proportional to glutamate concentrations in the medium.
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Glutamate + NADP" ------------------ ► 2-oxoglutarate + NADPH + NH4
Glutamate Dehydrogenase
Culture medium (100 pi) was diluted in basic medium (153 mM NaCl, 3.5 mM KC1,
1.3 mM CaCl2, 1.2 mM MgCl2, 0.4 mM KH2PC>4, 5 mM NaHC03, 1.2 mM Na2SC>4, 
5 mM glucose, 20 mM TES, pH 7.4; 900 pi), then incubated with NADP+ (1 mM) for 
2  minutes at 37 °C. Samples were subsequently incubated with glutamate 
dehydrogenase (32.4 U/ml) for 8  minutes at 37 °C. NADPH levels were determined 
using a Perkin Elmer fluorimeter with excitation set at 340 nm and emission greater 
than 400 nm was collected. The concentration of glutamate was determined against a 
standard curve (Fig. 2.4). Glutamate experiments were performed in triplicate on 
samples isolated on three independent occasions.
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Figure 2.4 Representative standard curve of glutamate concentration against 
fluorescence intensity. Glutamate standards were treated with NADP+ then glutamate 
dehydrogenase. NADPH levels were subsequently measured at a wavelength of 340 nm and 
emission greater then 400 nm was collected.
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2.2.8 Measurement of nitrite
In aqueous solution NO is rapidly oxidised to nitrite and nitrate. Therefore, the 
presence of NO in the culture medium was assessed by spectrophotometric 
quantification of nitrite using Griess reagent (Kingham et al., 1999). To avoid 
underestimation of NO production, nitrate was converted to nitrite using nitrate 
reductase. The Griess assay is based on the production of a diazonium salt by the 
reaction of nitrite with sulphanilamide in acidic solution. The sulfanilamide 
diazonium salt subsequently reacts with naphthylethylenediamine producing a 
diazonium chromophore that can be detected at 540 nm.
Nitrate (NOs-) + NADPH ---------------► Nitrite (N02) + NADP+ + H20
Nitrate Reductase
To determine nitrite concentrations, culture medium was incubated with nitrate 
reductase (0.028 U/ml) and (3 NADPH (100 pM) for 15 minutes at 37 °C in the dark. 
Lactate dehydrogenase (111 U/ml) and sodium pyruvate (110 mg/ml) were 
subsequently added for 10 minutes at 37 °C to consume any residual NADPH. Griess 
reagent (0.1 % naphthylethylenediamine, 1 % sulfanilamide, 5 % H3PO4) was then 
added and the OD was read at 540 nm. The efficiency o f conversion of nitrate to 
nitrite was determined against a standard nitrate curve (Fig. 2.5). Nitrite experiments 
were performed in triplicate on samples isolated on three independent occasions.
104
3.0
| 2.0
|  1JS 
P
o  1.0
600 80 10020 40
(Nitrite](pM)
Figure 2.5 Representative standard curve of nitrite concentration against OD
Nitrite standards (circles) were incubated with Griess reagent and the OD was measured at 
540 nm. To demonstrate the efficiency of conversion of nitrate to nitrite, nitrate standards 
(triangles) were converted to nitrite using (3-NADPH and nitrite reductase. OD was 
subsequently measured at 540 nm.
2.2.9 Measurement of TNFa
The presence of TNFa in culture medium was assessed using a ‘TNFa Quantikine 
ELISA (enzyme linked immunosorbent assay) kit’ (Xaus et al., 2000; Choi et al., 
2002). Assays were performed by Ms Fleur Jones (Cell Signalling Laboratory, 
Department o f Neuroinflammation, Institute of Neurology, UCL) in accordance with 
the manufacturer’s instructions. In brief, cell culture supernatants (50 pi) were diluted 
in calibration buffer (100 pi) before being added to an ELISA plate containing assay 
diluent (50 pi/ well). The plate was agitated for one minute and then incubated at 
room temperature for 2 hours. Next, the plate was washed in four changes of wash 
buffer (40 pl/well), then primary TNFa antibody conjugated to HRP (100 pl/well)
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was added and incubated with the samples for 2 hours at room temperature. The plate 
was subsequently washed in four changes of wash solution (40 pl/well) then substrate 
solution (100 pl/well) was incubated with the samples for a further 30 minutes. 
Finally, the OD was read at 450 nm with the reference filter set to 570 nm to correct 
for plate imperfections. The concentration of TNFa was determined against a 
standard curve (Fig. 2.6). Experiments were performed in triplicate on samples 
isolated on three independent occasions.
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Figure 2.6 Representative standard curve of TNFa concentration against OD
TN Fa standards were added to an ELISA plate and treated in accordance with the 
manufacturer’s instructions. OD was subsequently measured at 450 nm with the reference 
filter set at 620 nm.
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2.2.10 Measurement of TGFp
The presence of TGFp in culture medium was assessed using a ‘TGFp I Emax ELISA 
kit’ (Bruno et al., 1998). Assays were performed by Ms Fleur Jones in accordance 
with the manufacturer’s instructions. In brief, a nunc maxi-sorp cell culture plate was 
coated with TGFp monoclonal antibody (100 pl/well) overnight at 4 °C. Next the 
plate was washed in five changes of wash buffer (40 pl/well) then blocking reagent 
was incubated with the plate for a further 35 minutes at 37 °C. The plate was 
subsequently washed in five changes of wash buffer (40 pl/well) then cell culture 
supernatants (100 pl/well) were added to the plate and incubated at room temperature 
for 1.5 hours with shaking. Following the incubation period, the plate was washed in 
5 changes of wash buffer then primary TGFp polyclonal antibody (100 pl/well) was 
added and incubated with the samples for 2 hours at room temperature with shaking. 
Next die plate was washed in five changes of wash buffer (40 pl/well), after which 
TGFp HRP conjugate (100 pl/well) was added and incubated for 2 hours at room 
temperature with shaking. Finally, the plate was washed in five changes of wash 
buffer (40 pl/well) before TMB one solution (100 pl/well) was added to the wells. 
The plate was then left at room temperature for 15 minutes before the reaction was 
terminated by the addition of hydrochloric acid (1M; 100 pl/well). The OD was read 
at 450 nm with the reference filter set to 620 nm to correct for plate imperfections. 
The concentration of TGFp was determined against a standard curve (Fig. 2.7). 
Experiments were performed in triplicate on samples isolated on three independent 
occasions.
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Figure 2.7 Representative standard curve of TGFp concentration against OD
TGFp standards were added to an ELISA plate and treated as per the manufacturer’s 
instructions. OD was subsequently measured at a wavelength of 450 nm with the reference 
filter set to 570 nm.
2.2.11 Measurement of cell proliferation
Under pathological conditions microglia proliferate resulting in the production of 
identical daughter cells (Graeber et al., 1988c). In this thesis, proliferation was 
assessed by counting the number of cells present per field of view. Cells were 
counted on three coverslips per treatment on three independent occasions (each 
coverslip comprised 10 fields of view). In addition, proliferation was assessed using 
the ‘Cell titer 96 Aqueous one solution proliferation assay kit’ (Vairano et al., 2002; 
Wang et al., 2002). This proliferation assay is based on the reaction between NADH, 
which is produced by proliferating cells as a consequence of increased respiration and 
MT S (3 -(4,5 -di methyl th i azo 1 -2 -yl)-5 -(3 -c arboxy metho xypheny 1 )-2- (4 -sul fopheny 1 )-
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2H-tetrazolium). The reaction results in the formation of a coloured formazan end 
product that can be assessed spectrophotometrically. The amount of formazan product 
generated, as measured by the absorbance at 492 nm is directly proportional to the 
number of proliferating cells in culture. The kit was used according to the 
manufacturer’s instructions. In brief, cell proliferation reagent (50 pi) was added to 
culture medium (200 pi) bathing treated and untreated primary microglia, N9 
microglia or peritoneal macrophages at the appropriate time points. Cells were 
incubated in the presence of reagent for 4 hours at 37 °C. Samples (50 pi) were then 
removed from the cultures and the absorbance was read at 492 nm. Proliferation 
assays were performed in triplicate. Samples were collected from cells isolated on 
three independent occasions.
2.2.12 Fluorescence microscopy
Fluorescence microscopy was used to assess intracellular calcium fluxes, 
mitochondrial membrane depolarisation, cellular viability, cellular death and FTTC 
labelled albumin uptake.
2.2.12.1 Fluorescence imaging system
Single cell fluorescence imaging was performed using an Olympus 1X70 epi- 
fluorescence microscope coupled to a Perkin Elmer Life Science Resources Merlin 
imaging system (version 1.863) unless otherwise stated (see section 2.2.12.7). Using 
this set up, cells loaded with a fluorescent dye were illuminated with UV light, the 
exact excitation wavelength obtained using a Perkin Elmer Life Science Resources 
SpectraMaster monochromator (Pocock and Evans 2000). UV light from the 
monochromator passes through a light tube to a dichroic mirror, which reflects light
109
through an objective lens and on to the cells. The emitted light is then channelled 
back to a dichroic filter, which allows light of a particular wavelength to travel to a 12 
bit digital camera. The camera comprises a set of light sensitive diodes, each of which 
digitises the intensity of fluorescence it receives. This results in the generation of 
computerised images and graphical representations of the data (Fig. 2.8).
uv lamp □
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Camera ► Computer
Microscope
Figure 2.8 Schematic diagram of the imaging system
Cells loaded with a fluorescent dye can be illuminated with UV light, the exact excitation 
wavelength obtained using a monochromatic filter. UV light passes through a light tube to a 
dichroic mirror, which reflects light through an objective lens and on to the cells. The emitted 
light is channeled back to a dichroic filter, which allows light of a particular wavelength to 
travel to a digital camera then on to a computer.
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Imaging was performed under conditions of very low ambient light to prevent dye 
bleaching (Pocock and Evans 2000). The major advantages of fluorescence imaging 
over a fluorometer are that recording can be made from individual cells. Recordings 
can also be made from specific cell types allowing elimination of data from 
contaminating cells. Furthermore, imaging allows recordings to be made from many 
cells simultaneously; therefore it is possible to determine the homogeneity of a 
response (Pocock and Evans 2000).
2.2.12.2 Introduction to calcium imaging
A number of fluorescent dyes are available which can be used to appraise calcium ion 
fluxes at the sub-cellular level (reviewed by Tsien 1988; Hallet et al., 1999; Pocock 
and Evans 2000). These dyes are sub-classified into single or dual wavelength 
(ratiometric) dyes based on their fluorescent properties. Single wavelength dyes are 
excited by a single wavelength and emit at a single wavelength. Examples of single 
wavelength dyes include quin-2, calcium green and fluo 3. In contrast, dual 
wavelength calcium indicators use two excitation or emission wavelengths. This 
enables a ratio of the shift in excitation or emission intensity to be calculated, which 
is proportional to the calcium concentration within the cell. Frequently used dual 
wavelength dyes include fura-2 and indo-1. A number of advantages are associated 
with the use of dual wavelength dyes. For example, artifactual changes in 
fluorescence generally only affect one of the excitation or emission wavelengths and 
are therefore easily detectable, the concentration of the dye is not critical and 
calibration of the system is possible, thus calcium concentrations can be easily 
determined.
i l l
In this study the ratiometric fluorescent probe fura-2 (AM modified) was used to 
perform single cell calcium imaging. Fura-2 contains a ligand binding moiety which 
is based on the calcium chelator EGTA, therefore this dye displays a very high 
affinity for calcium over it’s most fierce competitor magnesium. In the acetoxymethyl 
ester (AM) form, fura-2 readily penetrates cell membranes, rendering redundant the 
need for micro-injection which can be detrimental to cell survival and time 
consuming. Once inside the cell fura-2 is de-esterified by endogenous esterases, 
which consequently prevents the dye leaching back out across the cell membrane.
In the absence of calcium, fura-2 exhibits an excitation maxima of 380 nm. The 
excitation maxima shifts in the presence of calcium from 380 nm to 340 nm (Fig 2.9). 
In contrast, the emission peak is 510 nm in the presence or absence o f calcium. 
Therefore, it is the intensity of the emissions elicited by excitation at both 380 and 
340 nm that is used to calculate the ratio. The intensity of the emission after 
illumination at 340 nm is divided by the intensity of fluorescence resulting from 
illumination at 380 nm. The value of this ratio is dependent on the concentration of 
free calcium in the cell. A high ratio indicates that there is a high concentration of 
calcium within the cell, whereas a low ratio is indicative of low calcium.
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Figure 2.9 Emission profile of fura-2 in the presence of calcium
In the presence of calcium the excitation maxima of fura-2 shifts from 380 nm to 340 nm.
2.2.12.2.1 Assessment o f  intracellular calcium fluxes
Changes in intracellular calcium were assessed using the fluorescent probe fura-2 
(Pocock et al., 1998; Moller et al., 2001). Cells on coverslips were loaded with fura-2 
(5 pM) in the presence of pluronic acid (0.02 %) for 45 minutes at 37 °C in the dark. 
Coverslips were then inserted into a thermostatically controlled holder set to 37 °C 
and basic medium was added (150 pi). The dye was subsequently excited at 340 nm 
and 380 nm and emission greater than 510 nm was collected. Compounds diluted in 
basic medium (50 pi) were added directly to the cells whilst a continual sequence of 
images was recorded. Data from a minimum of 10 cells per field of view was 
analysed and values were expressed as 340/380 nm fluorescence ratios. Experiments 
were performed in triplicate therefore the results shown are representative of a single 
experiment.
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2.2.12.3 Assessment o f  mitochondrial membrane polarisation
Mitochondrial depolarisation was assessed using 5,5’6,6’-tetraethylbenzimidazole 
carbo-cyanine iodide (JC-1), a fluorescent dye which is sensitive to changes in 
mitochondrial membrane potential (Kingham and Pocock 2000). Cells on coverslips 
were incubated with basic medium containing JC-1 (5 pM) for 10 minutes at 37 °C in 
the dark. Coverslips were then inserted into a thermostatically controlled holder set to 
37 °C and basic medium was added (150 pi). Mitochondrial polarisation was 
subsequently assessed at 490 nm with emission greater than 520 nm collected. In 
cells possessing polarised mitochondria, JC-1 exists in the aggregated form, which 
emits at 585 nm and appears as punctate red/orange mitochondrial staining on a green 
cytoplasmic surround. In cells possessing depolarised mitochondria, JC-1 exists in the 
monomeric form, which emits at 527 nm and appears as green mitochondrial staining 
indistinguishable from the green cytoplasm (Salvoli et al., 1997). Cells possessing 
depolarised mitochondria were counted on three coverslips per treatment on three 
independent occasions (each coverslip comprising 10 fields of view). Microglia 
exhibiting depolarised mitochondria were expressed as a percentage of the total 
number of cells counted per field.
2.2.12.4 Assessment o f cell membrane integrity
Cell membrane integrity was assessed using the fluorescent dyes fluoroscein diacetate 
and propidium iodide (Jones and Senfi 1985; Kingham et al., 1999). Cells on 
coverslips were incubated with basic medium containing fluoroscein diacetate (15 
(ig/ml) and propidium iodide (5 p.g/ml) for 10 minutes at 37 °C in the dark. Cell 
viability was subsequently assessed at 380 nm with emission greater than 505 nm 
collected. Fluoroscein diacetate is metabolised in healthy cells to form a fluorescent
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product, which emits at 530 nm, staining live cells green. Propidium iodide, however, 
penetrates dead cells possessing compromised plasma membranes where it 
intercalates between the bases of DNA and emits at 600 nm appearing red. Live and 
dead cells fluorescing green or red respectively were counted on three coverslips per 
treatment on three independent occasions (each coverslip comprised 1 0  fields of 
view). Dead cells were expressed as a percentage of the total number of cells counted 
per field.
2.2.12.5 Assessment o f apoptosis
Apoptosis was assessed using the fluorescent dye 2'[epoxyphenyl]-5-[4-methyl-l- 
piperazinyl]-2,5'-bi-lH-benzimidazol (Hoechst 33342) (Rivera et al., 1998; Kingham 
et al., 1999). Hoechst 33342 binds to the minor groove of DNA with a preference for 
AT sequences (Portugal and Waring 1988). Cells on coverslips were fixed in 
formaldehyde (4 %) in phosphate buffered saline at 4 °C, then incubated with 
Hoechst 33342 (17.8 pM) for 10 minutes at 20 °C in the dark. Nuclear morphology 
was subsequently appraised at 365 nm with emission greater than 490 nm collected. 
Following staining, apoptotic cells possess brightly stained pyknotic nuclei, whereas, 
non apoptotic cells possess large weakly stained nuclei. Apoptotic cells were counted 
on three coverslips per treatment on three independent occasions (each coverslip 
comprised 10 fields of view). Apoptotic cells were expressed as a percentage of the 
total number of cells counted per field.
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2.2.12.6 Assessment o f apoptosis and necrosis
Hoescht 33342 and propidium iodide staining was used to distinguish necrotic and 
apoptotic cells (Thuret et al., 2003). Cells on coverslips were incubated with basic 
medium containing Hoescht 33342 (17.8 pM) and propidium iodide (5 pg/ml) for 10 
minutes at 37 °C in the dark. Cell viability was subsequently assessed at 380 nm with 
emission greater than 505 nm collected. Apoptotic cells were counted as those cells 
possessing brightly stained pyknotic nuclei as demonstrated by Hoescht 33342 
staining. Late apoptotic cells also stained with propidium iodide in addition to 
exhibiting pyknotic nuclei. Necrotic cells were counted as those cells possessing 
propidium iodide staining accompanied with large unstained nuclei as demonstrated 
by Hoescht 33342. Healthy cells were counted as cells possessing large unstained 
nuclei as demonstrated by Hoescht 33342 with no propidium iodide staining. Cells 
were counted on three coverslips per treatment on three independent occasions (each 
coverslip comprised 10 fields of view). Apoptotic and necrotic cells were expressed 
as a percentage of the total number of cells counted per field.
2.2.12.7 FITC albumin uptake
Microglia or peritoneal macrophages were incubated with FITC labelled albumin (0.5 
mg/ml) in SFM for 1 hour at either 37 °C or 4 °C (Tabemero et al., 2002a, b). Cells 
were then washed in three changes of PBS and examined with a Zeiss epi- 
fluorescence microscope coupled to an Axiovision imaging system (version 3.1). 
Phase contrast and fluorescent images of the cells were immediately photographed 
with an exposure time of 30 seconds.
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2.2.13 Statistical analysis
To compare a single treatment with a control group, a two sided, unpaired T-test was 
used. Comparison of two or more treatments with a control group (or other treatment) 
was made using a one way analysis of variance (ANOVA) in combination with the 
Tukey post test. P values < 0.05 were considered statistically significant.
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j3.0 Characterisation of primary cultures
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3.1 Introduction
3.1.1 Preparation of microglial cultures
Microglia can be isolated from the brain using percoll density gradients (Havenith et al., 
1998; Kingham and Pocock 2000); alternatively microglia can be harvested based on their 
differential adhesive properties by agitating mixed glial cultures after 7-12 days in vitro 
(Nolte et al., 1996; McDonald et al., 1997; Moller et al., 2000a, b; Casal et al., 2002). In 
this thesis microglia were prepared using percoll gradients because this method yields 
extremely pure microglial cultures (Kingham et al., 1999; Kingham and Pocock 2000). 
Furthermore, the microglia are less activated since they are in culture for very short 
periods of time (Slepko and Levi 1996).
3.1.2 Identification of microglia
Microglial identification has been hampered due to the lack of microglial specific 
antigens; all antibodies used for the detection of microglia are raised against macrophage 
specific antigens. However, recent advances in microglial identification have been 
achieved using FACS. Using this approach ramified parenchymal microglia have been 
demonstrated to possess the phenotype CD1 lb+CD45low, whilst other CNS macrophages 
and peripheral macrophages exhibit the phenotype C D llb+CD45high (Ford et al., 1995; 
Becher and Antel 1996). A number of other techniques are available for the identification 
of microglia, although these procedures fail to distinguish microglia from macrophages 
(due to the lack of microglial specific markers). Thus, it is not surprising that these 
techniques preferentially label reactive and amoeboid microglia, which are more akin to 
active macrophages than ramified microglia. Nevertheless, ramified microglia can be 
detected using monoclonal antibodies raised against macrophage specific antigens. OX-42 
(Graeber et al., 1989) and MAC-1 (Perry et al., 1985) recognise the CR3 complement 
receptor (CDllb/CD18) in rat and murine microglia respectively. The 2.4G2 antibody
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recognises the Fc receptor and F4/80 binds an unknown antigen on murine ramified 
microglia (Perry et al., 1985). Alternatively, ED-1 an antibody that recognises a lysosomal 
protein can be used to stain microglia (Graeber et al., 1990; Slepko and Levi 1996). High 
levels of ED-1 expression are associated with activated microglia whilst low levels of 
expression are associated with quiescent ramified microglia (Graeber et al., 1990; Slepko 
and Levi 1996). Furthermore, identification of ramified microglia can be achieved using 
Rio Hortega's original silver staining technique, phosphatase staining or lectin binding. 
Lectins are carbohydrate binding proteins that selectively label microglia through the 
recognition of d-galactose. Commonly used lectins include B4 isolectin (Murabe and Sano 
1981a), mistletoe lectin (Streit and Kreutzberg 1987) and agglutinin-120 (Suzuki et al., 
1988).
Techniques are also available for the identification of reactive and amoeboid microglia, 
however these procedures do not stain ramified microglia. Such procedures include 
staining for non-specific esterases (Murabe and Sano 1981b; Giulian and Baker 1986) or 
the intermediate filament vimentin (Graeber et al., 1988a). Alternatively, fluorescently 
labelled acetylated low-density lipoprotein (LDL) can be used which selectively labels 
LDL receptors expressed by reactive microglia (Giulian and Baker 1986).
3.1.3 Preparation of cerebellar granule cells
Cerebellar granule neurones constitute approximately 94 % of the cells in the human 
(Anderson et al., 1992) and rat (Korbo et al., 1993) cerebellum; therefore it is easy to 
prepare pure cultures of granule neurones from the undifferentiated cerebellum without 
contamination from other neuronal cell types (Gallo et al., 1982; Pearce et al., 1987). 
Furthermore, contamination by glia can be minimised by supplementing the culture
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medium with the mitotic inhibitor cytosine arabinofuranoside (Gallo et al., 1982; Xu and 
Chuang 1987).
3.1.4 Identification of cerebellar granule cells
At present there are no known cerebellar granule neurone specific markers, therefore in 
this thesis granule cells were identified according to morphological criteria. Following 
plating cerebellar granule cells appear rounded, however after 7 days in vitro granule cell 
somas form clusters and extend cable like neurites. It is interesting to note that 7 day old 
cerebellar granule neurones exhibit other features of mature neurones including expression 
of glutamatergic (Pearce et al., 1987; Aronica et al., 1993; Archibald et al., 1998; Pocock 
and Nicholls 1998), serotineigic, adrenergic and histaminergic receptors (Xu and Chuang 
1987). Moreover, mature granule neurones express voltage dependent calcium channels 
(Pocock et al., 1995) and display synaptic connectivity (Xu and Chuang 1987). Since 
cultured granule cells lack afferent mossy fiber input they require depolarising conditions 
for survival (Gallo et al., 1987). This was achieved in vitro by supplementing the medium 
with potassium chloride (20-40 mM).
3.1.5 Summary of results
Primary microglial cultures isolated by percoll density gradient were rich in resting 
microglia as determined by 0X42, CD45 and ED-1 staining. Microglia exhibited low 
granularity reflecting a down-regulated phenotype and cultures did not contain any 
contaminating astrocytes. Peritoneal macrophage cultures were also found to be extremely 
pure, although these cells were more activated than microglia. Furthermore, staining 
revealed that cerebellar granule cell cultures exhibited minimal contamination from glia.
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32  Immunological profiling of the microglial cultures
The purity of microglial cultures was assessed by immunocytochemistry using a number 
of monoclonal antibodies. Microglia were stained with OX-42, wbich recognises the CR3 
complement receptor (CD1 lb/CD 18) (Graeber et al., 1989) and ED-1 an antibody that 
recognises a lysosmal protein (Graeber et al., 1990; Slepko and Levi 1996). Furthermore, 
the presence of astrocytes in the microglial cultures was assessed by staining for glial 
fibrillary acidic protein (GFAP), which is an astrocytic marker (Eliasson et al., 1999). 
Macrophages isolated from the peritoneal cavity of adult (> 6  months) rats were also 
stained with OX-42 and ED-1 to check for purity.
Immunocytochemistry revealed that the vast majority of microglia and macrophages 
exhibited CR3 (CDllb) reactivity as demonstrated by OX-42 staining (Fig. 3.1AJB). 
Approximately half of the microglial cells in the cultures expressed ED-1, whereas the 
majority of macrophages expressed this lysosomal antigen. Furthermore, microglial 
cultures did not contain any GFAP positive astrocytes. Control cultures that were not 
exposed to primary antibody did not exhibit any positively stained cells, which 
demonstrates that the staining is specific. Taken together, these results suggest that the 
microglial and macrophage cultures are extremely pure.
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Figure 3.1 (see overleaf for figure legend)
B%  Im  mu no reactivity
CR3 (CD llb) ED-1 GFAP
Microglia 99 ±1.4 55.2 ±6.2 0
Macrophages 96.5 ±4.6 95.7 ±5.6 N/A
Figure 3.1 Immunological profile of microglial and peritoneal macrophage cultures
A: Microglia and peritoneal macrophages (isolated from adult rats) were stained with antibodies 
recognizing CR3(CD11b) (OX-42), ED-1 or GFAP after 24 hours in culture. Primary antibodies 
were detected using anti-mouse IgG secondary antibody conjugated to biotin. The staining was 
subsequently visualized by incubating the cells with a pre-formed avidin-biotin horseradish 
peroxidase (HRP) complex for 1 hour at room temperature, followed by treatment with DAB. Cells 
were counterstained with haematoxylin to provide an estimation of total cell number. Control cells 
were processed omitting the incubation with primary antibody. B: The values represent the mean 
number of positively stained cells present per field of view ± sem.
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A number of disadvantages are associated with immunocytochemical staining. Firstly, it 
cannot be used to quantify levels of receptor expression and secondly it cannot be used to 
distinguish microglia from other CNS macrophages (or peripheral macrophages) due to 
the lack of microglial specific antigens. Recent advances in microglial identification have 
been made using FACS. This technique enables quantification of receptor expression 
through the measurement of fluorescent staining intensity. Therefore, using FACS 
ramified parenchymal microglia have been demonstrated to possess the phenotype 
C D llb+CD45low. In contrast, peripheral macrophages and CNS macrophages found in the 
meninges, the subarachnoid space, the choroid plexus or in a perivascular location possess 
the phenotype C D llb+CD45high (Ford et al., 1995; Becher and Antel 1996). The 
immunological profile of the microglial cells was subsequently assessed according to 
these parameters. In this way, the presence of other CNS macrophages in the microglial 
cultures could be appraised. Microglia were also stained with ED-1 to further characterise 
the activational state of the cells and to complement immunocytochemical data. 
Macrophages isolated from the peritoneal cavity of neonatal (3-6 day old) or adult (> 6  
months) rats were used as positive controls, the former providing aged matched 
equivalents to the microglia.
FACS analyses revealed that most microglia (80.4 %) and macrophages isolated from 
neonatal (98.1 %) or adult (95.8 %) rats expressed CD1 lb (Fig 3.2). Macrophages derived 
from neonatal rats exhibited a mean fluorescence intensity (MFI) which was twice as great 
as the microglial value, whereas macrophages isolated from adult rats possessed a MFI 
that was approximately 19 times as great. Therefore, macrophages derived from neonatal 
rats express less CD1 lb than their adult counterparts; however, in general macrophages 
express considerably more CD1 lb than microglia.
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Only a small proportion of microglia (21.8 %) displayed CD45 reactivity, which is 
consistent with the report published by Ford et al., (1995) (Fig. 3.3). In contrast, the 
majority of macrophages isolated from neonatal (98.1 %) or adult (93.9 %) rats expressed 
CD45. Macrophages derived from neonatal tissue exhibited a MFI that was twice as great 
as the microglial value, whilst macrophages isolated from adult tissue possessed a MFI 
that was about 21 times as great. Thus, macrophages isolated from neonatal rats express 
less CD45 than macrophages derived from adult rats, although macrophages per se 
express higher levels of CD45 than microglia.
A fairly large number of microglia were shown to express ED-1 (63.6 %), albeit at 
extremely low levels (Fig. 3.4). Furthermore, most macrophages isolated from neonatal 
(98.9 %) or adult (99.4 %) rats expressed ED-1. Macrophages isolated from either age rat 
exhibited similar MFIs and these values were approximately 14 fold higher than the MFI 
obtained with microglia. This indicates that macrophages generally express much more 
ED-1 than microglia.
The forward scatter (FSC) and side scatter (SSC) of ‘aged matched’ microglia and 
peritoneal macrophages (isolated from 3-6 day old rat pups) were subsequently compared. 
FSC reflects the size of a cell, whilst SSC provides a measure of intracellular granularity. 
FACS analysis revealed that microglia and peritoneal macrophages are comparable in 
size, but microglia are considerably less granular (Fig. 3.5).
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Figure 3.2 Expression of CD11b by microglia and peritoneal macrophages
Representative FACS plots of CD11b expression. Microglia and peritoneal macrophages were 
isolated and left in culture for 24 hours. The cells were subsequently harvested, fixed then 
analysed by flow cytometry. A: Expression of CD11b by microglia isolated from 3-6 day old rats. 
B: Expression of CD11b by peritoneal macrophages isolated from 3-6 day old rats. C: Expression 
of CD11b by peritoneal macrophages isolated from adult rats. The CD11b labelled cells are 
represented by the black shaded populations, whereas the unlabelled cells are depicted by the 
grey line (%: % of cells in M1 or M2 region, MFI: mean fluorescence intensity).
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Figure 3.3 Expression of CD45 by microglia and peritoneal macrophages
Representative FACS plots of CD45 expression. Microglia and peritoneal macrophages were 
isolated and left in culture for 24 hours. The cells were subsequently harvested, fixed then 
analysed by flow cytometry. A: Expression of CD45 by microglia isolated from 3-6 day old rats. B: 
Expression of CD45 by peritoneal macrophages isolated from 3-6 day old rats. C: Expression of 
CD45 by peritoneal macrophages isolated from adult rats. The CD45 labelled cells are 
represented by the black shaded populations, whereas the unlabelled cells are depicted by the 
grey line (%: % of cells in M1 or M2 region, MFI: mean fluorescence intensity).
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Figure 3.4 Expression of ED-1 by microglia and peritoneal macrophages
Representative FACS plots of ED-1 expression. Microglia and peritoneal macrophages were 
isolated and left in culture for 24 hours. The cells were subsequently harvested, fixed then 
analysed by flow cytometry. A: Expression of ED-1 by microglia isolated form 3-6 day old rats. B: 
Expression of ED-1 by peritoneal macrophages isolated from 3-6 day old rats. C: Expression of 
ED-1 by peritoneal macrophages isolated from adult rats. The ED-1 labelled cells are represented 
by the black shaded populations, whereas the unlabelled cells are depicted by the grey line (%: % 
of cells in M1 or M2 region, MFI: mean fluorescence intensity).
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Figure 3.5 Size and granularity of microglia and peritoneal macrophages
Representative FACS plots of size and granularity of microglia and macrophages. Microglia and 
peritoneal macrophages were isolated from 3-6 day old rats and left in culture for 24 hours. The  
cells were subsequently harvested, fixed then analysed by flow cytometry. A: Comparison of 
microglial and peritoneal macrophage side scatter (SSC) as an indication of intracellular 
granularity. B: Comparison of microglial and peritoneal macrophage forward scatter (FSC) as a 
measure of cell size. The microglial cell population is represented by the grey line, whereas the 
peritoneal macrophage population is depicted by the black shaded population.
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33  Assessment of cerebellar granule neurone preparation purity
The presence of contaminating microglia and astrocytes in the cerebellar granule neuronal 
cultures was assessed by immunocytochemistry. Microglia and astrocytes were stained 
with antibodies recognizing CR3/CDllb (OX-42) and GFAP respectively, whilst 
neurones were identified according to morphological criteria. Immunocytochemistry 
revealed that cerebellar granule neuronal cultures contained very few microglia and 
astrocytes (Fig. 3.6A,B). Moreover, control cultures that were not exposed to primary 
antibody did not exhibit any positively stained cells, which demonstrates that the staining 
is specific. These findings indicate that the cerebellar granule neuronal cultures are 
extremely pure.
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Figure 3.6 Purity of cerebellar granule neurone cultures
A: Cultures of cerebellar granule neurones were stained with antibodies recognizing CR3/CD11b  
or GFAP after 7 days in culture to identify microglia and astrocytes respectively. Primary 
antibodies were detected using anti-mouse IgG secondary antibody conjugated to biotin. The  
staining was subsequently visualized by incubating the cells with a pre-formed avidin-biotin 
horseradish peroxidase (HRP) complex for 1 hour at room temperature, followed by treatment with 
DAB. Cells were counterstained with haematoxylin to provide an estimation of total cell number 
and neurones were identified according to morphological criteria. Control cultures were processed 
omitting the incubation with primary antibody. B: The values represent the mean number of cells 
present per field of view ± sem
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3.4 Discussion
Microglial, peritoneal macrophage and cerebellar granule neurone cultures were found to 
be almost entirely pure. Therefore, the results presented in this thesis can be interpreted 
with confidence, since the responses are likely to reflect a true representation of each cell 
type.
3.4.1 Microglial cultures
Microglial cultures were demonstrated to comprise of parenchymal microglia as 
demonstrated by FACS. Using this technique parenchymal microglia can be identified 
because these cells exhibit the phenotype CD1 lb+CD45low, whereas other CNS 
macrophages and peripheral macrophages exhibit the phenotype CD1 lb+CD45b‘gh (Ford et 
al, 1995). This is useful to note since each distinct population of macrophages in the brain 
(supraependymal cells, epiplexus cells, subarachnoid/ leptomeningeal macrophages, 
perivascular macrophages or microglia) exhibit different morphological characteristics 
and perform different functions (Jordon and Thomas 1988; Streit 2002).
CD45 also known as leucocyte common antigen was identified as the first and 
prototypical transmembrane protein tyrosine phosphatase (Sasaki et al., 2001). Cell 
signalling depends on the subtle balance between tyrosine kinases and tyrosine 
phosphatases, which in concert control phosphorylation and dephosphoiylation events 
(Berg et al., 2002). CD45 is expressed by all nucleated haematopoieic cells except 
erythrocytes and platelets. CD45 is a critical positive regulator of T and B cell receptor 
mediated signalling, which is required for the activation of lymphocytes (Sasaki et al., 
2001). The main role described for CD45 in macrophages is the regulation of integrin 
mediated adhesion (Roach et al., 1997). Therefore, the finding that microglia express less 
CD45 than macrophages probably reflects the down-regulated phenotype of microglia.
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Likewise, microglia were demonstrated to express less CD llb and ED-1 than 
macrophages. C D llb is part of CR3 complement receptor (CDllb/CD18), which is 
involved in phagocytosis (Dana et al., 1991; Ueda et al., 1994), cell adhesion and 
chemotaxis (Dana et al., 1991), whilst ED-1 binds an unknown lysosomal antigen, which 
is also involved in phagocytosis (Damoiseaux et al., 1994). Thus, the finding that 
microglia express low levels of C D llb and ED-1 substantiates the notion that microglia 
exhibit a quiescent down-regulated phenotype and is in accord with previous findings 
(Kingham et al., 1999). Interestingly, macrophages isolated from neonates express less 
C D llb and CD45 than macrophages isolated from adults. This might be because 
macrophages isolated from adult rats have been exposed to more antigen and are 
consequently more activated.
Analysis of side scatter demonstrated that microglia were less granular than macrophages. 
Granularity provides a measure of intracellular inclusions such as phagosomes and 
endosomes and therefore provides further evidence that microglia are less activated than 
macrophages. In summary, these findings illustrate that microglial cultures mainly 
comprise of resting parenchymal microglia with no contamination from astrocytes or other 
CNS macrophages. In addition, experimental data revealed that peritoneal macrophage 
cultures are extremely pure.
3.4.2 Cerebellar granule neuronal cultures
Immunocytochemical staining demonstrated that cerebellar granule cell cultures contain 
minimal contamination form microglia and astrocytes. Given that the cerebellum 
comprises mainly of granule cells (Anderson et al., 1992; Korbo et al., 1993) it is likely 
that these cells represent the majority of the neuronal population in the cultures. 
Contamination by glia was minimized by adding Ara C to the culture medium. Ara C is a
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drug used in the treatment of cancer; it is an analogue of the naturally occurring 
nucleoside 2’deoxycytidine and is therefore incorporated into DNA to a limited extent, but 
it’s main cytotoxic action is the inhibition of DNA polymerase (Rang et al., 1999). Under 
normal culture conditions neurones do not divide, therefore Ara C preferentially inhibits 
glial DNA synthesis because these cells retain the propensity to replicate. Consequently, 
glial proliferation is prevented and the cultures are neurone rich, which in accord with 
previous findings (Kingham et al., 1999).
3.43 Conclusion
Results presented in this chapter exemplify that the methods used in this thesis enable the 
preparation of pure microglial, macrophage and cerebellar granule cell cultures. Thus, 
these primaiy cultures provide a robust model for studying cell signalling and microglial- 
neuronal interactions. Moreover, microglia were demonstrated to exhibit a down-regulated 
phenotype, thereby providing a large window for activation.
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4.0 Investigation of microglial signalling elicited by albumin
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4.1 Introduction
This chapter explores the signalling cascades elicited in microglia following treatment 
with albumin. The effects of albumin were studied because this plasma protein has been 
implicated in stroke (Homig et al., 1983), AD (Alafiizoff et al., 1983; Skoog et al., 1998) 
and multiple sclerosis (Gay and Esiri 1991) in cases where BBB damage is evident. The 
effects of albumin on peritoneal macrophages were also investigated, the rationale being 
that macrophages are accustomed to high concentrations of albumin, whilst microglia are 
subjected to much lower levels of this protein. The concentration of albumin in the blood 
ranges from 35-50 mg/ml (Diem 1962; reviewed by Nadal et al., 2001), whilst the 
concentration in peritoneal fluid ranges from 12.5-25 mg/ml (Kelton et al., 1978; Barber et 
al., 1990). In contrast, the concentration of albumin in the CSF is considerably lower and 
ranges from 35-50 pg/ml (reviewed by Nadal et al., 2001).
4.1.1 Physiological roles of albumin
Albumin is a 6 6  kDa protein that constitutes approximately 50 % of all plasma proteins 
(reviewed by Nadal et al., 2001). Albumin exhibits a globular shape and at physiological 
pH, its surface is covered by a number of charged groups accounting for its water 
solubility. An important function of albumin is to bind fatty acids and thereby make them 
more soluble in aqueous solutions such as plasma (reviewed by Nadal et al., 2001). Each 
albumin molecule possesses 3 primary, 3 secondary and 63 tertiary fatty acid binding sites 
(Spector et al., 1969). Albumin binds almost all fatty acids released into the blood from 
adipose cells including palmitic acid, oleic acid, linoleic acid and steric acid. The form of 
albumin that comprises attached fatty acids is known as fraction V, owing to the 
separation method by which it is extracted. Fraction V can be further sub-divided into 
semm and plasma albumin, which are derived from coagulated or un-coagulated blood 
respectively (reviewed by Nadal et al., 2001). Consequently, serum albumin comprises
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bound coagulation factors such as lysophosphatidic acid (LPA), which is a phospholipid 
that is released from platelets during coagulation (reviewed by Nadal et al., 2001). Other 
physiological roles of albumin include the maintenance of blood pressure and the 
buffering of blood pH (Sherwood 1993).
4.1.2 Effects of albumin on ‘brain’ cells
Recently, a group from Japan have demonstrated that serum, plasma and fatty acid free 
albumin potentiate phorbal myristate acetate (PMA) induced superoxide production in 
microglia (Si et al., 1997). The same group have identified the active sequence of albumin 
to be a 12mer that is located near the N-terminus on the outer surface of the protein 
(Nakamura et al., 2000). In astrocytes, plasma and serum albumin (fraction V) evoke 
calcium waves and a calcium-dependent proliferative response (Nadal et al., 1995; 1997). 
However, these effects are due to the presence of an unidentified polar lipid that is 
normally bound to both the plasma and serum forms of albumin (fraction V). This lipid is 
unlikely to be the calcium mobilizing phospholipid LPA (Moller et al., 2001) since plasma 
and serum albumin (fraction V) are equi-potent (Nadal et al., 1995). Nevertheless, the 
protein component of albumin irrespective of the presence of attached lipids promotes the 
uptake of calcium into intracellular stores (Nadal et al., 1996). From a functional point of 
view, this may serve to potentiate the effects of calcium mobilizing agonists such as 
glutamate and bradykinin.
Other studies have shown that essentially fatty acid free albumin stimulates the synthesis 
of oleic acid (a fatty acid) from glucose and lactate through a mechanism involving the 
transcription factor SREBP-1 (Tabemero et al., 2002a). Astrocyte derived oleic acid 
subsequently induces neuronal phospholipid synthesis, which in turn promotes axonal 
growth (Tabemero et al., 2001). Therefore, albumin may play a role in axonal sprouting in
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the fetus when the concentration of albumin is known to be much higher than in the adult 
(Tabemero et al., 2001). Furthermore, astrocytes (Tabemero et al., 2002a) and neurones 
(Tabemero et al., 2002b) have been reported to internalize albumin. Essentially fatty acid 
free albumin also increases the oxidation of glucose or lactate through the pyruvate 
dehydrogenase catalysed reaction in both astrocytes (Tabemero et al., 1999) and neurones 
(Tabemero et al., 2002b). This results in the increased production of acetyl coenzyme A 
(acetyl Co A) without affecting the rate of pyruvate oxidation through the citric acid cycle. 
This phenomenon is believed to be a consequence of intracellular fatty acid sequestration 
since fatty acids are known to inhibit pyruvate dehydrogenase.
From these studies it is clear that the protein component of albumin triggers several 
distinct cellular functions and can therefore be considered as an agonist in its own right. 
Interestingly, in healthy individuals reactive microglia are evident in areas where the BBB 
is absent. These areas are collectively known as the circumventricular organs, which 
include the pineal gland, the median eminence, the subfornical organ, the area postrema, 
the subcommissural organ, the organum vasculosum of the lamina terminalis and the 
pituitary gland (Cagnin et al., 2001, Perry 2001). This provides evidence that plasma 
proteins such as albumin may mediate microglial activation in vivo.
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4.1.3 Summary of results
Treatment of microglia with essentially pure rat serum albumin containing 0.005 % fatty 
acids and 0.005 % immunoglobulins (hereafter referred to as albumin) induced iNOS 
expression and glutamate release, whilst exerting no effect on COX-2 expression. 
Furthermore, albumin triggered microglia to proliferate. These findings were mirrored 
using rat fraction V serum albumin (hereafter referred to as fraction V), suggesting that 
albumin bound fatty acids, lipids or immunoglobulins do not contribute to cell signalling. 
Lipopolysaccharide (LPS) was shown to induce iNOS expression, COX-2 expression and 
glutamate release in microglia, although LPS did not trigger microglia to proliferate.
Peritoneal macrophages isolated from neonatal or adult rats were resistant to the 
concentrations of albumin or fraction V used to activate microglia. Even at a concentration 
of 12 mg/ml, albumin or fraction V failed to induce glutamate release or proliferation in 
these cells. However, peritoneal macrophages isolated from neonatal or adult rats 
expressed iNOS when exposed to 12 mg/ml of albumin or fraction V. Albumin or fraction 
V also failed to induce COX-2 expression in macrophages, even at concentrations of 12 
mg/ml. Interestingly, LPS (2 pg/ml) induced iNOS and COX-2 expression in 
macrophages but did not potentiate glutamate release or proliferation.
The microglial signalling cascades that mediate albumin or fraction V-induced iNOS 
expression, glutamate release and proliferation were subsequently studied using a number 
of inhibitors. iNOS expression was attenuated by U0126, which suggests that signalling is 
mediated by ERK. Consistent with this, the phosphorylated forms of ERK 1 and 2 were 
detectable in microglia but not macrophages (isolated from neonatal or adult rats) treated 
with albumin or fraction V. Glutamate release was prevented by aminoadipate, suggesting 
a role for the Xc" transporter in secretion. Proliferation was inhibited by BAPTA, U73122
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or PP2. This indicates that the proliferative response is calcium dependent and that release 
is mediated through IP3 gated stores via a Src kinase-dependent mechanism. Accordingly, 
albumin or fraction V evoked calcium release from thapsigargin-sensitive intracellular 
stores in N9 microglia and release was inhibited by U73122 or PP2. Albumin or fraction 
V treatment did not induce changes in intracellular free calcium in macrophages isolated 
from neonatal or adult rats. Conversely, fraction V induced calcium transients in TSA-3 
astrocytes, whereas albumin exerted no discemable effects on intracellular free calcium in 
these cells.
In a parallel experiment, conditioned medium harvested from albumin or fraction V 
treated microglia was demonstrated to be neurotoxic. Neuronal death was not attenuated 
by the iNOS inhibitor, AMT-HC1 or a cocktail of glutamate receptor antagonists (MK801, 
CNQX and MSPG). These results suggest that neuronal death is NO and glutamate 
independent In contrast, boiling the microglial conditioned medium afforded 
neuroprotection, which suggests that the neurotoxic agent(s) are heat labile. Neurotoxin 
release from microglia occurred 6  hours after the addition of albumin or fraction V and the 
neurotoxicity of the conditioned medium increased with time.
Finally, albumin was demonstrated to bind to myosin heavy chain IX in N9 microglia. 
Albumin was also found to bind to myosin heavy chain IX in TSA-3 astrocytes and 
cerebellar granule neurones. This suggests that myosin heavy chain IX may serve as a 
non-conventional receptor in these cells through which albumin mediates signalling. 
Conversely, albumin did not appear to bind to myosin heavy chain IX in peritoneal 
macrophages isolated from adult rats. Myosin IX has recently been implicated in 
phagocytosis, consistent with this microglia but not macrophages internalised FITC 
labelled albumin in a temperature sensitive fashion.
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4.2 Albumin induces iNOS expression in microglia
Microglia were analysed for iNOS expression following exposure to albumin. Microglia 
were treated with albumin in serum free medium (SFM) for 2 hours. The SFM was then 
replaced with serum containing medium (SCM) for the remainder of the experimental 
period. This activation protocol was used in all subsequent experiments described in this 
chapter. Therefore, it should be emphasised that the time points described in the text 
include the initial 2 hour incubation with albumin in SFM. Microglia were treated with 
albumin in SFM because serum contains endogenous albumin, fatty acids, lipids and other 
factors that may synergise with the exogenously applied albumin.
Western blot analyses revealed that albumin (0.1-2 mg/ml) induced a dose dependent 
increase in iNOS expression after 24 hours in culture (Fig. 4.1 A). All blots were cropped 
to depict the area of interest; iNOS was visualised as a single band exhibiting a molecular 
weight of 130 kDa (Bhat et al., 1998; Kingham et al., 1999; Combs et al., 2001; Bhat and 
Fan 2002). In contrast, iNOS was not present in untreated microglia at the same time point 
(basal). Similarly, iNOS was undetectable in microglia treated with SFM for 2 hours 
(without albumin) then SCM for 22 hours (SFM). Analysis of p-actin levels demonstrated 
that the observed changes were not due to differences in protein loading, p-actin was 
visualised as a single band possessing a molecular weight of 42 kDa (Clancy et al., 2000; 
Kingham and Pocock 2000).
To confirm that residual fatty acids, lipids or immunoglobulins bound to albumin were not 
responsible for inducing iNOS, the effects of fraction V on iNOS expression were 
investigated (Fig. 4.IB). As with albumin, microglia were treated with fraction V in SFM 
for 2 hours. The SFM was then replaced with SCM for the remainder of the experiment.
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Fraction V (1 mg/ml) induced similar levels of iNOS expression as albumin after 24 hours 
in culture as demonstrated by Western blotting. The effect of the known microglial 
activator, LPS on iNOS expression was also investigated (Fig. 4.IB). In all experiments 
described in this chapter microglia were treated with LPS (2 pg/ml) in SCM for the 
designated length of time. Western blotting revealed that microglia treated with LPS (2 
pg/ml) expressed comparable levels of iNOS as those cells treated with albumin (1 
mg/ml) or fraction V (1 mg/ml) after 24 hours in culture. Time course analysis revealed 
that iNOS was initially detectable 6  hours after the addition of albumin (1 mg/ml) or 
fraction V (1 mg/ml) (Fig. 4.1C). iNOS expression was found to increase with time and 
the activators induced identical expression profiles temporally. In contrast, iNOS was 
undetectable in microglia treated with SFM for 2 hours then SCM for 46 hours.
In a parallel experiment, nitrite, a stable breakdown product of NO was measured in 
microglial conditioned medium. Nitrite was not detectable above control levels (‘basal’ or 
‘SFM’) in medium collected 48 hours after albumin (1 mg/ml) or fraction V (1 mg/ml) 
treatment (table 4.1). Similarly, negligible amounts of nitrite were present in medium 
collected from microglia treated with LPS (2 pg/ml) for 48 hours. This was not due to 
assay failure since nitrite was detectable in culture medium collected from activated 
macrophages (see table 4.3).
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Figure 4.1 iNOS expression in microglia
Representative Western blots of iNOS expression in microglial cell lysates. A: Microglia were 
treated with increasing concentrations of albumin (0.1-2 mg/ml) in SFM for 2 hours. The SFM was 
then replaced with SCM for 22 hours before lysates were prepared. Control lysates were prepared 
from microglia left untreated for 24 hours (basal) or microglia exposed to SFM for 2 hours then 
SCM for 22 hours (SFM). B: Microglia were exposed to albumin (Alb: 1 mg/ml) or fraction V  (Fv: 1 
mg/ml) in SFM for 2 hours, after which the SFM was replaced with SCM  for a further 22 hours 
before lysis. Lysates were also prepared from microglia treated with LPS (2 ng/ml) in SCM for 24 
hours. Control lysates were prepared from microglia treated as described in A. C: Microglia were 
treated with albumin (1 mg/ml) or fraction V  (1 mg/ml) in SFM for 2 hours. The SFM was then 
replaced with SCM for a further 1 , 4 , 6 ,  22 or 46 hours before lysis. Control lysates were prepared 
from microglia subjected to SFM for 2 hours then SCM for 46 hours (SFM). Lysates were 
subjected to Western blot analysis using an antibody raised against iNOS (1:5000), which in turn 
was detected by goat anti-rabbit IgG (HRP) (1:500). To ensure equal protein loading blots were 
reprobed with an antibody recognising (3-actin (1:1000) followed by exposure to goat anti-mouse 
IgG (HRP) (1:1000).
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Treatment [Nitrite] (nM/pg protein)
Basal 1.04 ±0.03
SFM 0.94 ± 0.03
Albumin (1 mg/ml) 1.29 ±0.20
Fraction V (1 mg/ml) 1 . 1 2  ± 0 . 0 2
LPS (2 pg/ml) 1.13 ±0.03
Table 4.1 Nitrite release from microglia
Nitrite concentrations (nM/^g of protein) were measured in microglial conditioned medium using 
Griess reagent Microglia were treated with albumin (1 mg/ml) or fraction V  (1 mgAnl) in SFM lor 2 
hours. The SFM was then replaced with SCM for a further 46 hours before medium was collected. 
Medium was also collected from microglia treated with LPS (2 ng/ml) in SCM for 48 hours. Control 
medium was collected from microglia left untreated for 48 hours (basal) or microglia exposed to 
SFM for 2 hours then SCM for 46 hours (SFM). The values shown represent the mean 
concentration in nM/pg of protein ± SEM of data from experiments performed in triplicate. 
Statistical analysis was performed using ANOVA followed by the Tukey post test According to this 
test there was no statistical difference between the treatments.
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The signalling pathways that mediate albumin or fraction V induced iNOS expression 
were subsequently studied using a number of inhibitors. At the concentrations used in 
these experiments the inhibitors (pertussis toxin, 2 pg/ml; BAPTA-AM, 10 pM; U73122, 
2 pM; PP2, 100 nM; U0126, 5 pM) did not induce morphological changes or detachment 
from the coverslips. Confirmation that the inhibitors were not toxic was obtained using 
propidium iodide and fluoroscein diacetate. Propidium iodide penetrates dead or damaged 
cells possessing compromised plasma membranes where it intercalates between the bases 
of DNA and fluoresces upon excitation. In contrast, fluoroscein diacetate is metabolised 
by healthy cells to form a fluorescent product and therefore provides an estimation of the 
total number of viable cells.
Microglia were treated with the inhibitors in SFM for 2 hours. The SFM was then replaced 
with SCM supplemented with the appropriate concentration of inhibitor for a further 22 
hours before staining. Microglial cultures exposed to the inhibitors contained very few 
propidium iodide positive cells after 24 hours in culture (table 42). Similarly, microglial 
cultures left untreated for 24 hours (basal) or cultures treated with SFM for 2 hours then 
SCM for 22 hours (SFM) contained few cells exhibiting propidium iodide staining. These 
findings emphasize that at the concentrations used the inhibitors were not toxic to the 
microglia.
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Treatment % of propidium iodide stained cells
Basal 2 . 1  ± 1 . 1
SFM 2 . 0  ± 1 . 6
Pertussis toxin (2 pg/ml) 1.4 ±0.4
BAPTA-AM (10 pM) 1.6 ±0.3
U73122 (2 pM) 1.9 ±0.7
PP2 (100 nM) 22  ± 0 . 6
U0126 (5 pM) 2 . 1  ± 2 . 1
Table 4.2 Analysis of inhibitor toxicity using propidium iodide
Inhibitor treated microglia were stained with propidium iodide and fluoroscein diacetate to provide 
an estimation of toxicity. Microglia were treated with inhibitors (pertussis toxin, 2 pg/tnl; BAPTA- 
AM, 10 pM; U73122, 2 pM; PP2, 100 nM; U0126, 5 pM) in SFM for 2 hours. The SFM was then 
replaced with SCM supplemented with the appropriate concentration of inhibitor for a further 22 
hours before staining. Control microglia were either left untreated for 24 hours of were treated 
with SFM for 2 hours then SCM for 22 hours before staining. Dead cells possessing propidium 
iodide staining were expressed as a percentage of the total number of cells counted (cells 
possessing propidium iodide staining or fluoroscein diacetate staining). The values shown 
represent the mean ± SEM of data from experiments performed in triplicate. Statistical analysis 
was performed using ANOVA followed by the Tukey post test According to this test there was no 
statistical difference between the treatments.
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Western blot analyses revealed that pre-treating microglia with pertussis toxin (Ptx: 2 
pg/ml) a Gi/o protein inhibitor, BAPTA-AM (10 pM) a membrane permeable calcium 
chelator, U73122 (2 pM) a phospholipase C inhibitor or PP2 (100 nM) a Src kinase 
inhibitor did not modulate iNOS expression induced by albumin (1 mg/ml) or fraction V 
(1 mg/ml) (Fig. 4.2A). Furthermore, microglia treated with the inhibitors alone did not 
express significantly different levels of iNOS from control (‘basal’ or ‘SFM’). Conversely, 
pre-treating microglia with U0126 (5 pM) an ERK inhibitor dramatically attenuated 
iNOS expression induced by albumin (1 mg/ml) or fraction V (1 mg/ml). Maximal 
inhibition was obtained with a concentration of 5 pM and at this concentration microglia 
treated with U0126 alone contained similar levels of iNOS as controls (‘basal’ or ‘SFM’). 
Densitometric analysis was used to quantify the iNOS bands. To correct for slight 
variations in protein loading the intensity of the iNOS bands were normalised with respect 
to p-actin levels. Using this approach U0126 (5 pM) was demonstrated to cause a four 
fold reduction in the levels of iNOS expression induced by albumin (1 mg/ml) or fraction 
V (1 mg/ml) (Fig. 4.2B).
148
- in h ib ito r +  in h ib ito r
Basal SFM Alb Fv Alb Fv in
iNOS
Actin
Ptx
iNOS
Actin
BAPTA
iNOS
Actin
U73122
iNOS
Actin
PP2
iNOS
Actin
U0126
B e
u
•>5
C /3
O 1
S
©
o
68
CO
+ Alb
£
to<z>
n
to
eq
<sn
to
to £
o
to
.S
U
O 1
5
©
o
+ Fv
« £
SS to
£  05
a
to
©
* * *
149 Figure 4.2 (see overleaf for figure legend)
Figure 4.2 Modulation of albumin or fraction V induced iNOS expression in microglia
Representative Western blots of iNOS expression in microglial cell lysates. A: Microglia were 
treated with albumin (1 mg/ml) or fraction V  (1 mg/ml) in SFM for 2 hours. The SFM was then 
replaced with SCM for 22 hours before lysates were prepared. In addition, microglia were treated 
with albumin (Alb: 1 mg/ml) or fraction V  (Fv: 1 mg/ml) in SFM in the presence of pertussis toxin 
(Ptx; 2 pg/ml), BAPTA (10 pM), U73122 (2 pM), PP2 (100 nM) or U0126 (5 pM). At 2 hours the 
SFM was replaced with SCM supplemented with the appropriate concentration of inhibitor for a 
further 22 hours before lysates were prepared. Lysates were also prepared from microglia treated 
with the inhibitors (iii: Ptx; 2 pgAnl, BAPTA; 10 pM, U73122; 2 pM, PP2; 100 nM, U0126; 5 pM) in 
the absence of albumin or fraction V. Control lysates were prepared from microglia left untreated 
for 24 hours (basal) or microglia exposed to SFM for 2 hours then SCM for 22 hours (SFM). 
Lysates were subjected to Western blot analyses using an antibody raised against iNOS (1:5000). 
To ensure equal loading blots were re-probed using an antibody recognising p-actin (1:1000). B: 
Densitometric analysis of iNOS and p-actin bands was performed and levels of iNOS were 
normalised with respect to p-actin levels. Statistical analysis was performed using ANOVA 
followed by the Tukey post test. *** p > 0.001 vs ‘albumin’ or ‘fraction V treated respectively.
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Since U0126 inhibited albumin or fraction V induced iNOS expression, the presence of 
phospho-ERK was assessed in microglial lysates. Western blot analyses revealed that 
albumin (1 mg/ml) elicited a rapid phosphorylation of ERK 1 and 2 (Fig. 4.3A). Phospho- 
ERK was detectable as a doublet (Bhat et al., 1998; McDonald et al., 1998; Combs et al., 
2001; Bhat and Fan 2002). The bands exhibited molecular weights of 42 and 44 kDa 
respectively, corresponding to ERK 1 (p44) and ERK 2 (p42). Phospho-ERK was initially 
detectable 30 minutes after albumin treatment and expression increased with time. 
Maximal phosphorylation was reached at 1 hour, followed by a decline in phosphorylation 
reaching lower levels by 48 hours post treatment.
Parallel time courses using microglia treated with SFM for 2 hours then SCM revealed 
that ERK phosphorylation did not significantly increase over the experimental period (Fig. 
4.3A). This demonstrates that the increases in ERK phosphorylation are due to the 
addition of albumin and not the medium changes. Furthermore, analysis of total ERK 
indicated that these results were not due to differences in protein loading. Total ERK 
recognises both the unphosphorylated and phosphorylated forms of ERK. Total ERK is 
also visualised as a doublet Like phospho-ERK the bands exhibit molecular weights of 42 
and 44 kDa respectively. Microglia treated with fraction V (1 mg/ml) in SFM for 1 hour 
were also found to express comparable levels of phospho-ERK as those cells treated with 
albumin (1 mg/ml) (Fig. 4.3B).
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Figure 4.3 Albumin or fraction V evokes ERK phosphorylation in microglia
Representative Western blots of ERK phosphorylation in microglial cell lysates. A: Microglia were 
treated with albumin (1 mg/ml) in SFM and lysates were prepared after 0.25, 0.5 or 1 hour. At 2 
hours the SFM was removed from the remaining cultures and replaced with SCM. Lysates were 
then prepared after a further 2, 4, 22 or 46 hours. Control lysates were prepared from microglia 
treated with SFM then SCM at the same time points (SFM). B: Lysates were prepared from 
microglia treated with fraction V  (1 mg/ml) in SFM for 0 or 1 hour. Lysates were subjected to 
Western blot analyses using an antibody raised against phospho-ERK (1:750), which in turn was 
detected by goat anti-mouse IgG (HRP) (1:1000). To ensure equal loading blots were re-probed 
using an antibody recognising total ERK (1:500) followed by exposure to goat anti-rabbit IgG 
(HRP) (1:500).
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The finding that albumin induced iNOS expression in microglia led to the question as to 
whether peripheral macrophages are responsive to albumin considering that they are 
exposed to high concentrations of albumin under physiological conditions. Subsequently, 
the effects of albumin or fraction V on peritoneal macrophage iNOS expression were 
investigated. In these experiments, macrophages were isolated from the peritoneal cavity 
of neonatal or adult rats; the former providing ages matched equivalents to the microglia. 
In all experiments described in this chapter macrophages were treated with albumin or 
fraction V in SFM for 2 hours, after which the SFM was replaced with SCM for the rest of 
the experimental period.
Western blot analyses revealed that peritoneal macrophages isolated from neonatal or 
adult rats were resistant to the concentrations of albumin or fraction V (2 mg/ml or less) 
that evoked iNOS expression in microglia (Fig. 4.4A). Exposure to 12 mg/ml of albumin 
or fraction V for 24 hours was required to induce iNOS expression in these cells. 
Furthermore, iNOS was undetectable in macrophages left untreated for 24 hours (basal) or 
macrophages treated with SFM for 2 hours then SCM for 22 hours (SFM). The effect of 
the classical activator, LPS on macrophage iNOS expression was also studied. As with 
microglia, macrophages were treated with LPS (2 pg/ml) in SCM in all experiments. 
Western blot analyses revealed that macrophages treated with LPS (2 pg/ml) for 24 hours 
expressed similar levels of iNOS as those cells treated with albumin (12 mg/ml) or 
fraction V (12 mg/ml) (Fig. 4.4B).
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Figure 4.4 (see overleaf for figure legend)
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Figure 4.4 iNOS expression in peritoneal macrophages
Representative Western blots of iNOS expression in peritoneal macrophage cell lysates. A: 
Peritoneal macrophages isolated from neonatal or adult rats were treated with increasing 
concentrations of albumin (Alb: 1-12 mg/hil) or fraction V  (Fv: 1-12 mg/ml) in SFM for 2 hours. The 
SFM was then replaced with SCM for 22 hours before lysates were prepared. Control lysates were 
prepared from macrophages left untreated for 24 hours (basal) or macrophages exposed to SFM 
for 2 hours then SCM for a further 22 hours (SFM). B: Macrophages were exposed to albumin 
(Alb: 1 mgAnl) or fraction V  (Fv: 1 mg/ml) in SFM for 2 hours, after which the SFM was replaced 
with SCM for 22 hours before lysis. Lysates were also prepared from macrophages treated with 
LPS (2 pg/ml) in SCM for 24 hours. Control lysates were prepared from macrophages treated as 
described in A. Lysates were subjected to Western blot analysis using an antibody raised against 
iNOS (1:5000). To ensure equal protein loading blots were reprobed with an antibody recognising 
p-actin (1:1000).
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Culture medium collected from macrophages isolated from neonatal or adult rats was 
subsequently assessed for the presence of nitrite. Significant levels of nitrite were only 
present in medium collected from macrophages treated with 1 2  mg/ml of albumin, 1 2  
mg/ml of fraction V or LPS (2 pg/ml) after 24 hours in culture (table 4.3). Considerably 
lower levels of nitrite were present in medium collected from macrophages treated with 
lower concentrations of albumin (1-8 mg/ml) or fraction V (1-8 mg/ml). Similarly, low 
levels of nitrite were present in medium collected from macrophages that were left 
untreated for 24 hours (basal) or macrophages treated with SFM for 2 hours then SCM for 
22 hours (SFM).
In contrast to microglia, macrophages isolated from neonatal or adult rats did not exhibit 
increases in phospho-ERK expression after treatment with albumin (1 or 12 mg/ml), 
fraction V (1 or 12 mg/ml) or LPS (2 pg/ml) for 1 hour (Fig. 4.5). Similarly, low levels of 
phospho-ERK were detectable in macrophages left untreated for 1 hour (basal) or 
macrophages treated with SFM for 1 hour (SFM). These findings were not attributed to 
failure of the Western since prominent total ERK bands were visible, which exhibited 
molecular weights of 42 and 44 kDa respectively. Furthermore, the antibody used 
recognised p-ERK in microglial lysates (see Fig. 4.3). This indicates that in macrophages 
ERK is primarily present in the un-phosphoiylated form following treatment with 
albumin, fraction V or LPS.
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Adult Neonate
Treatment [Nitrite](nM/pg) [Nitrite](nM/|ig)
Basal 8.5 ± 8.5 6 . 1  ± 1 1 . 6
SFM 12.7 ± 7.2 17.1 ± 12.4
Albumin (1 mg/ml) 10.9 ±9.6 7.3 ± 14.3
Albumin (2 mg/ml) 4.9 ± 8 . 8 3.0 ± 12.1
Albumin (4 mg/ml) 3.6 ±6.0 3.3 ±7.6
Albumin ( 8  mg/ml) 9.7 ± 7.4 3.8 ±8.0
Albumin (12 mg/ml) 517.7 ± 13.4 *** 507.8 ± 4.7 ***
Fraction V (1 mg/ml) 17.5 ±17.4 6 . 8  ± 0
Fraction V (2 mg/ml) 2 2  ± 0 . 0 14.0 ± 6.4
Fraction V (4 mg/ml) 8.3 ± 24.5 12.4 ± 17.2
Fraction V ( 8  mg/ml) 102 ±5.5 0 ± 2.03
Fraction V (12 mg/ml) 481.8 ±14.7*** 510 ±6.0***
LPS (2 pg/ml) 490.9 ± 16.4 *** 488 ± 3.2 ***
Table 4.3 Nitrite release from peritoneal macrophages
Nitrite concentrations (nM/|xg of protein) were measured in macrophage conditioned medium using 
Griess reagent Peritoneal macrophages isolated from neonatal or adult rats were treated with 
albumin (1-12 mg/hil) or fraction V  (1-12 mg/hil) in SFM for 2 hours. The SFM was then replaced 
with SCM for 22 hours before medium was collected. Medium was also collected from 
macrophages treated with LPS (2 ng/ml) in SCM for 24 hours. Control medium was collected from 
macrophages left untreated for 24 hours (basal) or macrophages exposed to SFM for 2 hours then 
SCM for a further 22 hours (SFM). The values shown represent the mean (nM/jig of protein) ± 
SEM of data from experiments performed in triplicate. Statistical analysis was performed using 
ANOVA followed by the Tukey post test *** P < 0.001, vs ‘basal’ or ‘SFM’.
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Figure 4.5 Phospho-ERK expression in peritoneal macrophages
Representative Western blots of ERK phosphorylation in macrophage cell lysates. A: Peritoneal 
macrophages isolated from neonatal or adult rats were treated with albumin (Alb: 1 or 12 mg/ml) 
or fraction V  (1 or 12 mg/ml) in SFM and lysates were prepared after 1 hour. Lysates were also 
prepared from macrophages treated with LPS (2 pg/ml) in SCM after 1 hour. Control lysates were 
prepared from macrophages left untreated for 1 hour (basal) or macrophages exposed to SFM for 
1 hour. Lysates were subjected to Western blot analyses using an antibody raised against 
phospho-ERK (1:750). To ensure equal loading blots were re-probed using an antibody 
recognising total ERK (1:500).
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43 Albumin does not induce COX-2 expression in microglia
Microglia were assessed for COX-2 expression following exposure to albumin. Western 
blotting revealed that neither albumin (0.1-2 mg/ml) nor fraction V (1 mg/ml) evoked 
COX-2 expression in microglia after 24 hours in cultures (Fig. 4.6A). In contrast, COX-2 
was detectable in microglia treated with LPS (2 pg/ml) for 24 hours. COX-2 was visible 
as a single protein band exhibiting a molecular weight of 72 kDa (Chen et al., 1999; Dean 
et al., 1999; Pyo et al., 1999; Clancy et al., 2000). COX-2 was absent in microglia left 
untreated for 24 hours (basal) or microglia treated with SFM for 2 hours then SCM for 22 
hours (SFM). Furthermore, time course analysis demonstrated that COX-2 was 
undetectable in microglial lysates 3, 8  or 48 hours after albumin (1 mg/ml) or fraction V (1 
mg/ml) treatment (Fig. 4.6B). Therefore, microglial signalling induced by albumin does 
not involve COX-2, although COX-2 expression can be induced by independent signalling 
pathways.
The ability of albumin or fraction V to induce COX-2 expression in peritoneal 
macrophages was also assessed. Western blot analyses revealed that peritoneal 
macrophages isolated from neonatal or adult rats did not express COX-2 following 
exposure to albumin (1 or 12 mg/ml) or fraction V (1 or 12 mg/ml) for 24 hours (Fig. 
4.6C). Conversely, macrophages treated with LPS (2 pg/ml) for 24 hours did upregulate 
the expression of this inflammatory mediator.
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Figure 4.6 COX-2 expression in microglia or peritoneal macrophages
Representative Western blots of COX-2 expression in microglial or peritoneal macrophage cell 
lysates. A: Microglia were treated with increasing concentrations of albumin (0.1-2 mg/ml) or 
fraction V  (Fv: 1 mg/ml) in SFM for 2 hours. The SFM was then replaced with SCM for 22 hours 
before lysates were prepared. Lysates were also prepared from microglia treated with LPS (2 
pg/ml) in SCM for 24 hours. Control lysates were prepared from microglia left untreated for 24 
hours (basal) or microglia exposed to SFM for 2 hours then SCM for 22 hours (SFM). B: Microglia 
were treated with albumin (Alb: 1 mg/ml) or fraction V  (Fv: 1 mg/ml) in SFM for 2 hours. The SFM 
was then replaced with SCM for a further 1, 6, or 46 hours before lysis. Lysates were also 
prepared from microglia treated with LPS (2 ng/ml) in SCM for 24 hours. Control lysates were 
prepared from microglia left untreated for 48 hours (basal) or microglia exposed to SFM for 2 
hours then SCM for 46 hours (SFM). C: Peritoneal macrophages isolated from neonatal or adult 
rats were treated with albumin (Alb: 1 or 12 mg/ml) or fraction V  (Fv. 1 or 12 mg/ml) in SFM for 2 
hours. The medium was then replaced with SCM for 22 hours before lysis. Lysates were also 
prepared from macrophages treated with LPS (2 i^g/rnl) in SCM for 24 hours. Control lysates were 
prepared from macrophages treated as described in A. Lysates were subjected to Western blot 
analysis using an antibody raised against COX-2 (1:750), which in turn was detected by donkey 
anti-goat IgG (HRP) (1:1000). To ensure equal protein loading blots were reprobed with an 
antibody recognising p-actin (1:1000) followed by exposure to goat anti-mouse IgG (HRP) 
(1:1000).
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4.4 Albumin induces glutamate release from microglia
Previous studies have demonstrated that activated microglia secrete large quantities of 
glutamate (Piani and Fontana 1994; Kingham et al., 1999; Barger and Basile 2001). 
Furthermore, albumin treated neurones have been reported to release glutamate into the 
extracellular milieu (Tabemero et al., 2002b). These findings prompted the effects of 
albumin on glutamate release from microglia to be evaluated.
Microglia treated with albumin (0.1- 2 mg/ml) were demonstrated to release glutamate in 
a dose dependent fashion after 24 hours in culture (Fig. 4.7A). Glutamate concentrations 
ranged from 127 ± 45.5 to 904 ± 14 nM/pg of protein. In contrast, glutamate was present 
at much lower concentrations in medium collected from microglia left untreated for 24 
hours (basal) or microglia treated with SFM for 2 hours then SCM for 22 hours (SFM) 
(Basal: 11.5 ± 18.4 nM/pg of protein, SFM: 61.1 ± 21.7 nM/pg of protein). In addition, 
microglia exposed to fraction V (1 mg/ml) or LPS (2 pg/ml) released similar levels of 
glutamate as those cells treated with albumin (1 mg/ml) after 24 hours in culture (Fig. 
4.7B) (Fv: 709.9 ±15.7 nM/pg of protein, LPS: 733 ±41  nM/pg of protein, albumin: 
698.3 ± 52.7 nM/pg of protein). Time course analyses revealed that glutamate was 
initially detectable 3 hours after the addition of albumin (1 mg/ml) or fraction V (1 mg/ml) 
(Fig. 4.7C). Furthermore, the concentration of glutamate in the medium increased with 
time and both activators were found to induce similar profiles of glutamate release 
temporally.
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Figure 4.7 Assessment of glutamate release from microglia
Glutamate concentrations (nM/^g of protein) were measured in microglial conditioned medium 
using a fluorometric assay. A: Microglia were treated with increasing concentrations of albumin 
(0.1-2 mg/ml) in SFM for 2 hours. The SFM was then replaced with SCM for 22 hours before the 
medium was collected. Control medium was collected from microglia left untreated for 24 hours 
(basal) or microglia treated with SFM for 2 hours then SCM for 22 hours (SFM). B: Microglia were 
treated with albumin (Alb: 1 mg/ml) or fraction V  (Fv: 1 mg/ml) in SFM for 2 hours. The SFM was 
then replaced with SCM  for 22 hours before the medium was collected. In addition, medium was 
collected from microglia were treated with LPS (2 ^ig/ml) in SCM  for 24 hours. Control medium 
was collected from microglia treated as described in A. C: Microglia were treated with albumin (1 
mg/ml: open circles) or fraction V  (1 mg/ml: closed circles) in SFM and medium was collected after 
0.25, 0.5, or 1 hour. At 2 hours the SFM was removed from the remaining cultures and replaced 
with SCM. Medium was then collected after a further 1, 2, 4, 6, 22 or 46 hours. Control medium 
was collected from microglia treated with SFM, then SCM at the same time points (dotted line). 
The values shown represent the mean (nM/jig of protein) ±  SEM of data from experiments 
performed in triplicate. Statistical analysis was performed using ANOVA followed by the Tukey 
post test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs control (A, B: control describes ‘basal’ or ‘SFM ’; 
C: control describes time 0).
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To verify that glutamate release was not due to cell membrane disruption, albumin or 
fraction V treated microglia were stained with propidium iodide and fluoroscein diacetate. 
Microglial cultures exposed to albumin (2 mg/ml) or fraction V (2 mg/ml) contained very 
few cells that stained with propidium iodide after 48 hours in culture (table 4.4). Similarly, 
microglia left untreated for 48 hours (basal) or microglia treated with SFM for 2 hours 
then SCM for 46 hours (SFM) contained few cells exhibiting propidium iodide staining. 
This suggests that glutamate release induced by albumin or fraction V occurs via a 
regulated pathway and is not due to loss of microglial cell membrane integrity.
The signalling pathways that mediate albumin or fraction V induced glutamate release 
were investigated using a range of inhibitors. Previously, it has been demonstrated that 
glutamate secretion can be mediated by the cysteine-glutamate antiporter (Xc‘ transporter) 
in activated microglia (Piani and Fontana 1994; Kingham et al., 1999). Subsequently, the 
effect of the Xc' transporter antagonist aminoadipate on glutamate release was studied. 
Additionally, the effect of the iNOS inhibitor AMT-HC1 was investigated to determine 
whether NO is involved in glutamate secretion. Pre-treating microglia with aminoadipate 
(2.5 mM) reduced albumin (1 mg/ml) or fraction V (1 mg/ml) induced glutamate release 
to control levels (‘basal’ or ‘SFM’) (Fig. 4.8A3)* In contrast, pre-treating microglia with 
AMT-HC1 (03 pM) did not modulate glutamate release induced by either activator (Fig. 
4.8A,B). Furthermore, medium collected from microglia treated with the inhibitors alone 
did not contain significantly different levels of glutamate from controls (‘basal’ or ‘SFM’).
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The effects of pertussis toxin (Ptx; 2 pg/ml), BAPTA-AM (10 pM), U73122 (2 pM), PP2 
(100 nM), or U0126 (5 pM) on albumin or fraction V induced glutamate release were also 
explored. However, these inhibitors did not modulate glutamate release elicited by 
albumin (1 mg/ml) or fraction V (1 mg/ml) treatment (Fig. 4.8A,B). Moreover, medium 
collected from microglia treated with the inhibitors alone did not contain significantly 
different levels of glutamate from controls (‘basal’ or ‘SFM’).
The effect of albumin or fraction V on glutamate release from peritoneal macrophages was 
subsequently investigated. As before, macrophages were isolated from neonatal and adult 
rats. However, glutamate was not present above control levels (‘basal’ or ‘SFM’) in 
medium collected 24 hours after the addition of albumin (1, 2 or 12 mg/ml) or fraction V 
(1, 2 or 12 mg/ml) (table 4.5). Medium obtained from macrophages treated with LPS (2 
pg/ml) for 24 hours also contained a similar level of glutamate to that of control (‘basal’ 
or ‘SFM’). Furthermore, there were no differences between the results obtained with 
macrophages isolated from neonatal or adult rats.
Macrophages isolated from neonatal or adult rats were stained with propidium iodide and 
fluoroscein diacetate to determine whether disturbances in cell membrane integrity were 
responsible for the high basal levels of glutamate, which may have subsequently masked 
the effects of the activators. Staining revealed that macrophage cultures left untreated for 
24 hours (basal) or cultures treated with SFM for 2 hours then SCM for 22 hours (SFM) 
contained few propidium iodide positive cells (table 4.6). Furthermore, macrophage 
cultures exposed to albumin (12 mg/ml) or fraction V (12 mg/ml) contained very few cells 
that stained with propidium iodide after 24 hours in culture. These results suggest that 
glutamate release is not due to loss of macrophage cell membrane integrity.
165
Basal SFM Albumin Fraction V
% of propidium iodide stained microglia 1 . 1  ± 1 . 2 12 ± 1 . 2 1.4 ± 0 2 2.0 ± 0.9
Table 4A  Analysis of microglial membrane integrity
Microglia were stained with propidium iodide and fluoroscein diacetate to provide an estimation of 
cell membrane integrity. Microglia were treated with albumin (2 mg/ml) or fraction V  (2 mg/ml) in 
SFM for 2 hours. The SFM was then replaced with SCM for 46 hours before staining was 
performed. Control microglia were either left untreated for 48 hours (basal) or were treated with 
SFM for 2 hours then SCM tor a further 46 hours (SFM) before staining. Cells possessing 
propidium iodide staining were expressed as a percentage of the total number of cells counted 
(cells possessing propidium iodide staining or fluoroscein diacetate staining). The values shown 
represent the mean ± SEM of data from experiments performed in triplicate. Statistical analysis 
was performed using ANOVA followed by the Tukey post test According to this test there was no 
statistical difference between the treatments.
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Figure 4.8 Modulation of albumin or fraction V induced glutamate release from microglia
Glutamate concentrations (nM/pg of protein) were measured in microglial conditioned medium 
using a fluorometric assay. Microglia were treated with albumin (Alb: 1 mg/ml) (A) or fraction V  
(Fv: 1mg/ml) (B) in SFM for 2 hours. The SFM was then replaced with SCM for 22 hours before 
medium was collected. In addition, microglia were treated with albumin (Alb: 1 mg/ml) or fraction V  
(Fv: 1 mg/ml) in SFM in the presence of aminoadipate (A-pate: 2.5 mM), AMT-HCI (0.3 pM) 
pertussis toxin (Ptx: 2 pg/ml), BAPTA-AM (10 pM), U73122 (2 pM), PP2 (100 nM) or U 0126 (5 
pM). At 2 hours the SFM was replaced with SCM supplemented with the appropriate concentration 
of inhibitor for 22 hours before medium was collected. Control medium was collected from 
microglia left untreated for 24 hours (basal) or microglia exposed to SFM for 2 hours then SCM for 
22 hours (SFM).The values shown represent the mean (nM/pg of protein) ± SEM of data from 
experiments performed in triplicate. Statistical analysis was performed using ANOVA followed by 
the Tukey post test. *** P < 0.001 vs albumin (Alb) or fraction V  (Fv) treated respectively.
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Adult Neonate
Treatment [GIutamate](nM/pg) [Glutamate](nM/pg)
Basal 260 ±16.6 245 ±4.2
SFM 255 ±17.5 265 ±4.6
Albumin (1 mg/ml) 245 ±16.1 256 ±11.9
Albumin (2 mg/ml) 255 ±21.2 260 ± 14.6
Albumin (12 mg/ml) 255 ±15.5 262 ± 5.9
Fraction V (1 mg/ml) 250 ±15.7 248 ± 14.6
Fraction V (2 mg/ml) 266 ±24.3 246 ±19.4
Fraction V (12 mg/ml) 254 ±17.7 261 ± 13.7
LPS (2 pg/ml) 267 ±12.1 249 ± 7.1
Table 4.5 Glutamate release from peritoneal macrophages
Glutamate concentrations (nM/pg of protein) were measured in peritoneal macrophage 
conditioned medium using a fluorometric assay. Peritoneal macrophages isolated from neonatal or 
adult rats were treated with albumin (1 ,2  or 12 mg/ml) or fraction V  (1 ,2  or 12 mg/ml) in SFM for 2 
hours. The SFM was then replaced with SCM for 22 hours before the medium was collected. 
Medium was also collected from macrophages treated with LPS (2 pg/ml) in SCM for 24 hours. 
Control medium was collected from macrophages left untreated for 24 hours (basal) or 
macrophages exposed to SFM for 2 hours then SCM for 22 hours (SFM). The values shown 
represent the mean (nM/pg of protein) ± SEM of data from experiments performed in triplicate. 
Statistical analysis was performed using ANOVA followed by the Tukey post test According to this 
test there was no statistical difference between the treatments.
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% of propidium iodide stained cells Basal SFM Albumin Fraction V
Macrophages (neonatal) 1.5 ±1.2 1.6 ±1.4 1.3 ±0.6 1.1 ±1.5
Macrophages (adult) 1.7 ±1.3 1.3 ±1.1 1.6 ±0.9 1.5 ± 1.7
Table 4.6 Analysis of peritoneal macrophage membrane integrity
Peritoneal macrophages isolated from neonatal or adult rats were stained with propidium iodide 
and fluorescein diacetate to provide an estimation of cell membrane integrity. Macrophages were 
treated with albumin (12 mg/ml) or fraction V  (12 mg/ml) in SFM for 2 hours. The SFM was then 
replaced with SCM for 22 hours before staining was performed. Control macrophages were either 
left untreated for 24 hours (basal) or were treated with SFM for 2 hours then SCM for 22 hours 
(SFM) before staining was performed. Cells possessing propidium iodide staining were expressed 
as a percentage of the total number of cells counted (cells possessing propidium iodide staining or 
fluoroscein diacetate staining). The values shown represent the mean ± SEM of data from 
experiments performed in triplicate. Statistical analysis was performed using ANOVA followed by 
the Tukey post test According to this test there was no statistical difference between the 
treatments.
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4.5 Albumin induces microglial proliferation
It was noticed that 24 hours after the addition of albumin, microglial cultures contained a 
greater number of cells than controls (‘basal’ or ‘SFM’). Subsequently, proliferation was 
quantified by counting the number of microglia present per field of view. Using this 
approach albumin (0.1-2 mg/ml) was confirmed to induce a dose dependent increase in 
microglial number after 24 hours in culture (Fig. 4.9A). Furthermore, albumin treated 
microglia displayed an increase in the number of processes radiating from their cell 
bodies, whereas control microglia (‘basal’ or ‘SFM’) were amoeboid in appearance 
exhibiting just a few short processes (Fig. 4.9B).
Albumin induced microglial proliferation was investigated fiirther using the Cell titer 96 
Aqueous one solution proliferation assay kit (cell titer assay). Using this technique, albumin 
(0.1-2 mg/ml) was also found to induce a dose dependent increase in proliferation after 24 
hours in culture (Fig. 4.10A). Since these results corroborated the data obtained by cell 
counting, the cell titer assay was used in isolation in subsequent proliferation experiments 
described in this chapter. The effects of fraction V or LPS on microglial proliferation were 
subsequently studied. Microglia exposed to fraction V (1 mg/ml) proliferated to a similar 
extent as microglia treated with albumin (1 mg/ml) after 24 hours in culture (Fig. 4.1 OB). 
Conversely, microglia treated with LPS (2 pg/ml) for 24 hours did not proliferate above 
control levels (‘basal’ or ‘SFM’). Next the time course of albumin or fraction V induced 
proliferation was investigated. This experiment revealed that albumin (1 mg/ml) or 
fraction V (1 mg/ml) induced similar proliferation profiles temporally. Microglial 
proliferation was initially detectable between 16-24 hours after albumin (1 mg/ml) or 
fraction V (1 mg/ml) treatment (Fig. 4.10C). The proliferative response then plateaued 
between 24-48 hours.
170
2
c
a.u<u
X!sse
U
30
20
10
[ A 1 b u m i n ] (m g/m  1)
1
I
■ ■ I
Basal SFM 0.1 0.25 0.5 1
B
B asal SFM 20Alb
Figure 4.9 Albumin induces microglial proliferation
Microglia proliferation was assessed by counting the number of cells present per field of view. A: 
Microglia were treated with increasing concentrations of albumin (0.1-2 mg/ml) in SFM for 2 hours. 
The SFM was then replaced with SCM for 22 hours before the cells were counted. Control 
microglia were either left untreated for 24 hours (basal) or were exposed to SFM for 2 hours then 
SCM for a further 22 hours (SFM). The values shown represent the mean number of cells present 
per field ± SEM  of data from experiments performed in triplicate. Statistical analysis was 
performed using ANO VA followed by the Tukey post test. ** P < 0.01, *** P < 0.001 vs ‘basal’ or 
‘SFM ’. B: The photographs represent control microglia ( ‘basal’ or ‘SFM ’) or microglia treated with 
albumin (Alb: 1 mg/ml) from right to left.
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Figure 4.10 Assessment of microglial proliferation
Microglia proliferation was appraised using the cell titer proliferation assay. A: Microglia were 
treated with increasing concentrations of albumin (0.1-2 mg/ml) in SFM for 2 hours. The SFM was 
then replaced with SCM for 22 hours before the assay was performed. Control microglia were 
either left untreated for 24 hours (basal) or were exposed to SFM for 2 hours then SCM for 22 
hours (SFM) before proliferation was assessed. B: Microglia were treated with albumin (Alb: 1 
mg/ml) or fraction V  (Fv: 1 mg/ml) in SFM  for 2 hours. The SFM was then replaced with SCM for 
22 hours before the assay was performed. In addition, microglia treated with LPS (2 p.g/ml) in SCM  
for 24 hours were assessed for proliferation. Control microglia were treated as described in A. C: 
Microglia were exposed to albumin (1 mg/ml; open circles) or fraction V  (1 mg/ml; closed circles) in 
SFM for 2 hours. The SFM  was then replaced with SCM for 6, 14, 22 or 46 hours before the 
proliferation assay was performed. Control microglia were subjected to SFM for 2 hours then SCM  
for 46 hours (SFM) (dotted line). The values shown represent the mean ± SEM of data from 
experiments performed in triplicate. Statistical analysis was performed using ANOVA followed by 
the Tukey post test. *** P < 0.001 vs control (A,B: control describes ‘basal’ or ‘SFM’; C: control 
describes time 0).
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The signalling cascades that mediate albumin or fraction V induced proliferation were 
explored using a variety of inhibitors. Pre-treating microglia with AMT-HC1 (03 pM), 
pertussis toxin (Ptx: 2 pg/ml) or U0126 (5 pM) did not modulate albumin (1 mg/ml) or 
fraction V (1 mg/ml) induced proliferation (Fig. 4.11 A,B). Furthermore, microglia treated 
with the inhibitors alone proliferated to a similar extent as control microglia (‘basal* of 
‘SFM’). In contrast, pre-treating microglia with BAPTA-AM (10 pM), U73122 (2 pM) or 
PP2 (100 nM) reduced albumin (1 mg/ml) or fraction V (1 mg/ml) induced proliferation to 
control levels (‘basal’ or ‘SFM’). Moreover, these inhibitors did not adversely effect 
proliferation when incubated with the microglia alone.
Since BAPTA-AM inhibited albumin or fraction V induced proliferation the response was 
deemed to be calcium dependent, consequently intracellular calcium fluxes were 
monitored in N9 microglia using fura-2. The N9 cell line is a well characterised microglial 
cell line, which exhibits similar responses to primary microglia (Corradin et al., 1993; 
Ferrari et al., 1996; Kingham et al., 1999). Accordingly, albumin (1 mg/ml) or fraction V 
(1 mg/ml) triggered iNOS expression in N9 microglia, whereas control N9 cells (‘basal’ or 
‘SFM’) did not express iNOS (Fig. 4.12A). Furthermore, albumin (1 mg/ml) or fraction V 
(1 mg/ml) induced a large increase in N9 proliferation above control levels (‘basal’ or 
‘SFM’) (Fig. 4.12B). However, control N9 microglia (‘basal’ or ‘SFM’) exhibited a higher 
basal level of proliferation in comparison to control primary microglia (‘basal’ or ‘SFM’), 
which was attributed to the fact that the N9 cell line actively proliferates in culture.
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Figure 4.11 Modulation of albumin or fraction V induced microglial proliferation
Microglia proliferation was appraised using the cell titer proliferation assay. Microglia were treated 
with albumin (Alb: 1 mg/ml) (A) or fraction V (Fv: 1 mg/m I) (B) in SFM for 2 hours. The SFM was 
then replaced with SCM for 22 hours before the assay was performed. In addition, microglia were 
treated with albumin (Alb: 1 mg/ml) or fraction V (Fv: 1 mg/ml) in SFM in the presence of AMT-HCI 
(0.3 hM), pertussis toxin (Ptx: 2 ng/ml), BAPTA-AM (10 ^M), U73122 (2 pM), PP2 (100 nM) or 
U0126 (5 pM). At 2 hours the SFM was replaced with SCM supplemented with the appropriate 
concentration of inhibitor for a further 22 hours before proliferation was assessed. Control 
microglia were left untreated for 24 hours (basal) or exposed to SFM for 2 hours then SCM for 22 
hours (SFM). The values shown represent the mean ± SEM of data from experiments performed in 
triplicate. Statistical analysis was performed using ANOVA followed by the Tukey post test. *** P < 
0.001 vs albumin (Alb) or fraction V (Fv) treated respectively.
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Figure 4.12 Albumin or fraction V induces iNOS synthesis and proliferation in N9 microglia
Representative Western blot of iNOS expression in N9 microglia cell lysates (A). N9 Microglia 
were exposed to albumin (Alb: 1 mg/ml) or fraction V  (Fv: 1 mg/ml) in SFM for 2 hours. The SFM  
was then replaced with SCM for 22 hours before lysates were prepared. Control lysates were 
prepared from N9 microglia left untreated for 24 hours (basal) or N9 microglia exposed to SFM for 
2 hours then SCM  for 22 hours (SFM). Lysates were subjected to Western blot analysis using an 
antibody raised against iNOS. To ensure equal protein loading blots were reprobed with an 
antibody recognising p-actin. N9 proliferation was appraised using the cell titer proliferation assay 
(B). N9 microglia were treated with albumin (Alb: 1 mg/ml) or fraction V  (Fv: 1 mg/ml) in SFM  for 2 
hours. The SFM was then replaced with SCM for 22 hours before the assay was performed. 
Control N9 microglia were left untreated for 24 hours (basal) or were exposed to SFM for 2 hours 
then SCM for 22 hours (SFM). The values shown represent the mean ± SEM of data from 
experiments performed in triplicate. Statistical analysis was performed using ANOVA followed by 
the Tukey post test. *** P < 0.001 vs control (control describes ‘basal’ or ‘SFM ’).
175
Calcium imaging was performed in basic medium in the absence of serum; therefore 
interference from endogenous albumin in the serum was not a problem. Albumin (1 
mg/ml) or fraction V (1 mg/ml) was found to induce a mono-phasic increase in 
intracellular calcium, whereas calcium transients were not elicited in control N9 microglia 
(Fig. 4.13). In a subsequent experiment calcium transients induced by albumin (Fig. 4.14) 
or fraction V (Fig. 4.15) were demonstrated to be dose dependent; a minimum of 0.5 
mg/ml of albumin or fraction V was required to elicit a response and maximal responses 
were obtained with 4 mg/ml of either activator. To ascertain whether calcium fluxes were
a I
store mediated, the effect of the Ca -ATPase inhibitor thapsigargin on albumin or 
fraction V-induced calcium transients was explored. The application of thapsigargin (1 
pM) elicited an extended calcium response of low amplitude, which returned to baseline 
after approximately 600 seconds (Fig. 4.16). This phenomenon was attributed to the 
depletion of intracellular calcium stores occurring as a result of the inhibition of calcium 
re-uptake. The subsequent application of albumin (1 mg/ml) or fraction V (1 mg/ml) to 
thapsigargin pre-treated N9 microglia did not elicit increases in intracellular calcium. 
These findings imply that albumin or fraction V evoke calcium release from intracellular 
stores. To determine the signalling pathways upstream of calcium release the effects of 
various inhibitors were studied. Pre-treating microglia with pertussis toxin (Ptx: 2 pg/ml) 
or U0126 (5 pM) did not modulate albumin (1 mg/ml) (Fig. 4.17) or fraction V (1 mg/ml) 
(Fig. 4.18) induced calcium transients. Furthermore, the inhibitors did not evoke changes 
in intracellular calcium when incubated with the microglia alone. In contrast, pre-treating 
microglia with U73122 (2 pM) or PP2 (100 nM) entirely abated albumin (1 mg/ml) (Fig. 
4.17) or fraction V (1 mg/ml) (Fig. 4.18) induced calcium transients. Again, these 
inhibitors did not evoke changes in intracellular calcium when incubated with the 
microglia alone.
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Figure 4.13 Effects of albumin or fraction V on intracellular calcium transients in N9 cells
Representative false colour images and traces depicting intracellular calcium transients evoked in 
albumin or fraction V  treated N9 microglia. N9 microglia were loaded with fura-2 (5 jiM) in basic 
medium for 45 minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 and 
380 nm and emission was collected at a wavelength of 510 nm. Albumin (1 mg/ml) or fraction V  (1 
mg/ml) diluted in basic medium was added to the cells 60 seconds after the commencement of 
excitation. Control N9 cells were treated with basic medium in the absence of albumin or fraction V  
at the same time point. Calcium responses were recorded from ten cells and the results were 
expressed as 340/380 fluorescence ratios. False colour images corresponding to each treatment 
are also displayed. Images were captured at 0, 70 and 300 seconds (from left to right) and the 
scale bar provides an indication of intracellular calcium levels.
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Figure 4.14 Dose dependency of albumin on intracellular calcium transients in N9 cells
Representative traces depicting intracellular calcium transients evoked by increasing 
concentrations of albumin in N9 microglia. N9 microglia were loaded with fura-2 (5 pM) in basic 
medium for 45 minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 and 
380 nm and emission was collected at a wavelength of 510 nm. Albumin (0.25-4 mg/ml) diluted in 
basic medium was added to the cells 60 seconds after the commencement of excitation. Control 
N9 cells were treated with basic medium in the absence of albumin at the same time point. 
Calcium responses were recorded from ten cells and the results were averaged and expressed as 
340/380 fluorescence ratios.
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Figure 4.15 Dose dependency of fraction V on intracellular calcium transients in N9 cells
Representative traces depicting intracellular calcium transients evoked by increasing 
concentrations of fraction V  in N9 microglia. N9 microglia were loaded with fura-2 (5 pM) in basic 
medium for 45 minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 and 
380 nm and emission was collected at a wavelength of 510 nm. Fraction V  (0.25-4 mg/ml) diluted 
in basic medium was added to the cells 60 seconds after the commencement of excitation. Control 
N9 cells were treated with basic medium in the absence of fraction V  at the same time point. 
Calcium responses were recorded from ten cells and the results were averaged and expressed as 
340/380 fluorescence ratios.
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Figure 4.16 Thapsigargin inhibits albumin or fraction V induced calcium fluxes in N9 cells
Representative traces illustrating the effects of thapsigargin on intracellular calcium transients 
evoked by albumin or fraction V  in N9 microglia. N9 microglia were loaded with fura-2 (5 ^M) in 
basic medium for 45 minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 
and 380 nm and emission was collected at a wavelength of 510 nm. Albumin (1 mg/ml) or fraction 
V  (1 mg/ml) diluted in basic medium was added to the cells 760 seconds after the commencement 
of excitation. In addition, N9 microglia were treated with albumin (1 mg/ml) or fraction V  (1 mg/ml) 
in the presence of thapsigargin (1 jiM), which was added at 60 seconds. Microglia were also 
treated with thapsigargin (1 ^M) alone. Control microglia were treated with basic medium in the 
absence of any other stimulus. Calcium responses were recorded from ten cells and the results 
were averaged and expressed as 340/380 fluorescence ratios.
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Figure 4.17 Modulation of albumin induced calcium transients in N9 cells
Representative traces depicting the effects of various inhibitors on intracellular calcium transients 
evoked by albumin in N9 microglia. N9 microglia were loaded with fura-2 (5 jaM) in basic medium 
for 45 minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 and 380 nm and 
emission was collected at a wavelength of 510 nm. Albumin (1 mg/ml) diluted in basic medium 
was added to the cells 60 seconds after the commencement of excitation. In addition, N9 microglia 
were treated with albumin (1 mg/ml) in the presence of pertussis toxin (2 pg/ml), U73122 (2 pM), 
PP2 (500 nM) or U 0 1 2 6  (20 nM). Microglia were also treated with the inhibitors alone. Control 
microglia were treated with basic medium in the absence of any other stimulus. Calcium 
responses were recorded from ten cells and the results were averaged and expressed as 340/380  
fluorescence ratios.
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Figure 4.18 Modulation of fraction V induced calcium transients in N9 cells
Representative traces depicting the effects of various inhibitors on intracellular calcium transients 
evoked by fraction V  in N9 microglia. N9 microglia were loaded with fura-2 (5 pM) in basic medium 
for 45  minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 and 380 nm and 
emission was collected at a wavelength of 510 nm. Fraction V  (1 mg/ml) diluted in basic medium 
was added to the cells 60 seconds after the commencement of excitation. In addition, N9 microglia 
were treated with fraction V  (1 mg/ml) in the presence of pertussis toxin (2 pg/ml), U73122 (2 pM), 
PP2 (500 nM) or U 0 1 2 6  (20 pM). Microglia were also treated with the inhibitors alone. Control 
microglia were treated with basic medium in the absence of any other stimulus. Calcium 
responses were recorded from ten cells and the results were averaged and expressed as 340/380  
fluorescence ratios.
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The ability of albumin or fraction V to induce proliferation in macrophages isolated from 
neonatal or adult rats was subsequently investigated. Counting the number of 
macrophages present per field of view revealed that exposure to albumin (1, 2 or 12 
mg/ml) or fraction V (1,2 or 12 mg/ml) did not increase cell numbers above control levels 
after 24 hours in culture (‘basal’ or ‘SFM’) (Table. 4.7A). These findings were mirrored 
using the cell titer assay (Table. 4.7B). Furthermore, LPS (2 pg/ml) did not induce 
macrophage proliferation after 24 hours in culture as assessed using either assay (Table. 
4.7 A,B). Interestingly, macrophages adopted a bipolar morphology in the presence of high 
concentrations of albumin (12 mg/ml) or fraction V (12 mg/ml), whereas macrophages 
treated with LPS (2 pg/ml) or lower concentrations of albumin or fraction V were 
amoeboid in appearance as were control macrophages (‘basal’ or ‘SFM’) (Fig. 4.19). 
Moreover, albumin (1-12 mg/ml) or fraction V (1-12 mg/ml) did not induce calcium 
transients in macrophages isolated from either neonatal (Fig. 4.20) or adult rats (Fig. 
4.21). In contrast, thapsigargin (1 pM) evoked the release of calcium from intracellular 
stores in macrophages isolated from either age rat, which confirms that the stores are frill 
and capable of mounting a response. Macrophages were more sensitive than microglia to 
thapsigargin treatment; thapsigargin led to a sustained enhancement of intracellular 
calcium, which did not return to baseline even after 1200 seconds (20 minutes) (Fig. 4.20, 
Fig. 4.21: insets). To determine whether calcium release from intracellular stores was 
sufficient to initiate proliferation, microglia and macrophages were treated with 
thapsigargin (1-1000 nM) for 8, 24, or 48 hours. However, thapsigargin treatment did not 
induce a proliferative response in either of the cell types at any of the time points studied 
(Table. 4.8).
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Cell number per field
Treatment Adult Neonate
Basal 6.3 ± 3.7 6.3 ±1.6
SFM 6.4 ± 8.2 6.4 ± 0.4
1 mg/ml albumin 6.5 ± 0.1 6.1 ± 0.2
1 mg/ml fraction V 6.0 ± 0.5 6.2 ± 0.0
2 mg/ml albumin 6.2 ± 6.1 6.4 ± 7.4
2 mg/ml fraction V 6.0 ± 4.9 6.4 ± 4.9
12 mg/ml albumin 6.1 ± 1.2 6.2 ± 2.9
12 mg/ml fraction V 6.2 ± 2.9 6.1 ± 0.4
LPS (2 pg/ml) 6.3 ± 2.0 6.2 ± 0.6
Optical density (492 nm)
Treatment Adult Neonate
Basal 023 ± 0.1 022 ±0.1
SFM 0.24 ± 0.1 023 ±0.1
1 mg/ml albumin 0.25 ± 0.1 020 ±0.1
1 mg/ml fraction V 0.25 ± 0.1 026 ±0.2
2 mg/ml albumin 0.24 ± 0.1 022 ±0.1
2 mg/ml fraction V 0.24 ± 0.1 023 ±0.1
12 mg/ml albumin 0.22 ± 0.1 023 ± 0.1
12 mg/ml fraction V 025 ± 0.1 022 ±0.1
LPS (2 pg/ml) 0.23 ± 02 0.2 ± 0.3
Table 4.7 Assessment of peritoneal macrophage proliferation
Macrophage proliferation was assessed by counting the number of cells present per field (A) or 
the cell titer assay (B). Peritoneal macrophages isolated from neonatal or adult rats were treated 
with increasing concentrations of albumin (1, 2 or 12 mg/ml) or fraction V  (1, 2 or 12 mgAnl) in 
SFM for 2 hours. The SFM was then replaced with SCM for 22 hours before proliferation was 
assessed. In addition, macrophages treated with LPS (2 ng/ml) in SCM for 24 hours were 
assessed for proliferation. Control macrophages were left untreated for 24 hours (basal) or were 
exposed to SFM for 2 hours then SCM for 22 hours (SFM). The values shown represent the mean 
± SEM of data from experiments performed in triplicate. Statistical analysis was performed using 
ANOVA followed by the Tukey post test. There was no statistical difference between treatments.
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Figure 4.19 Peritoneal macrophage morphology
The photographs represent control macrophages (‘basal’ or ‘SFM ’) or macrophages treated with 
albumin, fraction V  or LPS. Peritoneal macrophages isolated from neonatal or adult rats were 
treated with albumin (Alb: 2 or 12 mgAnl) or fraction V  (Fv: 2 or 12 mg/ml) in SFM for 2 hours. The 
SFM was then replaced with SCM for 22 hours before photographs were taken. In addition, 
macrophages were treated with LPS in SCM for 24 hours. Control macrophages were left 
untreated for 24 hours (basal) or were exposed to SFM for 2 hours then SCM for 22 hours (SFM).
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Figure 4.20 (see overleaf for figure legend)
Figure 4.20 Calcium transients elicited in peritoneal macrophages from neonatal rats
Representative false colour images and traces depicting intracellular calcium levels in albumin, 
fraction V  or thapsigargin treated peritoneal macrophages (isolated from neonatal rats). Peritoneal 
macrophages isolated from neonatal rats were loaded with fura-2 (5 pM) in basic medium for 45 
minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 and 380 nm and 
emission was collected at a wavelength of 510 nm. Albumin (Alb: 1 or 12 mg/ml), fraction V  (Fv: 1 
or 12 mg/ml) or thapsigargin (Thaps: 1 pM) diluted in basic medium was added to the cells 60 
seconds after the commencement of excitation. Control cells were treated with basic medium in 
the absence of any other stimulus at the same time point. Calcium responses were recorded from 
ten cells and the results were expressed as 340/380 fluorescence ratios. False colour inages 
corresponding to each treatment are also displayed. Images were captured at 0, 70 and 300 
seconds (from left to right) and the scale bar provides an indication of intracellular calcium levels. 
Inset: Trace depicting the effects of thapsigargin (1 pM) over a 1200 second period.
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Figure 4.21 (see overleaf for figure legend)
188
Figure 4,21 Calcium transients elicited in peritoneal macrophages from adult rats
Representative false colour images and traces depicting intracellular calcium levels in albumin, 
fraction V  or thapsigargin treated peritoneal macrophages (isolated from adult rats). Peritoneal 
macrophages isolated from adult rats were loaded with fura-2 (5 pM) in basic medium for 45 
minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 and 380 nm and 
emission was collected at a wavelength of 510 nm. Albumin (Alb: 1 or 12 mg/ml), fraction V  (Fv: 1 
or 12 mg/ml) or thapsigargin (Thaps: 1 pM) diluted in basic medium was added to the cells 60 
seconds after the commencement of excitation. Control cells were treated with basic medium in 
the absence of any other stimulus at the same time point. Calcium responses were recorded from 
ten cells and the results were expressed as 340/380 fluorescence ratios. False colour images 
corresponding to each treatment are also displayed. Images were captured at 0, 70 and 300 
seconds (from left to right) and the scale bar provides an indication of intracellular calcium levels. 
Inset: Trace depicting the effects of thapsigargin (1 pM) over a 1200 second period.
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[Thapsigargin] Macrophage (adult) Macrophage (neonate) Microglia
0 (basal) 021 ±0.06 0.16 ±0.01 0.1 ±0.01
InM 0.16 ±0.02 0.19 ±0.04 0.09 ± 0.02
10 nM 0.18 ±0.06 0.13 ± 0.03 0.08 ±0.01
100 nM 0.17 ±0.06 0.18 ±0.04 0.09 ±0.01
1000 nM 0.17 ±0.04 0.19 ±0.01 0.1 ± 0.01
[Thapsigargin] Macrophage (adult) Macrophage (neonate) Microglia
0 (basal) 0.2 ± 0.05 0.18 ±0.06 0.17 ±0.03
1 nM 023 ± 0.02 02  ± 0.07 0.18 ±0.02
10 nM 0.17 ±0.06 0.18 ±0.05 0.18 ±0.02
100 nM 0.16 ±0.02 024 ± 0.06 0.17 ±0.01
1000 nM 0.2 ± 0.03 02  ± 0.02 0.2 ±0.01
[Thapsigargin] Macrophage (adult) Macrophage (neonate) Microglia
0 (basal) 0.16 ±0.01 0.15 ±0.01 0.16 ±0.01
InM 022 ±0.01 0.15 ±0.01 0.17 ±0.02
10 nM 021 ±0.01 0.13 ±0.01 0.16 ±0.01
100 nM 024 ± 0.02 0.14 ± 0.02 0.15 ±0.01
1000 nM 0.17 ±0.01 0.13 ±0.01 0.15 ± 0.02
Table 4.8 Effects of thapsigargin on microglial or peritoneal macrophage proliferation
Proliferation was assessed using the cell titer assay. Microglia or peritoneal macrophages isolated 
from neonatal or adult rats were treated with increasing concentrations of thapsigargin (1-1000 
nM) in SCM for 8 (A), 24 (B), or 48 (C) hours. Control cells were left untreated for 8, 24 or 48 
hours respectively (0: basal). The values shown represent the mean ± SEM of data from 
experiments performed in triplicate. Statistical analysis was performed using ANOVA followed by 
the Tukey post test According to this test there was no statistical difference between the 
treatments.
190
Next the effects of albumin or fraction V on intracellular free calcium in astrocytes were 
studied. Fraction V (serum albumin) has previously been shown to evoke calcium waves 
in astrocytes (Nadal et al., 1995), whilst at low concentrations fraction V causes the uptake 
of calcium into intracellular stores. The calcium mobilizing action of fraction V is due to 
the presence of an unidentified protein bound polar lipid, whereas calcium uptake is 
mediated by the protein component of albumin (Nadal et al., 1996).
In this experiment the TSA-3 astrocyte cell line was used, these cells exhibit similar 
responses to primary astrocytes and are 100 % pure as determined by GFAP staining 
(Personal communication: Gareth Pryce). Fraction V was found to trigger calcium 
transients in TSA-3 astrocytes, whereas lower concentrations of fraction V caused the 
uptake of calcium into intracellular stores (Fig. 422). However, in contrast to the findings 
reported by Nadal et al., (1995) albumin did not evoke calcium uptake into intracellular 
stores in TSA-3 astrocytes (Fig. 4.23). In fact albumin did not exert any discemable 
effects on calcium transients in these cells, which is consistent with findings reported by 
Tabemero et al., (1999). Collectively, these findings illustrate that albumin triggers 
different signalling pathways in microglia, macrophages and astrocytes. In particular 
albumin induces calcium transients in microglia but not macrophages or astrocytes.
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Figure 4.22 Effects of fraction V on intracellular calcium transients in TSA-3 astrocytes
Representative false colour images and traces depicting intracellular calcium transients evoked in 
fraction V  treated TSA-3 astrocytes. TSA-3 astrocytes were loaded with fura-2 (5 |iM) in basic 
medium for 45 minutes at 37 °C. Cells were excited with wavelengths of 340 and 380 nm and 
emission was collected at a wavelength of 510 nm. Fraction V  (0.5, 1 or 5 mg/ml) diluted in basic 
medium was added to the cells 60 seconds after the commencement of excitation. Control cells 
were treated with basic medium in the absence of fraction V  at the same time point. Calcium 
responses were recorded from ten cells and the results were expressed as 340/380 fluorescence 
ratios. False colour images corresponding to each treatment are also displayed. Images were 
captured at 0, 70 and 300 seconds (from left to right) and the scale bar provides an indication of 
intracellular calcium levels. Inset: In the presence of fraction V  (0.5 mg/ml) the intensity of the 
excitation maxima for fura-2 shifts creating a higher reference point at 380 nm (red line), whereas 
a reduction occurs at 340 nm (black line). This is indicative of a decrease in intracellular calcium.
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Figure 4.23 Effects of albumin on intracellular calcium transients in TSA-3 astrocytes
Representative false colour images and traces depicting intracellular calcium levels in albumin 
treated TSA-3 astrocytes. TSA-3 astrocytes were loaded with fura-2 (5 nM) in basic medium for 45 
minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 and 380 nm and 
emission was collected at a wavelength of 510 nm. Albumin (0.25, 1 or 5 mg/ml) diluted in basic 
medium was added to the cells 60 seconds after the commencement of excitation. Control cells 
were treated with basic medium in the absence of albumin at the same time point. Calcium 
responses were recorded from ten cells and the results were expressed as 340/380 fluorescence 
ratios. False colour images corresponding to each treatment are also displayed. Images were 
captured at 0, 70 and 300 seconds (from left to right) and the scale bar provides an indication of 
intracellular calcium levels.
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4.6 Albumin treated microglia induce neuronal death
Activated microglia (Thery et al., 1991; Kingham et al., 1999; Combs et al 1999) and 
peripheral macrophages (Flavin et al., 1997) that invade the CNS in stroke and other 
disease states have been demonstrated to trigger neuronal apoptosis. Therefore, the effects 
of albumin or fraction V treated microglia on neuronal death was assessed. Microglia were 
treated with albumin or fiaction V in SFM for 2 hours. The SFM was then replaced with 
SCM for 22 hours before the medium was collected. Medium was subsequently applied to 
cultures of cerebellar granule neurones for 24 hours before neuronal apoptosis was 
appraised using Hoescht 33342. Medium collected from microglia treated with albumin (1 
mg/ml) (Fig. 4.24A) or fiaction V (1 mg/ml) (Fig. 4.24B) was found to induce a 
significant increase in neuronal apoptosis. Conversely, untreated cerebellar granule 
neurones (‘basal’) contained few apoptotic cells after 24 hours in culture. Neuronal 
cultures exposed to medium collected from microglia left untreated for 24 hours (control) 
or microglia treated with SFM for 2 hours then SCM for 22 hours (SFM) also contained 
low levels of apoptosis. The increase in apoptosis was not attributable to the presence of 
albumin (1 mg/ml) or fraction V (1 mg/ml) in the medium; since the direct application of 
these agents to neuronal cultures did not increase apoptosis above control levels (‘basal’ or 
‘SFM’). Furthermore, the addition of control microglial conditioned medium to neurones 
in the presence of albumin (1 mg/ml) or fraction V (1 mg/ml) did not increase neuronal 
death above controls (‘basal’ or ‘SFM’).
To ascertain whether microglial derived NO or glutamate contribute to neuronal apoptosis, 
the effect of AMT-HC1 or a cocktail of glutamate receptor antagonists on cell death was 
appraised. AMT-HC1 (0.3 pM) was pre-incubated with microglia before the addition of 
albumin of fraction V, medium was then collected after 24 hours and applied to cultures of 
cerebellar granule neurones. In contrast, the glutamate antagonist cocktail (CNQX, 20
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pM; MK801, 10 pM; MSPG, 200 pM) was pre-incubated with the neurones before the 
addition of microglial conditioned medium. Neither AMT-HC1 nor the glutamate 
antagonists attenuated neuronal death induced by microglia treated with albumin (1 
mg/ml) or fraction V (1 mg/ml). Furthermore, neuronal cultures treated with AMT-HC1 or 
the glutamate receptor antagonists directly did not contain significantly different levels of 
apoptosis from control cultures. These findings suggest that neuronal apoptosis induced by 
albumin or fraction V treated microglia is NO and glutamate independent. In contrast, 
boiling the microglial conditioned medium afforded neuroprotection, which suggest that 
the neurotoxic agent(s) are heat labile (Zhao and Eghbali-Webb 2001).
To determine at which time point microglia release the neurotoxic agent (s), microglia 
were treated with albumin (1 mg/ml) or fraction V (1 mg/ml) in SFM for 2 hours. The 
SFM was then replaced with SCM for 1, 4, 6, 14 or 22 hours. Microglia conditioned 
medium was subsequently incubated with cerebellar granule cells for a further 24 hours 
before apoptosis was assessed. Using this approach, neurotoxin release was demonstrated 
to occur 6 hours after the addition of albumin (1 mg/ml) or fraction V (1 mg/ml) and the 
neurotoxicity of the conditioned medium increased with time (Fig. 4.25). Furthermore, 
medium collected from albumin (1 mg/ml) or fraction V (1 mg/ml) treated microglia 
induced similar profiles of neuronal death temporally.
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Figure 4.24 (see overleaf for figure legend)
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Figure 4.24 Albumin or fraction V treated microglia induce neuronal death
Neuronal apoptosis induced by medium obtained from albumin or fraction V  treated microglia was 
assessed using Hoescht 33342. Microglia were treated with albumin (Alb: 1 mg/ml) (A) or fraction 
V (Fv: ImgAnl) (B) in SFM for 2 hours. The SFM was then replaced with SCM for 22 hours before 
the medium was collected. In addition, microglia were treated with albumin (Alb: 1 mg/ml) or 
fraction V  (Fv: 1 mg/ml) in SFM in the presence of AMT-HCI (0.3 ^M). At 2 hours the SFM was 
replaced with SCM supplemented with AMT-HCI (0.3 pM) for a further 22 hours before the 
medium was collected. Control medium was collected from microglia left untreated for 24 hours 
(control) or microglia exposed to SFM for 2 hours then SCM for 22 hours (SFM). Microglial 
conditioned medium was subsequently applied to cultures of cerebellar granule neurones for 24 
hours then the neurones were fixed. To assess the effect of glutamate on neuronal death, 
glutamate receptor antagonists (CNQX, 20 pM; MK801, 10 pM; MSPG, 200 pM) were pre­
incubated with the neurones for 1 hour before the addition of medium collected from albumin (1 
mg/ml) or fraction V  (1 mg/ml) treated microglia (‘glutamate antagonists’). In addition, medium 
obtained from albumin or fraction V  treated microglia was boiled before being applied to cultures of 
neurones (‘boiling’). Neurones were also left untreated for 24 hours (basal) or were treated with 
albumin (Alb alone: 1 mg/ml) or fraction V  (Fv alone: 1 mg/ml) in the presence or absence of 
control microglial conditioned medium (control medium + Alb or Fv respectively) for 24 hours 
before being fixed (to the right of dashed line). Following fixation, neurones were stained with 
Hoescht 33342. Non-apoptotic cells possessed large brightly stained nuclei, whereas apoptotic 
cells possessed brightly stained pyknotic nuclei. Neurones displaying pyknotic nuclei were 
counted and the degree of apoptosis was expressed as a percentage of the total number of cells 
counted. The values shown represent the mean ± SEM of data from experiments performed in 
triplicate. Experiments consisted of 3 coverslips per treatment comprising ten fields of view. 
Statistical analysis was performed using ANOVA followed by the Tukey post test. *** p < 0.001 vs 
‘control’ or ‘SFM’. *** P < 0.001 vs neurones treated with conditioned medium collected from 
albumin (Alb) or fraction V  (Fv) treated microglia respectively.
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Figure 4.25 Time course of neuronal death
The time course of neuronal apoptosis induced by medium collected from albumin or fraction V  
treated microglia was assessed using Hoescht 33342. Microglia were treated with albumin (Alb: 1 
mg/ml; open circles) or fraction V  (Fv: 1 mg/ml; closed circles) in SFM for 2 hours. The SFM was 
then replaced with SCM for 1, 4, 6 14 or 22 hours before the medium was collected. Microglial 
conditioned medium was subsequently applied to cultures of cerebellar granule neurones for 24  
hours then the neurones were fixed. Following fixation, neurones were stained with Hoescht 
33342. Non-apoptotic cells possessed large brightly stained nuclei, whereas apoptotic cells 
possessed brightly stained pyknotic nuclei. Neurones displaying brightly stained pyknotic nuclei 
were counted and the degree of apoptosis was expressed as a percentage of the total number of 
cells counted. The values shown represent the mean ± SEM of data from experiments performed 
in triplicate. Experiments consisted of 3 coverslips per treatment, comprising ten fields of view. 
Statistical analysis was performed using ANOVA followed by the Tukey post test. *** P < 0.001 vs 
control (control describes time 0).
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The effects of albumin or fraction V treated macrophages on neuronal apoptosis were 
subsequently studied. Macrophages isolated from neonatal or adult rats were treated with 
albumin (12 mg/ml) or fraction V (12 mg/ml) in SFM for 2 hours. The SFM was then 
replaced with SCM for 22 hours before the medium was collected. Medium was 
subsequently applied to cultures of cerebellar granule neurones for 24 hours before 
neuronal apoptosis was appraised using Hoescht 33342. Medium collected from 
macrophages treated with albumin (12 mg/ml) or fraction V (12 mg/ml) induced neuronal 
apoptosis (Fig. 426). Conversely, untreated cerebellar granule neurones (‘basal’) 
contained few apoptotic cells after 24 hours in culture. Neuronal cultures exposed to 
medium collected from macrophages left untreated for 24 hours (control) or macrophages 
treated with SFM for 2 hours then SCM for 22 hours (SFM) also induced similar levels of 
neuronal apoptosis as those macrophages treated with albumin (12 mg/ml) or fraction V 
(12 mg/ml). Moreover, there were no differences between the results obtained with 
macrophages isolated from neonatal or adult rats.
The increase in apoptosis was not attributable to the presence of high concentrations of 
albumin (12 mg/ml) or fraction V (12 mg/ml) in the medium; since the direct application 
of these proteins to neuronal cultures did not increase apoptosis above control levels 
(‘basal’). Furthermore, the addition of control macrophage conditioned medium to 
neurones in the presence of albumin (12 mg/ml) or fraction V (12 mg/ml) did not 
significantly increase neuronal death above controls (‘basal’).
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Figure 4.26 Effects of albumin or fraction V treated macrophages on neuronal death
Neuronal apoptosis induced by medium obtained from albumin or fraction V  treated macrophages 
was assessed using Hoescht 33342. Peritoneal macrophages isolated from neonatal (grey bars) 
or adult rats (open bars) were treated with albumin (Alb: 12 mg/ml) or fraction V  (Fv: 12 mg/ml) in 
SFM for 2 hours. The SFM was then replaced with SCM for 22 hours before the medium was 
collected. Control medium was collected from macrophages left untreated for 24 hours (control) or 
macrophages exposed to SFM for 2 hours then SCM for 22 hours (SFM). Conditioned medium 
was subsequently applied to cultures of cerebellar granule neurones for 24 hours then the 
neurones were fixed. Control neurones were either left untreated for 24 hours (basal) or were 
treated with albumin (Alb alone: 12 mg/ml) or fraction V  (Fv alone: 12 mg/ml) in the presence or 
absence of control macrophage conditioned medium (control medium + Alb or Fv respectively) for 
24 hours before being fixed (to the right of dashed line). Following fixation, neurones were stained 
with Hoescht 33342. Non-apoptotic cells possessed large brightly stained nuclei, whereas 
apoptotic cells possessed brightly stained pyknotic nuclei. Neurones displaying pyknotic nuclei 
were counted and the degree of apoptosis was expressed as a percentage of the total number of 
cells counted. The values shown represent the mean ± SEM of data from experiments performed 
in triplicate. Experiments consisted of 3 coverslips per treatment, comprising ten fields of view. 
Statistical analysis was performed using ANOVA followed by the Tukey post test. ** P < 0.01 vs 
‘basal’ (basal describes untreated neurones).
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4.7 Isolation of the putative albumin ‘binding protein’
The putative albumin ‘binding protein’ was isolated from a preparation of N9 microglial 
cell lysates using albumin conjugated to agarose beads as ‘bait’. The N9 microglial cell 
line (N9) was used in these experiments because a very large amount of cellular protein 
was required. Using this approach a single protein was precipitated that exhibited a 
molecular mass of approximately 225 kDa, which corresponds to a protein that is 
predicted to be 1875 amino acids in length (Fig. 4.27). The putative albumin ‘binding 
protein’ was also present in lysates prepared from TSA-3 astrocytes (TSA-3) and 
cerebellar granule neurones (CGC). Furthermore, a prominent band was detectable at 
approximately 45 kDa in lysates prepared from TSA-3 astrocytes. Conversely, no 
discemable bands were detectable in lysates prepared from peritoneal macrophages (Mac) 
isolated from adult rats. Peritoneal macrophages isolated from adult rats were used in 
these experiments because adult rats yield approximately 1 0  times more macrophages then 
neonates. Moreover, the results in this chapter suggest that peritoneal macrophages 
isolated from adult or neonatal rats behave similarly. As a control ‘neat’ albumin agarose 
complex, which had not been incubated with cell lysates was resolved on a Tris-HCl pre­
cast gel (Beads). This resulted in the visualisation of a band at approximately 6 6  kDa, 
which corresponds to the molecular weight of albumin. Therefore, the observed results are 
not merely due to the presence of the albumin agarose complex.
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Figure 4.27 Expression patterns of the putative albumin ‘binding protein’
Representative PVDF membrane stained with coumassie blue demonstrating the presence of the 
putative 225 kDa albumin ‘binding protein’. N9 microglia (N9), TSA-3 astrocytes (TSA-3), 
cerebellar granule neurones (CGC) and peritoneal macrophages isolated from adult rats (Mac) 
were lysed after 24 hours in culture. The lysates were incubated with albumin conjugated to 
agarose beads for 3 hours at 4 °C with end over end mixing. The albumin-bead complex was 
pelleted by centrifugation then washed in three changes of lysis buffer. The samples were 
subsequently mixed with laemelli buffer, boiled then resolved by SDS-page electrophoresis. The 
albumin-bead complex was mixed with laemelli buffer, boiled then ran on a gel as a control 
(Beads). After which the proteins were transferred on to a PVDF membrane before being stained 
with coumassie blue.
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4.8 Characterisation of the putative albumin ‘binding protein’
To identify the 225 kDa ‘binding protein’ the protein was subjected to N-terminal 
sequencing by Dr Fox (Alta Bioscience, Birmingham, UK). Edmun degradation was used 
to sequentially remove the amino acids from the N-terminus. The amino acids were 
subsequently identified using HPLC against standards. However, this approach was 
unsuccessful due to the presence of an ‘N-terminal block’. This suggests that the putative 
‘binding protein’ possesses a post-translational modification such as an acetyl, formyl or 
myristyl group, which prevents the amino acids situated at the N-terminus from being 
sequenced.
MALDI fingerprinting was employed in a further attempt to identify the putative ‘binding 
protein’. Fingerprinting was performed by Dr Packman (PNAC facility, Cambridge 
University, UK). Using this approach the putative ‘binding protein’ was determined to be 
myosin heavy chain DC (accession number: NP 071855), which exhibits a precise 
molecular mass o f227 kDa.
The functions of myosin DC have received little attention; however it has been proposed to 
mediate phagocytosis of bacteria (Graf et al., 2000). Subsequently the ability of microglia 
or macrophages to internalise FITC labeled albumin was explored. Microglia or 
macrophages (isolated from neonatal or adults rats) were incubated with FITC tagged 
albumin for 1 hour in SFM at 37 °C. Fluorescence microscopy revealed that microglia but 
not peritoneal macrophages internalise albumin (Fig. 4.28). Microglial staining was 
punctate indicative of a vesicular location and uptake was inhibited at 4 °C, which suggest 
that the process is active and dynamic.
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Figure 4.28 Internalisation of FITC labelled albumin by microglia or peritoneal macrophages
Images representing FITC labelled albumin uptake in microglia and peritoneal macrophages. 
Microglia were treated with FITC labelled albumin (0.25 mg/ml) in SFM for 1 hour at 37 °C (A) or 4 
°C (B). Peritoneal macrophages isolated from neonatal (C) or adult rats (D) were also incubated 
with FITC-albumin for 1 hour at 37 °C. Phase contrast and fluorescent images were subsequently 
photographed with an exposure time of 30 seconds.
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4.9 Discussion
Albumin was found to induce microglial iNOS expression, glutamate release and 
proliferation possibly by binding and activating myosin heavy chain IX. The 
concentrations of albumin that were found to elicit microglial signalling (025-2 mg/ml) 
are likely to fell in the range associated with BBB damage. Conversely, albumin did not 
appear to bind to myosin heavy chain IX in peritoneal macrophages; which may account 
for the inability of albumin to induce signalling in these cells. Similar results were 
obtained with macrophages isolated from neonatal or adult rats; consequently in the 
following discussion the ‘age’ of macrophage is not mentioned. Experimental data 
revealed that albumin and fraction V were equi-potent and induced similar signalling 
events. This suggests that albumin bound fatty acids, lipids or immunoglobulins do not 
contribute to the cell signalling cascades described here. Therefore, in the following 
discussion the term ‘albumin’ is used to describe the results obtained with both albumin 
and fraction V.
4.9.1 Myosin IX the putative albumin ‘binding protein’ in microglia
Putative albumin ‘binding proteins’ have been described in various cell types. The 60 kDa 
glycoprotein (gp60) or albondin mediates transcellular albumin transport across 
endothelial cells, which is critical for the maintenance of normal oncotic pressure across 
microvessels (Minshall et al., 2000). 125I-albumin has also been demonstrated to bind 
specifically, saturably, and reversibly to hepatocytes, a process that may mediate the 
hepatic extraction of fatty acids and other substances that tightly bind to albumin 
(Weisiger et al., 1981). Furthermore, maleylated albumin has been shown to function as a 
scavenger receptor ligand (Alford et al., 1998). In this study albumin was demonstrated to 
induce microglial cell signalling, which appeared to be mediated at least in part by an 
interaction with myosin heavy chain IX (isolated from murine N9 microglia). The most
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extensively characterised class IX myosins include Myr 5 and Myr 7 in the rat and myosin 
EXa and IXb in humans. Class IX myosins are unconventional non-muscle forms of 
myosin. Class II myosins are defined as conventional myosins, the best studied example 
of which is the skeletal muscle isoform. In contrast, unconventional myosins play a role in 
many diverse functions including cell locomotion, phagocytosis, organelie transport and 
signal transduction (Mermall et al., 1998). All members of the myosin family share a 
common structure. They are typically composed of two heavy chains that are 
approximately 2000 amino acids in length (Alberts et al., 2002). The amino terminal of the 
heavy chain forms the actin binding motor head domain, which converts chemical energy 
liberated by ATP hydrolysis into mechanical force, whilst the carboxyl terminal domain of 
the heavy chain forms an extended a  helix. Two heavy chains generally associate by 
twisting their a  helical tail domains together into a coiled-coil conformation, which forms 
a stable dimer comprising two head domains and a single rodlike tail (Alberts et al., 2002). 
The rodlike tail is responsible for binding to specific proteins and cargo and therefore 
determines the function and cellular location of a particular myosin isoform (Soldati 
2003). Each myosin heavy chain is also associated with up to 3 myosin light chains, which 
co-localise with the head domain. Myosin light chains function to stabilize the head 
domain and regulate motor activities (Bahler 2000).
Class IX myosins are associated with the cytoskeleton, which underlies the plasma 
membrane (Wirth et al., 1996; Muller et al., 1997). In particular, myosin IX (myr 5) 
associates with dynamic regions of the cell periphery including membrane ruffles and 
laemellipodia (Muller et al., 1997). In support of this, myosin heavy chain IX was only 
precipitated with an album in-agarose conjugate when cell lysates were incubated on ice 
for long periods of time, a process which serves to fully solubilise membranes. This
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therefore provides evidence that myosin heavy chain IX is indeed membrane anchored. 
Furthermore, N-terminal sequencing of myosin heavy chain IX proved unsuccessful, 
which suggests that the N-terminus of myosin heavy chain IX is post-translationally 
modified. Candidate modifications include membrane anchors such as myristyl groups.
Considering myosin I (Allen and Aderem 1995), IIV (Titus 1999) and X (Cox et al., 2002) 
are involved in phagocytosis, it seems plausible that myosin IX may mediate albumin 
uptake into microglia, which in turn triggers intracellular signalling. Indeed microglia but 
not macrophages were demonstrated to take up FITC labelled albumin in a temperature 
sensitive manner. Moreover, the labelled albumin appeared to be located in vesicles, 
which is consistent with the notion that albumin is phagocytosed in a receptor-dependent 
regulated manner. To date little has been published regarding the precise roles of myosin 
IX in cells, although myr 5 has been reported to mediate the uptake of the bacterium 
Shigella flexneri into epithelial cells (Graf et al., 2000). Since it is unlikely that albumin 
comes into direct contact with myosin heavy chain IX at the plasma membrane, it is 
conceivable that albumin interacts with a transmembranous adapter/receptor, which 
couples to myosin IX. Collectively, these components may constitute an ‘albumin entry 
complex’ in the plasma membrane. Nevertheless, such an ‘adaptor’ was not isolated using 
albumin-agarose precipitation; it is possible that the concentration of this putative 
‘adaptor’ was below the sensitivity range for coumassie staining and therefore eluded 
detection, alternatively the adaptor may not be proteinaceous.
Recently, astrocytes (Tabemero et al., 2002a) and neurones (Tabemero et al., 2002b) have 
also been reported to internalize albumin in vitro. Moreover, a protein that migrates to the 
same position as myosin heavy chain IX was isolated from both of these cell types using 
an albumin-agarose conjugate. These findings suggest that myosin heavy chain EX may
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mediate the effects of albumin in astrocytes and neurones as well as microglia. 
Interestingly, N9 microglia express more myosin heavy chain IX than astrocytes or 
neurones, which may reflect the highly phagocytic nature of microglia. Therefore, it 
would be interesting to investigate whether microglial activators which induce 
phagocytosis also trigger the up-regulation of myosin IX.
In agreement with previous findings albumin did not induce any discernible effects on 
intracellular calcium transients in TSA-3 astrocytes (Tabemero et al., 1999), however this 
conflicts with data published by Nadal et al., (1995) who demonstrated that albumin 
evokes calcium uptake into stores in primary astrocytes. In a parallel experiment, fraction 
V was found to induce calcium release from stores in TSA-3 astrocytes, which is 
consistent with previous reports (Nadal et al., 1995). The calcium mobilizing effects of 
fraction V have been attributed to the presence of a protein bound lipid other than LPA 
(Nadal et al., 1995) and are therefore probably mediated by a different receptor. In support 
of this, a protein with an approximate molecular weight of 45 kDa was also precipitated 
from TSA-3 astrocyte lysates using an albumin-agarose conjugate, which suggests that the 
albumin used in the conjugate contains attached lipid groups (information unavailable 
from the supplier). Putative candidates for the 45 kDa protein include the Gi protein 
coupled receptors Edg-1 (Zondag et al., 1998), Edg-3 or H218 (An et al., 1999), which 
bind shingosine-1-phosphate (SIP) a lysophospholipid lipid that is known to associate 
with fraction V serum albumin (Nadal 2001). Nadal et al., (1995) demonstrated that 
calcium transients induced by the albumin bound lipid were pertussis toxin sensitive as 
was the proliferative response. In support of this, SIP induces calcium transients in 
activated monocytes (Fueller et al., 2003) and cells transfected with Edg-3 or H218 
proliferate when stimulated with SIP (An et al., 2000). Regardless of the identity of the 
albumin bound lipid, these results highlight that albumin induces different signalling
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cascades in microglia and astrocytes, which seems plausible considering that these cells 
exhibit different embiyological origins (Ling et al., 1980; Kitamura et al., 1984; Hickey 
and Kimura 1988).
Interestingly, albumin did not induce intracellular signalling in peritoneal macrophages. 
Myosin IX (human IXb) has been demonstrated to move to a cytoplasmic location in 
differentiated macrophages, which may subsequently preclude signal transduction (Wirth 
et al., 1996). However, the results presented in this chapter reveal that myosin heavy chain 
IX is undetectable in peritoneal macrophages using the albumin-agarose precipitation 
method. This suggests that either myosin heavy chain IX does not bind albumin in 
macrophages, or that myosin heavy chain IX is not expressed by peritoneal macrophages. 
Nevertheless, macrophages adopted a bipolar morphology in the presence of high 
concentrations of albumin, whereas at lower concentrations macrophages were amoeboid 
in appearance. This suggests that albumin promotes cytoskeletal reorganisation in 
macrophages, possibly via an interaction with a different iso form of myosin.
In contrast to the typical structure of other myosin heavy chains, myosin heavy chain IX 
functions as a monomer (Wirth et al., 1996). Moreover, the rodlike tail domains of IXb 
and myr 5 contain a GTPase activating domain (GAP) for Rho GTPases (Reinhard et al., 
1995; Post et al., 1998). Interestingly, the expression of myr 5 in insect or mammalian 
cells induces the formation of long cellular processes, which is dependent on GAP activity 
(Muller et al., 1997). Thus, it seems likely that myosin IX may be involved in the 
formation of microglial ramifications. In support of this, albumin increases the number of 
branches emanating from microglial cell bodies, which corroborates the theory that 
albumin modulates the function of myosin IX.
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In addition to a GAP domain, myosin IXb comprises a diacylglycerol binding domain, 
which is similar to those found in PKC (Wirth et al., 1996). The presence of such a 
domain is consistent with the finding that albumin induces phospholipase c activity, which 
subsequently leads to the generation of IP3 and DAG. Thus, DAG may regulate the 
activity of myosin heavy chain IX by relaying feedback signals to the DAG binding 
domain. Indeed PIP2 (IP3 precursor) and DAG (Botelho et al., 2000) have recently been 
implicated in actin reorganization during phagocytosis in RAW macrophages.
The motor domain of myosin IX (myr 5) has been also been reported to play a role in cell 
signalling. Myr 5 comprises an N terminal extension that is structurally homologous to a 
RAS binding domain, although an expressed N-terminal truncation of myosin IX (amino 
acids 2-117) has been demonstrated to lack intrinsic RAS binding activity (Kalhammer et 
al., 1997). This however may be an experimental artifact since albumin induces ERK 
activation in microglia, which implies that the RAS binding domain is active in native 
myosin IX. A prerequisite for RAS binding is the presence of basic residues. The RAS 
binding domain of myosin IX is uncharged; therefore it is possible that RAS binding 
requires the presence of basic amino acids in other regions of the heavy chain (amino 
acids 118-1875), which would explain why RAS binding was not observed in experiments 
using N-terminal truncations.
4.9.2 Downstream pathways: iNOS expression
This study provides evidence that albumin treated microglia upregulate the expression of 
iNOS but not COX-2. iNOS expression was found to be ERK dependent. Accordingly, 
other microglial activators including LPS (Bhat et al., 1998; Pyo et al, 1998), thrombin 
(Ryu et al., 2000) and adenovirus infection (Bhat and Fan 2002) induce iNOS expression 
via ERK-dependent mechanisms. This is consistent with the feet that the iNOS promoter
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contains an AP-1 binding site, which is a transcription factor that is produced by activated 
ERK (Kristof et al., 2001). Interestingly, nitrite was undetectable in the culture medium 
collected from albumin treated microglia. This discrepancy could be attributed to a lack of 
essential enzymatic co-factors such as tetrahydrobiopterine (BH4) (Ding et al., 1997; 
Barker et al., 1998) or NADPH (Shin et al., 2002), without which NO cannot be generated 
even in the presence of iNOS. This may be an advantageous mechanism in the CNS, 
which serves to safeguard neurones against free radical damage. Another possible 
explanation for the absence of nitrite in the culture medium is that NO rapidly reacts with 
superoxide to form peroxynitrite which in turn nitrates tyrosine residues therefore 
rendering NO (nitrite) undetectable. Alternatively, iNOS may fulfill other functions in 
microglia, which are distinct from the canonical NO producing role.
Macrophages were resistant to the concentrations of albumin that stimulated iNOS 
expression in microglia. In contrast, macrophages and microglia expressed iNOS in 
response to LPS, which suggests that macrophages and microglia do share common 
signalling pathways. However, it should be noted that exposure of macrophages to 12 
mg/ml of albumin triggered iNOS expression and NO production (as indicated by the 
presence of nitrite in the culture medium). In this instance iNOS expression and nitrite 
production may be a consequence of non-specific receptor binding, considering that 
receptor mediated events are evoked by low concentrations of agonist. Moreover, 
phosphorylated ERK was not detectable in macrophages treated with 12 mg/ml of albumin 
or fraction V, which provides further evidence that iNOS expression, occurs via an 
alternate route in this case. Similarly, phosphorylated ERK was undetectable in 
macrophage lysates treated with LPS, which conflicts with a previous report (Chen and 
Wang 1999). Moreover, phosphorylated ERK has been implicated in LPS induced iNOS 
expression in RAW macrophages (Ajizian and English 1999). Although, Ajizian and
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English (1999) co-stimulated their macrophages with LPS and IFNy, whereas in this study 
LPS was used in isolation.
4.93 Downstream pathways: glutamate release
Albumin was demonstrated to induce microglial glutamate release via the Xc' transporter, 
which mediates the exchange of glutamate for cystine (Piani and Fontana 1994). This 
transport system is important in regulating glutathione concentrations, since the 
availability of cystine is a rate limiting step in synthesis (Piani and Fontana 1994). 
Interestingly, albumin also increases the synthesis and release of glutamate from neurones 
(Tabemero et al., 2002b). This phenomenon was attributed to the increased production of 
acetyl Co A, which in turn augments a-ketoglutarate efflux from the citric acid cycle, a 
bio-synthetic intermediate from which glutamate is synthesized (Tabemero et al., 2002b) 
(Fig. 4.29). Therefore, it seems plausible that albumin stimulates microglial metabolism 
resulting in the increased production of glutamate. This is turn may trigger glutamate 
exchange for cystine, from which glutathione and other enzymes involved in the 
management of oxidative stress can be synthesized. Therefore, glutamate release by 
activated microglia may be an intrinsic survival mechanism designed to protect microglia 
from the reactive nitrogen and oxygen species they produced during inflammatory 
reactions. However, as a consequence microglia may inadvertently contribute to 
excitotoxic damage in neurodegenerative diseases.
Macrophages did not release glutamate into the culture medium in response to albumin (1- 
12 mg/ml). This is consistent with the finding that albumin does not appear to bind to 
myosin heavy chain EX in macrophages. Interestingly, LPS did not induce glutamate 
release from macrophages either, although the same concentration of LPS triggered
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glutamate release from microglia. Similarly, Klegaris and McGeer (1997) reported that 
LPS, PMA and Ap only slightly increased glutamate release from peritoneal macrophages. 
This might be because resting macrophages are actively synthesizing a number of 
enzymes, which concomitantly enhances the basal glutamate cystine exchange rate so that 
stimulation by LPS or other inflammatory stimuli cannot increase glutamate release 
further. In support of this, untreated macrophages released very high levels of glutamate 
into the culture medium, which is in accord with previous findings (Klegaris and McGeer 
1997). The concentration of glutamate released from untreated macrophages was 
approximately 5 fold higher than the concentrations found in culture medium harvested 
from untreated microglia. Therefore, it would appear that resting macrophages are in a 
higher activational state then resting microglia, which corroborates FACS data presented 
in chapter 3. Moreover, ramified microglia are known to down regulate macrophage 
associated properties including non-specific esterase activity, the ability to perform 
phagocytosis and to bind acetylated low density lipo-protein, which is indicative of their 
resting phenotype (Giulian and Baker 1986). Consequently, microglia are exquisitely 
sensitive to subtle changes in the brain’s microenvironment (Kreutzberg 1996).
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Figure 4.29 Synthesis of glutamate from the citric acid cycle intermediate a-ketoglutarate
The citric acid cycle begins with the condensation of acetyl co-enzyme A with oxaloacetate. The 
cycle ultimately results in the regeneration of oxaloacetate and the production of two molecules of 
carbon dioxide. The cycle also produces three NADH, one FADH2 and one ATP per pyruvate 
molecule. In addition, glutamate and other amino acids can be sythesised from a-ketoglutarate. 
The reactions of the citric acid cycle are catalysed by the following enzymes (as numbered in the 
diagram): 1, Citrate synthase; 2, Aconitase; 3, Aconitase; 4, Isocitrate dehydrogenase; 5, a  
Ketoglutarate dehydrogenase complex; 6, Succinyl CoA synthase; 7, Succinate dehydrogenase; 
8, Fumerate; 9, Malate dehydrogenase (adapted from Berg et al., 2002).
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4.9.4 Downstream pathways: proliferation
In vivo microglia proliferate in response to pathogen invasion or injury (Graeber et al., 
1988c; Streit and Graeber 1993). The results presented here show that albumin-treated 
primary microglia or N9 microglia proliferate, whereas albumin-treated peritoneal 
macrophages do not. Albumin-induced proliferation may be an intrinsic host immune 
response. Expansion of the local microglial population would be an advantageous 
response to BBB damage in terms of minimising tissue damage and infection. Similarly, 
albumin with attached lipids may be involved in the formation of astrocytic scars 
following BBB damage, since fraction V induces astrocyte proliferation in vitro (Nadal et 
al., 1995). Moreover, thrombin has been reported to induce microglial proliferation and 
activation (Moller et al., 2000a), which suggests that a number of plasma proteins may act 
in synergy following BBB breakdown. Conversely, LPS did not induce microglial or 
macrophage proliferation, the former is consistent with previous reports (Suzumura et al., 
1991; Liu etal., 2001).
Albumin-induced proliferation in primary microglia was mediated by a Src kinase, 
phospholipase c and was calcium-dependent. In support of this, albumin triggered 
calcium release from thapsigargin-sensitive intracellular stores in N9 microglia but not 
macrophages. Albumin-induced calcium transients were also Src kinase and 
phospholipase c dependent, which is consistent with the proliferation data obtained in 
primary microglia. Phospholipase c y is known to comprise SH2 domains and is activated 
by receptor tyrosine kinases or non receptor tyrosine kinases which include members of 
the Src family (Berridge 1993; Carpenter and Ji 1999; Kim et al., 2000). Therefore, it is 
likely that a Src kinase lies upstream of phospholipase c activation and subsequent IP3 
sensitive calcium release. Moreover, Src kinases (Stzelecka-Kiliszek et al., 2002) have
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been implicated in FcyRIII dependent phagocytosis, which indicates that these kinases 
may also be involved in the internalization of FITC albumin in microglia. It is worth 
noting that the albumin used in this study was essentially immunoglobulin free, which 
rules out die possibility that albumin interacts with an Fc receptor to mediate myosin 
heavy chain IX activation and intracellular signalling. Interestingly, proliferation was not 
instigated by the application of thapsigargin to microglia or macrophages, which implies 
that calcium per se is not sufficient to initiate cell division. It may be that the amplitude 
and/or the duration of a calcium transient encodes a particular response.
4.9.5 Albumin treated microglia exhibit a neurotoxic phenotype
Medium harvested from albumin treated microglia induced neuronal apoptosis. These 
findings provide evidence that albumin activated microglia may aggravate 
neurodegeneration in disorders involving loss of BBB integrity. Neuronal death was not 
attenuated by the iNOS inhibitor AMT-HC1 or a cocktail o f glutamate receptor antagonists 
(MK801, CNQX and MSPG). These results suggest that neuronal death is NO and 
glutamate independent. The former is not suiprising given that the half life of NO in 
biological systems is approximately 5 seconds (Kulkami and Sharrna 1993; Alberts et al., 
2002; Berg et al., 2002). In contrast, boiling the microglial conditioned medium afforded 
neuroprotection, which suggests that the neurotoxic agent(s) are heat labile (Zhao and 
Eghbali-Webb 2001). The increase in neuronal apoptosis was not attributed to the 
presence of albumin (or fraction V) in the medium since the direct application of albumin 
to neurones did not induce death. Neuronal death was not induced by the addition of 
albumin (or fraction V) in the presence of control microglial conditioned medium either. 
Taken together, these findings imply that the neurotoxins are secreted by albumin treated 
microglia. Candidate neurotoxins may include cytokines (Combs et al., 2002) or proteases
216
(Flavin et al., 1997; Flavin et al., 2000; Kingham and Pocock 2001), which have 
previously been demonstrated to induce neuronal death in vitro.
Interestingly, untreated macrophages (‘basal’ or ‘SFM’) triggered neuronal apoptosis, 
which is in accord with previous findings (Flavin et al., 1997). This suggests that 
peripheral monocytes, which invade the CNS during injury, may contribute to neuronal 
degeneration. These findings also support the hypothesis that peripheral macrophages are 
more ‘activated’ than microglia. Furthermore, neuronal death was not augmented by 
treating macrophages with albumin, which is consistent with other results presented in this 
chapter and corroborates the notion that albumin does not bind and activate myosin IX 
signalling in these cells.
4.9.6 Conclusion
Here it is shown that albumin induces iNOS expression, glutamate release, proliferation 
and the release of neurotoxins possibly via an interaction with myosin heavy chain IX in 
microglia. Signalling is mediated intracellularly by a number of second messengers 
including ERK, a Src kinase and IP3 induced calcium release (Fig. 4.30). In contrast, 
albumin does not induce signalling in peritoneal macrophages. These findings are 
interesting considering that both microglia and macrophages are of the same lineage. 
Thus, it may be that microglia represent a distinct subset of macrophages that are destined 
for the CNS during development (Perry 2001) and therefore possess intrinsically different 
biochemical properties to peripheral macrophages.
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Figure 4.30 Signalling cascades elicited in albumin treated microglia
Albumin interacts with myosin IX to induce iNOS expression, glutamate release, proliferation and 
the release of as yet undetermined neurotoxins. iNOS expression is mediated intracellularly by 
ERK. The pathway leading to glutamate release is currently undetermined; however secretion 
involves the Xc transporter. Proliferation is calcium dependent, the source of which is the 
endoplasmic reticulum. The release of calcium is mediated by PLC and therefore involves IP3. A  
Src kinase, probably lying upstream of PLC, is also involved in calcium release and subsequent 
proliferation.
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5.0 Investigation of microglial signalling elicited by CgA or Ap
219
5.1 Introduction
This chapter explores the intracellular signalling cascades elicited in microglia treated 
with chromogranin A (CgA) or Ap<25-35) (see below for a description of CgA and 
section 1.6 for a description of Ap);two proteins that are associated with the 
pathology of AD.
5.1.1 Physiological roles of chromogranin A
CgA consists of 457 amino acids and is a member of the Granin family of acidic 
glycoproteins. CgA was originally identified in the secretoiy granules of chromaffin 
cells. However, it is now known that CgA is widely distributed in the secretory 
granules of nervous tissue (Volknandt et al., 1987) as well as endocrine tissue 
(Fischer-Colbrie et al., 1987).
The exact functions of CgA in the brain are currently under investigation, although 
CgA has been demonstrated to act as a calcium binding protein within secretory 
vesicles (Reiffen and Gratzl 1986). CgA has also been reported to possess 
neuromodulatory properties, exemplified by its ability to attenuate the effect of 
dopaminergic transmission in the nucleus accumbens (Brudzynski et al., 1994). In the 
periphery, CgA is proteolytically processed leading to the formation of pancreastatin, 
parastatin, catestatin, and vasostatin. These peptides mediate the regulation of 
pancreatic (Ishizuka et al., 1989) and parathyroid secretions (Fasciotto et al., 1993), 
the control of catecholamine release from chromaffin cells (Mahata et al., 1997) and 
vasoinhibition respectively (Angeletti 1994). Thus, it is conceivable that derivatives 
of CgA may also play functional roles in the CNS.
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5.1.2 Pathological roles of chromogranin A
CgA is implicated in a number of neurodegenerative disorders including AD, stroke, 
Parkinson’s disease and Pick’s disease. In AD, CgA accumulates in granular deposits, 
which are associated with senile plaques (Rangon et al., 2003) and in the surrounding 
dystrophic neurites (Munoz 1991; Yasuhara et al., 1994; Rangon et al., 2003). 
Furthermore, the CgA gene maps to a chromosomal locus associated with APP, 
which indicates that CgA and APP may act syneigistically in pathology (Modi et al., 
1989). Following a stroke CgA is upregulated in axonal swellings located at the 
infarct periphery (Yasuhara et al., 1994). CgA also accumulates in the Lewy bodies 
present in the substantia nigra in Parkinson’s disease (Nishimura et al., 1994). 
Similarly, CgA is upregulated in the Pick bodies and swollen neuronal processes in 
Pick’s disease (Yasuhara et al., 1994). Pertinent to this study, CgA is a potent 
microglial activator inducing microglia to switch from a resting ramified phenotype 
into a reactive neurotoxic state (Ciesielski-Treska et al., 1998; Kingham et al., 1999; 
Ciesielski-Treska et al., 2001). Taken together these findings suggest that common 
pathways involving CgA may underlie pathological processes in neurodegenerative 
disorders.
5.1.3 Summary of results
Previously it has been reported that CgA treated microglia assume an activated 
amoeboid morphology characterised by ED-1 immunoreactivity, iNOS expression, 
NO production and glutamate release (Kingham et al., 1999). The continuous 
synthesis of NO in CgA activated microglia subsequently leads to mitochondrial 
depolarisation and apoptosis (Kingham and Pocock 2000). Work in this chapter 
revealed that iNOS expression, glutamate release, mitochondrial depolarisation and 
apoptosis are inhibited by poly I, which suggests that signalling is mediated by the
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scavenger receptor. These events with the exception of glutamate release were also 
attenuated by pre-treatment with U0126 or PP2, implying that signalling is mediated 
intracellularly by a Src kinase and ERK. Consistent with this, the phosphorylated 
forms of ERK 1 and 2 were detectable 30 minutes after the addition of CgA and 
reached maximal levels 3 hours after treatment. Furthermore, PP2 inhibited CgA 
induced ERK phosphorylation, which suggests that a Src kinase lies upstream of 
ERK activation.
AP(25-35) (hereafter referred to as Ap) was also demonstrated to trigger microglia to 
apoptose and cell death was mediated by mitochondrial depolarisation. Furthermore, 
apoptosis and mitochondrial depolarisation were attenuated by poly I, which suggests 
that these signalling events are also scavenger receptor-dependent. In contrast to 
CgA treatment, apoptosis and mitochondrial depolarisation were iNOS and ERK 
independent Although, Ap induced apoptosis and mitochondrial depolarisation were 
abrogated by pertussis toxin and PP2, implicating Gj/0 proteins and Src kinases in 
signalling.
In a parallel series of experiments, conditioned medium harvested from CgA or Ap 
treated microglia was found to induce neuronal apoptosis. Microglial derived 
neurotoxin(s) were heat labile. Appearance of the neurotoxin(s) in microglial 
conditioned medium became apparent 16 hours after CgA or Ap treatment, which 
suggests that the neurotoxin(s) are synthesised de novo.
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5.2 CgA but not Ap induces iNOS expression in microglia
Microglia treated with CgA or Ap in SCM were analysed for iNOS expression after 
24 hours in culture. It should be noted that microglia were treated with CgA or Ap in 
SCM in all subsequent experiments described in this chapter. Western blot analyses 
revealed that CgA (50-1000 nM) induced a dose dependent increase in iNOS 
expression (Fig. 5.1 A), whereas Ap (15-55 pM) did not evoke the expression of this 
inflammatory mediator (Fig. 5.IB). iNOS was also undetectable in untreated 
microglia after 24 hours in culture (basal). (Fig 5.1 A 3). Analysis of P-actin levels 
demonstrated that the observed changes were not due to differences in protein 
loading. The concentrations of Ap used in this study may seem very high, however 
the aim was to replicate the high concentrations of Ap found in senile plaques in an in 
vitro system.
Time course analysis revealed that iNOS was initially detectable 6 hours after the 
addition of CgA (100 nM) and that iNOS expression increased with time (Fig. 5.1 C). 
Conversely, Ap (55 pM) did not induce microglial iNOS expression at any point over 
the same time course. In a parallel experiment, nitrite, a stable breakdown product of 
NO was measured in microglial conditioned medium. However, nitrite was not 
detectable above control levels (basal) in medium collected 24 hours after CgA (100 
nM) or Ap (55 pM) treatment (table 5.1). These findings were not attributed to assay 
failure since nitrite was detectable in medium collected from LPS (2 pg/ml) treated 
peritoneal macrophages.
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Figure 5.1 CgA but not Ap induces iNOS expression
Representative Western blots of iNOS expression in microglial cell lysates. A: Microglia were 
treated with increasing concentrations of CgA (50-1000 nM) for 24 hours before lysates were 
prepared. Control lysates were prepared from microglia left untreated for 24 hours (basal) B: 
Microglia were treated with increasing concentrations of Ap (15-55 nM) for 24 hours before 
lysates were prepared. Control lysates were prepared from microglia treated as described in 
A C: Microglia were treated with CgA (100 nM) or Ap (55 j^M) for 0.5, 1, 3, 6 or 24 hours 
before lysis. Lysates were subjected to Western blot analyses using an antibody raised 
against iNOS (1:5000), which in turn was detected by goat anti-rabbit IgG (HRP) (1:500). To  
ensure equal protein loading blots were reprobed with an antibody recognising p-actin 
(1:1000) followed by exposure to goat anti-mouse IgG (HRP) (1:1000).
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Treatment [Nitrite](nM/pg protein)
Basal 1.04 ±0.03
CgA (100 nM) 0.97 ±0.08
AP (55 pM) 0.82 ± 0.06
Macrophage (LPS: 2 pg/ml) 493.1 ± 0.9 ***
Table 5.1 Nitrite release from microglia
Nitrite concentrations (nM/^g of protein) were measured in microglial conditioned medium 
using Griess reagent Microglia were treated with CgA (100 nM) or Ap (55 nM) for 24 hours 
before medium was collected. Medium was also collected from peritoneal macrophages 
(isolated from adult rats) treated with LPS (2 ng/ml) for 24 hours. Control medium was 
collected from microglia left untreated for 24 hours (basal). The values shown represent the 
mean concentration in nM/jig of protein ± SEM of data from experiments performed in 
triplicate. Statistical analysis was performed using an ANOVA followed by the Tukey post 
test *** P < 0.001, vs ‘basal’.
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The signalling pathways that mediate CgA-induced iNOS expression were 
subsequently studied using a number of inhibitors. Western blot analyses revealed 
that pre-treatment with poly I (i: 0.1 pg/ml; ii: 0.5 pg/ml), a scavenger receptor 
antagonist, entirely abated CgA-induced iNOS expression (Fig. 5.2A,B). Pre- 
treatment with pertussis toxin (Ptx; i: 1 pg/ml; ii: 2 pg/ml), a Gi/o protein inhibitor or 
BAPTA-AM (i: 1 pM; ii: 10 pM), a membrane permeable calcium chelator did not 
exert an inhibitory effect on iNOS expression. Furthermore, microglia treated with 
the inhibitors alone did not express significantly different levels of iNOS from control 
(basal). In contrast, pre-treatment with PP2 (i: 50 nM; ii: 100 nM), a Src kinase 
inhibitor or U0126 (i: 1 pM; ii: 5 pM) an ERK inhibitor significantly attenuated 
CgA-induced iNOS expression. Maximal inhibition was obtained with PP2 or U0126 
at concentrations of 100 nM and 5 pM respectively. Densitometry revealed that at 
these concentrations the inhibitors caused a five fold reduction in iNOS expression 
(Fig. 5.2B). Furthermore, microglia treated with PP2 (100 nM) or U0126 (5 pM) 
alone contained similar levels of iNOS as control microglia (basal).
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Figure 5.2 Modulation of CgA-induced iNOS expression
Representative Western blots of iNOS expression in microglial cell lysates. A: Microglia were 
treated with CgA (100 nM) for 24 hours before lysates were prepared. In addition, lysates 
were prepared from microglia treated with CgA (100 nM) in the presence of poly I (0.1 ng/ml; 
ii: 0.5 ng/ml), pertussis toxin (Ptx, i: 1 i^g/rnl; ii: 2 ng/ml), BAPTA (i: 1 ^M; ii: 10 p.M), PP2 (i: 
50 nM; ii: 100 nM) or U 0126  (i: 1 (iM; ii: 5 nM). Lysates were also prepared from microglia 
treated with the inhibitors (iii: poly I; 0 .5 ng/ml, Ptx; 2 ng/ml, BAPTA; 10 (iM, PP2; 100 nM, 
U0126; 5 ^M) alone. Control lysates were prepared from microglia left untreated for 24 hours 
(basal). Lysates were subjected to Western blot analyses using an antibody raised against 
iNOS (1:5000). To ensure equal loading blots were re-probed using an antibody recognising 
p-actin (1:1000). B: Densitometric analysis of iNOS bands (in the presence of the highest 
concentration of inhibitor where applicable) and p-actin bands was performed and levels of 
iNOS were normalised with respect to p-actin. Statistical analysis was performed using 
ANOVA followed by the Tukey post test. *** P < 0.001 vs ‘CgA’.
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Since U0126 inhibited CgA-induced iNOS expression, the presence of phospho-ERK 
was assessed in microglial lysates. CgA (100 nM) but not Ap (55 pM) elicited a rapid 
phosphorylation of ERK 1 and 2 (Fig. 5.3A). Phospho-ERK was initially detectable 
30 minutes after the addition of CgA (100 nM) and expression increased with time. 
Maximal phosphorylation was reached by 3 hours, followed by a decline in 
phosphorylation reaching lower levels by 24 hours post CgA treatment. Analysis of 
total ERK levels indicated that these results were not due to differences in protein 
loading. Furthermore, parallel time courses using untreated microglial cells 
demonstrated that ERK phosphorylation did not significantly increase over the 
experimental period (Fig. 5.3B). This suggests that the increases in ERK 
phosphorylation are due to the addition of CgA.
The order of second messenger activation leading to iNOS expression was 
subsequently investigated. Src kinases are involved in membrane proximal signalling 
events (Alberts et al., 2002), therefore the effects of PP2 pre-treatment on CgA (100 
nM) induced ERK phosphorylation were assessed. Western blot analyses 
demonstrated that, pre-treatment with PP2 (50 nM; 100 nM) caused the complete 
inhibition of CgA-induced ERK phosphorylation in microglia (Fig. 5.3C). 
Furthermore, pre-treatment with Poly I (0.1 pg/ml; 0.5 pg/ml) completely abolished 
the phosphorylation of ERK. Analysis of total ERK expression demonstrated that 
these results were not a consequence of unequal protein loading.
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Figure 5.3 CgA but not Ap induces the phosphorylation of ERK
Representative Western blots of ERK phosphorylation in microglial cell lysates. A: Microglia 
were treated with CgA (100 nM) or Ap (55 jaM) and lysates were prepared after 0, 0.5, 1, 3, 6 
or 24 hours. B: Control lysates were prepared from untreated microglia after 0 and 24 hours 
in culture. C: Microglia were treated with CgA (100 nM) for 24 hours before lysates were 
prepared. In addition, microglia were treated with CgA (100 nM) in the presence of PP2 (i: 50  
nM; ii; 100 nM) or poly I (0.1 ng/ml; ii: 0.5 ng/ml). Lysates were also prepared from microglia 
treated with the inhibitors (iii: PP2; 100 nM, poly I; 0.5 j^g/ml) alone. Control lysates were 
prepared from microglia left untreated for 24 hours (basal). Lysates were subjected to 
Western blot analyses using an antibody raised against phospho-ERK (1:750), which in turn 
was detected by goat anti-mouse IgG (HRP) (1 :1000). To ensure equal loading blots were re­
probed using an antibody recognising total ERK (1:500) followed by exposure to goat anti­
rabbit IgG (HRP) (1:500).
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53  Neither CgA nor Ap induce COX-2 expression in microglia
Microglia were analysed for COX-2 expression following exposure to CgA or Ap for 
24 hours. COX-2 was undetectable in CgA (50-1000 nM) or Ap (15-55 pM) treated 
microglia as demonstrated by Western blotting (Fig. 5.4A,B). hi contrast, microglia 
treated with LPS (2 pg/ml) for 24 hours expressed COX-2, whereas COX-2 was 
absent in microglia left untreated for 24 hours (basal). Furthermore, time course 
analyses demonstrated that COX-2 was undetectable in microglial lysates 1, 3, 8  or 
48 hours after CgA (100 nM) or Ap (55 pM) treatment (Fig. 5.4C).
5.4 CgA but not Ap induces glutamate release from microglia
Microglia exposed to CgA (50-1000 nM) for 24 hours released glutamate in a dose 
dependent fashion (Fig. 5.5A). Glutamate concentrations ranged from 244-598 
nM/pg of protein. Microglia left untreated for 24 hours (basal) secreted very low 
concentrations of glutamate, giving a basal reading of approximately 40 nM/pg of 
protein. Time course analysis revealed that glutamate was initially detectable 3 hours 
after the addition of CgA (100 nM) and that the levels of released glutamate increased 
with time (Fig. 5.5B). Conversely, Ap (55 pM) did not stimulate the release of 
glutamate above control levels (basal). The signalling pathways that mediate CgA- 
induced glutamate release were subsequently studied. Pre-treatment with poly I (0.5 
pg/ml) reduced CgA-induced glutamate secretion to control levels (Fig. 5.5C). In 
contrast, pre-treatment with pertussis toxin (Ptx; 2 pg/ml), BAPTA-AM (10 pM), 
PP2 (100 nM) or U0126 (5 pM) did not modulate CgA-induced glutamate release. 
Furthermore, medium collected from microglia treated with the inhibitors alone did 
not contain significantly different levels of glutamate from control medium (basal).
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Figure 5.4 Neither CgA nor Ap induce COX-2 expression
Representative Western blots of COX-2 expression in microglial cell lysates. A: Microglia 
were treated with increasing concentrations of CgA (50-1000 nM) for 24 hours before lysates 
were prepared. Lysates were also prepared from microglia treated with LPS (2 ^g/ml) for 24 
hours. Control lysates were prepared from microglia left untreated for 24 hours (basal) B: 
Microglia were treated with increasing concentrations of Ap (15-55 i^M) for 24 hours before 
lysates were prepared. Lysates were also prepared from microglia treated with LPS (2 ng/ml) 
for 24 hours. Control lysates were prepared from microglia treated as described in A. C: 
Microglia were treated with CgA (100 nM) or Ap (55 nM) for 0, 1, 3, 8 or 48 hours before 
lysis. As a positive control microglia were treated with LPS (2 ng/ml) for 24 hours. Lysates 
were subjected to Western blot analysis using an antibody raised against COX-2 (1:750), 
which in turn was detected by donkey anti-goat IgG (HRP) (1:1000). To ensure equal protein 
loading blots were reprobed with an antibody recognising p-actin (1:1000) followed by 
exposure to goat anti-mouse IgG (HRP) (1:1000).
231
[G
lu
ta
m
at
e]
 (
nM
/|x
g)
 
[G
lu
ta
m
at
e]
 (
nM
/|x
g)
 
[G
lu
ta
m
at
e]
 (
nM
/n
g)
\  800 
600
400 
200
0
Basal 50 100 500 1000
[CgA](nM)
**
600 CgA
* * *
400
200
0 12 18 246
Time (h)
600
400
200
■«3V)
ca
+  C gA
©Oh
£
cl
09
<s
Oh
VO
O
P
Figure 5.5 (see overleaf for figure legend)
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Figure 5.5 CgA but not Ap stimulates glutamate release
Glutamate concentrations (nM/pg of protein) were measured in microglial conditioned 
medium using a fluorometric assay. A: Microglia were treated with increasing concentrations 
of CgA (50-1000 nM) for 24 hours before the medium was collected. Control medium was 
collected from microglia left untreated for 24 hours (basal). B: Microglia were treated with 
CgA (100 nM; closed circles) or Ap (55 pM; open circles) for 0, 0.25, 0.5, 1, 3, 6  or 24 hours 
before medium was collected. C: Medium was collected from microglia treated with CgA (100 
nM) for 24 hours. In addition, medium was collected from microglia treated with CgA (100 
nM) in the presence of poly I (0.5 pg/ml), pertussis toxin (Ptx; 2 pg/ml), BAPTA-AM (10 pM), 
PP2 (100 nM) or U0126 (5 pM). Control medium was collected from microglia treated as 
described in A. The values shown represent the mean (nM/pg of protein) ± SEM of data from 
experiments performed in triplicate. Statistical analysis was performed using ANOVA followed 
by the Tukey post test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs control. (A: control describes 
basal. B; control describes 0 hours. C: control describes CgA treated).
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To verify that glutamate release was not due to cell membrane disruption, CgA (1000 
nM) treated microglia were stained with propidium iodide and fluoroscein diacetate. 
Staining revealed that microglial cultures exposed to CgA for 24 hours (1000 nM) 
contained few cells exhibiting propidium iodide staining (table 5.2). Similarly, 
microglial cultures left untreated for 24 hours contained few cells that stained with 
propidium iodide. This suggests that CgA induced glutamate release occurs via a 
regulated pathway and is not due to loss o f cell membrane integrity.
Basal CgA (1000 nM)
% propidium iodide stained cells 2.8 ±1.2 2.7 ± 22
Table 5.2 Analysis of microglial membrane integrity following exposure to CgA
Microglia treated with CgA were stained with propidium iodide and fluoroscein diacetate to 
provide an estimation of cell membrane integrity. Microglia were treated with CgA (1000 nM) 
for 24 hours before staining was performed. Control microglia were left untreated for 24 hours 
before staining (basal). Cells possessing propidium iodide staining were expressed as a 
percentage of the total number of cells counted (cells possessing propidium iodide staining or 
fluoroscein diacetate staining). The values shown represent the mean ± SEM of data from 
experiments performed in triplicate. Statistical analysis was performed using a two sided 
unpaired students T-Test. According to this test there was no difference between the 
treatments.
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5.5 CgA or Ap induces microglia to apoptose
Following CgA or Ap treatment, microglia ultimately adopt a shrunken conformation 
that is characteristic of dying cells. This phenomenon was investigated further using 
the fluorescent dyes JC-1 and Hoechst 33342, which enable the identification of 
depolarised mitochondria and pyknotic nuclei respectively. Staining revealed that 
exposure of microglia to CgA (50-1000 nM) for 48 hours resulted in a dose 
dependent increase in the number of cells displaying depolarised mitochondria or 
nuclear pyknosis (Fig. 5.6A). In contrast, the vast majority of untreated microglia 
possessed polarised mitochondria and large healthy nuclei at the same time point 
(basal). Time course analyses demonstrated that mitochondrial depolarisation induced 
by CgA preceded apoptosis temporally (Fig. 5.6B). Microglia displaying depolarised 
mitochondria were initially detectable 24 hours after the addition of CgA (100 nM), 
whereas microglia exhibiting significant levels of nuclear pyknosis were not 
detectable until 32 hours post treatment.
Exposure of microglia to Ap (15-55 pM) for 48 hours also induced in a dose 
dependent increase in mitochondrial depolarisation and nuclear pyknosis (Fig. 5.6C). 
Conversely, microglia treated with the reverse peptide, Ap(35_25) (55 pM) for 48 
hours, possessed polarised mitochondria and large healthy nuclei. This indicates that 
apoptosis and mitochondrial depolarisation are a specific response to Ap treatment. 
As with CgA treatment, Ap induced mitochondrial depolarisation preceded apoptosis 
temporally. Microglia displaying depolarised mitochondria were initially detectable 
32 hours after the addition of Ap (55 pM), whereas apoptotic cells were not 
detectable until 40 hours after Ap (55 pM) treatment (Fig. 5.6D).
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Figure 5.6 CgA or Ap induces mitochondrial depolarisation and apoptosis
Microglia treated with CgA or Ap were stained with JC-1 or Hoechst 33342 to provide an 
estimation of mitochondrial depolarisation and apoptosis respectively. A: Microglia were 
treated with increasing concentrations of CgA (50-1000 nM) for 48 hours then the cells were 
stained with JC-1 (grey bars) or Hoechst 33342 (open bars). Control microglia were left 
untreated for 48 hours before staining (basal). B: Microglia were treated with CgA (100 nM) 
for 0, 8, 16, 24, 32 or 48 hours before being stained with JC-1 (closed circles) or Hoechst 
33342 (open circles). C: Microglia were treated with increasing concentrations of Ap (15-55  
^M) or the reverse peptide A p p ^  (55 ^iM) for 48 hours before the cells were stained with 
JC-1 (grey bars) or Hoechst 33342 (open bars). Control microglia were treated as described 
in A (basal). D: Microglia were treated with Ap (55 ^M) for 0, 16, 24, 28, 32, 40  or 48  hours 
before being stained with JC-1 (closed circles) or Hoechst 33342 (open circles). Cells 
displaying depolarised mitochondria or brightly stained pyknotic nuclei were counted and the 
degree of mitochondrial depolarisation or apoptosis was expressed as a percentage of the 
total number of cells counted. The values shown represent the mean ± SEM of data from 
experiments performed in triplicate. Experiments consisted of 3 coverslips per treatment, 
each comprising 10 fields of view and experiments were performed on three independent 
occasions. Statistical analysis was performed using ANO VA followed by the Tukey post test. 
* p < 0.05 vs control; ** p < 0.01 vs control (A, C: control describes basal. B, D: control 
describes 0 hours).
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Apoptosis is often preceded by a reduction in mitochondrial membrane potential 
(AT), which is caused by the opening of the PT pore (Zamzami et al., 1996). The 
involvement of the PT pore in CgA or Ap induced apoptosis was subsequently 
assessed using the pore inhibitor cyclosporin A (CsA) (Zamzami et al., 1996; Seaton 
et al., 1998; Yang and Cortopassi 1998; Kingham and Pocock 2000). Pre-treatment 
with CsA (1 pM) significantly attenuated CgA (100 nM) or Ap (55 pM) induced 
mitochondrial depolarisation and apoptosis after 48 hours in culture (Fig. 5.7A,B). 
This suggests that the PT pore is involved in both CgA or AP induced cell death.
The upstream signalling pathways involved in CgA or Ap induced mitochondrial 
depolarisation and apoptosis were also studied using the same battery of inhibitors 
employed in previous experiments. Pre-treatment with poly I (0.5 pg/ml) reduced 
CgA (100 nM) induced mitochondrial depolarisation and apoptosis to control levels 
(Fig. 5.7A). Pre-treatment with pertussis toxin (Ptx; 2 pg/ml) or BAPTA-AM (10 
pM) exerted no inhibitory effect on these parameters, whereas PP2 (100 nM) or 
U0126 (5 pM) pre-treatment significantly attenuated CgA-induced mitochondrial 
depolarisation and apoptosis. Furthermore, pre-treatment with poly I (0.5 mg/ml), 
pertussis toxin (Ptx; 2 pg/ml) or PP2 (100 nM) significantly attenuated Ap (55 pM) 
induced mitochondrial depolarisation and apoptosis (Fig. 5.7B), whilst pre-treatment 
with neutralising RAGE antibody (200 pg/ml), BAPTA-AM (10 pM) or U0126 (5 
pM) exerted no inhibitory effects. Moreover, microglial cultures treated with the 
inhibitors alone did not contain significantly different levels of mitochondrial 
depolarisation or apoptosis from control (basal).
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Figure 5.7 Modulation of mitochondrial depolarisation and apoptosis
Microglia treated with CgA or Ap in the presence of inhibitors were stained with JC-1 or 
Hoechst 33342 to provide an estimation of mitochondrial depolarisation and apoptosis 
respectively. Microglia were treated with CgA (100 nM) (A) or Ap (55 pM) (B) for 48 hours 
then the cells were stained with JC-1 (grey bars) or Hoechst 33342 (open bars). In addition, 
microglia treated with CgA (100 nM) or Ap (55 mM) in the presence of CsA (1 pM), Poly I (0.5 
pg/ml), neutralising RAGE antibody (200 pg/ml: Ap treated microglia only), Ptx (2 pg/ml), 
BAPTA-AM (10 pM), PP2 (50 nM) or U 0126  (5 pM) were stained with JC-1 (grey bars) or 
Hoechst 33342 (open bars) after 48 hours in culture. Control microglia were left untreated for 
48 hours before staining (basal). Cells displaying depolarised mitochondria or brightly stained 
pyknotic nuclei were counted and the degree of mitochondrial depolarisation or apoptosis 
was expressed as a percentage of the total number of cells counted. The values shown 
represent the mean ± SEM of data from experiments performed in triplicate. Experiments 
consisted of 3 coverslips per treatment, each comprising 10 fields of view and experiments 
were performed on three independent occasions. Statistical analysis was performed using 
ANOVA followed by the Tukey post test. ** p < 0.01 vs control. *** p < 0.001 vs control. (A: 
control describes CgA treated microglia. B: control describes A(3 treated microglia).
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5.6 Neither CgA nor Ap induce calcium transients in N9 microglia
Despite the finding that BAPTA-AM did not inhibit the CgA or Ap induced 
signalling events studied so far, the ability of these microglial activators to elicit 
intracellular calcium transients was tested in N9 microglia using fura-2. The N9 cell 
line is a well characterised microglial cell line, which exhibits similar responses to 
primary microglia (Corradin et al., 1993; Ferrari et al., 1996; Kingham et al., 1999). 
Accordingly, CgA (100 nM) induced iNOS expression in N9 microglia, whilst Ap 
(55 pM) did not (Fig. 5.8).
Calcium transients were undetectable in untreated N9 microglia (Fig. 5.9). Similarly, 
application of CgA (100 nM) or Ap (55 pM) did not evoke calcium transients in these 
cells (Fig. 5.9). In contrast, ATP (1 pM), a microglial activator known to induce 
calcium release from IP3 regulated stores (MoHer et al., 2000b; Nagai et al., 2001), 
evoked a rapid calcium response in N9 microglia. Furthermore, N9 cells were 
resistant to a wide range of CgA (100-10000 nM) (Fig. 5.10) or Ap (0.1-55 pM) 
concentrations (Fig. 5.11).
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Figure 5.8 CgA but not Ap induces iNOS expression in N9 microglia.
Representative Western blots of iNOS expression in N9 microglia cell lysates. N9 Microglia 
were exposed to CgA (100 nM) or Ap (55 pM) for 24 hours before lysates were prepared. 
Control lysates were prepared from N9 microglia left untreated for 24 hours (basal). Lysates 
were subjected to Western blot analyses using an antibody raised against iNOS (1:5000). To  
ensure equal protein loading blots were reprobed with an antibody recognising p-actin 
( 1:1000).
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Figure 5.9 Effect of CgA or Ap on intracellular calcium fluxes in N9 microglia
Representative false colour images and traces depicting the effects of CgA, Ap or ATP on 
intracellular calcium in N9 microglia. N9 microglia were loaded with fura-2 (5 nM) in basic 
medium for 45 minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 
and 380 nm and emission was collected at a wavelength of 510 nm. CgA (100 nM), Ap (55 
liM) or ATP (1 juM) diluted in basic medium were added to the cells 60 seconds after the 
commencement of excitation. Control N9 cells were treated with basic medium alone at the 
same time point. Calcium responses were recorded from ten cells and the results were  
expressed as 340/380 fluorescence ratios. False colour images corresponding to each 
treatment are also displayed. Images were captured at 0, 70 and 300 seconds (from left to 
right) and the scale bar provides an indication of intracellular calcium levels.
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Figure 5.10 Dose dependent effects of CgA on intracellular calcium in N9 microglia
Representative traces depicting the effects of increasing concentrations of CgA on 
intracellular calcium in N9 microglia. N9 microglia were loaded with fura-2 (5 ^iM) in basic 
medium for 45 minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 
and 380 nm and emission was collected at a wavelength of 510 nm. CgA (1-10000 nM) 
diluted in basic medium was added to the cells 60 seconds after the commencement of 
excitation, as a positive control microglia were treated with ATP (1 nM). Control N9 cells were 
treated with basic medium atone at the same time point. Calcium responses were recorded 
from ten cells and the results were averaged and expressed as 340/380 fluorescence ratios.
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Figure 5.11 Dose dependent effects of Ap on intracellular calcium in N9 microglia
Representative traces depicting the effects of increasing concentrations of Ap on intracellular 
calcium in N9 microglia. N9 microglia were loaded with fura-2 (5 jiM) in basic medium for 45  
minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 and 380 nm and 
emission was collected at a wavelength of 510 nm. Ap (0.1-55 pM) diluted in basic medium 
was added to the cells 60  seconds after the commencement of excitation, as a positive 
control microglia were treated with ATP (1 pM). Control N9 cells were treated with basic 
medium alone at the same time point. Calcium responses were recorded from ten cells and 
the results were averaged and expressed as 340/380 fluorescence ratios.
ATP (1 pM)
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5.7 CgA or Ap treated microglia induce neuronal death
Inflammatory mediators released from activated microglia can exacerbate 
neurodegeneration (Thery et al,. 1991; Kingham et al., 1999; Combs et al., 1999). 
Subsequently, conditioned medium harvested from CgA (100 nM) or Ap (55 jiM) 
treated microglia was applied to cultures of cerebellar granule neurones and neuronal 
apoptosis was assessed using Hoescht 33342. Cerebellar granule neurones exhibited a 
dense network of cable like neurites after 8  days in culture, and contained few 
apoptotic nuclei (Basal) (Fig. 5.12A,C). Similarly, neurones exposed to conditioned 
medium collected from microglia left untreated for 24 hours also contained low levels 
of apoptotic cells after 24 hours in culture. In contrast, medium obtained from 
microglia treated with CgA (100 nM) or Ap (55 pM) for 24 hours induced a 
significant increase in neuronal apoptosis (Fig. 5.12A,D). Neuronal death was 
reversed by boiling conditioned medium obtained from CgA (100 nM) or Ap (55 
pM) treated microglia, which suggests that the neurotoxic agent(s) are heat labile. 
The increase in apoptosis was not attributable to the presence of CgA (100 nM) or 
Ap (55 pM) in the culture medium, since the direct application of these agents to 
neuronal cultures did not increase apoptosis above basal levels. Furthermore, the 
addition of control microglial conditioned medium to neurones in the presence of 
CgA (100 nM) or Ap (55 pM) did not increase neuronal death above basal levels. To 
determine at which point neurotoxic agents were released, microglia were treated 
with CgA (100 nM) or Ap (55 pM) and the conditioned medium was removed over a 
period of 0-24 hours. Medium was subsequently incubated with cerebellar granule 
cells for 24 hours before apoptosis was appraised. Using this approach, significant 
levels of neurotoxin release were found to occur 16 hours after the addition of CgA or 
Ap and the neurotoxicity of the conditioned medium increase with time (Fig. 5.12B).
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Figure 5.12 CgA or Ap treated microglia induce neuronal apoptosis
Neuronal apoptosis induced by medium obtained from CgA or Ap treated microglia was 
assessed using Hoescht 33342. A: Microglia were treated with CgA (100 nM) or Ap (55 ^M) 
for 24 hours before medium was collected. Control medium was collected from microglia left 
untreated for 24 hours (control). Medium was then applied to cerebellar granule neurones for 
24 hours before the neurones were fixed and stained with Hoescht 33342. In addition, 
medium collected from CgA (100 nM) or Ap (55 pM) treated microglia was boiled before 
being applied to neuronal cultures (open bars). Neurones were also left untreated for 24 
hours (basal) or were treated with CgA (100 nM) or Ap (55 p.M) in the presence (hatched 
bars) or absence (black bars) of control microglial conditioned medium for 24 hours. B: 
Medium was collected from microglia treated with CgA (100 nM) (closed circles) or Ap (55 
pM) (open circles) for 0, 3, 6, 8, 16 or 24 hours. Medium was then applied to cerebellar 
granule neurones for 24 hours. Neurones were subsequently stained with Hoescht 33342. 
Following staining, non-apoptotic cells possessed large brightly stained nuclei (C), whereas 
apoptotic cells possess brightly stained pyknotic nuclei (D). Neurones displaying brightly 
stained pyknotic nuclei were counted and the degree of apoptosis was expressed as a 
percentage of the total number of cells counted. The values shown represent the mean ± 
SEM of data from experiments performed in triplicate. Experiments consisted of 3 coverslips 
per treatment comprising ten fields of view. Statistical analysis was performed using ANOVA 
followed by the Tukey post test. *** p < 0.001 vs control. (Control describes neuronal cultures 
treated with medium harvested from untreated microglia “Control”). *** p < 0.001 vs ‘CgA 
treated’. *** p < 0.001 vs ‘Ap’ treated.
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5.8 Discussion
There is compelling evidence that inflammatory processes play a significant role in 
AD. Indeed in a number of studies NSAIDs have been shown to reduce the incidence 
of AD (McGeer et al., 1996; Stewart et al., 1997). The principle action of these drugs 
is to suppress the production of pro-inflammatory products that are primarily secreted 
by activated microglia. This implies that microglia play an important role in disease 
progression. Consequently, in this chapter the signalling cascades elicited in CgA or 
Ap treated microglia were studied because both of these proteins are located at the 
inflammatory foci associated with senile plaques. Experimental data revealed that 
CgA and Ap stimulated microglial signalling pathways via scavenger receptor 
dependent mechanisms. Scavenger receptors are upregulated on microglia in AD 
tissue in particular around senile plaques (Honda et al., 1998). This implies that CgA 
and Ap may signal via scavenger receptors in vivo.
Ultimately, CgA or Ap treated microglia underwent mitochondrial depolarisation, 
which precipitated apoptotic cell death. Dissection of the signalling cascades elicited 
in CgA or Ap treated microglia revealed that these activators triggered different 
upstream signalling events. These findings suggest that CgA and Ap bind to different 
scavenger receptor isoforms, although the identity of which remains to be delineated. 
CgA was found to induce iNOS expression, mitochondrial depolarisation and 
apoptosis via a Src kinase and ERK. CgA also evoked the release of high 
concentrations of glutamate into the culture medium. In contrast, Ap did not induce 
iNOS expression or glutamate release. Ap mediated signalling was found to involve a 
Src kinase and a Gi protein, but not ERK.
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Previously, CD36 (a class B receptor) has been reported to induce the activation of 
ERK and Src kinases (Moore et al., 2002). Furthermore, class A scavenger receptors 
couple to Src kinases (Miki et al., 1996) and Gi proteins (Whitman et al., 2000; Post 
et al., 2002). This suggests that CgA may signal via CD36, whereas Ap might signal 
through a class A scavenger receptor in the pathways described in this chapter. A 
recent study has also demonstrated that scavenger receptors induce NO production 
following ligand induced activation (Alford et al., 1998). However, this is the first 
report to show that scavenger receptors trigger glutamate release and ultimately 
mitochondrial depolarisation and apoptosis. These are exciting observation since until 
recently scavenger receptors were not known to instigate cell signalling.
5.8.1 CgA and Ap act as scavenger receptor agonists
Additional evidence to suggest that CgA acts as a novel scavenger receptor agonist is 
provided by studying the proteins primary sequence. CgA comprises 457 amino acids 
a high proportion of which are consecutive negatively charged glutamic acid residues 
(Swiss Prot search) (Fig. 5.13). Negatively charged species are a recognised structural 
feature of scavenger receptor ligands. For example, native LDL does not function as a 
scavenger receptor ligand, whereas acetylated and oxidised LDL exhibit a high 
affinity for the receptor (Zhang et al., 1993). Other known scavenger receptor ligands 
include LPS (Hampton et al., 1991) and dextran sulphate (Pollaud-Cherion et al., 
1998).
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Figure 5.13 Sequence of CgA
CgA comprises 457 amino acids a high proportion of which are consecutive negatively 
charged glutamic acid residues (e) (Swiss Prot search).
Numerous reports have demonstrated that Ap acts as an agonist for the scavenger 
receptor. In particular Ap (1-42) has been shown to bind to a class A scavenger 
receptor (Paresce et al., 1996, 1997), CD36 (a class B receptor) (Moore et al., 2002; 
El Khoury et al., 2003) and SR-B1 (a class B receptor) (Husemann et al., 2001). A 
recent report extends these findings to demonstrate that a multi-protein assembly 
comprising of CD36, a6pl integrin and CD47 mediates AP(l-42, 1-40 or 25-35) 
binding (Bamberger et al., 2003). Additionally, Ap (1-42) has been reported to 
interact with formylpeptide receptors (Le et al., 2001; Tiffany et al., 2001) and Ap (1- 
42, 1-40 or 25-35) can also bind RAGE (Yan et al., 1996; 1997), although this study 
reveals that RAGE is not involved in Ap-induced apoptosis. Thus, it is likely that a 
multitude of receptors play complementary roles in the varying responses of 
microglia to Ap in vivo.
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5.8.2 Downstream pathways: iNOS and COX-2
Microglia treated with CgA upregulated the expression of iNOS, which is consistent 
with previous findings (Taupenot et al., 1996; Kingham et al., 1999). However, 
nitrite, the stable breakdown product of NO was undetectable in the culture medium 
(see section for 4.9.2 for theories to explain this discrepancy). CgA-induced iNOS 
expression was mediated intracellularly by the Src kinase-dependent phosphorylation 
of ERK. Furthermore, other microglial activators including LPS (Bhat et al., 1998; 
Pyo et al, 1998), thrombin (Ryu et al., 2000) and adenovirus infection (Bhat and Fan
2002) trigger iNOS expression via ERK-dependent mechanisms. Previous studies 
have also demonstrated that Src kinases mediate ERK phosphorylation (Combs et al., 
1999; Moore et al., 2002), which corroborates the findings presented in this chapter. 
In vivo, microglia surrounding senile plaques display enhanced phosphotyrosine 
staining, which suggests that similar signalling events may occur in AD (Wood and 
Zinsmeister 1991). It should be noted that additional transcription factors must 
contribute to iNOS expression in CgA treated microglia, given that U0126 
completely inhibited ERK phosphorylation but only partially attenuated iNOS 
expression. One potential candidate is NFicp whose ability to evoke iNOS 
transcription has been documented (Nathan et al., 1994; Chao et al., 1997; Kim et al.,
2003).
In contrast to CgA treatment, Ap did not trigger the up-regulation of iNOS 
expression. There have been contradictory reports regarding the effects of Ap on NO 
metabolism. Li et al., 1996 reported that Ap(25-35) does not induce microglial NO 
production, whereas microglia treated with Ap (1-40) or AP(l-42) do synthesis NO. 
Other reports have shown that neither Ap(25-35) (Kopec and Carroll 1998; Casal et
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al, 2002) nor AP(l-42) (Casal et al, 2002) induce iNOS expression or NO production 
in microglia. Moreover, some investigators have observed an increase in NO 
production only when microglia are treated with A(3(25-35) (Goodwin et al., 1995; 
Meda et al., 1995), Ap(l-42) (Meda et al., 1995) or Ap(l-40) (Murphy et al., 1998; 
Gasic-Milenkovic et al., 2003) in combination with cytokines. These findings imply 
that AP may require the presence of a ‘co-stimulator’ to induce microglial activation. 
In support of this the extracellular environment surrounding senile plaques is rich in a 
variety of pro-inflammatory agents including cytokines and complement proteins 
(McGeer and McGeer 1997,1999), which are likely to augment the effects of Ap on 
microglia in vivo.
Ap also failed to stimulate the phosphorylation o f ERK in microglia. On the contrary, 
Ap(25-35) (McDonald et al., 1998) or Ap(l-42) (Moore et al., 2002) have previously 
been reported to induce ERK activation in cultured microglia. AP(25-35) also elicits 
the activation of p38 (McDonald et al., 1998; Pyo et al., 1998) and JNK, which are 
other members of the MAPK family. The variation in these results may reflect 
differences in the tissue culture models employed, since microglia were isolated by 
percoll gradients in this study, whereas McDonald et al., (1998), Pyo et al., (1998) 
and Moore et al., (2002) isolated microglia from mixed glial cultures after 7-14 days 
in vitro. Thus, their microglia may have been more activated and therefore ‘primed’ 
to Ap activation (Slepko and Levi 1996).
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CgA or Ap did not induce COX-2 expression in microglia. As yet the effects of these 
activators on COX-2 synthesis by cultured microglia have not been reported in the 
literature. Nevertheless, epidemiological studies have demonstrated that NSAIDs 
reduce the risk of developing AD (McGeer et al., 1996; Stewart et al., 1997), which 
suggests that COX-2 does plays a central role in AD.
5.8.3 Downstream pathways: glutamate
Microglia treated with CgA released glutamate into the culture medium. Glutamate is 
a nonessential amino acid, which is generated in the mitochondria from a  
ketoglutarate (Berg et al., 2002). Thus, in response to cellular stress, microglial 
metabolism and subsequent glutamate synthesis may be enhanced to support the 
production of the anti-oxidant glutathione (see section 4.9.3). Previously it has been 
reported that CgA-induced glutamate release is mediate in part by the Xc' transporter 
(Kingham et al., 1999). Other microglial activators including soluble APPa (Barger 
and Basile 2001), LPS (Piani and Fontana 1994), PMA (Nakamura et al., 2003) and 
albumin (chapter 4) also trigger glutamate secretion via this transporter. Furthermore, 
zymosan (stimulates phagocytosis), TNFa and various bacterial products including 
protein A and tuberculin induce microglial glutamate release, although the 
involvement of the Xc' transporter has not been investigated (Piani and Fontana 
1994). This suggests that glutamate secretion by activated microglia is a common 
phenomenon. However, it should be noted that Ap did not evoke glutamate release 
from microglia. Consistent with this, cultured microglia treated with AP(l-42) or 
Ap(l-42) plus IFNy have previously been reported to release very low levels of 
glutamate (Barger and Basile 2001). Similarly, Ap(25-35) does not induce glutamate 
release from peritoneal macrophages (Klegaris and McGeer 1997).
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The signalling cascades involved in glutamate release from activated microglia have 
received little attention, although, PKC (Nakamura et al, 2003), NO (Kingham et al., 
1999; Nakamura et al, 2003) and reactive oxygen species (Kingham et al., 1999) have 
recently been implicated. In this study, CgA induced glutamate release was deemed 
to be scavenger receptor-dependent but ERK and Src independent. Glutamate release 
preceded iNOS expression; therefore it would appear that release is NO independent, 
however this supposition conflicts with previous findings (Kingham et al., 1999; 
Nakamura et al, 2003). This inconsistency may be due to differences in assay 
sensitivities, since in this study glutamate was measured fluorometrically, whereas 
Kingham et al., (1999) and Nakamura et al, (2003) used a commercially available 
colorimetric kit. Considering glutamate is a potent neurotoxin, the elucidation of 
signalling pathways involved in microglia glutamate release may provide targets for 
therapeutic intervention.
5.8.4 Downstream pathways: apoptosis
Cell loss in AD was originally believed to be confined to specific neuronal 
populations, however apoptotic microglia have been detected around senile plaques in 
AD post-mortem tissue (Yang et al., 1998). Furthermore, fragmented DNA has been 
demonstrated to co-localise with microglia and oligodendrocytes as well as neurones 
in AD brains (Lassmann et al., 1995). Activation induced apoptosis may be an 
intrinsic self-regulatory mechanism; considering that activated microglia produce 
prodigious quantities of neurotoxic agents, a commitment to death may prevent 
bystander damage to neighbouring neurones. This theory is supported by the finding 
that activation induced microglial apoptosis in vitro is associated with LPS treatment 
(Liu etal., 2001).
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Previously, it has been demonstrated that CgA treated microglia ultimately undergo 
apoptotic cell death, which is mediated by a NO dependent fall in mitochondrial 
membrane potential (Kingham and Pocock 2000). CgA-induced apoptosis is 
cytochrome c independent, although microglia exhibit other signatures of apoptosis 
including DNA fragmentation and caspase-1 activity (Kingham et al., 1999; Kingham 
and Pocock 2000). In this study nitrite was undetectable in the culture medium 
collected from CgA treated microglia, although inhibition of the scavenger receptor, 
Src kinases or ERK attenuated iNOS expression and subsequent death, implying that 
apoptosis is NO dependent. It is possible that NO reacts with superoxide to form 
peroxynitrite, which in turn nitrates tyrosine residues in susceptible proteins, 
therefore rendering NO (nitrite) undetectable in the culture medium. Activation of 
mGluRs are also involved in CgA-induced microglial apoptosis (Kingham et al., 
1999; Taylor et al., 2002; 2003), which suggests that secreted glutamate feeds back 
on to membrane bound receptors to instigate a self perpetuating cycle of cell death.
In this investigation, apoptotic microglia were initially detectable 40 hours after the 
addition of CgA, whereas Kingham et al., (1999) detected apoptotic microglia 24 
hours after CgA treatment; a discrepancy that was attributed to differences in culture 
conditions or batch to batch CgA variability. In accordance with previous findings 
CgA also induced mitochondrial depolarisation (Kingham and Pocock 2000; Taylor 
et al., 2002). Mitochondrial depolarisation preceded apoptosis temporally, but 
succeeded iNOS expression, whilst inhibition of the mitochondrial PT pore 
ameliorated apoptosis (Kingham and Pocock 2000). Moreover, inhibition of the 
scavenger receptor, Src kinases or ERK attenuated CgA-induced mitochondrial 
depolarisation as well as iNOS expression, which implies that mitochondrial 
dysfunction is indeed a result o f NO production. Collectively, this data corroborates
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previous findings, which illustrate that mitochondrial depolarisation is NO dependent 
and that apoptosis is mediated by mitochondrial depolarisation (Kingham and Pocock
2000). Increasing evidence is accumulating to suggest that NO plays a key role in cell 
death. NO has been reported to promote the activation of caspases and apoptosis in 
macrophage cell lines (Messmer et al., 1998). Furthermore, Complexes I, II and IV of 
the electron transport chain are readily nitrated by NO dependent mechanisms 
(Clementi et al., 1998; Murray et al., 2003). Oxidative damage subsequently results in 
mitochondrial dysfunction, which in turn may precipitate mitochondrial PT pore 
opening and downstream apoptosis (Hortleno et al., 1997; Heales and Bolanos 2002).
Analogous to CgA treatment, Ap was found to trigger microglial apoptosis, which is 
consistent with recent findings (Taylor et al., 2002, 2003). Korotzer et al., (1993) 
have also demonstrated that process bearing microglia show signs of degeneration 
after exposure to AP(25-35). In addition, it has been demonstrated that a low dose (5 
pM) of Ap(25-35) induces microglial cell rounding (Casal et al., 2002), which is a 
morphological transition that often precedes activation induced death in microglia. 
Ap induced apoptosis was also mediated by mitochondrial depolarisation as 
demonstrated using the PT pore inhibitor cyclosporin A. Likewise, oligodendrocytes 
treated with AP(25-35) or Ap(l-40) undergo apoptosis, which is accompanied by loss 
of mitochondrial function (Xu et al., 2001). Consistent with these findings AP(25-35) 
has been shown to selectively decrease complex IV (cytochrome oxidase) activity in 
isolated mitochondria (Canevari et al., 1999), therefore it is conceivable that 
internalised Ap may trigger mitochondrial damage via this mechanism in microglia.
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Microglial apoptosis and mitochondrial depolarisation induced by Ap involved an 
upstream Gi protein and a Src kinase. Scavenger receptors do not exhibit the 
characteristic seven membrane spanning topology of receptors that signal through Gi/0 
proteins (Peiser and Gordon 2001), although these results and others (Pollaud- 
Cherion et al., 1998; Whitman et al., 2000; Post et al., 2002) indicate that scavenger 
receptors can interact with Gi/0 proteins. Moreover, AP(l-42) has been demonstrated 
to induce Gi dependent signalling pathways in human monocytes (Le et al., 2001) and 
N9 microglia (Tiffany et al., 2001). With respect to Src kinases, Ap(25-35) has been 
reported to activate Lyn (a Src kinase) in microglia (McDonald et al, 1997). The 
order of second messenger activation induced by Ap was not delineated in this study. 
However, Gj proteins have been documented to directly evoke Src activity (Ma et al.,
2000). Additionally, Src kinases participate in ERK activation through Gi protein 
dependent mechanisms (Igishi et al., 1998); although it should be emphasised that 
phospho-ERK was not detectable following Ap treatment in this investigation. 
Nevertheless, it is conceivable that a Src kinase lies downstream of G protein 
activation in the Ap-induced signalling cascades that are described in this chapter.
5.8.5 Downstream pathways: calcium
CgA did not elicit calcium transients in N9 microglia, which is consistent with 
previous findings (Personal communication: Dr Jennifer Pocock). However, this 
challenges a study by Taupenot et al (1996), which states that CgA induces a rapid 
rise in intracellular calcium in primary microglia. These authors postulated that 
calcium transients mediate actin re-organisation, which subsequently causes 
microglia to adopt an amoeboid morphology, although no direct evidence for this was 
reported (Taupenot et al., 1996). Similarly, Ap(25-35) did not trigger calcium fluxes
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in the N9 microglial cell line. Consistent with this, Tiffany et al., (2001) 
demonstrated that A(3(l-42) does not elicit calcium transients in N9 microglia unless 
the cells are pre-treated with LPS, which serves to up-regulate microglial receptor 
expression. Conversely, Ap(25-35) has been reported to evoke increases in 
intracellular free calcium in cultured microglia (Korotzer et al., 1995). Furthermore, 
Combs et al., (1999) demonstrated that Ap(25-35) induces calcium transient in THP 
monocytes, which are often used to model microglial signalling (McDonald et al., 
1997, 1998). However, the signalling events elicited by CgA or Ap in this study were 
not modulated by BAPTA-AM, which supports the theory that CgA or Ap-induced 
signalling cascades leading to cell death are calcium independent in microglia.
5.8.6 CgA or Ap treated microglia exhibit a neurotoxic phenotype
Medium harvested from CgA or Ap treated microglia was found to induce neuronal 
apoptosis, which is consistent with previous reports (Ciesielski-Treska et al., 1998; 
Kingham et al., 1999; Ciesielski-Treska et al., 2001; Combs et al., 1999, 2001). 
Neurotoxin release was found to occur approximately 16 hours after the addition of 
CgA or Ap, which suggests that neurotoxins are synthesised de novo. Neuronal 
death evoked by CgA stimulated microglia is caspase 8 (Ciesielski-Treska et al.,
2001) and 3 dependent (Kingham et al., 1999; Ciesielski-Treska et al., 2001). 
Furthermore, the Fas transmembrane receptor (Fas/Apol/CD95), cytochrome c 
release and p38 are involved in the neuronal response to toxins derived from CgA 
stimulated microglia (Ciesielski-Treska et al., 2001). However, it should be 
emphasised that Ciesielski-Treska et al., (2001) used cortical neurones in their 
studies, whereas cerebellar granule neurones were employed in this investigation.
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Results presented in this chapter revealed that boiling microglial conditioned medium 
derived from CgA or Ap treated microglia conferred neuroprotection, which suggests 
that the neurotoxic agents are heat labile and therefore may be proteinaceaous. The 
increase in apoptosis was not attributed to the presence of CgA or Ap in the medium 
since the direct application of these agents to neurones did not induce death. The 
former is consistent with previous findings (Ciesielski-Treska et al., 1998; Kingham 
et al., 1999). Neuronal death induced by CgA activated microglia is NO independent 
(Kingham et al., 1999; Ciesielski-Treska et al., 1998). This also appears to be the case 
for Ap. Similarly, NO independent death has been observed for cultured hippocampal 
neurones exposed to peritoneal macrophage conditioned medium (Flavin et al,. 1997). 
These findings are not surprising considering the half life of NO is approximately 5 
seconds (Kulkami and Sharma 1993; Alberts et al., 2002; Berg et al., 2002). 
Consequently, NO should not be present in microglial conditioned medium by the 
time it is applied to neuronal cultures.
Recently, cathepsin B (Kingham and Pocock 2001) and glutamate (Kingham et al., 
1999) have been implicated in neuronal death induced by CgA activated microglia. In 
contrast, the neurotoxic factors released by Ap treated microglia have not been as 
extensively studied, although a recent report demonstrates that TNFa is implicated in 
neuronal death induced by Ap (25-35) treated microglia (Combs et al., 2001). On the 
contrary TNFa is not involved in neuronal death induced by CgA activated microglia 
(Ciesielski-Treska et al., 1998). Therefore, it appears that a combination of different 
microglial derived neurotoxins act in concert to mediate neuronal death in response to 
specific stimuli.
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The finding that Ap did not induce neuronal death directly is intriguing because many 
reports have demonstrated that Ap(25-35) (Loo et al., 1993; Pike et al., 1993; Watt et 
al., 1994; Abe and Saito 2000; Taylor et al., 2002,2003), Ap(l-42) (Loo et al., 1993; 
Troy et al., 2000) and AP(l-40) (Abe and Saito 2000) are neurotoxic. It is possible 
that cerebellar granule neurones can resist a 24 hour exposure to Ap. In support of 
this, senile plaques are predominantly located in the hippocampus and the cortex in 
AD (Crowther 1990), which implies that the cerebellum is less susceptible to AD 
pathology. Moreover, Marin et al., (2000) reported that active caspase 3 was not 
detectable in cerebellar granule neurones until 48 hours after Ap(25-35) treatment, 
whilst Allen et al., (2001) demonstrated that cerebellar granule neurones subjected to 
Ap(25-35) did not undergo apoptosis until 120 hours post treatment. Neurones were 
found to die more rapidly when exposed to Ap(25-35) in SFM, however this 
represent a ‘double insult’ (Allen et al., 2001).
5.8.7 Conclusion
Previously, it has been reported that CgA induces glutamate release and a NO 
dependent decrease in mitochondrial polarisation, which in turn triggers microglial 
apoptosis (Kingham et al., 1999; Kingham and Pocock 2000). The data presented in 
this chapter extends these findings by demonstrating that CgA induces microglial 
iNOS expression, glutamate release, mitochondrial depolarisation and apoptosis via 
an interaction with a scavenger receptor. These signalling events with the exception 
of glutamate release are subsequently mediated by the Src kinase dependent 
phosphorylation of ERK (Fig. 5.14). Similarly, Ap was demonstrated to induce 
microglial apoptosis via a scavenger receptor-dependent mechanism. Ap induced cell 
death was also mediated by mitochondrial depolarisation and involved a Gi protein
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and a Src kinase (Fig. 5.15). Furthermore, microglia treated with either activator 
promoted neuronal apoptosis. In light of these findings, manipulation of scavenger 
receptor coupled signalling pathways may provide novel therapeutic strategies for the 
prevention of neurodegeneration in AD and possibly other neurological disorders.
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Figure 5.14 Signalling cascades elicited in CgA treated microglia
CgA induces iNOS expression, glutamate release, mitochondrial depolarisation and 
apoptosis via the scavenger receptor. These signalling events with the exception of 
glutamate release were subsequently mediated intracellularly by the Src kinase dependent 
phosphorylation of ERK. The pathways leading to glutamate release are currently 
undetermined; however secretion is known to be mediated by the Xc' transporter (Kingham et 
al., 1999). CgA treated microglia were also found to release neurotoxins.
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Figure 5.15 Signalling cascades elicited in Ap treated microglia
Ap induces mitochondrial depolarisation, which in turn triggers apoptosis; events that are 
mediated via the scavenger receptor. Signalling also involves a Gi/o protein and a Src 
kinase. Although, the precise order of second messenger activation remains to be 
determined. Hence in reality the depicted sequence may be reversed: ie a Src kinase 
upstream of a Gi/o protein. Ap treated microglia were also found to release neurotoxins.
262
6.0 Effects of ischaemia on microglial signalling
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6.1 Introduction
In this chapter the effects of an ischaemic insult on microglial signalling were explored. In 
addition, the effects of ischaemia followed by fraction V or Ap(25-35) (hereafter referred to 
as Ap) treatment were studied; the rationale being that stroke is a known risk factor for 
AD (Tatemichi et al., 1994; Kokmen et al., 1996; Moroney et al., 1996; Desmond et al., 
2000; Madureira et al., 2001). Pure albumin was not used in these experiments because 
fraction V and albumin were found to elicit identical effects in chapter 4.
6.1.1 Models of ischaemia
Ischaemia can be modelled using a number of paradigms, which are briefly outlined 
below.
6.1.1.1 In vitro models of ischaemia
Brain slices or cultured cells are frequently used in in vitro models of ischaemia, although 
the three dimensional architecture of the brain is not replicated in these models they are 
useful because they enable the signalling pathways in isolated cell types to be studied. 
Ischaemia can be modelled in vitro by exposing cells to 95 % N2 and 5 % CO2 in the 
presence of medium lacking glucose or other metabolic substrates (Yenari and Giffard
2001), and this was the method employed in this chapter. Alternatively, ischaemia can be 
modelled by inhibiting glycolysis and the electron transport chain (Pocock and Nicholls 
1998). 2-deoxy-glucose is commonly used to inhibit glycolysis (Lyons and Kettenmann 
1998; Pocock and Nicholls 1998), whilst the electron transport chain can be inhibited by 
agents such as antimycin A (Swanson 1992; Swanson et al., 1995), cyanide (Pocock and 
Nicholls 1998) or azide (Swanson 1992; Swanson et al., 1995,1997).
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6.1.1.2 In  vivo models of ischaemia
The anterior and posterior parts of the brain receive blood from the two internal carotid 
and the two vertebral arteries respectively. The internal carotid and vertebral arteries 
branch and divide many times thereby perfusing all areas of the brain (Snell 1997; Young 
and Young 1997; Kieman 1998). The middle cerebral artery (MCA) is the largest branch 
of the internal carotid artery and is often used to model focal ischaemia (Abe and Hayashi 
1997; Hayashi et al., 1999; Zhu D et al., 2002). Occlusion of the MCA is commonly 
achieved by inserting a thread into the carotid artery, which is then advanced to block the 
vessel (Abe and Hayashi 1997; Sharp et al., 1998; Hayashi et al., 1999). Other models of 
focal ischaemia include photochemical induced infarction, which is a non-invasive 
procedure. In this paradigm a photosensitive dye such as Rose Bengal is administered 
intravenously, the brain is then irradiated with laser light The reaction between the dye 
and the light induces platelet aggregation and thrombi formation, which subsequently 
produces a focal infarct (Yan et al., 1998; Sharp et al., 1998; Takamatsu et al., 2000; 
Eichenbaum et al., 2002).
As outlined above, focal ischaemia is produced by occlusion of specific cerebral blood 
vessels; therefore the brain suffers damage to select regions. In contrast, global ischaemia 
is caused by cardiac arrest or severe hypotension and produces widespread ischaemic 
damage (Sharp et al., 1998). Common models of global ischaemia include bilateral carotid 
artery occlusion (Braun et al., 1998; Homer et al., 1998; Sharp et al., 1998) or four vessel 
(carotid and vertebral) occlusion (Pulsinelli and Brierley 1979; Clemens et al., 1997; 
Schmidt-Kastner et al., 1997; Sharp et al., 1998;).
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6.1.3 Summary of results
Microglial signalling was investigated after exposure to ischaemia for 3 hours followed by 
‘reperfusion’ for 24 hours. In addition, the effects of ischaemia followed by fraction V or 
Ap treatment were studied. Experimental data revealed that ischaemia per se did not 
induce iNOS expression or nitrite production. Moreover, microglia exposed to ischaemia 
followed by fraction V or Ap treatment expressed similar levels of iNOS as those cells 
treated with the fraction V or Ap alone. Ischaemia did not elicit the phosphorylation of 
ERK or induce glutamate release either. Nor did ischaemia followed by fraction V or Ap 
treatment affect the levels of p-ERK expression or glutamate release induced by fraction V 
or Ap treatment alone. Analysis of microglial conditioned medium revealed that microglia 
subjected to ischaemia or Ap did not secrete TNFa or TGFp. Conversely, fraction V was 
a potent stimulus for TNFa but not TGFp release. Furthermore, microglia subjected to 
ischaemia then fraction V or Ap secreted identical levels of TNFa as those cells treated 
with either activator alone, whereas ischaemia potentiated TGFp release induced by Ap 
but not fraction V.
Assessment of cellular viability demonstrated that ischaemia per se did not adversely 
effect cell survival. However, ischaemia followed by fraction V treatment triggered 
microglia to undergo apoptosis, which was mediated by mitochondrial depolarisation. Cell 
death was found to be iNOS and calcium independent. Moreover, Gi proteins, Src kinases 
or ERK were not implicated in apoptosis or mitochondrial depolarisation induced by the 
combined insult. To recapitulate, fraction V induces a calcium-dependent proliferative 
response in microglia (see chapter 4). Interestingly, ischaemia did not induce any 
appreciable effects on calcium transients induced by fraction V as measured immediately 
after the ischaemic insult or 24 hours later, although proliferation was precluded.
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Moreover, ischaemia treatment alone did not modulate intracellular free calcium levels at 
the time points studied.
Ischaemia followed by Ap treatment potentiated the levels of microglial apoptosis and 
mitochondrial depolarisation induced by Ap alone. Mitochondrial depolarisation mediated 
apoptosis in microglia exposed to Ap alone or microglia subjected to ischaemia then Ap. 
Poly I, PP2 and pertussis toxin were found to attenuate apoptosis and mitochondrial 
depolarisation induced by the combined insult. This suggests the involvement of 
scavenger receptors, Src kinases and Gi proteins in signalling; the very same second 
messengers that mediate Ap-induced mitochondrial depolarisation and apoptosis. 
Furthermore, ischaemia did not induce any discemable effects on intracellular calcium 
levels associated with Ap treatment as measured immediately after the ischaemic insult or 
24 hours later.
In a parallel series of experiments, conditioned medium harvested from microglia 
subjected to ischaemia was found to be neurotoxic. Appearance of neurotoxins in 
conditioned medium became evident 6 hours after the ischaemic insult. Neuronal death 
was NO, glutamate and ATP independent. Moreover, depleting the microglia conditioned 
medium of TNFa or TGFp did not protect against neuronal death. This is in keeping with 
the finding that ischaemia did not induce the release of these cytokines from microglia. 
Boiling the conditioned medium conferred neuro-protection, which indicates that the 
neurotoxin(s) are heat labile, although the identity of which remains to be delineated. 
Finally, it was revealed that ischaemia did not potentiate neuronal apoptosis induced by 
microglia treated with fraction V or Ap. The combined insults induced essentially the 
same levels of neuronal death as microglia treated with fraction V or Ap alone.
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6.2 Effects of ischaemia on iNOS and p-ERK expression
Microglia were analysed for iNOS expression after exposure to ischaemia. In addition, 
microglial iNOS levels were appraised after exposure to ischaemia followed by fraction V 
or Ap treatment An ischaemic episode was modelled by exposing microglia to 95 % N2 in 
5 % CO2 for 3 hours in the presence of DMEM lacking glucose, pyruvate or foetal calf 
serum at 37 °C. Thus, the microglia were deprived of metabolic substrates that could be 
used for respiration under anaerobic conditions. Control microglia were maintained in an 
atmosphere of 5 % CO2 in air (normoxic) at a temperature of 37 °C for the same time 
period. Following the ischaemic episode some microglia were treated with fraction V (1 
mg/ml) in SFM for 2 hours. The SFM was then replaced with SCM for the remainder of 
the experimental period. Microglia were also exposed to Ap (45 pM) in SCM following 
the initial ischaemic insult. These activation protocols were used in all experiments 
described in this chapter. A 3 hour ischaemic insult was chosen because in pilot 
experiments this time period did not cause the microglia to detach from the coverslips, 
which is a phenomenon that has been reported with longer periods of ischaemia (Yu et al., 
1989; Personal communication: Ms Susan Griffin, Department of Molecular Pathogenesis, 
Institute of Neurology, UCL; Dr Amanda Liddle, Department of Neuroinflammation, 
Institute of Neurology, UCL).
Western blot analyses revealed that microglia subjected to ischaemia for 3 hours followed 
by either SCM for 24 hours (ischaemia SCM) or SFM for 2 hours then SCM for 22 hours 
(ischaemia SFM) did not express iNOS (Fig. 6.1 A). In contrast, fraction V (1 mg/ml) 
induced an increase in iNOS expression after 24 hours in culture, whilst iNOS was 
undetectable in microglia treated with Ap for 24 hours. Ischaemia prior to the addition of 
fraction V or Ap did not modulate the levels of iNOS expression induced by either
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activator alone. Moreover, control microglia that were left untreated for 27 hours (basal) 
or were treated with SFM for 2 hours then SCM for 22 hours (SFM) did not express 
iNOS. Analysis of p-actin levels demonstrated that the observed changes in iNOS 
expression were not due to differences in protein loading.
In a parallel experiment, nitrite, a stable breakdown product of NO was measured in the 
culture medium. Nitrite was not detectable in medium collected from microglia subjected 
to ischaemia for 3 hours followed by either SCM for 24 hours (ischaemia SCM) or SFM 
for 2 hours then SCM for 22 hours (ischaemia SFM) (Fig. 6.IB). Similarly, nitrite was 
undetectable in medium collected from fraction V (1 mg/ml) or Ap (45 pM) treated 
microglia, which is consistent with findings presented previously (see chapter 4 and 5 
respectively). An ischaemic insult prior to the addition of fraction V or Ap did not 
modulate the levels of nitrite induced by either activator alone. Furthermore, medium 
collected from control microglia, which were either left untreated for 27 hours (basal) or 
were treated with SFM for 2 hours then SCM for 22 hours (SFM) contained negligible 
amounts of nitrite. These findings were not attributed to assay failure since nitrite was 
detectable in culture medium collected from LPS (2 pg/ml) treated peritoneal 
macrophages.
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Basal 1.1 ±0.02
SFM 1.3 ±0.05
Fv (1 mg/ml) 1.0 ±0.03
Ap (45 pM) 1.1 ±0.04
Ischaemia (SCM) 1.2 ±0.02
Ischaemia (SFM) 1.1 ±0.4
Ischaemia +Fv (1 mg/ml) 1.2 ±0.02
Ischaemia + Ap (45 pM) 1.0 ±0.03
Macrophage (LPS: 2 pg/ml) 487.3 ± 4.5 ***
Figure 6.1 (see overleaf for figure legend)
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Figure 6.1 Modulation of iNOS expression and nitrite production by ischaemia
Representative Western blots of iNOS expression in microglial cell lysates. A: Lysates were 
prepared from microglia exposed to ischaemia for 3 hours followed by either SCM for 24 hours 
(ischaemia SCM) or SFM for 2 hours then SCM for 22 hours (ischaemia SFM). Microglia were also 
treated with fraction V  (Fv: 1 mg/ml) in SFM for 2 hours. The SFM was then replaced with SCM for 
22 hours before lysates were prepared. Furthermore, lysates were prepared from microglia treated 
with Ap (45 pM) in SCM for 24 hours. To assess the effects of ischaemia on subsequent microglial 
signalling, microglia were exposed to a 3 hour period of ischaemia before being treated with 
fraction V  (Fv. 1 mg/ml) or Ap (45 pM) then lysates were prepared. Control lysates were prepared 
from microglia left untreated for 27 hours (basal) or microglia exposed to SFM for 2 hours then 
SCM for 22 hours (SFM). Lysates were subjected to Western blot analyses using an antibody 
raised against iNOS (1:5000), which in turn was detected by goat anti-rabbit IgG (HRP) (1:500). 
To ensure equal loading blots were re-probed using an antibody recognising p-actin followed by 
exposure to goat anti-mouse IgG (HRP) (1:1000). Nitrite concentrations were also measured in 
microglial conditioned medium B: Medium was collected from microglia treated as above. Medium 
was also collected from peritoneal macrophages (isolated from adult rats) treated with LPS (2 
pg/ml) in SCM for 24 hours. Medium was subsequently appraised for nitrite using Griess reagent. 
The values shown represent the mean concentration in nM/mg of protein ± SEM of data from 
experiments performed in triplicate. Statistical analysis was performed using ANOVA followed by 
the Tukey post test *** P < 0.001, vs ‘basal’ or ‘SFM’.
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The effects of ischaemia on ERK phosphorylation were subsequently explored. Western 
blot analyses revealed that microglia subjected to ischaemia for 3 hours followed by either 
SCM (ischaemia SCM) or SFM (ischaemia SFM) for 1 hour did not express p-ERK (Fig. 
6.2A). In contrast, fraction V (1 mg/ml) evoked an increase in p-ERK levels after 1 hour 
in culture, whilst p-ERK was undetectable in microglia treated with Ap for 1 hour. A 3 
hour ischaemic insult prior to the addition of fraction V or Ap did not modulate the levels 
of p-ERK observed with either activator alone. Moreover, control microglia that were left 
untreated for 4 hours (basal) or were treated with SFM for 1 hour (SFM) did not express 
p-ERK either. Analysis of total ERK illustrated that the observed changes in ERK 
phosphorylation were not due to differences in protein loading.
Experimental data in chapter 4 demonstrated that ERK mediated iNOS expression in 
fraction V treated microglia. To determine whether ERK was responsible for mediating 
iNOS expression in microglia subjected to ischaemia then fraction V, the effects of 
U0126 on iNOS expression were investigated. Microglia were incubated with U0126 (5 
pM) during the ischaemic insult and also during fraction V exposure. Following these 
successive treatments the medium was replaced with SCM supplemented with U0126 for 
a further 22 hours before lysates were prepared. Western blotting revealed that U0126 
prevented iNOS expression in microglia subjected to ischaemia followed by fraction V 
treatment (Fig. 6.2B). This suggests that iNOS expression is also mediated by ERK under 
these conditions.
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Figure 6.2 Modulation of p-ERK expression by ischaemia
Representative Western blots of p-ERK and iNOS expression in microglial cell lysates. A: Lysates 
were prepared from microglia exposed to ischaemia for 3 hours followed by either SCM  
(ischaemia SCM) or SFM for 1 hour (ischaemia SFM). Microglia were also treated with fraction V  
(1 mg/ml) in SFM for 1 hour or Ap (45 |iM) in SCM for 1 hour before lysates were prepared. In 
addition, lysates were prepared from microglia that were exposed to a 3 hour period of ischaemia 
before being treated with fraction V  (Fv: 1 mg/ml) or Ap (45 |iM) for 1 hour. Control lysates were 
prepared from microglia left untreated for 4 hours (basal) or microglia exposed to SFM for 1 hour 
(SFM). Lysates were subjected to Western blot analyses using an antibody raised against p-ERK  
(1:750), which in turn was detected by goat anti-mouse IgG (HRP) (1:1000). To ensure equal 
loading blots were re-probed using an antibody recognising total ERK (1:500) followed by 
exposure to goat anti-rabbit IgG (HRP) (1:500). B: Lysates were prepared from microglia exposed 
to ischaemia for 3 hours followed by SFM for 2 hours then SCM for 22 hours (ischaemia SFM). 
Microglia were also treated with fraction V  (Fv: 1 mg/ml) in SFM for 2 hours. The SFM was then 
replaced with SCM for 22 hours before lysates were prepared. Furthermore, microglia were 
exposed to ischaemia for 3 hours before being treated with fraction V  (Fv: 1 mg/ml) then lysates 
were prepared. To determine the involvement of ERK in signalling, lysates were prepared from 
microglia exposed to fraction V  alone or in combination with ischaemia in the presence of U 0126  
(5 p.M). Microglia were incubated with U 0126  during the ischaemic insult and also during fraction 
V  exposure. Following these successive treatments the medium was replaced with SCM  
supplemented with U 0126  for a further 22 hours before lysates were prepared. Lysates were also 
prepared from microglia treated with U 0126  alone (U). Control lysates were prepared from 
microglia left untreated for 27 hours (basal) or microglia exposed to SFM for 2 hours then SCM for 
22 hours (SFM). Lysates were subjected to Western blot analyses using an antibody raised 
against iNOS. To ensure equal loading blots were re-probed using an antibody recognising p- 
actin.
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63  Effects of ischaemia on glutamate and cytokine release
The effects of an ischaemic insult on glutamate and TNFa release were subsequently 
explored. Microglia subjected to ischaemia for 3 hours followed by either SCM for 24 
hours (ischaemia SCM) or SFM for 2 hours then SCM for 22 hours (ischaemia SFM) 
released very low levels of glutamate (Fig. 6.3A) or TNFa (Fig. 6.3B) into the culture 
medium. In contrast, microglia treated with fraction V (1 mg/ml) released large amounts 
of glutamate and TNFa after 24 hours in culture, whilst these mediators were present in 
very low concentrations in medium collected from microglia treated with Ap for 24 hours. 
An ischaemic insult prior to the addition of fraction V or Ap did not modulate levels of 
glutamate or TNFa release induced by either activator alone. Moreover, control microglia 
that were left untreated for 27 hours (basal) or were treated with SFM for 2 hours then 
SCM for 22 hours (SFM) released very low levels of glutamate or TNFa.
Next the effects of ischaemia on TGFp release were studied. Very low levels of TGFp 
were detectable in culture medium collected from microglia subjected to ischaemia for 3 
hours followed by either SCM for 24 hours (ischaemia SCM) or SFM for 2 hours then 
SCM for 22 hours (ischaemia SFM) (Fig. 6.3C). Similarly, low levels of TGFp were 
present in medium collected from microglia treated with fraction V (1 mg/ml) or Ap after 
24 hours in culture. An ischaemic insult prior to the addition of fraction V or Ap did not 
modulate fraction V induced TGFP levels, whereas Ap induced TGFp levels were 
significantly augmented. Moreover, control microglia that were left untreated for 27 hours 
(basal) or were treated with SFM for 2 hours then SCM for 22 hours (SFM) released very 
low levels of this cytokine
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Figure 6.3 (see overleaf for figure legend)
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Figure 6.3 Modulation of glutamate and cytokine release by ischaemia
Glutamate (nM/pg of protein), TNFa (pg/pg of protein) and TGFp concentrations (pg/pg of protein) 
measured in microglial conditioned medium. Medium was harvested from microglia exposed to 
ischaemia for 3 hours followed by either SCM for 24 hours (ischaemia SCM: red bars) or SFM for 
2 hours then SCM for 22 hours (ischaemia SFM: red bars). Microglia were also treated with 
fraction V  (Fv. 1 mg/ml) in SFM for 2 hours. The SFM was then replaced with SCM for 22 hours 
before medium was collected. Furthermore, medium was collected from microglia treated with 
Ap (45 pM) in SCM for 24 hours. To assess the effects of ischaemia on subsequent microglial 
signalling, microglia were exposed to a 3 hour period of ischaemia before being treated with 
fraction V  (Fv 1 mg/ml) or Ap (45 pM) then medium was collected (red bars). Control medium was 
obtained from microglia left untreated for 27 hours (basal) or microglia exposed to SFM for 2 hours 
then SCM for 22 hours (SFM). Medium was subsequently appraised for the presence of glutamate 
(A), TNFa (B) or TGFp (C). The values shown represent the mean (nM/pg or pg/pg of protein 
respectively) ±  SEM of data from experiments performed in triplicate. Statistical analysis was 
performed using ANOVA followed by the Tukey post test. * P < 0.05, ** P < 0.01, *** p < 0.001 vs 
control (A, B: control describes ‘basal’ or ‘SFM’. C: control describes Ap treated)
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To verify that the observed changes in glutamate and cytokine release were not due to cell 
membrane disruption, microglia were stained with propidium iodide and fluoroscein 
diacetate after 24 hours in culture. Staining revealed that microglial cultures exposed to 
ischaemia (‘ischaemia SCM’ or ‘ischaemia SFM’), fraction V (1 mg/ml) or Ap (45 pM) 
contained very few cells that stained with propidium iodide after 24 hours in culture (table 
6.1). Furthermore, microglial cultures subjected to ischaemia followed by fraction V or 
Ap contained negligible numbers of cells exhibiting propidium iodide staining as did 
control cultures. This suggests that the observed increases in glutamate and cytokine 
release occur via regulated pathways and that the changes are not due to loss o f cell 
membrane integrity.
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Treatment % Propidium iodide positive microglia
Basal 0.6 ± 0.3
SFM 1.0 ±0.6
Ischaemia (SCM) 1.5 ±0.5
Ischaemia (SFM) 1.4 ±0.4
Fv (1 mg/ml) 0.7 ± 0.4
AP (45 pM) 1.1 ±0.3
Ischaemia + Fv (1 mg/ml) 1.2 ±0.6
Ischaemia + Ap (45 pM) 1.3 ±1.5
Table 6.1 Analysis of microglial membrane integrity
Microglia were stained with propidium iodide and fluoroscein diacetate to provide an estimation of 
cell membrane integrity. Microglia exposed to ischaemia for 3 hours followed by either SCM for 24 
hours (ischaemia SCM) or SFM for 2 hours then SCM for 22 hours (ischaemia SFM) were stained. 
Microglia were also treated with fraction V  (Fv: 1 mg/ml) in SFM for 2 hours. The SFM was then 
replaced with SCM for 22 hours before staining. Furthermore, microglia were treated with Ap (45 
pM) in SCM for 24 hours before staining. To assess the effects of the combined insults on cell 
membrane integrity, microglia were exposed to ischaemia for 3 hours before being treated with 
fraction V  (Fv: 1 mg/ml) or Ap (45 pM) then the cells were stained. Control microglia were left 
untreated for 27 hours (basal) or were exposed to SFM for 2 hours then SCM for 22 hours (SFM) 
before staining. Cells possessing propidium iodide staining were expressed as a percentage of the 
total number of cells counted (cells possessing propidium iodide staining or fluoroscein diacetate 
staining). The values shown represent the mean ± SEM of data from experiments performed in 
triplicate. Statistical analysis was performed using an ANOVA followed by the Tukey post test. 
According to this test there was no significant difference between the treatments.
278
6.4 Effects of ischaemia on cellular viability and mitochondrial status
The effects of ischaemia on cellular viability were subsequently assessed. Microglial 
cultures subjected to ischaemia for 3 hours followed by either SCM for 48 hours 
(ischaemia SCM) or SFM for 2 hours then SCM for 46 hours (ischaemia SFM) contained 
veiy few cells showing signs of apoptosis, necrosis or mitochondrial depolarisation (Fig. 
6.4A). Similarly, microglial cultures treated with fraction V (1 mg/ml) contained very few 
cells exhibiting signs of apoptosis, necrosis or mitochondrial depolarisation after 48 hours 
in culture. Microglial cultures treated with Ap (45 pM) also contained few necrotic cells 
after 48 hours in culture, whereas a large proportion of the cells were apoptotic and 
exhibited depolarised mitochondria. An ischaemic insult prior to the addition of fraction V 
or Ap augmented the levels of apoptosis and mitochondrial depolarisation but not necrosis 
induced by either activator alone. Control cultures that were left untreated for 51 hours 
(basal) or were treated with SFM for 2 hours then SCM for 46 hours (SFM) contained 
veiy few microglia exhibiting signs of apoptosis, necrosis or mitochondrial depolarisation. 
Since none of the treatments caused a significant increase in microglial necrosis, the cells 
were only analysed for apoptosis in subsequent experiments.
Analysis of the total number of microglia per field of view revealed that microglial 
cultures treated with fraction V contained considerably more cells than cultures exposed to 
other treatments (Fig 6.4B), which is consistent with previous findings. Interestingly, 
fraction V treated microglial cultures that were pre-exposed to an ischaemic insult 
contained the same number of cells as control cultures (‘basal’ or ‘SFM’).
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Figure 6.4 Modulation of cellular viability by ischaemia
Amounts of apoptosis, necrosis and mitochondrial depolarisation were assessed in microglial 
cultures. A: Microglia were exposed to ischaemia for 3 hours followed by either SCM for 48 hours 
(ischaemia SCM) or SFM for 2 hours then SCM for 46 hours (ischaemia SFM). Microglia were also 
treated with fraction V  (Fv: 1 mg/ml) in SFM for 2 hours. The SFM was then replaced with SCM for 
46 hours. Furthermore, microglia were treated with Ap (45 pM) in SCM for 48 hours. To assess the 
effects of ischaemia on subsequent microglial signalling, microglia were exposed to a 3 hour 
period of ischaemia before being treated with fraction V  (Fv: 1 mg/ml) or Ap (45 pM). Control 
microglia were either left untreated for 51 hours (basal) or were exposed to SFM for 2 hours then 
SCM for 46 hours (SFM). Microglia were subsequently appraised for apoptosis using Hoechst 
33342 (open bars), necrosis using a combination of Hoechst 33342 and propidium iodide (black 
bars) and mitochondrial depolarisation using JC-1 (hatched bars). Cells displaying brightly stained 
pyknotic nuclei, signs of necrosis or depolarised mitochondria were counted and values were 
expressed as a percentage of the total number of cells counted. B: Proliferation was assessed by 
counting the number of microglia present per field of view. The values shown represent the mean 
± SEM of data from experiments performed in triplicate. Experiments consisted of 3 coverslips per 
treatment, each comprising 10 fields of view and experiments were performed on three 
independent occasions. Statistical analysis was performed using ANOVA followed by the Tukey 
post test. * p < 0.05 vs ‘Ap’. * * *  p < 0.01 vs ‘basal’ or ‘SFM ’. * * *  p < 0.001 vs 'FV.
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Next the time courses of apoptosis and mitochondrial depolarisation induced by the 
combined insults (ischaemia followed by fraction V or Ap treatment) were appraised. An 
ischaemic insult prior to the addition of fraction V (1 mg/ml) increased the levels of 
mitochondrial depolarisation and apoptosis (Fig. 6.5A). Microglia displaying depolarised 
mitochondrial were initially detectable between 24-32 hours after the addition of fraction 
V, whilst pyknotic nuclei were detectable between 32-42 hours. Therefore, mitochondrial 
depolarisation preceded apoptosis temporally. Conversely, microglial cultures treated with 
fraction V (1 mg/ml) alone contained very few cells displaying depolarised mitochondria 
and apoptosis over the 48 hour period studied.
Microglia subjected to an ischaemic insult prior to the addition of Ap (45 pM) followed 
the same time course of mitochondrial depolarisation and apoptosis as those microglia 
treated with Ap (45 pM) alone, although levels were augmented at each time point (Fig. 
6.5B). Here again mitochondrial depolarisation was found to precede apoptosis 
temporally. As a reference the results obtained from microglial cultures subjected to 
ischaemia for 3 hours then SCM for 48 hours were plotted. These cultures contained 
negligible numbers of cells displaying depolarised mitochondria (Fig. 6.5B: black 
triangle) or pyknotic nuclei over the 48 hour period studied (Fig. 6.5B: black square).
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Figure 6.5 (see overleaf for figure legend)
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Figure 6.5 Time axes of mitochondrial depolarisation and apoptosis
Time courses of mitochondrial depolarisation and apoptosis were assessed using JC-1 (bold lines) 
and Hoescht 33342 (dashed lines). A: Microglia were treated with fraction V  (1 mg/ml) in SFM for 
2 hours. The SFM was then replaced with SCM for 16, 22, 30, 40 or 46 hours before staining 
(black lines). In addition, microglia were exposed to ischaemia for 3 hours then fraction V  (1 
mg/ml) (green lines) for 16, 22, 30, 40 or 46 hours before staining. B: Microglia were stained 
following treatment with Ap (45 pM) in SCM for 18, 24, 32, 42 or 48 hours (blue lines). Microglia 
were also exposed to ischaemia for 3 hours then treated with Ap (45 pM) (red lines) for 18, 24, 32, 
42 or 48 hours before staining. As a reference, microglia subjected to ischaemia for 3 hours then 
SCM for 48 hours were stained (Hoescht 3342: black triangle and JC-1: black square). Microglia 
were stained for apoptosis using Hoechst 33342 (dashed lines) or mitochondrial depolarisation 
using JC-1 (bold lines). Cells displaying brightly stained pyknotic nuclei or depolarised 
mitochondria were counted and values were expressed as a percentage of the total number of 
cells counted. The values shown represent the mean ± SEM of data from experiments performed 
in triplicate. Experiments consisted of 3 coverslips per treatment each comprising 10 fields of view 
and experiments were performed on three independent occasions. Statistical analysis was 
performed using ANOVA followed by the Tukey post test. * p < 0.05, *** p < 0.01 vs control 
(control describes time 0 ).
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To determine whether mitochondrial depolarisation was responsible for initiating 
microglial apoptosis the effect of the PT inhibitor cyclosporin A (CsA) (Zamzami et al., 
1996; Seaton et al., 1998; Yang and Cortopassi 1998; Kingham and Pocock 2000) on 
these parameters was investigated. Ischaemia or fraction V treatment alone did not elicit 
cell death and results presented in chapter 5 revealed that Ap induced apoptosis is 
mediated by mitochondrial depolarisation, therefore the effects of CsA on mitochondrial 
depolarisation and apoptosis induced by the combined insults were studied in isolation. 
Pre-treatment with CsA (1 pM) was found to significantly attenuate mitochondrial 
depolarisation and apoptosis induced by ischaemia followed by fraction V (Fig. 6.6A) or 
AP(Fig. 6.6B) treatment. This suggests that the PT pore is involved in cell death 
associated with both insults. Next the upstream signalling pathways involved in 
mitochondrial depolarisation and apoptosis were studied. In these experiments the same 
range of inhibitors that were used in previous experiments were employed. In this way the 
signalling cascades induced by ischaemia followed by fraction V or Ap treatment could be 
compared with the second messenger pathways induced by each activator alone. Pre­
treatment with AMT-HC1 (0.3 pM), pertussis toxin (Ptx: 2 pg/ml), B APT A-AM (10 pM), 
U73122 (2 pM), PP2 (100 nM) or U0126 (5 pM) did not exert an inhibitory effect on 
mitochondrial depolarisation and apoptosis induced by an ischaemic insult followed by 
fraction V (1 mg/ml) treatment (Fig. 6.6A). In contrast, pre-treatment with poly I (0.5 
pg/ml) significantly attenuated mitochondrial depolarisation and apoptosis induced by 
ischaemia followed by Ap (45 pM) treatment (Fig. 6.6B). Pertussis toxin (Ptx: 2 pg/ml) or 
PP2 (100 nM) also significantly attenuated mitochondrial depolarisation and apoptosis 
induced by ischaemia then Ap treatment (Fig. 6.6B), whilst pre-treatment with 
neutralising RAGE antibody (200 pg/ml), AMT-HC1 (0.3 pM), BAPTA-AM (10 pM), 
U73122 (2 pM) or U0126 (5 pM) exerted no inhibitory effects.
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Figure 6.6  Signalling mechanisms involved in mitochondrial depolarisation and apoptosis
Apoptosis and mitochondrial depolarisation was assessed using JC-1 and Hoescht 33342 
respectively. A: Microglia were exposed to ischaemia for 3 hours followed by SFM for 2 hours then 
SCM for 46 hours (ischaemia) before staining. Microglia were also exposed to a 3 hour period of 
ischaemia, after which the cells were treated with fraction V  (Fv: 1 mg/ml) in SFM for 2 hours. The 
SFM was then replaced with SCM for 46 hours before staining was performed. In addition, 
microglia were exposed to ischaemia for 3 hours then treated with fraction V  (Fv: 1 mg/ml) in SFM 
in the presence of cyclosporin A (CsA: 1 pM), AMT-HCI (0.3 pM), pertussis toxin (Ptx: 2 pg/ml), 
BAPTA-AM (10 pM), U73122 (2 pM), PP2 (100 nM) or U0126 (5 pM). At 2 hours the SFM was 
replaced with SCM supplemented with the appropriate concentration of inhibitor for a further 46 
hours before staining. Microglia were also treated with fraction V  (1 mg/ml) alone in SFM for 2 
hours, after which the SFM was replaced with SCM for 46 hours before staining. Control microglia 
were left untreated for 51 hours (basal) or were exposed to SFM for 2 hours then SCM for 46 
hours (SFM) before staining. B: Microglia were exposed to ischaemia for 3 hours followed by SCM 
for 48 hours (ischaemia) then the cells were stained. Microglia were also exposed to a 3 hour 
period of ischaemia then treated with Ap (45 pM) in SCM for 48 hours before staining. In addition, 
microglia were exposed to ischaemia for 3 hours then treated with Ap (45 pM) in SCM in the 
presence of cyclosporin A (CsA: 1 pM), AMT-HCI (0.3 pM), poly I (0.5 pg/ml), neutralising RAGE 
antibody (200 pg/ml), pertussis toxin (Pbc 2 pg/ml), BAPTA-AM (10 pM), U73122 (2 pM), PP2 
(100 nM) or U0126 (5 pM) before staining. Furthermore, microglia were also treated with Ap (45 
pM) alone in SCM for 48 hours alone before staining. Control microglia were treated as described 
in A. Microglia were subsequently appraised for apoptosis using Hoechst 33342 (open bars) or 
mitochondrial depolarisation using JC-1 (grey bars). Cells displaying brightly stained pyknotic 
nuclei or depolarised mitochondria were counted and values were expressed as a percentage of 
the total number of cells counted. The values shown represent the mean ± SEM of data from 
experiments performed in triplicate. Experiments consisted of 3 coverslips per treatment, each 
comprising 10 fields of view and experiments were performed on three independent occasions. 
Statistical analysis was performed using ANOVA followed by the Tukey post test. *** p < 0.01 vs 
control (A: control describes fraction V  + ischaemia. B: control describes Ap + ischaemia).
286
6.5 Effects of ischaemia on intracellular free calcium
In this section the effects of an ischaemic insult on intracellular calcium levels in N9 
microglia were explored. N9 microglia were subjected to ischaemia for 3 hours then 
loaded with Fura-2 for 45 minutes at 37 °C, after which recordings were made (Smith et 
al., 2003). Changes in calcium levels were undetectable in N9 microglia subjected to 
ischaemia alone as measured immediately after the insult (Fig. 6.7) or 24 hours later (Fig. 
6.8). Consistent with previous findings, fraction V (1 mg/ml) induced a mono-phasic 
increase in intracellular calcium, whereas Ap (45 fiM) did not induce changes in 
intracellular free calcium. A 3 hour period of ischaemic did not alter the effects of fraction 
V (1 mg/ml) or Ap (45 pM) on calcium levels in N9 microglia as measured immediately 
after the insult (Fig. 6.7) or 24 hours later (Fig. 6.8). Furthermore, calcium fluxes were 
undetectable in control N9 microglia at each time point.
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Figure 6.7 Modulation of calcium transients immediately after ischaemia
Representative traces depicting the immediate effects of ischaemia on intracellular free calcium 
associated with fraction V  or Ap treatment in N9 microglia. N9 microglia were subjected to 
ischaemia for 3 hours then the cells were loaded with fura-2 (5 ^M) in basic medium for 45 
minutes at 37 °C. Cells were subsequently excited with wavelengths of 340 and 380 nm and 
emission was collected at a wavelength of 510 nm. Recordings were made from microglia 
subjected to ischaemia in the absence of any other stimulus. In addition, fraction V  (Fv: 1 mg/ml) 
or Ap (45 |iM) were added to ischaemia pre-treated N9 cells 60 seconds after the commencement 
of recording. Control N9 cells were treated with basic medium, fraction V  (Fv: 1 mg/ml) or Ap (45 
liM ) after 60 seconds of recording (without pre-exposure to ischaemia). Calcium responses were 
recorded from ten cells and the results were averaged and expressed as 340/380 fluorescence 
ratios.
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Figure 6.8 Modulation of calcium transients 24 hours after ischaemia
Representative traces depicting the effects of ischaemia on intracellular free calcium associated 
with fraction V  or Ap treatment in N9 microglia 24 hours post insult. N9 microglia were subjected to 
ischaemia for 3 hours, the cells were then returned to normoxic conditions for 24  hours before the 
cells were loaded with fura-2 (5 pM) in basic medium for 45 minutes at 37 °C. Cells were 
subsequently excited with wavelengths of 340 and 380 nm and emission was collected at a 
wavelength of 510 nm. Recordings were made from microglia subjected to ischaemia alone. In 
addition, fraction V  (Fv: 1 mg/ml) or Ap (45 pM) were added to ischaemia pre-treated N9 cells 60 
seconds after the commencement of recording. Control N9 cells were treated with basic medium, 
fraction V  (1 mg/ml) or Ap (45 pM) after 60 seconds of recording (without pre-exposure to 
ischaemia). Calcium responses were recorded from ten cells and the results were averaged and 
expressed as 340/380 fluorescence ratios.
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6.6 Effects of ischaemia treated microglia on neuronal apoptosis
The effect of microglial conditioned culture medium on neuronal death was subsequently 
assessed. Microglial conditioned medium was applied to cultures of cerebellar granule 
neurones for 24 hours then neuronal apoptosis was appraised using Hoescht 33342. 
Medium collected from microglia subjected to ischaemia for 3 hours followed by either 
SCM for 24 hours (ischaemia SCM) or SFM for 2 hours then SCM for 22 hours 
(ischaemia SFM) was found to induce neuronal apoptosis (Fig. 6.9A). Similarly, 
conditioned medium collected from microglia treated with fraction V (1 mg/ml) or Ap (45 
pM) for 24 hours induced a significant increase in neuronal death. An ischaemic insult 
prior to the addition of fraction V or Ap did not potentiate the levels of neuronal death 
induced by microglia treated with fraction V or Ap alone. Untreated cerebellar granule 
neurones (‘control’) contained few apoptotic cells after 24 hours in culture. Moreover, 
neuronal cultures that were exposed to medium collected from microglia left untreated for 
27 hours (control) or microglia treated with SFM for 2 hours then SCM for 22 hours 
(SFM) contained low levels of apoptosis.
To determine at which time point microglia subjected to ischaemia release the neurotoxic 
agent(s), microglia were exposed to ischaemia for 3 hours then the medium was replaced 
with SCM (since the results obtained with both SFM and SCM were essentially identical 
in all experiments described in this chapter) for 1, 4, 6, 14 or 22 hours. Microglia 
conditioned medium was subsequently incubated with cerebellar granule cells for a further 
24 hours before apoptosis was assessed. Using this approach, neurotoxin release was 
demonstrated to occur 6 hours after the ischaemic insult and the neurotoxicity of the 
conditioned medium increased with time (Fig. 6.9B).
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Figure 6.9 Effects of ischaemia treated microglia on neuronal apoptosis
Neuronal apoptosis induced by medium obtained from microglia was assessed using Hoescht 
33342. A: Medium was collected from microglia exposed to ischaemia for 3 hours followed by 
either SCM for 24 hours (ischaemia SCM: red bars) or SFM for 2 hours then SCM for 22 hours 
(ischaemia SFM: red bars). Microglia were also treated with fraction V  (Fv: 1 mg/ml) in SFM for 2 
hours. The SFM was then replaced with SCM for 22 hours before medium was collected. In 
addition, microglia were treated with Ap (45 pM) in SCM for 24 hours then medium was collected. 
To assess the effects of combined insults on neuronal death, microglia were exposed to ischaemia 
for 3 hours before being treated with fraction V  (Fv: 1 mg/ml) or Ap (45 pM) then medium was 
collected (red bars). Control medium was obtained from microglia that were left untreated for 27 
hours (control) or were exposed to SFM for 2 hours then SCM for 22 hours (SFM). Medium was 
subsequently added to cultures of cerebellar granule neurones then the neurones were fixed. 
Control neurones were left untreated for 24 hours (basal) before being fixed B: Microglia were 
subjected to ischaemia for 3 hours, then medium was collected at 0, 3, 6, 18 or 24 hours post 
insult (closed circles). Control medium was collected from untreated microglia at the same time 
points (open circles). Medium was subsequently applied to cerebellar granule neurones for 24 
hours then the cells were fixed. Neurones were stained with Hoescht 33342. Following staining, 
non-apoptotic cells possessed large brightly stained nuclei, whereas apoptotic cells possess 
brightly stained pyknotic nuclei. Neurones displaying brightly stained pyknotic nuclei were counted 
and the degree of apoptosis was expressed as a percentage of the total number of cells counted. 
The values shown represent the mean ± SEM of data from experiments performed in triplicate. 
Experiments consisted of 3 coverslips per treatment comprising ten fields of view. Statistical 
analysis was performed using ANOVA followed by the Tukey post test. ** p < 0.01, *** p < 0.001 
vs control. (A: Control describes neuronal cultures treated with medium harvested from untreated 
microglia “Control”. B: control describes tune 0).
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Next the identity of the neurotoxic agent(s) released by microglia subjected to ischaemia 
was investigated. To recap, ischaemia per se did not induce iNOS expression or NO 
production; neither did it induce glutamate release from microglia. Therefore, neuronal 
apoptosis was deemed to be NO and glutamate independent. This supposition was 
confirmed using the iNOS inhibitor AMT-HC1 and a cocktail of glutamate receptor 
antagonists (CNQX, 20 pM; MK801,10 pM; MSPG, 200 pM). AMT-HC1 (0.3 pM) was 
pre-incubated with microglia before they were exposed to ischaemia and medium was 
collected after 24 hours then applied to cultures of cerebellar granule neurones for a 
further 24 hours. In contrast, the glutamate antagonist cocktail (CNQX, 20 pM; MK801, 
10 pM; MSPG, 200 pM) was pre-incubated with the neurones before the addition of 
microglial conditioned medium. As postulated neither AMT-HC1 nor the glutamate 
antagonists attenuated neuronal apoptosis induced by ischaemia (Fig. 6.10). Furthermore, 
neuronal cultures treated with AMT-HC1 or the glutamate receptor antagonists alone did 
not contain significantly different levels of apoptosis from control cultures.
The effect of the broad spectrum purinergic antagonist PPADS (North and Barnard 1997; 
Troadec et al., 1999; von Kugelgen and Wetter 2000) on neuronal apoptosis induced by 
ischaemia treated microglia was subsequently assessed. In this way the role of microglial 
derived ATP in neurotoxicity could be ascertained. PPADS (100 pM) was pre-incubated 
with the neurones before the addition of microglial conditioned medium. PPADS did not 
protect the neurones against apoptosis, which suggests that apoptosis is ATP independent 
(Fig. 6.10). In support of this, the addition of ATPase (0.5 U/ml) to medium collected 
from microglia subjected to ischaemia did not attenuate neuronal apoptosis. Moreover, 
PPADS or ATPase did not adversely affect cell survival when incubated with the neurones 
alone.
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Boiling the microglial conditioned medium was found to afford neuroprotection, which 
suggests that the neurotoxic agent(s) are heat labile. However, depleting the microglia 
conditioned medium of TNFa or TGFP did not protect against neuronal apoptosis. This is 
consistent with the findings that ischaemia did not induce the release of these cytokines 
from microglia. Similarly, conditioned medium that was obtained from microglia treated 
with fraction V (1 mg/ml) alone and was depleted of TNFa did not attenuate neuronal 
apoptosis. In support of this, the direct addition of TNFa (100 pg/well) to neuronal 
cultures did not bring about apoptosis (Fig. 6.11), which is consistent with previous 
findings (Thery et al., 1991). Approximately 40 pg of TNFa was measured in microglial 
conditioned medium obtained from fraction V treated microglia, however 100 pg of TNFa 
was applied to neuronal cultures, in this way the effects of TNFa on neuronal apoptosis 
were not underestimated.
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Figure 6.10 Analysis of neurotoxins released from microglia subjected to ischaemia
Neuronal apoptosis induced by medium obtained from microglia subjected to ischaemia was 
assessed using Hoescht 33342. Microglia were exposed to ischaemia for 3 hours then the cells 
were incubated in SCM for a further 24 hours in the presence or absence of AMT-HCI (0.3 pM) 
before medium was collected. Microglial conditioned medium was subsequently applied to cultures 
of cerebellar granule neurones for 24 hours. To assess the effects of glutamate or ATP on 
neuronal death, glutamate receptor antagonists (CNQX, 20 pM; MK801, 10 pM; MSPG, 200 pM) 
(‘glutamate antags’) or PPADS (100 pM) were pre-incubated with the neurones for 1 hour before 
conditioned medium was applied to the neurones for a further 24 hours. In addition, ATPase (0.5 
U/ml) was added to microglial conditioned medium for 1 hour before the medium was applied to 
neuronal cultures for 24 hours. Conditioned medium was also boiled before being applied to 
cultures of neurones (‘boiling’) for 24 hours. Furthermore, microglial conditioned medium was 
immuno-depleted of TN Fa or TGFp before being applied to neurones. Control microglia were left 
untreated for 27 hours (control) then medium was collected and added to neurones fro 24 hours, 
whilst control neurones were left untreated for 24 hours (basal). Neurones were subsequently 
fixed then stained with Hoescht 33342. Neurones displaying brightly stained pyknotic nuclei were 
counted and the degree of apoptosis was expressed as a percentage of the total number of cells 
counted. The values shown represent the mean ± SEM of data from experiments performed in 
triplicate. Experiments consisted of 3 coverslips per treatment, comprising ten fields of view. 
Statistical analysis was performed using ANOVA followed by the Tukey post test. ** p < 0.01 vs 
‘ischaemia’.
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Figure 6.11 Assessment of fraction V induced neurotoxicity with respect to TNFa
Neuronal apoptosis induced by medium obtained from fraction V  treated microglia was assessed 
using Hoescht 33342. Microglia were treated with fraction V  (Fv: 1 mg/ml) in SFM for 2 hours. The 
SFM was then replaced with SCM for 22 hours before the medium was collected. Control medium 
was collected from microglia left untreated for 24 hours (control) or microglia exposed to SFM for 2 
hours then SCM for 22 hours (SFM). Microglial conditioned medium was subsequently applied to 
cultures of cerebellar granule neurones for 24 hours then the neurones were fixed. To assess the 
effect of TN Fa on neuronal death, fraction V  (1 mg/ml) conditioned medium was neutralised with 
anti-TNFa antibody. Neutralised medium was subsequently applied to cultures of neurones for 24 
hours before the neurones were fixed. TN Fa (100 pg/well) was also added directly to neuronal 
culture for 24 hours then the cells were fixed. Control neurones were left untreated for 24 hours 
(basal) before being fixed. Following fixation, neurones were stained with Hoescht 33342. Non- 
apoptotic cells possessed large brightly stained nuclei, whereas apoptotic cells possessed brightly 
stained pyknotic nuclei. Neurones displaying pyknotic nuclei were counted and the degree of 
apoptosis was expressed as a percentage of the total number of cells counted. The values shown 
represent the mean ± SEM of data from experiments performed in triplicate. Experiments 
consisted of 3 coverslips per treatment, comprising ten fields of view. Statistical analysis was 
performed using ANOVA followed by the Tukey post test. *** P < 0.001 vs control (Control 
describes neuronal cultures treated with medium harvested from untreated microglia ‘control’).
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6.7 Discussion
Research has mainly focussed on the effects of ischaemia on neurones (Goldsburg and 
Choi 1993; Strasser and Fischer 1995; Pringle et al., 1997; Pocock and Nicholls 1998). 
However, the results presented in this chapter clearly demonstrate that ischaemia can 
modulate microglial signalling. In light of the close proximity of microglia to neurones 
and the emerging awareness of microglial-neuronal interactions this area of research 
deserves further investigation. Experimental data presented in this chapter revealed that 
microglia exposed to ischaemia followed by fraction V or Ap treatment underwent 
mitochondrial depolarisation, which gave rise to apoptotic cell death. In contrast, 
microglia subjected to ischaemia alone remained viable. Examination of the signalling 
cascades elicited in microglia by ischaemia alone or in combination with fraction V or Ap 
demonstrated that these treatments triggered different upstream signalling events, which 
are discussed below.
6.7.1 Ischaemia and iNOS
In vivo, iNOS expression in microglia has been reported in post-natal rats subjected to 
hypoxia (You and Kaur 2000). iNOS and nitrite are also detectable in the penumbra after 
transient focal ischaemia and may be involved in the conversion of penumbra into 
infarction (Zhu D et al., 2002). Furthermore, inhibition of iNOS reduces infarct volume by 
30-40 % (Parmentier et al., 1999; Zhu D et al., 2002). In vitro, cultured microglia 
subjected to hypoxia up-regulate the expression of iNOS, which is accompanied by the 
concomitant production of NO (Park et al., 2002). Re-oxygenation was required for NO 
production but not iNOS expression, which is not surprising considering oxygen is 
essential for the oxidation of L-arginine. In support of these findings the iNOS gene has 
recently been demonstrated to contain a functional hypoxia response element (Melillo et
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al., 1995). However, the results presented in this chapter revealed that a 3 hour period of 
ischaemia did not induce iNOS expression or nitrite production in microglia following 
reoxygenation. The variations in these results and those published by Park et al., (2002) 
may reflect differences in the experimental methodologies employed. Firstly, Park et al., 
(2002) subjected microglia to hypoxia and not ischaemia and secondly these authors 
prepared their microglia by agitating mixed glial cultures after 10 days in vitro, which is 
known to cause a graded activation of microglial cells (Slepko and Levi 1996). As a result, 
their microglia may have exhibited a heightened activation state, rendering the cells more 
susceptible to hypoxic insults. An alternative explanation might be that ischaemia is not a 
suitable stimulus to promote iNOS expression, whereas hypoxia is. It could be that 
glucose is a requirement for iNOS expression in microglia (Shin et al., 2002). The data 
presented in this chapter also demonstrated that ischaemia followed by fraction V or Ap 
treatment did not potentiate the levels of iNOS or nitrite production associated with 
fraction V or Ap treatment alone. Consistent with this, a synergistic effect of LPS or IFNy 
on hypoxia induced iNOS expression was not observed by Park et al, (2002).
6.7.2 Ischaemia and ERK
Ischaemia did not induce the phosphorylation of ERK in microglia. In keeping with this, 
hypoxic (Park et al., 2002) or ischaemic (Walton et al., 1998) insults have been 
demonstrated to induce the activation of p38 but not ERK or JNK in microglia. It may be 
that phosphorylation events are reduced following ischaemia due to the depletion of ATP, 
which is an essential molecule required for phosphorylation (Berg et al., 2002). However, 
it is possible that the peak of ERK phosphorylation may have occurred during the 
ischaemic period; therefore the presence of phospho-ERK may have eluded detection by 
Western blot analyses. This seems unlikely however, considering ERK remained
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phosphoiylated for long periods of time after albumin or CgA treatment (see chapters 4 
and 5 respectively). Importantly, U0126 (ERK inhibitor) was found to abate iNOS 
expression in microglia subjected to ischaemia then fraction V treatment. This suggests 
that ischaemia does not affect the ability of fraction V to elicit ERK activation and 
subsequent iNOS expression. However, a synergistic effect of ischaemia on fraction V or 
Ap associated p-ERK levels was not found.
6.73 Ischaemia and glutamate
There is no enzyme to terminate the action of glutamate; hence the synaptic action of 
glutamate is terminated by the removal of glutamate from the extracellular space by a 
family of uptake transporters. These Na+ symporters transport glutamate by exploiting 
transmembrane ion gradients, which are ultimately set up by the Na+/K+ ATPase. 
Consequently, plasma membrane depolarisation occurring as a result of ischaemia causes 
glial and neuronal glutamate uptake carriers to operate in reverse, which in turn 
exacerbates the accumulation of extracellular glutamate (Szatkowski and Atwell 1994; 
Takahashi et al, 1997; Katsumori et al., 1999; Rossi et al., 2000). However, the results 
presented in this thesis demonstrate that ischaemia did not induce microglia to secrete 
glutamate into the culture medium. This might be because ramified microglia express very 
low levels of glutamate transporters, therefore glutamate is not pumped out of the cells 
when ion gradients are run down. In accordance with earlier findings fraction V but not 
Ap induced microglial glutamate release. Furthermore, ischaemia did not potentiate 
glutamate release associated with either activator alone. Collectively, these data provide 
evidence that microglia are probably not the main cell type involved in glutamate release 
and ensuing excitotoxic damage in response to ischaemia.
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6.7.4 Ischaemia and cytokine secretion
TNFa has recently been show to play a central role in ischaemic injury. In vivo, TNFa 
potentiates damage following transient or permanent focal ischaemia (Barone et al., 1997). 
Moreover, administration of the soluble TNFa receptor or anti-TNFa antibody 
ameliorates ischaemic damage (Barone et al., 1997; Nawashiro et al., 1997). This suggests 
that TNFa contributes to pathological inflammatory processes in ischaemia. Microglia are 
the main source of TNFa in the brain, therefore microglial activation is most likely to 
underlie TNFa dependent neuronal injury. Accordingly, cultured microglia subjected to 
hypoxia have been reported to secrete TNFa (Park et al., 2002). However, the results 
presented here revealed that ischaemia did not evoke the release of TNFa from microglia. 
A(3 treatment did not induce microglia to release TNFa either. There have been mixed 
reports regarding the effects of A(3 on TNFa secretion from microglia. Many investigators 
have demonstrated that microglia treated with Ap(l-42) (Nagai et al., 2001; Casal et al., 
2002) or AP(25-35) (Meda et al., 1995; Pyo et al 1998; Nagai et al., 2001) do secrete this 
cytokine. Conversely, a few studies have demonstrated that microglia treated with AP(25- 
35) (Forloni et al., 1997; Casal et al., 2002), Ap(l-40) (Gasic-Milenkovic et al., 2003) or 
Ap(l-42) (Kopec and Carroll 1998) do not secrete TNFa. One report has also shown that 
AP(l-40) fails to instigate TNFa release from THP monocytes (Klegaris et al., 1997), a 
cell type that is often used to model microglia. Furthermore, some studies have shown that 
AP(l-40) requires the presence of a co-stimulator such as M-CSF (Murphy et al., 1998) or 
LPS (Yates et al., 2000) to induce cytokine production. In line with this, the extracellular 
environment surrounding senile plaques is rich in pro-inflammatory agents including 
proteases and complement proteins (McGeer and McGeer 1997,1999), which are likely to 
augment the effects of Ap on microglia in vivo.
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In contrast to ischaemia and Ap treatment, fraction V was found to evoke a dramatic 
increase in TNFa secretion. Other blood borne factors have been demonstrated to 
potentiate LPS induced TNFa secretion (Si et al., 2000), which implies that TNFa may 
play a vital role in inflammatory processes following BBB damage. Results presented in 
this chapter also revealed that ischaemia followed by fraction V or Ap treatment did not 
potentiate the levels of secreted TNFa associated with fraction V or Ap treatment alone. 
This suggests that additional transcriptional factors are not activated in response to the 
‘combined’ insult and therefore a synergistic effect on TNFa release is not observed.
The ability of activated microglia to release TGFp in vitro has not been extensively 
researched. Data presented in this chapter revealed that ischaemia did not induce microglia 
to secrete TGFp. Fraction V or Ap did not evoke TGFp release from microglia either. The 
latter is consistent with previous findings in human monocytes (Meda et al., 1999). 
Interestingly, microglia subjected to ischaemia followed by Ap treatment secreted TGFp, 
whereas microglia treated with ischaemia followed by fraction V did not release this 
cytokine. Previously it has been reported that microglia synthesise TGFp following 
ischaemic insults in vivo (Gehrmann et al., 1995; Lehrmann et al., 1998). TGFp is known 
to reduce neuronal damage (Justica et al., 2001) and suppresses astrocytic scar formation 
(Hunter et al., 1993; Lindholm et al., 1993). Furthermore, TGFp is a classical wound 
healing factor, which acts through the enhancement of extracellular matrix deposition and 
the promotion of angiogenesis to instigate repair (Ling and Robinson 2002). Therefore, 
the up-regulation of TGFp expression may represent a beneficial response to injury. 
Indeed, it may be the balance between cytotoxic and neuro-protective cytokines that 
determines the extent of ischaemic injury in vivo.
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6.7.5 Ischaemia and microglial viability
Cultured microglia were resistant to a 3 hour period of ischaemia, after which the cells 
appeared healthy and did not exhibit morphological characteristics of necrosis, apoptosis 
or mitochondrial perturbations. Similarly, it has been reported that microglial cultures 
exposed to ischaemia for 3 or 6 hours followed by reoxygenation exhibit very low levels 
of death (Yenari and Giffard 2001). Lyons and Kettenmann (1998) also found that 
microglia are extremely resistant to 6 hours of hypoxia. In contrast, the vast majority of 
microglia died when subjected to chemical ischaemia involving 6 hours of hypoxia in the 
presence of 2-deoxyglucose (a non-hydrolysable analogue of glucose) (Lyons and 
Kettenmann 1998). Interestingly, if microglia were subjected to hypoxia in the presence of 
mannitol (a non-metabolizable sugar) considerably less microglia died (Lyons and 
Kettenmann 1998). Mannitol acts as a free radical scavenger and therefore may protect the 
microglia from reactive oxygen or nitrogen species these cells produce during ischaemic 
episodes. Together these findings demonstrate that microglia can tolerate ischaemic 
conditions for a few hours, after which the cells endure death, which is probably due to 
saturation of survival mechanisms.
Cultured astrocytes also exhibit a similar susceptibility to ischaemic-like insults as 
microglia (Yu et al., 1989; Goldsberg and Choi 1993; Smith et al., 2003). Conversely, 
other CNS cell populations appear to be more vulnerable to such insults. The majority of 
cultured neurones (Goldsburg and Choi 1993; Strasser and Fischer 1995; Pringle et al., 
1997) and oligodendrocytes (Lyons and Kettenmann 1998; Fem and Moller 2000) 
succumb to ischaemic insults after 25-60 minutes of exposure. The ability of microglia 
and also astrocytes to withstand ischaemia may reflect the feet that they possess large 
intracellular glycogen stores, which are depleted to fuel respiration under anaerobic 
conditions (Swanson and Choi 1993).
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Despite the finding that microglia are extremely tolerant of a 3 hour period of ischaemia, 
microglia underwent mitochondrial depolarisation, which in turn precipitated apoptosis 
when subjected to ischaemia followed by fraction V treatment. Microglial cultures 
subjected to ischaemia then fraction V contained the same number of cells per field as 
control cultures. This suggests that such an insult ‘overrides’ fraction V induced 
signalling, which would normally lead to proliferation. Although it should be noted that 
microglia subjected to ischaemia still react to fraction V with a robust calcium response. 
This suggests that a different signalling cascade is elicited in microglia subjected to 
ischaemia then fraction V treatment; however the involvement of Gi proteins, Src kinases, 
ERK or calcium was eliminated.
Microglial cultures subjected to ischaemia then Ap contained more cells displaying 
depolarised mitochondria and pyknotic nuclei than those cultures treated with Ap alone. 
Moreover, the pathway leading to cell death was the same with or without the initial 
ischaemic insult and involved scavenger receptor ligation coupled to the activation of a 
Src kinase and a Gi protein. Ischaemia may potentiate the signalling cascade induced by 
Ap by increasing the number of scavenger receptors on the cell surface, alternatively 
ischaemia may prime the intracellular pathway leading to apoptosis thereby heightening 
the response upon the application of Ap. Collectively, these findings illustrate that 
microglia are relatively resistant to ischaemia per se, although the cells are unable to 
withstand a double insult, which inevitably culminates in apoptosis.
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6.7.6 Ischaemia and calcium transients
Ischaemia did not modulate calcium fluxes in N9 microglia as measured immediately after 
the insult or 24 hours later. This is consistent with results obtained in astrocytes subjected 
to chronic hypoxia (24 hours) (Smith et al, 2003). Results in this chapter also 
demonstrated that ischaemia did not change the calcium response profiles obtained with 
fraction V or Ap. In contrast, Smith et al. (2003) reported that hypoxia augments the 
effects of the calcium mobilizing agonist bradykinin, a response that was store mediated. 
This phenomenon was attributed to the enlargement of store capacity by hypoxia or 
perhaps the reduced clearance of calcium from the cytoplasm (Smith et al, 2003).
6.7.7 Ischaemia and microglial induced neuronal apoptosis
Ischaemia treated microglia were demonstrated to induce neuronal apoptosis. In support of 
this, the appearance of activated microglia coincides with delayed neuronal death in the 
hippocampus (Morioka et al., 1991). Moreover, CNS injury can be reduced by inhibiting 
macrophage recruitment in spinal cord ischaemia (Giulian and Robertson 1990). In vivo, it 
is conceivable that microglia would induce more neuronal death because neurones would 
also be compromised by the ischaemic insult rendering them more vulnerable to 
subsequent damage.
Neuronal apoptosis induced by ischaemia treated microglia was glutamate, TNFa and 
TGFp independent, which is in accord with previous findings (Flavin et al., 1997; 2000). 
It has been proposed that macrophage-like cells induce neurotoxicity through the release 
of large proteins such as proteases and lipases (Flavin et al., 1997; 2000). In line with this, 
the neurotoxin(s) released by ischaemia treated microglia were heat labile indicative of a 
proteinaceous nature, although the precise identity of the neurotoxin(s) remains to be
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elucidated. Interestingly, ischaemia followed by fraction V or Ap treatment did not 
potentiate the levels of neuronal apoptosis induced by microglia subjected to fraction V or 
Ap alone. In light of these results, it would appear that neurotoxin release cannot be 
elevated beyond a certain threshold even in the presence of a combination of insults 
probably because ‘activation’ and subsequent ‘secretion’ pathways are saturated.
6.7.8 Conclusions
Cultured microglia appear to be relatively resistant to ischaemia. Nevertheless, microglia 
were extremely sensitive to ischaemia followed by another insult This suggests that a 
stroke may shape subsequent microglial responses. To summarise, microglia subjected to 
ischaemia then fraction V expressed similar levels of iNOS as those cells treated with 
fraction V alone. Furthermore, microglia subjected to ischaemia then fraction V expressed 
iNOS via an ERK dependent mechanism. Microglia exposed to ischaemia then fraction V 
also secreted similar levels of glutamate, TNFa, TGFp and neurotoxins as those cells 
treated with fraction V alone. Interestingly, there was no significant difference in the 
calcium responses detectable in microglia exposed to ischaemia then fraction V or fraction 
V alone. However, microglia subjected to ischaemia then fraction V did not proliferate. In 
contrast, the cells underwent mitochondrial depolarisation, which in turn induced 
apoptosis (Fig. 6.12).
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Figure. 6.12 Signalling elicited in microglia subjected to ischaemia then fraction V
Microglia subjected to ischaemia then fraction V  expressed similar levels of iNOS as microglia 
treated with fraction V  alone. Furthermore, microglia subjected to ischaemia then fraction V  
expressed iNOS via an ERK dependent mechanism. Microglia exposed to ischaemia then fraction 
V  also secreted similar levels of glutamate, TNFa, TGF|3 and neurotoxins as those cells treated 
with fraction V  alone. There was no significant difference in the calcium responses detectable in 
microglia exposed to ischaemia then fraction V  or fraction V  alone. However, microglia subjected 
to ischaemia then fraction V  did not proliferate. In contrast, the cells underwent mitochondrial 
depolarisation, which in turn precipitated apoptotic cell death.
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Microglia subjected to ischaemia then Ap secreted essentially identical quantities of 
neurotoxins as microglia treated with Ap alone. Furthermore, microglia underwent 
mitochondrial depolarisation, which precipitated apoptosis. However, microglial cultures 
subjected to ischaemia then Ap displayed greater levels of mitochondrial depolarisation 
and apoptosis than those cultures exposed to Ap alone. Importantly, upstream signalling 
was mediated via the scavenger receptor, a Src kinase and a Gi/o protein in response to 
either treatment. Microglia subjected to the combined insult were also found to secrete the 
anti-inflammatory cytokine TGFp, whereas TGFp was not secreted by microglia subjected 
to ischaemia or Ap alone (Fig. 6.13).
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Figure 6.13 Signalling elicited in microglia subjected to ischaemia then Ap
Microglia subjected to ischaemia then Ap secreted essentially identical quantities of neurotoxins 
as microglia treated with Ap alone. Furthermore, microglia underwent mitochondrial depolarisation, 
which precipitated apoptosis. However, cultures subjected to ischaemia then Ap displayed greater 
levels of mitochondrial depolarisation and apoptosis than those cultures exposed to Ap alone. 
Upstream signalling was mediated via the scavenger receptor, a Src kinase and a Gi/o protein in 
response to either treatment. Microglia subjected to the combined insult were also found to 
secrete the anti-inflammatory cytokine TGFp, whereas TGFp was not secreted by microglia 
subjected to ischaemia or Ap alone.
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7.0 General discussion
7.1 Evaluation of tissue culture models
Nowadays, in vitro models are widely used to study cell signalling. In this thesis, the 
effects of a number of activators on microglial signalling and subsequent neuronal 
survival have been explored using tissue culture models. The main advantages of in vitro 
systems over in vivo models are that they enable responses of individual cells type to be 
delineated. However, there is some concern that in vitro systems do not reflect the true 
properties of an individual cell type, since the 3-dimensional architecture of the brain is 
disrupted during isolation, therefore neighbouring cells cannot contribute to signalling as 
would occur in vivo. Nevertheless, cell culture models provide useful tools to explore cell 
signalling in ways that would not be feasible in vivo.
In this study microglia were isolated using percoll density gradients, a method that was 
validated according to the findings of Ford et al., (1995) (see chapter 3). Using percoll 
density gradients extremely pure cultures of microglia can be obtained. Furthermore, when 
prepared in this way microglia are less activated and more akin to their naturally occurring 
state in vivo because the cells are not cultured for long periods of time, which is a 
requirement when isolating microglia from mixed glial cultures (Nolte et al., 1996; 
McDonald et al., 1997; Moller et al., 2000a, b; Casal et al., 2002). Thus, microglia isolated 
by percoll density gradient provide a good model of the in vivo situation. An alternative 
6in vitro’ approach would have been to use post mortem tissue to isolate primary 
microglia. However, such an approach is problematic since it takes a considerable length 
of time to collect and prepare post mortem tissue during which time a number of cellular 
changes can occur. In addition, a frequent supply of post-mortem tissue is difficult to 
obtain. Slice cultures are another model that could have been used in this study, although 
responses from individual cells are difficult to dissect in such preparations.
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A major point that is thrown into light by this investigation is that macrophages, which are 
frequently used to study microglial signalling (Klegaris and McGeer 1997; Shalit et al., 
1997; Smits et al., 2001a, b), may not actually provide a suitable microglial model. 
Macrophages were demonstrated to possess different signalling properties to microglia. 
Macrophages also expressed more cell surface receptors than microglia, which suggests 
that macrophages are more activated than their CNS counterparts. Taken together these 
results indicate that macrophages may not provide an accurate representation of microglial 
responses.
The other major cell type utilised in this thesis were cerebellar granule neurones. 
Preparing neurones from the cerebellum leaves the rest of the brain spare from which 
microglia can be isolated, thereby minimising wastage. Moreover, the cerebellum 
develops post-natally (Jacobson 1991), which means that neurones can be prepared from 
neonatal animals. Hippocampal or cortical neurones may have provided better neuronal 
models, considering these regions are predominantly involved in the pathology of AD. 
However, lower yields are obtained from these preparations because cells have to be 
isolated from embryonic tissue.
12  Microglial signalling: common and divergent routes
In this thesis albumin, CgA, or Ap were demonstrated to trigger diverse signalling 
cascades in microglia. In contrast, ischaemia per se did not appear to exert any effects on 
microglial signalling, although ischaemia followed by albumin (fraction V) or Ap 
treatment altered the microglial responses observed with albumin or Ap treatment alone. 
These findings suggest that microglia are more sensitive to receptor mediated events as 
opposed to ‘physical’ stimuli such as ischaemia. Nevertheless, ischaemia was found to
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manipulate/prime receptor mediated signalling, which suggests that a stroke may 
condition subsequent microglial responses implying that microglia possess some form of 
‘molecular memory’. Thus, a stroke may alter the course of AD possibly by exacerbating 
inflammatory processes. Indeed microglia subjected to ischaemia followed by Ap 
treatment released more TGFp than cells exposed to either stimulus alone.
The ‘end point’ of microglial activation is a field of research that has not been extensively 
studied. In this investigation activated microglia were found to proliferate or apoptose. 
Proliferation may represent a beneficial response instigated to combat injury and minimise 
tissue damage. In vitro, cultured microglia that undergo proliferation do inevitably die. 
However, in vivo activated microglia may proliferate, then revert back to a ramified 
quiescent phenotype after the damaging event has subsided (Jordon and Thomas 1988). 
Activation induced apoptosis of microglia may also be an advantageous mechanism, 
which serves to terminate inflammatory reactions thereby limiting bystander damage to 
neighbouring neurones. Experimental data revealed that microglial apoptosis was 
mediated by mitochondrial depolarisation in response to CgA, Ap or combined insults 
involving ischaemia then a subsequent treatment (fraction V or Ap). This suggests that 
mitochondria are exquisitely sensitive to pathological changes and act as a common 
executioner of cell death in microglia. These findings provide a very small insight into the 
ultimate fate of activated microglia, but also highlight that this is an area of research that 
warrants further investigation.
Investigation of microglial signalling pathways revealed that these cells utilise a multitude 
of second messengers including calcium, G proteins, ERK and Src kinases. Interestingly, 
ERK and Src kinases are activated by different microglial activators and mediated both
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divergent and common responses. For example, Src kinases mediate albumin-induced 
proliferation as well as CgA or Ap-dependent apoptosis. Moreover, ERK is involved in 
LPS-induced iNOS expression (Bhat et al., 1998) and the expression of iNOS in response 
to albumin or CgA treatment COX-2 was not induced by albumin, CgA or Ap treatment, 
which implies that prostaglandins synthesis is not upregulated in response to these stimuli. 
However, LPS triggered the expression of this inflammatoiy mediator, therefore COX-2 
expression can be induced in microglia by independent signalling pathways. A complex 
interplay between iNOS and COX-2 signalling is emerging (Patel et al., 1999; Clancy et 
al., 2000), which may account for suppression of COX-2 expression in CgA or albumin 
activated microglia. Glutamate was another common mediator secreted by activated 
microglia. This amino acid is known to play a central role in neurodegeneration in 
particular following ischaemic damage. However, the results presented in this thesis, 
revealed that ischaemia per se did not evoke the release of glutamate from microglia, 
therefore it is conceivable that other activators associated with ischaemic injuiy such as 
leaked blood bome factors (i.e. albumin) or agents associated with dystrophic neurites (i.e. 
CgA) trigger microglia to release glutamate. Accordingly, activated microglia may be an 
important secondary source of glutamate in pathological states.
Collectively, the results presented in this thesis demonstrate that the outcome of microglial 
signalling is a conglomerate of a number of second messenger pathways, which act 
synergistically to instigate a coordinated response. In vivo, microglial signalling is likely 
to be influenced by a myriad of factors, which act via different receptors to initiate a 
complex response mediated by overlapping and divergent signalling pathways. Moreover, 
the finding that albumin may induce signalling via an interaction with myosin heavy chain 
IX suggests that microglia may also signal through non-conventional receptor types.
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73  Suggestions for future work
This project has opened a number of avenues for future work. It would be of interest to 
analyse the involvement of other second messengers including p38 and SAPKs in the 
signalling cascades induced by CgA, Ap, albumin or ischaemia. Investigation of 
respiratory burst activity or phagocytic capability following microglial activation would 
also be interesting. Perhaps inhibition of phagocytosis may provide a unifying approach to 
inhibit microglial activation and subsequent local inflammatory responses in disease 
states. Indeed albumin is internalized by microglia and Ap is also taken up by these cells 
(Paresce et al., 1996, 1997; Kopec and Carroll 1998). Moreover, scavenger receptors have 
recently been demonstrated to mediate phagocytosis (Platt et al., 1996; Paresce et al., 
1996), therefore it is conceivable that CgA is internalised too.
An in depth study o f the cytokine profiles released by microglia activated by albumin, 
CgA, Ap or ischaemia would be a valuable exercise. To follow on from this, the signalling 
pathways leading to cytokine secretion could be investigated. An expansion of this project 
could include the exploration of astrocyte signalling induced by CgA, Ap, albumin or 
ischaemia. Therefore, a wider picture of glial signalling in pathological situations could be 
portrayed. Furthermore, a comparison of the signalling cascades elicited by Ap(25-35), 
AP(l-40) or Ap(l-42) would be useful because the results presented in this thesis and by 
other investigators (Forloni et al., 1997; Kopec and Carroll 1998; Casal et al., 2002; 
Gasic-Milenkovic et al., 2003) have highlighted that these species of Ap elicit different 
signalling cascades. If it turns out that all Ap fragments fail to induce microglia 
inflammatory responses then the ability of CgA or albumin to act as co-stimuli could be 
explored.
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Finally, the use of peripheral monocytes as tools to deliver drugs into the CNS following 
ischaemia (peripheral blood cells are not recruited into the CNS in AD) could be explored. 
Circulating monocytes are inevitably recruited to the ischaemic core (Kato and Walz 
2000), therefore these cells could be exploited to directly target agents to damaged areas. 
Moreover, problems associated with crossing the BBB would be circumvented.
7.4 General conclusions
Under physiological conditions resident microglia are quiescent and are randomly 
scattered throughout the CNS (Thomas 1992). Occasionally microglia become activated to 
play a classical role as ‘scavenging cells’ for the maintenance and restoration of proper 
CNS homeostasis. Microglia proliferate, change morphology then phagocytose debris or 
cells that have become pathologically damaged or developmentally unnecessary. These 
functions however are strictly regulated and do not elicit secondary neuronal damage. In 
contrast, chronic microglial activation may be a cause of neurodegeneration. In this study 
the signalling pathways triggered in microglia treated with albumin, CgA, Ap, ischaemia 
or a combination of insults were explored in an attempt to model pathological conditions 
associated with stroke and Alzheimer’s disease. A common property shared by microglia 
subjected to these insults was the ability to induce neuronal death. Extrapolation of these 
findings implies that in vivo microglia are very sensitive to BBB injury, ischaemia or the 
presence of foreign bodies such as CgA or P-amyloid plaques. Thus, in neurodegenerative 
diseases the accumulation of numerous pathologies may lead to the development of a 
chronic inflammatory response, which in turn may exacerbate neuronal death and 
contribute to cognitive decline (Fig. 7.1). In light of this, selective modulation of 
microglial signalling pathways may provide avenues for therapeutic strategies to alleviate 
the symptoms of neurological disorders.
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Figure 7.1 Microglial activation in stroke and Alzheimer’s disease
A combination of pathological processes contribute to microglial activation in Alzheimer’s disease 
and stroke including the presence of amyloid plaques, the accumulation of extracellular and intra- 
neuronal deposits of CgA, BBB damage and ischaemic injury. Activated microglia subsequently 
release neurotoxins, which fuel neuronal damage thereby augmenting cognitive impairment.
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